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“The subjectivity of consciousness is an irreducible feature of reality, and it must occupy 
as fundamental a place in any credible world view as matter, energy, space, time and 
numbers”. 
Thomas Nagel, The View from Nowhere, 1986 
 
 
 
“The measure of a man’s real character is what he would do if he knew he would never 
be found out.” 
1st Baron Thomas Macaulay, 1926 
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Abstract 
 
A recent evaluation of medical error has shown it to be the third leading cause of death in the US, 
following heart disease and cancer. Better reporting and decision making could tackle this, but 
ultimately more accurate and precise measurement, with correct interpretation could make a 
significant difference to this unnecessary statistic. Clinical pathology measurement platforms are 
complex, requiring significant standardisation efforts to reduce false positives/negatives and the 
impacts these have on patient safety. Cell and Gene Therapy (CGT) manufacturing processes 
depend upon these platforms for measurement, with Flow Cytometry (FC) used for in-process and 
release metrics. However, the highly subjective nature of FC data analysis requires investigation to 
monitor impact on manufacturing and clinical decision making.  
 
FC standardisation efforts have reduced variation from sample preparation and setup, however, no 
efforts have purely focused on the final post-analytical stage, to quantify the effect of subjective 
analysis of data files. This research has isolated this section of FC analysis, providing better 
measurement precision to build up a realistic uncertainty budget for FC measurements. Through a 
series of participant analysis studies that build in complexity, it has been shown that as FC data 
becomes more complex, the uncertainty contributions from inter-operator data analysis increase 
from 8 % to 34 %. This increase could mean the difference between a CGT treatment being provided 
at the right time, being discarded when it was suitable for administration, or an unsuitable 
treatment administered to the patient at an unsuitable time, having costly implications for all. 
 
This variation does not correlate with operator experience or use frequency of the instrument, but 
is influenced by data visualisation effects, requiring further investigation at a later date to reduce 
this impact. Image parameters for other CGT measurement platforms are also impacted by 
subjective data analysis, requiring harmonisation to ensure the subjectivity is quantifiable, 
standardised and reduces manufacturing and hence medical error impacts to the patient and 
therapeutic product.  
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“The subjectivity of consciousness is an irreducible feature of reality, and it must occupy 
as fundamental a place in any credible world view as matter, energy, space, time and 
numbers”. 
Thomas Nagel, The View from Nowhere, 1986 
 
 
 
“The measure of a man’s real character is what he would do if he knew he would never 
be found out.” 
1st Baron Thomas Macaulay, 1926 
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Prelude: Thesis Context 
Problem Statement 
 
Subjective operator assessment is a common although often silent element of quantitative 
measurements. Flow Cytometry (FC) is a commonly used instrument within biological and 
particulate measurement, which requires manual subjective intervention for quantification and 
interpretation [1]. This platform is heavily used within clinical diagnosis and Cell and Gene Therapy 
(CGT) manufacturing and Quality Control (QC), with various standardisation and harmonisation 
efforts reporting large measurement variance [1,2]. This causes medical confusion, misdiagnosis 
and treatment error [3]. When used within CGT manufacturing, this poorly quantified measurement 
variation may be the difference between life and death. False positives, false negatives, opinions 
and inspector education cause medical error, with experts calling for international consensus for 
repeatability and reproducibility across sites [4]. As well as the impact on the patient, CGTs have 
time-, resource- and money-intensive manufacturing processes, so poor measures have significant 
impacts on product quality and therapy variability within international healthcare systems. 
Context 
 
The CGT market has accelerated over recent years, with the first licensed treatments becoming 
available across international healthcare systems.  CGTs have been heralded as the fourth pillar of 
healthcare, supporting pharmaceuticals, biologics and medical devices. The opportunities for cure 
and treatment of many degenerative diseases such as cancer, diabetes and Parkinson’s disease 
show promise for a new wave of healthcare innovation [5]. Cancer immunotherapy is leading the 
way for CGTs, with recent efforts demonstrating treatment of solid tumours and haematological 
malignancies [6]. Chimeric Antigen Receptor (CAR-T) therapies have provided the first treatments 
for B-cell malignancies, with Kymriah (tisagenlecleucel, Novartis) and Yescarta (axicabtagene 
ciloleucel, Kite Pharma) leading the way for many more regenerative medicine products [7]. 
However, these treatments are not without complications. These live products bring new challenges 
to reproducible manufacture and control, with a distinct lack of traceable reference material to 
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ensure accuracy and precision of measurement, impacting the clinical decision-making process 
[8]. Lack of traceability can make measurement more challenging across decentralised 
manufacturing systems, where the variability across sites also becomes an issues, in comparison 
to centralised manufacture where the CGT is manufactured on one site, removing inter-site 
reproducibility concerns. 
 
The manufacture of CGTs is marking the turn of a new industrial revolution, however, to ensure 
future demand for these treatments needs to be met with 100 % efficacy and right-first-time 
delivery [9]. To ensure effective manufacture of the product, the measurement of the product must 
be to an appropriate level of accuracy and precision, to effectively monitor the product in all stages 
of in-process analysis and product release. This provides greater control of the product and a better 
understanding of the sources of variation. CGTs present a significant challenge to underpinning 
metrology, because there is a lack of traceable reference materials for live, biological products [10]. 
This is not only a difficulty when defining calibrations and higher reference, but also with core 
metrological definitions, such as accuracy and bias, because they require a ‘true value’ to be 
known. A true value is a traceable measurement up to primary SI units, that is not continually 
redefined due to finite reference materials. This is further complicated by measurement issues to 
detect rare cell populations or monitoring residual disease levels throughout the course of 
treatment, as they approach sensitivity limits of instruments. There have been unified efforts for 
volume traceability, with standards still being explored for individual cell counting. 
 
FC is a core measurement platform used within the release and in-process measurement of CGTs, 
but it requires ‘expert’ interpretation of the data files on top of process optimisation [11,12]. Better 
quantification of this interpretation variability is required for greater manufacturing process control. 
This could be achieved using measurement uncertainty principles, required to report for ISO 17025 
and ICH Q7 standards for laboratory accreditation and good competence monitoring and reporting 
[13,14]. 
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Research Focus  
 
This research attempts to quantify the variability contributed specifically from operator subjectivity 
within analysis of FC data. This complements other initiatives that focus on variation of other 
upstream factors such as instrumental setup or fluorescence calibration [15,16]. It provides more 
specificity to the variation contribution from FC gating, not just a measure of the whole process, 
which other gating and analysis studies have previously quantified [1,2]. These studies have 
focused on cytokine assays, whereas this novel research has a CGT focus, assessing inter-operator 
measurement variation across three models of complexity from three cell models that relate to CGT 
products. 
 
Core Hypothesis and Objectives: 
 
As the complexity of the cell models increase in the FC data for participants (as defined by 
increasing protocol sequences and FC dimensions), the between-participant ranges of Coefficient 
of Variation (CV) and measurement uncertainty will increase, indicating greater contributions of 
variation from the participant analysis as shown in Figure 1. 
 
Figure 1 Core thesis hypothesis: as complexity of FC data increases, inter-participant analysis variation also increases. 
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The objectives of this research are as follows: 
 
• Explore the integration of External Quality Assessment Schemes into CGT manufacture, to 
identify benefits already seen within clinical chemistry and clinical Flow Cytometry. 
• Understand how measurement uncertainty works, and how it can be used to quantify 
variability components. 
• Initially investigate how much variation is present between operators when they analyse 
the same univariate data. 
• Identify differences in outlier specifications when different manufacturing performance 
criteria and log transformations are applied, to discuss whether harmonised boundaries 
can be achieved. 
• Design human participant experimental studies to effectively capture measurement 
uncertainty across multiple complexity models, using a Gauge Repeatability & 
Reproducibility structure. 
• Generate standard sets of FC data files to use for each representative complexity model, 
which increase in the number of gating steps to complete, due to increased data 
dimensionality. 
• Quantify measurement uncertainty of participant FC gating across three models, with 
participants gating increasingly complex data as each model progresses. 
• Investigate whether the use of operational procedures as protocols reduce inter-participant 
variability when gating. 
• Compare the inter-participant ranges of variability between the three complexity models, 
defined as either inter- and intra-participant Coefficient of Variation (CV) or measurement 
uncertainty, and discuss the suitability of these measures. 
• Compare human factor variables gathered within survey exercises to variability data from 
the complexity models to understand how experience affects variation of data. 
• Identify other concerns of participants when gating FC data, and interpreting it from 
literature, to identify where future efforts for standardisation of measurement are needed. 
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• Identify other frequently used CGT measurement platform, to determine common 
operator variability and subjectivity within post-analytical phases, and demonstrate 
translational potential of this novel research 
 
Thesis Structure 
 
This thesis is broken into three core stages: a critical review of current work and theory, core 
experimentation to monitor changes in variance between FC participants, and a comparison of 
variances to human factor issues present in FC. 
• Chapter 1 presents a concise literature review of background knowledge and relevant 
research efforts around operator subjectivity and variation measures within FC.  
• Chapter 2 explains the relevant measurement statistics and measurement uncertainty 
principles used for data analysis in this research. 
• Chapter 3 presents an initial investigation of the magnitude of variation within operator 
subjectivity, by monitoring the inter-participant variance when gating univariate histograms. 
It also questions the use of different performance acceptance criteria in relation to outlier 
specification and transformation of data within CGT manufacturing scenarios. 
• Chapter 4 defines a basic data model to initially measure operator variance within FC 
analysis using a 3-step 2-colour FC exercise, gating a pluripotent Embryonal Carcinoma cell 
line population (2102 Ep).  
• Chapter 5 uses an intermediate model with a more complex 5-step, 3-colour FC panel, to 
stratify a naïve T-cell subset from a Peripheral Blood Mononuclear Cell (PBMC) population.  
• Chapter 6 presents the final complex model which uses an 8-step, 8-colour FC panel to 
identify the percentage of transduced engineered T-cells in the population.  
• Chapter 7 compares CV and measurement uncertainty results from Chapters 4 to 6. 
• Chapter 8 extends this comparison against participant questionnaire results, to identify any 
potential human factor correlations to variance measured.  
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• Chapter 9 presents a translational pilot study of the subjectivity issues identified within 
imaging platforms and qPCR, to show post-analytical subjectivity exists across CGT 
measurement platforms. 
• Chapter 10 concludes the thesis, discussing novelty met, and future work identified to 
progress these research efforts. 
Proposed Novelty of Research 
 
• A critical review of current External Quality Assessment Schemes (EQAS), to identify 
opportunities for integration into CGT manufacturing. 
• Relevance of application of manufacturing outlier definitions to define process control 
limits. 
• Application of Gauge Repeatability & Reproducibility techniques to Flow Cytometry post-
analytical variation. 
• Use of measurement uncertainty for Flow Cytometry post-analytical variation. 
• Use of measurement uncertainty for better measurement resolution and control through 
FC measurement which is representative of CGT analytical techniques. 
• Quantification of participant subjectivity as a function of cell model complexity. 
• Increased variability as a function of cell complexity. 
• Development of a new performance monitoring diagram to aid continuous 
improvement of variation. 
• Comparison of measurement variability metrics suitable for precision of FC measurements 
within CGT manufacturing contexts. 
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Chapter 1: Background Knowledge 
 
1.0 Introduction to the Chapter 
Chapter 1 presents a background and critical review of current FC standards and procedures in 
place to monitor participant variability in data analysis. It gives a short overview of the FC technique, 
and then reviews current efforts to standardise post-analytical data analysis and use of 
measurement uncertainty for the technique. Identification of sources of uncertainty within post-
analytical data analysis are reviewed, to align with the core thesis hypothesis of measuring 
participant subjectivity contributions to the final measurement. Error components have already 
been attributed to sample preparation and instrumental setup, which have been investigated 
thoroughly by different working groups and therefore will not be covered within this specific review 
[16–20]. Current regulations for participant variation are also discussed, which currently exist for 
clinical applications of FC, and how this could integrate into a Cell and Gene Therapy (CGT) 
manufacturing context. Automation of FC data analysis is reviewed in comparison to manual gating 
efforts, because many recent efforts have attempted to remove the operator from the analysis, with 
different levels of success. Indeed, the use of automation is a recurring theme throughout this 
research, because of growing interest (but also scepticism) within the industry [20,21].  
 
1.1 A short overview of the Flow Cytometry technique 
 
Flow Cytometry is an analytical process used extensively within different biological fields, and within 
cell therapy it is mostly used for phenotyping [22]. Flow Cytometry is a laser-based technique that 
facilitates identification and analysis of individual cells and populations based upon size, 
granularity and expression of certain fluorochrome-conjugated markers, known to be indicative of 
specific cellular identification or function. Flow Cytometry can be used for a wide variety of 
applications such as assessing cell viability, analyzing DNA, cell death, pH and cellular membrane 
microparticles, cell surface or intracellular antigens and markers, chromosomes and specific 
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proteins [23,24]. However, a lack of traceability and reference materials within In Vitro Diagnostic 
(IVD) Medical Devices such as Flow Cytometers makes it much more difficult to provide confidence 
to results obtained [25]. If the measurement is ultimately incorrect (through a combination of added 
uncertainties and misinterpretations) then it becomes more challenging to define true 
representative values. Within a clinical context this can have severe knock-on effects, because if 
the metrology is wrong, the quantification and therefore diagnosis may be incorrect, which could 
be dangerous for a patient undergoing treatment [25,26]. This is also the case for CGT 
manufacturing, where Flow Cytometry is used as a core measurement technique at various 
manufacturing process steps, cell sorting and final therapy product release [27]. 
 
Analytical cytology dates back to the 1950s (and even earlier through the use of 
microspectrophotometers) [28] and as technology advanced through the decades, more advanced 
apparatus and data analysis software became available due to evolution of modern computer 
processing methods [28]. Modern Flow Cytometers are often combined with Fluorescence-
Activated Cell Sorting (FACS) techniques, however, for the purpose of this review the main focus 
will be on Flow Cytometry without cell sorting, because this reduces the amount of variability in the 
result due to simplified processes. 
 
 
1.1.1 Flow Cytometry Instrumentation 
 
FC relies upon a laminar flow cell aligning cells through a laser pathway, depicted in Figure 2. Cell 
size is detected by forward scatter (FSC) of the beam, and granularity and fluorescence emission 
spectra of the cell-specific markers are detected by side scattered light (SSC), split through various 
optical filters [29]. This data can be used to generate a flow cytometry standard (fcs) file and plots 
of target populations, ready for identification and stratification by an operator [30]. Typically, a 
minimum of 30,000 cell events would be run through the Flow Cytometer, to ensure a valid data 
set was captured to conduct further analysis on. 
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Figure 2 Flow Cytometer schematic 
 
 
1.1.2 Flow Cytometry post-analytical data analysis 
 
An example of fcs file data is shown in Figure 3, where each cell that is processed through the Flow 
Cytometer is shown as a single dot on each of the sequential plots, which build up to high (red) and 
low (blue) density regions indicative of cell populations. The location of the dot (or cell event) is 
determined by the respective fluorescence emission detected through each channel sensor [29]. 
The fluorescence intensity is plotted as a histogram (for univariate data), or a scatter plot of data 
can be created with two or more optical channels used for measurement, such as those seen in 
Figure 3. To distinguish a specific target population from the total sample, filtering or threshold 
gates are then applied manually by an operatpr (different shaped areas defined by boxes, ellipses, 
quadrants or polygons, working left to right in Figure) to further stratify the population. By stratifying 
the data, ‘noise’ created by debris and non-specific binding (for example) is removed, allowing 
relevant spectra to be analysed [31].  
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The emission spectra are excited by laser interaction with specific fluorophores conjugated to 
antibody markers which bind to extra-cellular or intracellular markers on the cell [29,32]. Other 
stains can be excited by laser interaction but are not bound to antigen markers on the cell surface, 
for example a variety of methods to stain cell debris or nuclei can be used to discriminate dead 
cells from the live population. Antibody markers are chosen based on the cell type in question and 
what specific sub-populations are being targeted. If these markers fluoresce, it indicates the 
marker has bound to the cell, so the target cell population can be identified because of higher or 
lower fluorescence intensity regions of the plots [29].  
 
 
Figure 3 Example of Flow Cytometry gating within post-analytical Flow Cytometry 
 
1.1.3 Flow Cytometry post-analytical controls 
 
Control files can be created for each fluorescent marker, to help separate positive expressing 
populations from dim or negative expressing cells [33]. These controls are commonly referred to 
as Fluorescence Minus One (FMO) controls, because they contain a mix of all the markers being 
tested in a Flow Cytometry panel, except the respective marker for the optical channel in question. 
This gives a good indication of fluorescence spillover from markers in the panel when combined to 
the specific cell type in question, to set a threshold between positive and negative expression [34]. 
Examples of these controls are shown in Figure 4, with the fully stained sample shown with the final 
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gate applied in (a), and the FMO control files for each respective channel plotted on the axes shown 
in (b) and (c), demonstrating how the positive thresholds for the x and y axes are set.  However, 
FMO controls cannot account for any background staining from the antibody used within that 
channel during analysis which could skew results, and is why isotype controls have been popular 
for many years [34]. Isotypes account for nonspecific staining of an antibody of a particular isotype 
conjugated to the required fluorochrome, because different isotypes can have different levels of 
background staining within the channel [32,33]. However, because these do not account for any 
other markers used within the Flow Cytometry panel, they are not preferred if they exhibit a lower 
amount of background staining than spillover from other markers within the panel [34]. 
 
Figure 4 Example of how FMO gates are applied, a) Fully stained sample with gates applied from FMO controls, b) FMO 
control for the marker on the horizontal x axis, c) FMO control for the marker on the vertical y axis. 
 
Placement of gates is aided by the various controls available to operators, but the decision of where 
the final gates are placed is mainly subjective, relying on the operator’s perception of density, 
influenced by plot presentation, graphics, understanding of the cell type, use of controls and many 
other factors. This research aims to address and measure this subjectivity issue, to quantify the 
variability contributed from an operator’s analysis of data. It is recognised that there are many other 
potential sources of variation in a FC measurement, but these are out of scope of this thesis and 
have been controlled within the experimentation in Chapters 3 to 6. 
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1.1.4 Flow Cytometry automated analysis 
 
Many recent efforts to automate FC data analysis have shown the ability of machine learning 
algorithms to identify common cellular subsets, processing more data in less time than a manual 
operator [21]. This potential capability of processing large batches of highly-dimensional data still 
requires start and end manual screening processes, to ensure the algorithms can run effectively 
[35]. Downsampling (decimation) of data is required to reduce the computational time (by reducing 
the number of events processed) [36]. A percentage of the original data points are taken as a 
representative sample of the whole file population, if datasets exceed 20,000 events. t-Stochastic 
Neighbour Embedding (t-SNE) is a popular analysis algorithm, which ‘plugs in’ to various software 
platforms and will be used as an example here, plugged into Flowjo Version 10.0.8r1, because this 
platform has been used for subsequent FC studies [37,38]. 
 
There are different variables that still need to be defined by the user for clustering purposes; 
specifically, ‘Perplexity’, number of algorithm iterations and Eta. Perplexity essentially defines the 
distance between clusters using a sliding scale from 2 to 100. This requires optimisation to best 
represent the balance between local and global cluster populations using ‘nearest neighbours’ 
clustering. Algorithm iterations can be set between 300 to 3,000 iterations (the number of times 
the computation is applied), where higher iterations cause greater separations of final clusters. Eta 
(the learning rate of the algorithm) controls how much of the ‘nearest neighbours’ weightings are 
adjusted to obtain a minimum probability difference between data points [39]. Finally, when t-SNE 
has clustered the data, the user still has to manually gate to choose populations, which are 
unlabelled, increasing difficulty of validating subsets [39]. An example of different variable choices 
have been shown in Figure 5, to exemplify how different variable scales affect the shape of the t-
SNE output, which still require gating. The data input was EC 2102 Ep cell line data, stained with 2 
pluripotency markers, which are used in the basic uncertainty model in Chapter 4. 
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Figure 5 t-SNE iterations of a single FC data file, analysed with different variation limits, for 1,000 algorithm iterations. 
The grey cell indicates commonly used variables. 
 
The algorithm repeatability has been explored to identify effects of t-SNE variables on simple 
clusters [39], concluding that multiple runs will produce the sample global shape, but certain data 
sets produced different cluster shapes on repeats, and there are no fixed number of repeats to 
validate settings. In addition, the t-SNE cluster size does not necessarily represent the actual size 
of the cell population, due to adaptation of the algorithm to create even cluster sizes to identify any 
smaller or rare subsets [39]. 
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When considering the application of machine learning algorithms for cellular analysis within a 
Quality Control or Manufacturing scenario, the inverse relationship between quality/uncertainty 
and time needs to be addressed. Whilst t-SNE is a computationally powerful tool which enables 
users to analyse multiple samples made up of high dimensionality data, it still requires users to 
manually clean up the data and select the appropriate clusters within the analysis, exhibiting the 
same variation issues found within traditional manual gating, as well as inherent variation from the 
machine learning algorithm itself. Use of such a tool would require a high level of validation and 
optimisation, which could cost manufacturers in time and therefore money when quantifying 
uncertainty in the system, when pre-determined operator metrics may already be established over 
time. 
 
1.1.5 Flow Cytometry uses within Cell and Gene Therapy manufacturing 
 
Quality Control (QC) measurements are required for all stages of CGT manufacture, not just the 
final product release for patient infusion. The versatility of FC means it is heavily utilised for CGT 
product measurements at various points during the manufacture of a therapy for different factors. 
For example, a recent review highlights common considerations for CAR-T product release tests, 
due to their accelerating prominence within the CGT market [8]. The manufacturing process of an 
autologous CAR-T cell therapy follows the process in Figure 6, with sample measurements taken at 
defined QC points [40].  
 
Phenotyping will be specific to the therapy being manufactured, however, it will always be 
conducted at the start of sample preparation to initially measure the donor material and achieve 
an idea of biological starting variation, which can range considerably [12]. Along with cell counts, 
this gives manufacturers an indication of expansion times for the product, or whether more starting 
material needs to be taken from the patient.  
 
  Chapter 1: Background knowledge 
15 
 
 
Figure 6 Flow Cytometry assays used within CAR-T manufacturing 
 
When selecting T-cells, FACS is a Flow cytometry-based method used to sort a cell sample for CD3+ 
Lymphocytes if this configuration is available, although a common method for separation uses 
Dynabeads, because they are also used to activate the cells, to simplify processing stages. They 
have also been shown to have strongly correlated cell counts with Flow Cytometry, making them a 
comparable but cheaper alternative [41]. During expansion of the product, phenotyping will be 
conducted at regular intervals to monitor phenotypic changes to the CGT product. In addition to 
this, transduction efficiency is an important measure of viable cells expressing the CAR+ to 
measure transduction efficiency of the viral vector.  
 
Once these checks are complete, the final therapy product will be formulated for administration to 
the patient. Final product release criteria has been reviewed in [8], with Flow Cytometry being used 
to identify the purity of the product, by counting the % T-cells and the % CAR+ cells, with this latter 
measure also being used to define the identity of the product. This composition needs to be 
quantified in order to deliver the correct dose to the patient, based upon their bodyweight. For 
example, to treat B-cell Acute Lymphoblastic Leukaemia (ALL) in paediatric patients < 50 kg, a dose 
of 1 to 3 bags containing 0.2 x 106 to 5 x 106 CAR+ viable T-cells/kg of body weight are required, 
and for those > 50 kg, this dosage increases to 1 to 3 bags of 0.1 x 108 to 2.5 x 108 cells/kg 
bodyweight [42]. This indicates the needs for repeatable, standardised measurements to ensure 
the therapy can be delivered effectively to the patient, having been optimised throughout 
manufacture.  
  Chapter 1: Background knowledge 
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1.2 Standardisation of Flow Cytometry Practice 
 
1.2.1 Summary of efforts across FC measurement 
 
Many efforts have been and are currently being made to standardise Flow Cytometry as a 
measurement technique, to make results more comparable between instruments and sites, with a 
variety of commercially available standards being sold to users [16,43–45]. Examples of these are 
SPHERO™ Rainbow beads used for cross-platform calibration of fluorescence [46], and NIBSC 
reference materials [47] for flow cytometry cell counting. A lot of emphasis has been placed on 
fluorescence standardisation [16] and instrument standardisation protocols [17], however, 
standardisation and traceability of these elements does not guard against downstream variation of 
manual data analysis and reproducibility concerns. 
 
1.2.2 Acceptable variability of post-analytical FC data 
 
Once the biological sample has been processed, the data is exported and stored in fcs file format, 
to allow processing across different software platforms with no data manipulation. The file standard 
provides uniform storage of data, for fair processing and reporting [30]. Software used for analysis 
need to comply with Part 11 of the Food and Drug Administration (FDA) Code of Federal Regulations 
(CFR), to ensure correct storage of electronic records for cell product traceability [48]. If publicly 
reporting Flow Cytometry experiments, the Minimum Information about a FC experiment 
(MIFlowCyt) guidelines should be followed for good reproducibility of data [49,50]. The minimum 
information project, also has guidelines to support further assay development and reporting, 
specific to T-cell and NK-cell experiments [51]. Within FC, there have been significant efforts to 
harmonise panels for experimental design, reporting and analysis to optimise experiments within 
the community [52], as well as harmonisation between instruments [53,54]. 
 
It has been recently reported that there is a large reproducibility crisis across science [55,56], and 
this exemplifies similar concerns for the development, manufacture and control of Cell and Gene 
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Therapy production [40,57–61], as well as standard Flow Cytometry experiments [20,62]. 
Reproducibility of measurements and products require traceable measurements and processes, 
and these must be validated and shown as part of regulatory Market Authorisation for CGT products 
[4,63,64]. Without reproducibility, there is less confidence in the measurement process, 
manufacturing decisions and more concern when releasing the product for the patient treatment 
[65]. Different metrics are commonly used to monitor variability, but may require more resolution 
to improve traceability, repeatability, reproducibility and therefore confidence and quality. 
 
Repeatability of FC measurements are commonly reported as precision (standard deviation (SD) of 
repeats) or CV (%). CV is a combination of the mean and standard deviation of repeats and is often 
easier to monitor variability [29]), and these variation metrics are fully defined in Chapter 2, Section 
2.2.2. Different studies have monitored CV contributed from different FC measurement 
components, to potentially provide guidance on experimental variability throughout the 
development of FC [66–68], and discussed the implications of validating FC in a regulated 
environment [62]. Different levels of acceptable variance have been defined across Flow Cytometry 
literature, with different metrics and resolution to address and reduce it over time. The International 
Council for Standardization of Haematology (ICSH) and the International Clinical Cytometry Society 
(ICCS) published a 5-part series summarising FC variability issues through the entire FC process 
[45,69–71]. Part V provides guidance on acceptable limits for CV, where < 10 % CV is suitable for 
measurements, or < 20 % CV where rare cell events are concerned [71].  
 
Percent CV is preferred to SD as acceptance criteria by the ICCS, because it normalizes variations 
at lower levels of event detection. This imprecision metric should be taken from a minimum of five 
samples assayed in triplicate (at least) during the same analytical cycle. It has been noted that 
although the data is impacted by a subjective analysis, the technical assay performance is 
reproducible [71]. This gives better clinical assurity of assays requested, and it is easier for 
pathologists and clinicians to make decisions for the patient with more confidence in the 
measurement process. These references ranges would have been defined by clinical cases for 
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normal and specific disease states (typically 60 males and 60 females included in range analysis) 
to ensure clinical comparability for specific test results. Disease states are inherently more 
challenging to generate ranges for, however, patient cohorts in need of routine checks may be more 
readily available for tests, which could aid this data generation [71]. 
 
CV has been considered to quantify measurement uncertainty within the UK National Health 
Service (NHS), for example providing Key Performance Indicators (KPIs) of Feto-Maternal 
Haemorrhage (FMH) monitoring with Flow Cytometry. Measurement uncertainty is usually a 
combination of SDs, but in this instance the NHS have used CV, with KPIs of < 15 % for good 
uncertainty, 15 % to 20 % for satisfactory and > 20 % as unacceptable [72]. A recent international 
research review of Flow Cytometry CD4+ count measurements indicates that BD FACSCount beads 
used as reference standards show an inter- and intra-laboratory precision of <15 % [73]. A 
breakdown of uncertainty variation sources within phenotypic measurement gives further 
identification of contributing amounts of variation of the measurement [74].  
 
Poor reporting and control of FC results leads to false positive and false negative results of samples, 
facilitating poor decision making of diagnoses and treatments, seen in many other laboratory 
measurements. A recent review has identified many pre- and post-analytical errors in laboratory 
haematology [3], specifically in automated cell counting. Haematology laboratory errors can 
contribute as much as 62 % and 23 % of measurement variability from these pre- and post-
analytical errors respectively, which has not changed over 10 years [75]. If not caught, these issues 
cause incorrect or missed opportunity for diagnosis, but if they are caught before the result is 
issued, it causes delays in diagnosis which increase patient anxiety and it is a missed opportunity 
for diagnosis if a specimen cannot be retaken or accessed [76]. Diagnostic error is difficult to 
accurately estimate, but approximately 12 million USA citizens having suffered a diagnostic error, 
half of which were significant, and can impact patient safety [77].  
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Standardisation of measurement positivity thresholds is required across many platforms, 
exemplified by anaemia reporting across international bodies. The World Health Organisation 
(WHO) define lower limits of haemoglobin (Hb) concentration at 130 g/L in adult males, compared 
to the Centre for Disease Control (CDC) lower limit of 135 g/L [3]. Although the difference is small, 
it has a significant impact on referrals or missed treatments. Different External Quality Assessment 
Schemes (EQAS) have different performance criteria for CD4+ counts returned from participating 
laboratories, which can have a significant impact in patient safety, as discussed in the next section. 
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1.3 External Quality Assessment for reproducibility 
 
1.3.1 Relevant standards for analytical competency 
 
Both ISO 17025 and ICH Harmonised Tripartite Guideline Good Manufacturing Practice Guide for 
Active Pharmaceutical Ingredients Q7 have grounds for personnel hired to work in the test 
environment [13,14], stating that personnel hired should have adequate qualifications for the role, 
and training should be provided regularly for operations performed by the employee. ISO 17025 
provides more depth with regards to processes that require interpretation (such as Flow Cytometry), 
stating they should be performed by operators who are familiar with the technology, how it is used 
and possible defects that can occur, but there is no stated requirement to formally measure 
operator variability, which can impact results [13].  
 
ISO 17025 is a standard which manufacturing and test laboratories ideally need to achieve 
accreditation with, providing patients, clinicians, healthcare trusts and companies with confidence 
that procedures are in place to deal with deviations and the site can monitor and control the 
product effectively. Uncertainty plays a part in this analysis, with ISO 17025 stating that all 
equipment used requires an uncertainty estimation (ISO 17025 Section 5.4) and any opinions or 
interpretations around measures need to be stated in test reports, under the basis in which they 
have been made (ISO 17025 Section 5.10.5). Flow Cytometry is a process that requires 
interpretation to generate a result/diagnosis, so this must be factored into release criteria, and is 
the subject of this research. Measurement uncertainty is explained in greater detail in Chapter 2. 
 
Flow Cytometry operators can also obtain Cytometry Accreditation (Specialist in Cytometry, SCYM) 
[78], to ensure knowledge of data analysis such as understanding gating tools, statistical methods 
and assay validation methods, as well as standards and controls. Clinical Flow Cytometrists require 
experience and accreditation to correctly identify a variety of diseases and disease states from a 
sample. The manufacturing and QC scenario differ, because product conformance is required. 
Therefore, the FC will not necessarily be diagnostic, it will be used to assess a specification.  
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As the cell therapy manufacturing environment may not be clinical, FC operator certification 
requirements need to be scoped as well as potential participation in an External Quality 
Assessment Scheme (EQAS). This may be an established EQAS or an EQAS with different guidance. 
Comparability can therefore be assessed at different levels, but there may be inherent differences 
between sites and companies with regards to output results. 
 
1.3.2 External Quality Assessment and accreditation 
 
EQAS are used to verify correct implementation of protocols and measurements of particular 
targets across multiple centres, and are also known as External Quality Control, Interlaboratory 
Comparison Surveys or Proficiency Testing [79]. Proficiency testing exists to provide greater 
metrological traceability of measurements to primary SI units, to ensure that calibrators and 
instrumentation are not negatively affected by poor use [80]. 
 
EQAS addresses standardisation of practice in which measurement equipment is used (once a 
problem is identified), as well as commutability of the standardised measurand to enable 
comparison of these factors [25]. Clinically, centres that analyse patient material need to have 
validation through an EQAS, which are further traceable to ISO 17043 for conformity assessment 
[81]. This helps centres achieve ISO 15189 accreditation for quality and competence of medical 
laboratories [82], replacing Clinical Pathology Accreditation (CPA) in the NHS. In Vitro Diagnostic 
(IVD) medical devices, such as FC are also required to show metrological traceability of biological 
quantification to obtain CE marking [83]. This ISO 17511 compliance must conform to one of the 
defined traceability chains depending on the availability of different primary and secondary 
calibrators and procedures, illustrated in Figure 7. 
 
CGT manufacturing centres would not necessarily need ISO 15189 accreditation, because they are 
not performing clinical pathology, although this is something that may translate from the clinical 
environment, due to different manufacturing scales. However the site, processes and QC would 
need to be Good Manufacturing Practice (GMP) compliant when manufacturing a licensed product, 
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and would need to follow guidelines set out in ICH Q7 [14] and gain ISO 17025 accreditation for 
competence of testing and calibration laboratories [13]. 
 
As previously stated, QC operators would need accreditation to ensure they remain GMP compliant, 
however, this calls into question how much further up the product development pipeline this level 
of competency and reporting is required. To design in quality to the product, all compliance should 
be adhered to from the start of product and process development stages, to ensure good 
translation further down the pipeline and to better maintain integrity and compliance. However, 
Process Development Scientists involved in later studies in this thesis (Chapter 8: Questionnaire 
results) have highlighted that this level of accreditation is not known or understood well. A lot of 
validation would be completed before handing over processes to further operations, however, this 
does not account for personnel accreditation.  
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Figure 7 Traceability chains of ISO 17511 calibrators 
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Traceability of EQAS as part of the diagnostic measurement process has been more thoroughly 
investigated for clinical biochemistry. In recent years, this has qualified particular analytes and 
proteins [25,26,79,80], with the quantification of measurement uncertainty (required by ISO 
15189 accreditation [82]) provided to indicate variability contributions to the measurements [84]. 
Many traceable calibrators have enabled these small uncertainties to be specifically defined, giving 
more measurement integrity and confidence to the analytical decisions [80]. These are 
underpinned by international metrology efforts to continually improve traceability of laboratory 
medicine, by the Joint Committee for Traceability in Laboratory Medicine (JCTLM) [85]. 
 
1.3.3 Flow Cytometry EQAS for CD4+ measurement 
 
Currently there are many immune-related diseases that are looking to be addressed through a 
variety of different CGT treatments. From HIV treatment to various blood cancers, reliance on 
reproducible CD4+ T-Cell counts is necessary and will be used as an exemplar for EQAS here, 
because of CD4+ analysis undertaken within T-cell therapy measurement [86,87].  
 
To establish comparability of T-cell measurements various External Quality Assessment Schemes 
(EQAS), have been in existence globally since the late 1980’s [88]. These initially looked at cell 
quantification across dual platforms using various haematological analysers, but it was quickly 
concluded that a single platform measurement was desirable to reduce variability in CD4+ T-cell 
counting, with FC the preferred technique for quantification [89]. This correlates with the increase 
of HIV cases in 1980’s, demanding higher throughput of blood samples and therefore treatment of 
patients. It has also been shown through various other studies that using a single platform of 
instrumentation reduces variation and error in measurement and diagnoses [54,90,91].  
 
Various CD4+ FC EQAS are in clinical operation around the globe, with the most notable bodies and 
advancements in standards and teaching coming from the United Kingdom, central Europe and 
Canada, with output summarised in Table 1. These have developed over the last 20 to 30 years 
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with increasing laboratory participation and increased frequency correlating with a reduction in 
variation in participants [92]. Significant developments were made in EQAS in the 1990’s and at 
the turn of the millennium. The most significant scheme developed is UK NEQAS (with international 
outreach) [93], which offers a variety of FC EQAS accredited by the United Kingdom Accreditation 
Service (UKAS) that relate to different Clinical assays required for haematology [92]. These include 
CD34+ Stem Cell Enumeration, Immune Monitoring, Leukaemia Immunophenotyping and 
Diagnostic Interpretation and Low Level Leucocyte Enumeration amongst other schemes for 
specific disease states [93].  
 
Table 1 Summary of CD4+ EQAS 
EQAS Variability metric Acceptance limit Literature 
UK NEQAS CV 
Reduction in Absolute 
residuals 
Trimmed mean ± 2SD [91,92,94–98] 
SIHON Score Point system: majors 
and minors 
Discordant % positive 
Within personalised 
boundaries for 
acceptable errors 
[88,99] 
 
 
Benelux EQA Residuals Robust multivariate 
regression 
[100] 
Central European 
Quality Control Program 
(CEQUAL) 
CV Mean ± 2SD [101] 
Gruppo Italiano di 
Citometria (GIC) 
Resolution Index 95 % Confidence 
Intervals 
[102] 
Canadian QASI-QMS Absolute deviation from 
Inter-laboratory mean 
Linear regression [103,104] 
Thailand and South 
East Asia CD4+ EQA 
program 
Mean, Standard 
Deviation Index (SDI), 
CV 
CV< 15 %, 
-2 < SDI < 2, 95 % CI for 
PanLeucogating 
methods 
[105,106] 
EuroFlow Consortium Personalised score 
using Medium 
Fluorescent Intensity 
and CV 
95th Percentile [15,17,18,18,107] 
AFREQUAS Regional 
African EQAS 
CV Trimmed mean ± 2SD [108] 
 
Despite the excellent efforts made by various EQAS to harmonise measurement and procedures, 
the CD4+ monitoring schemes indicate how there can still be inconsistency, because although the 
different EQAS can monitor the same cell counts, their acceptance criteria differ. Some of these 
acceptance criteria differences were summarised by a review in which another way of defining 
acceptance (through linear regression) was suggested [109]. When this variance in processing is 
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extrapolated to cover the number of different types of EQAS scheme for just Flow Cytometry, the 
state of affairs becomes more confusing to navigate for EQAS participants. Furthermore, pathology 
centres often take part in more than one EQAS, where different scoring metrics and variation 
metrics are used, increasing confusion between reporting criteria. The statistical standard that 
governs EQAS procedures, ISO 13528, actually provides several different ways that variance can 
be quantified and monitored [110], as well as other monitoring factors, shown in Figure 8. It 
provides options for defining the reference value (a), performance criteria (b), calculation of 
performance criteria (c) and different graphics for reporting (d). 
 
To initially consider how this could translate into CGT manufacturing, a change in performance 
statistics is required to align with ISO 15189 and ISO 17025 documentation. Currently most clinical 
CD4+ EQAS calculate performance as an estimation of deviation, albeit using a variety of metrics 
such as CV, residuals and self-defined statistics. To gain accreditation, laboratories also need to 
measure uncertainty, so inclusion of this in an EQAS not only provides better resolution of inter-
laboratory processing to improve the community, it also allows participants to use those values as 
part of required uncertainty calculations. This provides more confidence in the measurement, and 
allows internal continuous improvement, to highlight the variation of operators in comparison to 
other instrumental and process components. 
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Figure 8 ISO 13528 options for EQAS providers, a) Determination of the initial reference value, b) Performance criteria, 
c) Calculation of performance statistics, d) Graphical methods to report results 
 
Currently CD4+ EQAS allow participants to report back results for the respective schemes (absolute 
cell count, and the percentage of this population with respect to the original count in the sample). 
UK NEQAS have a patented blood stabilisation method used for reference wet sample send-out for 
analysis, qualified to ensure an assigned value and variance of this reference sample are known 
for comparison [111]. This provides a quantitative comparison of the reported laboratory results 
against the reference value, to quickly identify non-conformance. When non-conformance is 
identified, EQA providers can help respective centres find the root cause, however, because only 
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the final results are reported, this can be a long effort due to the many sources of contributing 
variation.  
 
The EuroFlow Consortium took a different perspective for identification of haematological 
malignancies, by providing participants with detailed instructions to setup  equipment and perform 
compensations [17], as well as providing lyophilised antibody tubes, to standardise the reagents 
used for defined panel markers [18]. EuroFlow is not an EQAS, however, has been used as a 
complementary tool to highlight variation in other areas of the FC measurement. By standardising 
upstream reagents and protocols, it aimed to identify the variation in the system if local blood 
donations were used (instead of standardised samples) for inter-laboratory comparison, to highlight 
that standardisation of upstream elements could be achieved. 
 
It also noted how complex panels are very subjective, which can cause more variability in the 
downstream measurement [17,107], although new software efforts as part of the EuroFlow 
consortium aimed to standardise reporting for ‘normal’ cellular subsets in CD4+ and CD34+ FC 
panels. Both UK NEQAS and Euroflow schemes make assumptions about participants’ cell 
identification abilities, where UK NEQAS assume if a participant can correctly classify the QA 
sample, they could also classify a leukaemia sample. Euroflow assumes if a participant can execute 
the Standard Operating Procedure (SOP) correctly and accurately assess lineage markers on 
normal cells, the laboratory could also assess these markers accurately on malignant cells [107]. 
 
Although UK NEQAS is based on final metrics rather than further controlling upstream variables, 
they have conducted studies to identify variation against standard analysis processes for FC data, 
in particular the ISHAGE protocol for CD34+ stem cell enumeration [112]. This protocol was 
established in 1996 by the International Society of Hematotherapy and Graft Engineering (ISHAGE) 
because lack of standardisation had led to divergent reporting of CD34+ stem cells in peripheral 
blood, which are considered to be extremely rare (0.01 % to 0.1 %). This standard recommended 
antibodies, gating strategies, cell separation and lysis techniques to use as well as reporting 
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mathematics [113]. The 2012 review sent out two stabilised samples to 255 clinical participants 
and asked them to analyse and report the required CD34+ data. 196 laboratories returned results, 
and 103 of these also returned dot plots for EQAS clarification. 83 of these participants claimed to 
use the ISHAGE protocol, but after further investigation only 57 % of these gating strategies were 
correctly setup. It was further shown that those using this protocol incorrectly on a single platform 
were twice as likely to fail EQA exercises, and those also using it in a dual platform scenario had a 
further two-fold increase in failure rate [112]. This indicates that even when standard samples, 
recommended panels and gating strategies are used, they can still be interpreted or used 
incorrectly, as well as being influenced by the measurement platform available. EQA always aims 
for 5 % of returns to be out of consensus, to ensure continuous improvement over time, however 
in this instance there were 13 % out of acceptance when following the protocol correctly, despite 
the further 41% of all used applying the strategy incorrectly [112]. 
 
1.4 Variability in Flow Cytometry Gating Studies 
 
 
It has been noted through various EQAS publications documented that variation exists throughout 
the Flow Cytometry measurement process, with various efforts to standardise these elements for 
greater measurement precision. These efforts have isolated reagents, instrumental processes and 
between-instrument variation to understand contributions to measurement deviation. Little focus 
has been given on the post-analytical gating process within FC, despite being known to contribute 
a lot of subjectivity to final reported results [21]. 
 
The greatest efforts to measure subjectivity from gating have been through standardised cytokine 
FC assays, which monitored Intracellular Cytokine Staining (ICS) across cryopreserved Peripheral 
Blood Mononuclear Cells (PBMCs) and shipped whole blood material [114,115]. Inter-laboratory 
variability was reported as 28 % CV for cryopreserved PBMC material, which reduced to 23 % when 
data was analysed centrally rather than by the respective laboratories [115]. This reduction has 
also been reflected in standardisation efforts by the Human ImmunoPhenotyping Consortium [20]. 
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Two gating strategies were tested within the Cancer Immunoguiding Program (CIP) for detecting 
and enumerating HLA-multimer binding cells, with group CVs reported as 53 % and 87 % for each 
strategy respectively, as well as noting that participant variability increased with low frequency T-
cells (< 0.1 %) [2]. All of these studies do not completely isolate the gating process, because the 
process of staining and running the sample still had to be completed by participants, even though 
correct reagents and procedures were provided, similar to EuroFlow efforts, which returned an 
inter-laboratory CV below 30 % for Median Fluorescence Intensity (MedFI) of markers analysed 
[107]. 
 
In an attempt to standardise Minimal Residual Disease (MRD) Flow Cytometry assays for Chronic 
Lymphocytic Leukaemia (CLL), electronic data files were analysed by multiple experienced Flow 
Cytometry operators, to remove any upstream variation built into the fcs file and respective 
measurements [116]. 141 MRD files were generated with 40 files containing normal cells, 69 files 
containing 0.01 % to 0.1 % CLL cells and 32 files containing 0.0001 % to 0.01 % CLL cells, to 
represent MRD analysis scenarios and identify false-positive reporting scenarios. A pilot study with 
26 files showed only 11 equivalent results returned, and then when given a more detailed operating 
procedure to re-analyse the files, equivalence increased to 23 cases. The use of a procedure to 
apply gates gave a 19 % improvement in accuracy, and a 44 % improvement in specificity, 
suggesting adoption of a physical protocol could reduce false positive rates in FC analysis [116]. 
 
This study catalysed efforts for standardised FC data analysis, through the use of automated 
machine learning platforms to remove the subjectivity and inter-laboratory variation element [117]. 
Numerous studies and consortia have evaluated different computational methods for FC data 
analysis, to identify lower variance with the same target-cell identification ability as a human 
operator [20,21,118–120]. However, whilst these methods are able to replicate operator gating 
for well-established cellular subsets, results are not ideal for subsets that are rare or difficult to 
separate, often requiring manual intervention for training or final analysis stratification [121], as 
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well as increasing chances of reported false positives for smaller populations, close to a cut-off 
limit. 
 
Whilst automated platforms serve a clear purpose for FC data analysis as data moves to more 
complex, highly dimensional assays, there are still some usability issues that require refinement in 
order for these tools to become accessible and to be used correctly. Currently three core challenges 
need to be addressed for more successful adoption [122]. Firstly, few immunologists are aware of 
these tools because outreach of literature does not exceed bioinformatics or computational biology 
journals. 
 
This is also the case for standardisation effort of FC experiments (MIFlowCyt) not leaving FC’s inner 
circle and being presented in more cell-specific journals [50]. Secondly, although automation 
platforms are open source through a variety of platforms, these computation and software methods 
are not necessarily user friendly, and not easy to learn alongside full-time immunology roles. Third 
and finally, a lack of understanding of how the tools work can lead to scepticism or overconfidence 
in the methods, which can cause culture change issues, an oversight of quality control and issues 
with validation [122]. This issue will also be explored within the survey in Chapter 8.  
 
Efforts to tackle the user interface challenge have been made by algorithms such as FLOCK, 
allowing participants to upload and test their own data on the platform, although this still requires 
an open mind set for trial and adoption [122]. Other software platforms such as Flowjo have 
algorithm plugins such as t-SNE, to allow participants to trial algorithms in a familiar environment 
[123]. Automated algorithms are still at the mercy of users, with improved analysis of data 
dependent on suitable data pre-processing, to clean the data and remove noise, reduce 
dimensionality to reduce computational time and sample back to the original cell count number 
[124]. 
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A comparison study between individual participant gating, central gating and three automated 
platforms, listed different ways the data had to be ‘pregated’ or ‘postgated’ to ensure the data was 
appropriate for automated analysis or the correct cluster identification, therefore requiring manual 
intervention and subjectivity [1]. The data analysed here were Major Histocompatibility Complex 
(MHC) Dextramer ™ staining of T-cells recognising two different virus-derived epitopes (Epstein-Barr 
Virus and Influenza) in PBMCs from healthy donors. These are also markers analysed for 
engineered T-cell receptor (TCR) therapeutic products, providing significant affinity to this research 
within the CGT manufacturing industry. The highest CVs from gating individually and centrally were 
122 % and 86 % respectively for one of the influenza epitopes, with the remaining CVs for other 
virus strains < 30 % CV. Again, analysis of the files was not isolated, with participants conducting 
staining and analysis of the files according to their own procedures and reagents available, 
contributing to downstream variation [1].  
 
1.5 Variation impacts on CGT manufacturing and adoption of 
measurement uncertainty  
 
 
Variation and advancement of measurement platforms has been identified as a core issue 
requiring attention for the development of CGTs [59,63], to ensure the successful validation of 
therapies requiring authorisation. This will only become more challenging when greater demand 
and throughput require more inline integration of measurement processes, to reduce the need for 
sampling. This creates a greater need for big data analytics, to ensure analysis can be completed 
quickly and reliably, as the panels for FC grow. Advances in measurement capability and resolution 
provide further understanding of the product, increasing measurement precision and control of the 
manufactured product [8,125]. Whilst FC analysis algorithms still require refinement for low level 
detection, they are a step in the right direction for integration into FC measurement against a pre-
defined manufacturing specification. Comparison to the manual gating is still required for validation 
and more precise quantification of allowable variation, which this research addresses.  
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Whilst many publications address FC gating’s significant contributions to overall measurement 
variance, this phase has not been fully isolated to purely quantify the user subjectivity within the 
post-analytical phase, which is investigated through experimentation in Chapters 3 to 6 of this 
thesis. A focus on purely subjective analysis of pre-prepared fcs files is being adapted by UK NEQAS 
for the Leucocyte Immunophenotying Scheme (Personal Communication with UK NEQAS) for 
clinical participants, as well as a monitoring scheme for image analysis of blood film morphology 
for participant Continued Professional Development (CPD) [126]. 
 
Future training of the required workforce has been identified as a big risk and challenge for the 
adoption of CGT manufacturing in the UK [127]. Operator application and position within CGT 
manufacture requires comparable consistency across multiple manufacturing sites, as well as 
within each centre, laboratory and team [9]. This presents an opportunity for proficiency testing 
schemes to enable continued training and development of staff across all CGT manufacturing sites, 
empowering operators to maintain good practice.  
 
This is a timely issue for accreditation to ISO 15189 and ISO 17025, to ensure suitable levels of 
competency, as well as an opportunity to integrate education of measurement uncertainty. This not 
only satisfies the accreditation criteria for equipment, it provides greater resolution, precision and 
control of the measurement process, for training and continuous improvement. This in turn should 
improve quality and manufacturability of the CGT product, increasing the delivery of treatments to 
patients in a timely manner.  
 
Whilst traceability of measurement and procedures through EQAS is important for analytical 
precision, it is also imperative for ‘post-post-analytical’ interpretation (clinician measurement 
interpretation), where results are used by clinicians for diagnosis and treatment decisions. Greater 
education and harmonisation of permissible limits for tests is needed for clinicians, due to poor 
assumptions that different numbers can be compared, leading to misinterpretation and impact on 
patient safety [128]. Harmonisation of clinical chemistry efforts have been pioneered by the 
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Australian Pathology units, to ensure general acceptance limits for analytes are the same across 
clinical centres to address this misinterpretation by clinicians [129]. 
 
Monitoring of correct units can be enforced through EQAS for harmony, and misinterpretations of 
limits are important to note for the sign off therapeutic products to the clinician to minimise issues 
due to misunderstanding. Greater focus on medical control limits for medical student training has 
been met with great interest, providing definition of the term “total error” of a measurement, which 
previously had negative connotations for clinicians, rather than being informative [130]. 
Measurement uncertainty has been recommended to be reported to clinicians as a set of 
acceptance boundaries for the test, to include reference limits, and remove any further 
mathematical interpretation error [130,131]. It should be seen as a quality indicator instead of a 
box-ticking exercise for pathologists and those completing in-process and release tests [132]. The 
use of measurement uncertainty will be tested within this research, to indicate its use as a quality 
and improvement tool within healthcare and Flow Cytometry post-analysis operations. 
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Chapter 2: Relevant Theory 
2.0 Introduction to the Chapter 
 
Chapter 2 provides an overview of relevant theory used to create the operator measurements for 
an Uncertainty estimate within Flow Cytometry analysis. This builds upon a ‘Quality by Design’ 
approach recommended by regulatory authorities, and it is one way of quantifying variation within 
a biomanufacturing Quality Control and measurement system.  This continues to build upon the 
reviewed literature and FC background provided in Chapter 1, and describes the theory and 
methodology used for Gauge Repeatability & Reproducibility (Gauge R&R), and uncertainty 
methods, used within subsequent data Chapters.  
2.1 Chapter Aims 
 
This chapter provides an overview of the background theory for Uncertainty measurements, 
including process control structures for the measurements to be taken, underlying statistical 
reporting required and calculation of final Uncertainty values. This Chapter presents a structure 
that subsequent data chapters will follow for analysis.  
2.1.1 Chapter Objectives 
 
• Provide an overview of Gauge R&R from a Measurement Systems Analysis perspective. 
• Investigate the use of Gauge R&R hybrid structure to enable measurement Uncertainty to 
be calculated. 
• Present a statistical report format for use in subsequent chapters and definitions behind 
statistics used. 
• Provide a detailed explanation of measurement Uncertainty and how it is calculated.   
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2.2 Measurement Systems Analysis 
 
Measurement Systems Analysis (MSA) is the analysis of a “collection of instruments or gages, 
standards, operation, methods, fixtures, software, personnel, environment and assumptions used 
to quantify a unit of measure or fix assessment to the feature characteristic being measured; the 
complete process used to obtain measurements.” [133]. 
 
MSA falls under the ‘Measure’ category of the Design-Measure-Analyse-Improve-Control (DMAIC) 
Cycle, part of Six Sigma methodology frequently used to reduce variability and waste within a 
production system. An overview of the DMAIC cycle can be seen in Figure 9, along with different 
tools and methods that can be used within each stage of the Continuous Improvement (CI) cycle 
[134,135].  
 
 
• Data collection 
• Statistical Process Control 
• Measurement Systems Analysis 
• Observation 
• Y=f(x) process map 
Design
Measure
Analyse
Improve
Control
• Multi-variate 
• Design of Experiments (DoE) 
• Control Chart 
• ANOVA 
• FMEA 
• Measurement Uncertainty 
• Training 
• Design of 
Experiments 
(optimisation) 
  
Control Plans 
• Control Chart 
• Standard Operating 
Procedures 
• Action Plan 
Figure 9 DMAIC Cycle  
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DMAIC is very similar to the Plan-Do-Check-Act (PDCA) Cycle developed by Walter Shewhart and 
championed by W.Edwards Deming, Quality Gurus and pioneers of Quality Control approaches 
[136–138]. This can also be used as a Lean manufacturing method to reduce variance in a system 
and improve output quality and is described in Figure 10.  
 
 
Figure 10 PDCA Cycle [136,138] 
 
The DMAIC cycle tends to be prescriptive in its process, with clear tools that can be used at each 
point in the Continuous Improvement loop, so it is generally preferred within manufacturing control 
scenarios. Following this cycle helps CGT manufacturers to continually improve processes and 
quality, to comply with a ‘Quality-by-Design’ approach using risk analysis in line with Quality 
Management principles. This is a preferred strategy by major regulatory authorities such as the 
European Commission, placing more focus on front-end development to assure product quality 
[14,64,139]. 
 
Various tools can be used within MSA, most notably Statistical Process Control (SPC), Gauge 
Repeatability & Reproducibility (Gauge R&R), and Function (y=f(x)) Process Maps. SPC is a 
methodology used to monitor and continuously improve process performance and to reduce 
variability within important metrics. SPC is generally an on-line process that measures performance 
metrics in real time, so a better idea of measures and variability can be attained over time. Many 
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types of chart are used within SPC, but the most commonly used tools are process control charts, 
histograms or stem-and-leaf plots, check sheets, Pareto diagrams, cause-and-effect diagrams and 
scatter diagrams [134]. These allow trends or variance causes to be picked up over time, however 
it can be more difficult to measure the exact error or variance of a process item at one point in 
time. SPC is often used to measure multiple process parameters, so it can be costly in terms of 
time and resource to ensure SPC is setup correctly to identify the correct measurands, but also in 
terms of training and labour over time [140]. It relies on process operators correctly inputting data 
(and doing it honestly) if an SPC system is not integrated into the process itself.  
 
Similar time and cost constraints are also found when using Function (y = f(x)) Process Maps. These 
are tools often used within Six Sigma methodology to identify a specific output measurand to 
quantify the process (y) and monitor this as a function of other process attributes (x) [135]. A good 
understanding of all attributes and measurands are required by operators, and honest input of 
results to ensure issues can be identified through trends in time. Operational definitions should be 
calculated when starting to use functional process maps, through analysis such as Gauge R&R 
measures to quantify isolated variances as a function of part or operator. This is a type of analysis 
session, run by an independent assessor that allows errors to be calculated at a point in time, for 
a process or application. This can then be repeated over time to check the alignment of tools such 
as SPC or Process Maps.  
 
An adaptation of the Gauge R&R process will be used throughout this research to quantify variance 
and therefore uncertainty of operator gating subjectivity. Gauge R&R has been used because it 
generates measurements that show a combined estimate of a system’s repeatability and 
reproducibility (sum of within-system and between-system variances). This can become part of an 
SPC log, because SPC often monitors a variety of control factors within a production environment 
such as mean and range of product measures and change over time to catch possible drift, whilst 
giving an accurate measure of a controlled variable without other system interactions to consider. 
However, Gauge R&R does not fully isolate variation components, often combining repeat 
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measures across a series of parts, which is not specific enough for combining in an uncertainty 
calculation. 
 
2.2.1 Gauge Repeatability & Reproducibility 
 
“Gauge R&R is the variance equal to the sum of within-system and between-system variances” 
[133]. Equation 1 depicts this, and in this instance, it is used to calculate intra- and inter-operator 
variation (Equation 2). 
 
𝜎𝜎𝐺𝐺𝐺𝐺𝐺𝐺𝐺𝐺𝐺𝐺 𝑅𝑅&𝑅𝑅2 = 𝜎𝜎𝑟𝑟𝐺𝐺𝑟𝑟𝐺𝐺𝐺𝐺𝑟𝑟𝐺𝐺𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟2 + 𝜎𝜎𝑟𝑟𝐺𝐺𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝐺𝐺𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟2  
Equation 1 Gauge R&R 
𝜎𝜎𝑂𝑂𝑟𝑟𝐺𝐺𝑟𝑟𝐺𝐺𝑟𝑟𝑟𝑟𝑟𝑟 𝐺𝐺𝐺𝐺𝐺𝐺𝐺𝐺𝐺𝐺 𝑅𝑅&𝑅𝑅2 = 𝜎𝜎𝑟𝑟𝑖𝑖𝑟𝑟𝑟𝑟𝐺𝐺−𝑟𝑟𝑟𝑟𝐺𝐺𝑟𝑟𝐺𝐺𝑟𝑟𝑟𝑟𝑟𝑟2 + 𝜎𝜎𝑟𝑟𝑖𝑖𝑟𝑟𝐺𝐺𝑟𝑟−𝑟𝑟𝑟𝑟𝐺𝐺𝑟𝑟𝐺𝐺𝑟𝑟𝑟𝑟𝑟𝑟2  
Equation 2 Operator Gauge R&R 
 
The role of Gauge R&R contributes to a broader Measurement System context in Equation 3 and 
Equation 4, for measurement capability and performance respectively.  
 
𝜎𝜎𝑟𝑟𝐺𝐺𝑟𝑟𝐺𝐺𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟
2 = 𝜎𝜎𝑟𝑟𝑟𝑟𝐺𝐺𝑏𝑏 (𝑟𝑟𝑟𝑟𝑖𝑖𝐺𝐺𝐺𝐺𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟)2 + 𝜎𝜎𝐺𝐺𝐺𝐺𝐺𝐺𝐺𝐺𝐺𝐺 𝑅𝑅&𝑅𝑅2  
Equation 3 System Capability 
𝜎𝜎𝑟𝑟𝐺𝐺𝑟𝑟𝑝𝑝𝑟𝑟𝑟𝑟𝑝𝑝𝐺𝐺𝑖𝑖𝑟𝑟𝐺𝐺
2 = 𝜎𝜎𝑟𝑟𝐺𝐺𝑟𝑟𝐺𝐺𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟2 + 𝜎𝜎𝑏𝑏𝑟𝑟𝐺𝐺𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟2 + 𝜎𝜎𝑟𝑟𝑟𝑟𝑖𝑖𝑏𝑏𝑟𝑟𝑏𝑏𝑟𝑟𝐺𝐺𝑖𝑖𝑟𝑟𝑟𝑟2  
Equation 4 System Performance 
 
Gauge R&R is a form of MSA that gives a combined estimate of Measurement System Repeatability 
and Reproducibility. Repeatability and Reproducibility are respectively defined as: 
 
“Measurement precision under a set of repeatability conditions … that includes the same 
measurement procedure, same operators, same measurement system, same operating conditions 
  Chapter 2: Relevant Theory 
40 
 
and same location, and replicate measurements on the same or similar objects over a short period 
of time.” [141] 
 
“Measurement precision under reproducibility conditions of measurement … that includes 
different locations, operators, measuring systems, and replicate measurements on the same or 
similar objects.” [141] 
 
Repeatability measures precision within batches, whereas reproducibility measures precision 
between batches, operators, gauges etc. Figure 11 illustrates this difference within a 
manufacturing context. In a manufacturing facility, numerous replicate products are created every 
single day, by multiple operating staff on the shop floor. To calculate repeatability, n replicate 
measures would be taken at one time, by one operator on one product. According to the Guide to 
the expression of Uncertainty of Measurement (GUM), this should be between 3 and 10 replicates, 
with a higher number of repeats providing a better representation of the precision of the 
measurement [142]. However, within a CGT manufacturing scenario, this may not be economical 
or necessary. This measure of repeatability or variance is the SD of repeat measures taken at the 
same time.  
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Figure 11 Illustration of repeatability, reproducibility and product variation within a manufacturing facility 
Reproducibility compares these measures of precision across the different factors described 
earlier: - operators, environment, time etc. It can often show up the differences between operating 
shifts, operators or environments to understand the uncertainty or variance in a system when 
measures of a product fall out of specification and control. Comparing repeatability across different 
products, i.e. product variation, would require the same operator to perform the repeat measures 
on different products to ensure multiple sources of variance did not interact. Gauge R&R helps to 
generate an acceptable variation over the range of expected results. It can be used to support 
estimates of measurement system capability (random error over a short time period) by combining 
errors from linearity and uniformity of a system. It can also support estimates of measurement 
system performance, which is the effect of all variation sources over time [133]. 
 
Traditionally, there are three ways a Gauge R&R study can be conducted to populate a data 
collection template as seen in Table 2; the Range method, the Average and Range method, and 
the Analysis of Variance (ANOVA) method. The ANOVA method is usually preferred because it can 
measure operator-part interaction (in this instance ‘parts’ refers to .fcs files of the data for 
operators to analyse), whereas the other two options do not do this. However, for this thesis this 
interaction is not required because the part is kept uniform between participants, to create a Gauge 
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R&R-Uncertainty measurement hybrid. In addition, the ANOVA method assumes a normal 
distribution of measurements, so if the distribution of datasets used in this research are non-
parametric this method is not ideal. The Range method is used to provide a quick estimate of 
measurement variation and is generally used to ensure the Gauge R&R has not changed over time. 
Traditionally, this method compares two appraisers and 5 components to be measured, where each 
appraiser measures each part once [133]. The range between appraiser A and B is calculated and 
a total Range average is taken from these part ranges (𝑅𝑅�). Total variability is identified in Equation 
5, where 𝑑𝑑2∗  is looked up using a 𝑑𝑑2∗  table [133].  
𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇 𝑣𝑣𝑇𝑇𝑣𝑣𝑣𝑣𝑇𝑇𝑣𝑣𝑣𝑣𝑇𝑇𝑣𝑣𝑇𝑇𝑣𝑣 =  𝑅𝑅� × 𝑑𝑑2∗  
Equation 5 Total Variability using the Range method  
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Table 2 Example Gauge R&R Data Collection Sheet 
Appraiser PART AVERAGE 
 1 2 3 4 5 6 7 8 9 10  
A                1            
2            
3            
Average           𝑋𝑋�𝐺𝐺 = 
Range           𝑅𝑅�𝐺𝐺 = 
B                1            
2            
3            
Average           𝑋𝑋�𝑟𝑟 = 
Range           𝑅𝑅�𝑟𝑟 = 
C                1            
2            
3            
Average           𝑋𝑋�𝑟𝑟 = 
Range           𝑅𝑅�𝑟𝑟 = 
Part Av           𝑋𝑋� = 
𝑅𝑅𝑟𝑟 = 
𝑅𝑅� = [𝑅𝑅�𝐺𝐺 =    ] + [𝑅𝑅�𝑟𝑟 =    ] + [𝑅𝑅�𝑟𝑟 =    ][# 𝑇𝑇𝑜𝑜 𝑇𝑇𝑎𝑎𝑎𝑎𝑣𝑣𝑇𝑇𝑣𝑣𝑎𝑎𝑎𝑎𝑣𝑣𝑎𝑎] = 𝑅𝑅� = 
𝑋𝑋�𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷 = �𝑀𝑀𝑇𝑇𝑀𝑀 𝑋𝑋� =    � − [𝑀𝑀𝑣𝑣𝑀𝑀𝑋𝑋� =    ]  
  
Notes  
 
The Average and Range method (𝑋𝑋� 𝑇𝑇𝑀𝑀𝑑𝑑 𝑅𝑅) provides estimates of both repeatability and 
reproducibility, splitting them into two measurements unlike the Range method’s single 
measurement. Numerous appraisers can be used for this method and ideally more than 10 parts 
are preferred for measurement. Each appraiser takes turns to measure the components in a blind 
order, which can be pre-determined by a Design of Experiments (DoE) style randomisation [133]. 
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 All measurement equipment must be calibrated before the analysis begins and results are entered 
into the appropriate cells of the data collection sheet in Table 2. Subsequent appraisers measure 
the same components in different random orders and the results are further tabulated. From this 
Gauge R&R information both averages and ranges can be calculated for each part, for overall part 
averages and ranges to be determined. Various SPC charts can be plotted from this information, 
such as Average and Range Charts, to monitor the overall trend of the data and variance of the 
measurements, if required in a process.  
 
This Gauge R&R process can be modified to enable uncertainty calculations to be taken for 
operators, which required multiple factors (including number of analysed parts) to be controlled. 
The framework of the Gauge R&R process will be used in subsequent participant studies, so 
participants are given multiple files to analyse, although only one of those will be used for 
uncertainty calculation.  
 
Participants will be required to analyse the same data multiple times, to ensure a repeatability 
measure can be taken as an exemplar. It is possible to include more parts for operators to measure, 
however, due to potential time constraints with human participant research, Display Screen 
Equipment usage, attention span and cost of operator time this may not be feasible because repeat 
measures are more important to build confidence in the uncertainty metric.  
2.3 Representative Metrics: Basic Statistics 
 
The following section outlines basic statistics used to describe results, samples and populations. 
These form the basis of uncertainty measurements calculated for the Gauge R&R studies 
conducted within this thesis.  IBM SPSS Statistical Software Version 24, supported by Microsoft 
Excel and Matlab R2019, will be used to calculate advanced statistical testing throughout this 
thesis, unless otherwise specified. 
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Many mathematical methods exist for the analysis and transformation of data sets and respective 
distributions. It is inefficient to provide full data sets to quantitatively describe a population, so 
measures of location, spread, skewness and normality have traditionally been used to represent 
distributions. These metrics enable processes and products to be measured over time to build 
confidence into Product Design Specifications (PDS), Process Performance Metrics or allowable 
tolerances for Critical Quality Attributes (CQAs). These basic statistics have been described in 
subsequent sections for their use in later statistical and uncertainty calculations.  
 
2.3.1 Measures of Location 
 
Measures of Location take one sample value to represent the outcome of an entire population or 
distribution. Measures of Location are absolute points and do not include judgement of spread or 
variance. Arithmetic mean and median are measures of central tendency, and all location values 
calculated are inclusive of all data points. Outliers can affect the final location metric but may not 
be excluded because they represent real analysis scenarios with patient data. They will, however, 
be investigated to understand the differences in technique.  
 
Figure 12 shows how measures of Location can change depending on the spread of data within 
the population. When a normal distribution can represent the population, the mean, median and 
mode should all be equal, or very similar. The non-parametric distribution in Figure 12 is positively 
skewed and can be assessed quantitatively if the central tendency Location measures are unequal. 
Table 3 provides definitions and calculations for measures of Location that are used in subsequent 
chapters.  
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Figure 12 Measures of Location and Central tendency within normal and non-parametric distributions. 
Table 3 Descriptions and equations to calculate measures of Location 
Arithmetic Mean 
(denoted µ) 
The total sum of results divided by the number of results present in the distribution. 
𝜇𝜇 =  1
𝑀𝑀
� 𝑇𝑇𝑟𝑟
𝑖𝑖
𝑟𝑟=1
= 𝑇𝑇1 + 𝑇𝑇2 + ⋯+ 𝑇𝑇𝑖𝑖
𝑀𝑀
 
Equation 6 Arithmetic Mean 
 
Median The 50th percentile of ordered results within the distribution.  
Mode The most popular or recurring value in a data set. This is less common in continuous data sets 
where lots of analysis results in different values.  
Minimum The lowest value generated within the data set. 
Maximum The highest value generated within the data set. 
 
2.3.2 Measures of Spread 
 
Measures of Spread or Dispersion monitor the amount of variance within a data set. They are used 
in conjunction with a Measure of Location to provide a statistical description of a population which 
can then be used to compare against other populations or data sets. Spread can also be used to 
show how well location measures represent the data [143]. For example, when plotting the 
arithmetic mean and SD on a non-parametric distribution, the mean would not be on the peak 
maxima, indicative of the central point of the population. Therefore, the median and absolute 
deviation could be used.  
 
Table 4 provides definitions and calculations used to describe spread or variance of data 
throughout the remainder of the thesis. Figure 13 shows how these spread measures relate to 
normal or non-parametric distributions. Normal distributions are described by stating a location 
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measure of central tendency and a SD to represent the amount of variance. The normal distribution 
in Figure 13 details the percentage amount of data within the population that traditionally lie within 
standard deviation boundaries.  
 
CV is a commonly used statistic within FC measurements, because it provide a single measurement 
used to represent variability, that considers both the SD and mean [29]. Due to its common use, 
this will also be calculated through this research in comparison with uncertainty, to identify 
potential differences between the two variance metrics.  
  
Table 4 Descriptions and calculations for Measures of Spread 
Range The total width of the data set. 
𝑅𝑅 = 𝑀𝑀𝑇𝑇𝑀𝑀𝑣𝑣𝑀𝑀𝑀𝑀𝑀𝑀 −𝑀𝑀𝑣𝑣𝑀𝑀𝑣𝑣𝑀𝑀𝑀𝑀𝑀𝑀 
Equation 7 Range 
 
25th Percentile The 25th percentile of ordered results within the distribution. 
75th Percentile The 75th percentile of ordered results within the distribution. 
Interquartile range The range of data across the central quartiles of data. 
𝐼𝐼𝐼𝐼𝑅𝑅 = 75𝑇𝑇ℎ 𝑎𝑎𝑎𝑎𝑣𝑣𝑝𝑝𝑎𝑎𝑀𝑀𝑇𝑇𝑣𝑣𝑇𝑇𝑎𝑎 − 25𝑇𝑇ℎ 𝑎𝑎𝑎𝑎𝑣𝑣𝑝𝑝𝑎𝑎𝑀𝑀𝑇𝑇𝑣𝑣𝑇𝑇𝑎𝑎 
Equation 8 Interquartile Range 
 
Standard Deviation 
(denoted σ) 
The unit of dispersion across a data set, which can be used to measure variation from the 
central point of a normal distribution. It can also be used to estimate confidence limits with 1 
either side of the location metric representing 68%. 
𝜎𝜎 = �∑(𝑋𝑋 − 𝜇𝜇)2
𝑀𝑀
 
Equation 9 Standard Deviation 
 
Absolute Deviation This is an alternative unit of dispersion that is used for data spread that include both positive 
and negative values and controls for the signs cancelling each other out. 
𝑀𝑀𝑎𝑎𝑇𝑇𝑀𝑀 𝐴𝐴𝑣𝑣𝑎𝑎𝑇𝑇𝑇𝑇𝑀𝑀𝑇𝑇𝑎𝑎 𝐷𝐷𝑎𝑎𝑣𝑣𝑣𝑣𝑇𝑇𝑇𝑇𝑣𝑣𝑇𝑇𝑀𝑀 =  ∑|𝑋𝑋 − 𝜇𝜇|
𝑀𝑀
 
Equation 10 Mean Absolute Deviation 
 
Coefficient of 
Variation 
This is a representative measure of variability, which considers both the mean and 
standard deviation of repeat measures, displayed as a percentage.  
 
𝐶𝐶𝐶𝐶 =  𝜎𝜎
𝜇𝜇
× 100 
Equation 11 Coefficient of Variation 
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Figure 13 Measures of spread for normal and non-parametric distribution 
 
2.3.3 Skewness 
 
Skewness and kurtosis measurements are further characterisation metrics for a population 
distribution. They are often used as a quick judgement of normality of a distribution, because they 
are visual graphical representations of the data. However, whilst being good for a quick judgement, 
they are ill advised for small data sets as they may not represent a complete population. More 
detailed descriptions and calculations of skewness and kurtosis are listed in Table 5 and are used 
within statistical reporting throughout this thesis. 
 
Table 5 Descriptions and calculations of Skewness and Kurtosis 
Skewness The measure of symmetry, or lack thereof, of a distribution. A positive skew will show the maxima 
of the distribution move towards the left of the arithmetic mean or central tendency. The mean will 
be on the right of the median for positive skewness. Examples of skewness can be seen in Figure 
14. A negative skew will show the maxima of the distribution move towards the right of the 
arithmetic mean or central location point, with the median being to the right of the mean. SPSS 
provides a skewness metric and an associated standard error to calculate a skewness z-score. 
Using the following equation, a positive or negative result indicates a positive or negative skew 
respectively. If the z-score falls within ± 2.58 limits, as defined by SPSS, it is deemed as normally 
distributed. If greater than 2.58, the distribution has a strong positive skew and if less than -2.58 a 
strong negative skew [144].  
 
𝑎𝑎𝑠𝑠𝑎𝑎𝑠𝑠𝑀𝑀𝑎𝑎𝑎𝑎𝑎𝑎 𝑧𝑧 − 𝑎𝑎𝑝𝑝𝑇𝑇𝑣𝑣𝑎𝑎 =  𝑎𝑎𝑠𝑠𝑎𝑎𝑠𝑠𝑀𝑀𝑎𝑎𝑎𝑎𝑎𝑎
𝑎𝑎𝑇𝑇𝑇𝑇𝑀𝑀𝑑𝑑𝑇𝑇𝑣𝑣𝑑𝑑 𝑎𝑎𝑣𝑣𝑣𝑣𝑇𝑇𝑣𝑣 
Equation 12 Skewness z-score 
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Kurtosis This is a measure of how heavy or light tailed the distributions are in comparison to a normal 
distribution which has a central tendency. It is also a measure of how the distribution is affected by 
outliers. Distributions with a heavy tail are more likely to be affected by outliers due to their 
frequency at one end of the data set. Low kurtosis would indicate small tails due to minimal effect 
from outliers. Examples of low and high kurtosis about a normal distribution are visualised in Figure 
15. As with skewness in SPSS, a z-score can be calculated for kurtosis using the standard error of 
the data set. If the z-score falls within ± 2.58 limits it is deemed as normally distributed [144]. If 
outside of these limits, the distribution is strongly kurtosed. 
𝑠𝑠𝑀𝑀𝑣𝑣𝑇𝑇𝑇𝑇𝑎𝑎𝑣𝑣𝑎𝑎 𝑧𝑧 − 𝑎𝑎𝑝𝑝𝑇𝑇𝑣𝑣𝑎𝑎 =  𝑠𝑠𝑀𝑀𝑣𝑣𝑇𝑇𝑇𝑇𝑎𝑎𝑣𝑣𝑎𝑎
𝑎𝑎𝑇𝑇𝑇𝑇𝑀𝑀𝑑𝑑𝑇𝑇𝑣𝑣𝑑𝑑 𝑎𝑎𝑣𝑣𝑣𝑣𝑇𝑇𝑣𝑣 
Equation 13 Kurtosis z-score 
 
 
 
Figure 14 Examples of positive and negative skewness. 
 
Figure 15 Examples of low and high kurtosis around a normal distribution. 
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2.3.4 Test for Normality 
 
For a deeper statistical analysis of distribution shape, normality tests can be run within Statistical 
Software packages. 
 
The Kolmogorov-Smirnov (K-S) test and Shapiro-Wilk (S-W) test both present null hypotheses that 
the distribution of a data set will be normally distributed, with an alternative hypothesis of a non-
parametric distribution, requiring more investigation to understand its shape and parameters. A 
key difference between the K-S and S-W tests, is the K-W test has a much lower power, often leading 
to false results due to Type I error because it is more impacted by extreme values within datasets 
[145]. The S-W test has greater power when dealing with different distribution types, so may be the 
preferred normality test within this research, however this is dependent on the number of 
participants included in each study [146]. 
 
Type I errors (or α errors) are defined as:  
 
“The probability of assuming that there is a difference or association between two or more 
variables when there is none. It is usually set at 0.05 or 5 % level” [147].  
 
In contrast, a Type II error (or β error) is defined as: 
 
“The probability of assuming that there is no difference or association between two or more 
variables when there is one. This probability is generally unknown.” [147] 
 
2.3.5 Testing Statistical Power and required Sample Size 
 
Power and sample size are defined for statistical tests where two or more conditions are tested to 
identify significant differences between the groups. Power is defined as:  
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“The probability of a statistical test of finding a relationship between two variables when there is 
such a relationship. The maximum power a test can have is 1, and the minimum 0 with 0.80 
indicating an acceptable level of power. The power of a test is generally greater for one- than two-
tailed hypotheses, parametric than non-parametric tests, lower (e.g. 0.05) than higher (e.g. 0.001) 
significance levels and larger samples” [147].  
 
Sample size in the context of power analysis is defined as “the minimum number of samples 
needed to run a study to find a desired effect” [147]. 
 
Power is used when testing for a significant difference between two samples. Various parameters 
are considered when calculating power [148]: 
• One- or two-sided test 
• Level of significance, α 
• Sample Size 
• Effect Size relative to noise 
 
2.3.5.1 One- or two-sided tests 
One- or two-sided tests differ in their alternative hypotheses (HA).  Both tests have a null hypothesis 
(H0) as follows: 
H0 = there will be no difference between the sample means. 
H0 = HA 
Two-sided tests simply have an alternative hypothesis that tests for difference, with no further 
specificity: 
HA-2 = There will be a difference between the sample means 
H0 ≠ HA 
One-sided tests have an alternative hypothesis based upon size of the difference: 
H1-1 = One sample mean will be greater than the other. 
H0 < HA 
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It is more common to use a two-sided test, because this simply states that means will be different, 
without giving an indication of differences in size or location. One-sided tests are used throughout 
this research, because it investigates a difference in variance, with respect to increasing 
complexity. 
 
2.3.5.2 Errors and Significance Levels 
Two types of error can be made when testing hypotheses, as defined previously and simplified 
below: 
• Type I error (α): Null hypothesis is rejected when it is true 
• Type II error (β): Null hypothesis is not rejected when it is false  
 
α is also known as the level of significance chosen for a test, to specify a percentage confidence 
interval for the results. A 95 % (0.95) confidence interval is commonly chosen for tests and this 
carries a risk of 5% of cases where a Type I error may occur. This equates to α = 0.05 because 
there is a 5 % risk in the null hypothesis being rejected when it should be accepted. For greater 
confidence, lower the α value towards 0.00, although this will impact other factors such as sample 
size in a power calculation [134].  
 
2.3.5.3 Effect size 
The effect size for statistical power is the between-group difference divided by the within-group 
standard deviation. For all statistical tests, because the effect size increases, the power will 
increase, if the other variables are kept constant. The greater the between-group difference, the 
less likely a Type II error becomes. The effect size is inversely related to sample size (if all other 
variables are constant), because small effects can only be detected with larger samples due to 
increased information, and large effects can often be detected with smaller samples as there may 
be less noise present.  
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Cohen’s d statistic is a common calculation of effect size, computed using Equation 13 to show the 
difference in means (between two test groups, X1 and X2), divided by the SD (s, the error or ‘noise’) 
[149]. If two groups have different standard deviations, then the standard deviation used is often 
taken from the control group or it can be pooled.  
?̂?𝑑 = 𝑋𝑋�1 − 𝑋𝑋�2
𝑎𝑎
 
Equation 14 Cohen's d statistic 
General reference values for effect size can be used to compute other power statistics, based on 
whether a small, medium or large effect (respectively) is desired, but the context should always be 
considered when choosing an appropriate effect size [149]. 
 
2.3.5.4 Types of Power Analysis 
Statistical power is calculated as follows, as the complement of Type II errors: 
𝑃𝑃𝑇𝑇𝑠𝑠𝑎𝑎𝑣𝑣 = 1 − 𝛽𝛽 
Equation 15 Statistical Power 
 
G*Power 3 is a statistical power software that will be used to estimate desired Power and sample 
size throughout this thesis. It has been routinely used throughout social, behavioural and 
biomedical sciences to provide an easy way to determine the correct parameters for a study, 
ensuring conclusions are as significant as possible [150].  
 
The two common types of power analysis are A Priori and Post Hoc power analysis, relating to Power 
calculated before and after a data gathering exercise respectively. A Priori is completed before a 
study begins and it is the ideal choice because it provides users with options to control α and β 
[150,151]. It provides up-front calculation of how many participants to recruit to meet desired 
power and effect levels. Post Hoc analysis is performed after a study takes place, so the sample 
size can be used to calculate an observed power value. These are less desirable, because only α 
has been controlled, even though β has been assessed [150,151].  
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Throughout this research it is likely that A-Priori and Post Hoc Power Analysis will be computed for 
each study phase, where appropriate. To attain the appropriate power (0.80) [147], high sample 
sizes are often required (depending on effect size), which could be difficult to achieve considering 
constraints such as access to participants within the timeframe of the research. However, this 
research aims to quantify uncertainty, so Post Hoc Analysis can indicate the sample size needed 
for potential future studies to further confirm initial effects seen within this research, whilst giving 
a measure of current statistical power.  
 
To calculate statistical power using A Priori or Post Hoc analysis, different tests can be used 
depending on the variable being compared. The most common tests are T-tests, F-tests and 𝟀𝟀2 
tests and they often calculate power based on the following metrics [151]: 
• T-tests: Linear bivariate regression; difference in means between test groups 
• F-tests: Analysis of Covariance (ANCOVA); Analysis of Variance (ANOVA); Hotelling’s T2; 
Multivariate Analysis of Variance (MANOVA); Test of equality in variance 
• 𝟀𝟀2 tests: Goodness-of-fit tests: Contingency tables 
 
This research hypothesises an increase in variance is seen as increases in complexity (due to 
number of Flow Cytometry processing steps) are achieved through each study stage. It is most likely 
that F-tests will be used to assess statistical power in this case because this family of power tests 
are designed to measure variance rather than goodness-of-fit or a difference in mean location 
values. When looking at the cell population counts that operators achieve (absolute results rather 
than variance), it is most likely that a t-test will be used. The actual tests used are more likely to be 
applied Post Hoc, once an understanding of the population distribution has been attained, and a 
suitable test selected to represent this parameter. Where applicable, power analysis will be 
discussed after initial statistical reporting of results has been listed in each data Chapter.  
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2.3.6 Statistical Report Formats 
 
The statistical calculations detailed above have been used to create Statistical Reports for data 
distributions occurring throughout this thesis, shown in Table 6. These reports provide a brief 
summary of the Absolute data results, showing the variance of actual final data values operators 
have defined to represent a sample. These reporting tools will also be used to define the 
measurement uncertainty of how these absolute values were attained. This gives a reporting 
viewpoint on the variation of the data sets and how they were calculated, rather than a single 
representative value.  
 
Table 6 Statistical Report Format used throughout this Thesis 
Arithmetic Mean  
Median  
Mode  
Minimum  
Maximum  
 
Range  
25th Percentile  
75th Percentile  
Interquartile Range  
Standard Deviation  
Median Absolute Deviation  
 
Skewness  
Skewness standard Error  
Skewness z-score  
Kurtosis  
Kurtosis Standard Error  
Kurtosis z-score  
 
Shapiro-Wilk statistic  
Significance  
Normal/Non-parametric  
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2.4 Measurement Uncertainty 
 
Measurement uncertainty is defined as: 
 
“A non-negative parameter characterizing the dispersion of the quantity values being attributed to 
a measurand, based on the information used” [141] 
 
This measure of spread provides users with a range containing the true value of the measurand, 
which has taken into account contributions or sources of variation that can cause the result to vary. 
This can provide users with greater certainty and confidence in their measurement result [152].  
 
Within manufacturing, metrology and measurements are important to make key decisions, which 
are also true for many other scenarios. Within healthcare, clinicians make diagnosis or treatment 
decisions based upon the results they receive from pathology measurements. Therefore, an 
understanding of uncertainty of measurements is not only needed by metrologists and quality 
inspectors, it is also needed by those who can make influential decisions based upon the 
measurement reports they receive. This allows them to be more confident in their judgement of a 
situation, and an important trade-off with quality and cost of a product or service.  
 
Sources of measurement uncertainty can arise from a number of factors, which all impact the 
variance directly or indirectly. These sources include, but are not limited to equipment, operators, 
time intervals, place, environment, chemicals and reagents and biology [153]. Figure 16 shows a 
fishbone diagram listing potential sources of uncertainty affecting FC results. This thesis focuses 
on factors affecting the operator and later chapters look at effects listed such as visual perception 
and gating strategies used. 
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Figure 16 Fishbone diagram listing some sources of uncertainty within Flow Cytometry results [154] 
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2.4.1 Relationship between Error and Uncertainty 
 
Calculating uncertainty provides a better understanding of the measurement methodology and the 
impact of each component, than measurement error. This provides opportunity for improvements 
in quality by tackling the largest identified sources of uncertainty. This also provides opportunity to 
increase product quality, save costs and there is an increased acceptability of results due to better 
understanding of the measurement and its attainment.  
 
The true value of a product attribute cannot experimentally be known and be certain, therefore, 
there is always error associated with the observed value. Measurement error is defined as: 
 
“the result of a measurement minus the true value of a measurand” [153] 
 
A measurand is defined as: 
 
“A quantity intended to be measured” [141] 
 
Therefore, measurement error is a quantified difference, where a true value needs to be known. 
This differs from uncertainty because this is a defined range, calculated as a combination of 
variance from factors discussed above. Rather than being a stated number (like error), coverage 
factors are used to calculate the measurement tolerance, because these provide a range of 
confidence that the measured value will more certainly lie within. For example, a 95% confidence 
interval gives the user 95% confidence that the measurement lies within the ranges, defined by the 
combined and expanded measurement uncertainty calculation. That also means there is a 5% risk 
that the measurement does not fall within these stated boundaries. Due to this compilation of 
sources of variance and confidence, it provides a more realistic estimate of results than 
measurement error alone, because it is more representative of the true spread. 
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2.4.2 Quantifying Uncertainty 
 
Quantifying uncertainty has been well documented in official literature from national and 
international standards coordinating bodies [141,152]. These methodologies will be followed to 
calculate the uncertainty of the operator variance within FC gating and is detailed in this section as 
methodology for subsequent chapters.  
 
The process of quantifying uncertainty has been split into four sections to define the final 
uncertainty value: 
• Identify the measurand and the process of obtaining it 
• List sources of uncertainty for each stage of the measurement 
• Quantify uncertainty components identified 
• Combine values and calculate expanded uncertainty 
These steps will be defined here for general process, theory and calculation and discussed with 
more specificity in the subsequent data chapters.  
 
2.4.2.1 Measurand Identification and Methodology 
 
To quantify variation within FC gating, each study phase will have a target cellular subpopulation 
that participants need to reach. This target will be accompanied by a process for participants to 
follow: a series of parent and child gates in a prescribed order to ensure measurement accuracy 
and comparability within- and between-participants. This will provide enough control for the 
measurement procedure to ensure variance comes from the participant application of gates, and 
not a difference in gating sequence.  
 
To calculate variance, each absolute cell count representing each parent and child gate in the 
gating sequence will be used across a series of repeat measures. This structure has already been 
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described in Figure 11, depicting the repeat measures taken for each gate, and their combination 
to calculate a particular participant’s reproducibility. 
 
Within each gating stage, participants will repeat the gating process to define a measure of 
repeatability which can be used to compare against other operators. 3 repeats will be performed 
each time so that statistically a representative SD can be calculated, and session times do not 
exceed 1 hour with participants. This number of repeats were defined from a small pilot study with 
two operators (experienced and inexperienced) to monitor how long it took them to complete the 
gates. As only 3 repeats can be taken, SD will be used to compare variance, which assumes a 
normal distribution of data. Increased repeats may show a different distribution, but due to 
constraints of this experimental work a normal distribution is assumed, and SD is used to further 
calculate uncertainties. 
 
This is a calculation of Type A uncertainty, by definition, as it is focused on the aim at hand 
[142,152]. Type A uncertainties are always calculated from a series of repeat measures. Type B 
uncertainty uses pre-determined uncertainty statements from documentation such as calibration 
certificates, historical records, manufacturer specification of guidelines from a data book 
[142,152]. 
 
A SD is calculated from repeat measures of the different hierarchical levels of the gating strategy 
participants followed during the different experimental studies. These representative variances for 
each level are then combined according to the root sum of squares rule for standard deviations, 
otherwise known as Pythagoras’ theorem. Uncertainty sources cannot simply be added together, 
because this would be a misleading amount of variation, so it is combined in quadrature with the 
following equation: 
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𝑀𝑀𝑟𝑟 = �𝑀𝑀12 + 𝑀𝑀22 + ⋯+ 𝑀𝑀𝑖𝑖2  
Equation 16 combined Uncertainty 
 
 
The combined uncertainty (uc) provides an uncertainty range that reflects the variation from a 
specific measurement point. To give this measurement more confidence, it is then multiplied by a 
coverage factor (k) which represents confidence intervals of the normal distribution. Different 
coverage factors are noted in Table 7, but bespoke values can be calculated using the desired two-
tailed confidence interval with known degrees of freedom to find the right coverage of value in a T-
test table.  
 
Table 7 Coverage factors (k) and respective Confidence Intervals 
Coverage Factor (k) Confidence Interval (%) 
1 68 
2 95 
2.58 99 
3 99.73 
 
Expanded uncertainty (U) is calculated by multiplying the combined uncertainty with the chosen 
coverage factors according to Equation 16. 
 
𝑈𝑈 = 𝑠𝑠 × 𝑀𝑀𝑟𝑟  
Equation 17 Expanded Uncertainty 
 
 
This value gives the user greater certainty that the measured value lies within the specified 
uncertainty limits calculated. When reporting this, the final expanded uncertainty would be written 
as the value following the calculated average or measurement (often denoted after a sign, instead 
if just the SD of measurement repeats).  
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2.5 Chapter Conclusions 
 
This Chapter has provided a concise review of relevant measurement theory and how it will be 
applied to data analysis throughout this thesis. Gauge R&R is a form of MSA that can be used in a 
variety of methods to understand variance within a system. This becomes a core function of 
production SPC with various control charts that can be displayed to monitor quality over time. The 
Gauge R&R method will be abridged to ensure measurement uncertainty can be calculated for 
operators in multiple analysis scenarios, shown in subsequent chapters. This could then provide a 
basis to calculate a full Gauge R&R analysis in future. 
 
To open the results analysis a basic statistical report format has been generated, to provide an 
initial basis for further investigation and root-cause analysis. This will be applied to absolute 
reported results and measurement uncertainty results in each Chapter, to better define the 
distributions being dealt with. An initial understanding of the data-set populations and respective 
distributions are becoming more important within CGT manufacturing as many biometric 
populations are not-normally distributed, a model which has been used extensively through 
traditional manufacturing paradigms. This non-parametric distribution issue is explored in greater 
detail within Chapter 3, to highlight the effect of control limit choice and potential transformation 
of data.  
 
Finally, measurement uncertainty has been defined in detail here, but more specificity will be 
provided in subsequent chapters as the method is applied in each scenario. Measurement 
uncertainty is becoming more common to calculate, due to its inclusion within key regulatory 
documentation that manufacturers are required to follow. However, cell counts and reported data 
within the community still report measurement CV, which only focuses on the end of an analysis 
pipeline, whereas uncertainty can combine variances from the whole measurement process. Often 
this is calculated for measurement equipment, however, where subjective interpretation is 
concerned a combined uncertainty should be calculated to capture this variance.   
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Chapter 3: Pre-Study Variation Investigation 
3.0 Introduction to the Chapter 
Chapter 3 presents a preliminary study conducted before measurement uncertainty models were 
completed to investigate range in variance contributed by participants in a very uniform data 
analysis gating exercise. This was also an opportunity to define the structure of participant studies 
and ensure time parameters were correct, whilst confirming the procedures used were clear and 
repeatable to translate into future stages of work. The results of this Chapter were used to inform 
the structure of the uncertainty models used within Chapters 4 to 6. This Chapter compares the 
robust Coefficient of Variation (rCV) results of gates applied to a series of univariate histograms 
provided to participants for peak identification. This was conducted in a two-phase experimental 
study, to monitor the effect of participants applying gates based upon their own judgement, and 
when given a more prescriptive diagrammatical protocol to follow. This Chapter discusses the use 
of CV metrics which are heavily utilised within the FC industry. 
 
Non-normality of data is present within CGT manufacturing data, so the effect of log 
transformations (often used to obtain a normal distribution) and different outlier boundaries will 
also be tested here to observe effects on the data and optimise for future study analyses presented 
later in this thesis. 
 
A full data integrity check has been completed for all participant data used to create figures 
throughout this thesis. These have been independently verified by Loughborough University internal 
and collaborator external delegates and shows full traceability of data from the starting files, 
through participant analysis, to data extraction, interpretation and visualisation.  
  
  Chapter 3: Pre-Study Variation Investigation 
64 
 
3.1 Chapter Aims 
 
This Chapter aims to provide an initial understanding of whether there is variability contributed 
from participants when they analyse the same data. This will be completed with a series of peak 
separation diagrams, where participants will have to draw an area across where they believe one 
of the peaks resides. The variability in the participant results will be compared because they are all 
gating the same data, which will be used to inform future studies, with how much potential variation 
could be seen from the analyst alone. This also aims to monitor the effect of log transformation 
and different outlier classifications on a set of exemplar data. 
 
3.1.1 Chapter Aims & Objectives 
 
The Aims and Objectives of this Chapter can be defined as follows: 
• Identify initial variation in data analysis contributed by operators when analysing the 
same data, on a simple univariate histogram example.  
• Identify if diagrammatical protocols can reduce between-participant variability when 
gating univariate data. 
• Identify if log transformations should be used in future analysis if results are non-normal. 
• Validate the use of different outlier boundary estimators when dealing with non-normal 
distributions of data. 
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3.2 Methodology 
 
The methodology for the development of this preliminary study and the respective developmental 
components are detailed in this section. An outline of the exemplar data set that participants 
analysed is provided, along with methodology on how this data was created, for reproducibility 
purposes. This expands upon how the studies were organised for participants and how the data 
was extracted and analysed.  
 
3.2.1 fcs File Generation 
 
A series of fcs 3.0 files were generated using a BD Bioscience FACSCanto II Flow Cytometer with 4-
2-2 optical configuration, by running a suspension of BD Bioscience Cytometer Setup and Tracking 
(CS&T) beads (1 drop of beads within 500 µl of Phosphate Buffered Saline (PBS)), once a daily 
calibration was completed (Lot: 74538, Successful calibration) [155]. These files were generated 
because they provide a steady shift in fluorescence peak spectra required for this phase. The CS&T 
beads were a mix of dim, medium and brightly fluorescing polystyrene beads and are used to 
monitor baseline and daily performance of FC instruments. The beads were selected for use due 
to their lesser variation compared to biological material. The beads were run through the 
allophycocyanin (APC) channel, excited by the red laser (633 nm) at a medium flow rate (60 
µL/min). The APC channel was used because it is a common channel across a wide variety of FC 
instruments.  
 
Voltages, and therefore fluorescence peaks, were adjusted to determine the optimal analysis 
parameters in line with instrument sensitivity. The gain was changed using the ‘voltage’ setting to 
alter the position of the fluorescence peaks seen through the APC channel on a univariate scale. 
Many methods have been developed to determine FC analysis parameters, but the most popular, 
referred to as the ‘Peak 2 method’ involves running a control sample at different voltage intervals 
[34], which has been used as the methodology here.  
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Figure 17 Images of histograms provided for participant gating studies [154] 
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The fcs files generated for this work (Figure 17) were gathered at ten different voltages from 250 
V to 700 V, in 50 V intervals, allowing for resolution differences to be seen whilst not over-exerting 
the concentration of operators involved in the study. 10,000 beads were used to acquire each fcs 
file, which is the minimum number of events required for gathering bead-based data [156]. The fcs 
figure elements show the progression of the three data peaks across the univariate scale, in 
relation to the gain increase of the APC channel of the Flow Cytometer. Figure 17 also shows the 
range gates (red circle) applied to the histograms, which participants were asked to copy. The range 
gates were applied by the study coordinator (thesis author), to act as an independent reference 
point, so no participants were familiar with the data before taking part in the sessions. The 
univariate scale was kept to bi-exponential, because this is the default scaling used within Flowjo 
Version 10.0.8r1, the analysis software, and provided resolution of the three peaks across all 
voltage files created. 
 
3.2.2 Flow Cytometry Study Organisation 
 
36 participants across 3 centres were enrolled in this study to analyse the histogram files; 10 from 
an academic institution, 19 from an industrial cell therapy process development team and 7 as 
part of a data gathering exercise at the 2017 Future Investigators of Regenerative Medicine (FIRM) 
Symposium [157]. Ethical and GDPR approval was obtained for this study by the local University 
Human Participant Ethics Sub-Committee, which can be seen in Appendix A and covers human 
participant research conducted throughout this thesis. Participants completed the study 
individually within a 30-minute time-slot and were asked to complete two phases of analysis within 
this session. The two phases aimed to monitor the effects of personal data interpretation, in 
comparison to following a pre-defined protocol, or interpretation thereof, with the hypothesis of 
reduced inter-operator variation for FC analysis when following the latter. It was not expected to 
find much variation throughout this exercise, but to provide an ‘observed effect’ as a starting point. 
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During Phase 1, participants were asked to apply range gates to the area of the plots where they 
estimated the medium fluorescing peak lay. Five of the plots were considered to have ‘poor’ peak 
separation (Figure 17 a-e), where there was difficulty in discerning peaks. The remaining five files 
were considered to have ‘good’ peak separation (Figure 17 f-j) and to be more representative of 
good FC data. Participants used the third-party software Flowjo to examine the .fcs files and apply 
gates, using default bi-exponential scaling and maintaining the histogram view setting to ensure 
inter-participant consistency.  
 
For Phase 2, participants were provided with printed images of range gates (highlighted by the red 
circles in Figure 17) that had been pre-applied to the series of files and asked to adjust their gates 
to try and match these ‘diagrammatical protocols’. These gates were applied to aid precision of 
application, not accuracy, because accuracy can be translated into different subject contexts. The 
‘poor’ gated files (Figure 17 a-e) were included to investigate the potential impact and worth of 
using diagrammatical protocols in difficult analysis conditions.  
 
3.2.3 Variation Calculation 
 
Range gates applied to histograms of one fluorescence channel show variation in spread and 
location parameters, chosen by perception of the operator. The robust Coefficient of Variation (rCV) 
(as defined in Equation 17) is used to compare variation amounts between operators within the 
two phases and is a common metric within FC data analysis [29]. It helps the operator to 
understand and monitor variation within a system, because it combines both location and spread 
parameters into one measure. rCV was used in this instance instead of CV (as previously defined 
in Chapter 2, Section 2.2.2), because fluorescence peak spectra often have a non-parametric 
shape, so using robust statistics was more representative of the FC data gathered. 
 
𝑣𝑣𝐶𝐶𝐶𝐶 (%) =  𝑣𝑣𝑟𝑟𝐷𝐷
𝑀𝑀𝑎𝑎𝑑𝑑𝑣𝑣𝑇𝑇𝑀𝑀
× 100 
Equation 18 robust Coefficient of Variation (rCV) (%) 
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The rCV measures were exported from Flowjo and are the combination of the rSD and the median 
of the data within the gate they have applied. Robust SD is the SD of the data points, based around 
the median rather than the mean. These rCV measures have subsequently been used to calculate 
a total range of variation between participants, per histogram file, per phase. Range was used to 
monitor reduction and therefore improvement in between-participant variation attributed to the 
results, because it is an easily understood measure of spread and monitors the total range rather 
than an arbitrary measure of spread (such as SD). The difference in range between operators can 
be used to observe the effectiveness of protocol instigation, with percentage of variation reduction 
monitored alongside this. 
 
3.3 Results & Discussion 
 
3.3.1 Flow Cytometry Pre-study statistical reporting Phase 1 
 
The results reported here for each analysis file are taken from the inter-participant gates applied 
to each file using their own judgement (Phase 1). The rCV of the gate applied was extracted and 
tabulated per file (columns), per participant (rows). Table 8, Table 9, Table 10 and Table 11 provide 
a descriptive statistics overview of the inter-participant distributions for each file in the sequence 
and Figure 18 shows the inter-participant rCV distributions for each of these sets of file results. 
These descriptive statistics have been calculated following the statistical methods and definitions 
provided in Chapter 2, alongside the mean inter-participant rCV values for each file. 
 
Table 8 Measures of Location for Phase 1 inter-participant rCV results (%) 
 
250 V 300 V 350 V 400 V 450 V 500 V 550 V 600 V 650 V 700 V 
Average 207.9 134.2 68.9 34.5 20.2 15.6 15.1 15.2 15.2 15.0 
Median 122.0 64.7 42.8 32.6 21.0 16.3 15.9 15.9 16.1 15.9 
Min -650.0 0.0 4.0 3.3 15.4 8.7 6.4 8.7 6.4 5.7 
Max 1500.0 400.0 146.0 107.0 21.4 16.7 16.7 16.9 16.7 16.3 
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Table 9 Measures of spread for Phase 1 inter-participant rCV results (%) 
 
250 V 300 V 350 V 400 V 450 V 500 V 550 V 600 V 650 V 700 V 
Range 2150.0 400.0 142.0 103.7 6.0 8.0 10.3 8.2 10.3 10.6 
25%ile 50.1 29.1 35.1 28.5 19.8 15.5 15.2 14.9 15.4 15.0 
75%ile 304.0 283.0 137.8 38.4 21.4 16.6 16.4 16.8 16.5 16.1 
IQR 253.9 253.9 102.6 9.9 1.6 1.2 1.2 2.0 1.2 1.1 
SD 349.6 127.0 48.7 15.6 1.6 1.7 2.2 2.3 2.3 2.2 
CV (%) 168.2 94.6 70.7 45.1 7.9 11.1 14.3 15.3 15.3 14.9 
 
Table 10 Measures of skew for Phase 1 inter-participant rCV results (%) (3dp used for resolution from SPSS) 
 
250 V 300 V 350 V 400 V 450 V 500 V 550 V 600 V 650 V 700 V 
Skewness 1.300 0.646 0.683 2.791 -1.894 -2.821 -2.865 -2.008 -2.86 -3.134 
Skew std error 0.403 0.403 0.403 0.403 0.403 0.403 0.403 0.403 0.403 0.403 
Skew z-score 3.226 1.603 1.695 6.926 -4.700 -7.000 -7.109 -4.983 -7.097 -7.777 
Kurtosis 5.661 -1.271 -1.210 13.318 3.483 8.728 9.073 3.345 8.785 10.955 
Kurt std error 0.788 0.788 0.788 0.788 0.788 0.788 0.788 0.788 0.788 0.788 
Kurtosis z-
score 
7.184 -1.613 -1.536 16.901 4.420 11.076 11.514 4.245 11.148 13.902 
 
Table 11 S-W test for normality for Phase 1 inter-participant rCV results (3dp used for resolution from SPSS) 
 
250 V 300 V 350 V 400 V 450 V 500 V 550 V 600 V 650 V 700 V 
S-W statistic 0.833 0.788 0.805 0.731 0.747 0.624 0.635 0.705 0.613 0.584 
Significance 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Normal/Non-
Parametric 
Non-
parametric 
Non-
parametric 
Non-
parametric 
Non-
parametric 
Non-
parametric 
Non-
parametric 
Non-
parametric 
Non-
parametric 
Non-
parametric 
Non-
parametric 
 
Figure 18 x-axis limits are much wider for 250 V to 400 V files because of the large inter-participant 
range returned for these files. If all file histograms were plotted with the same axis limitations, 
resolution of distribution shape would be lost for 450 V to 700 V files. 
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Figure 18 Inter-participant rCV distributions when gating fcs files using their own judgement (red lines represent mean 
rCV values for each file distribution). 
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Both average and median results for inter-participant gates appear to stabilise as the file voltage 
increases past 450 V and therefore peak separation increases. Inter-participant rCV averages are 
much higher for lower voltages due to little or no separation of the middle peak from other data. 
This difficulty in gating has created a wider range of inter-participant results when gating ‘poor 
separation’ files (Table 9), which in turn creates higher average and median values to represent 
the distribution. 
 
The inter-participant ranges in Table 9 have a clear cluster of high and low ranges for low voltage 
and high voltage files respectively. This is also the case for interquartile ranges (IQR) for the set of 
files. Across all files, the IQR is small in comparison to the overall range, indicating a wide 
distribution of results, which suggests a location measure such as the mean or median could not 
confidently represent the datasets. The shape of the distributions further indicates this because 
the skewness and kurtosis z-scores fall out of the ± 2.58 limitations for normality for all file inter-
participant distributions (Table 10), aside from the 300 V and 350 V files. Upon visual inspection 
of these distributions in Figure 18, the distributions appear to be bimodal, indicating a potential 
split in how participants have applied these gates, causing some to have a higher result rCV and 
some to have a lower result rCV. The Shapiro-Wilk normality test results in Table 11 further confirms 
this non-normality, with all file distributions having a significance value p < 0.0005. This rejects a 
null hypothesis of a normal distribution, accepting an alternative, non-parametric distribution (as 
described in Chapter 2, Section 2.2.4). 
 
This data supports the use of correct upstream equipment and process validation because poor 
voltage choices can significantly affect downstream subjective judgement on where to place a 
histogram gate, with higher variability occurring when it is more difficult to separate required data 
from the noise or unnecessary populations at the limit of sensitivity. 
 
Files with better peak separation (450 V to 700 V) also qualitatively appear non-normal due to a 
strong negative skew as also indicated in the skewness z-scores in Table 10. Qualitative 
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assessment of distributions adds significant value to this analysis because if basic statistics are 
used to represent data without considering distribution shape, mean values (shown in Figure 18 
sub-plots, denoted as a red line for the mean rCV for each file) do not fall within frequency maxima 
bins on any occasion. This supports the use of robust statistical assessment when analysing FC 
data with medians better representing distributions overall. This will therefore be considered 
throughout each statistical data set in this research, if the distributions are non-normal.  
 
3.3.2 Flow Cytometry Pre-study statistical reporting Phase 2 
 
The results reported here for each analysis file are taken from the inter-participant gates applied 
to each file following a diagrammatical protocol, which participants had to follow and copy, shown 
in Figure 17. Table 12 to Table 15 provide a descriptive statistics overview of the inter-participant 
distributions for each file in the sequence and Figure 19 shows these distributions for each set of 
file results with the mean rCV values identified in each case.  
Table 12 Measures of Location for Phase 2 inter-participant rCV results (%) 
 
250 V 300 V 350 V 400 V 450 V 500 V 550 V 600 V 650 V 700 V 
Average 163.5 118.2 83.7 35.4 21.0 16.5 16.3 16.6 16.4 15.9 
Median 207.0 96.2 76.8 31.9 21.1 16.6 16.4 16.7 16.5 16.1 
Minimum -1300.0 31.5 43.6 15.1 17.6 15.8 15.7 15.6 15.6 14.7 
Maximum 800.0 283.0 139.0 75.7 22.9 16.6 16.5 16.8 16.6 16.2 
 
Table 13 Measures of Spread for Phase 2 inter-participant rCV results (%) 
 
250 V 300 V 350 V 400 V 450 V 500 V 550 V 600 V 650 V 700 V 
Range 2100.0 251.5 95.4 60.6 5.3 0.8 0.8 1.2 1.0 1.5 
25%ile -93.8 71.1 61.9 29.0 20.8 16.4 16.3 16.6 16.4 15.9 
75%ile 488.0 150.0 109.0 37.8 21.4 16.6 16.5 16.7 16.5 16.1 
IQR 581.8 78.9 47.1 8.8 0.6 0.2 0.2 0.1 0.1 0.2 
SD 443.5 66.2 28.7 11.8 0.9 0.2 0.2 0.3 0.2 0.3 
CV (%) 271.2 56.0 34.3 33.2 4.2 1.2 1.2 1.8 1.3 2.0 
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Table 14 Measures of skew for Phase 2 inter-participant rCV results (%) (3dp used for resolution from SPSS) 
 
250 V 300 V 350 V 400 V 450 V 500 V 550 V 600 V 650 V 700 V 
Skewness -1.355 0.905 0.406 2.064 0.588 -1.559 -1.372 -2.104 -2.763 -2.762 
Skew std error 0.414 0.414 0.414 0.414 0.414 0.414 0.414 0.414 0.414 0.414 
Skew z-score -3.273 2.186 0.981 4.986 1.420 -3.766 -3.314 -5.082 -6.674 -6.671 
Kurtosis 2.630 -0.130 -1.074 6.077 1.618 3.151 1.108 3.815 8.895 8.076 
Kurt std error 0.809 0.809 0.809 0.809 0.809 0.809 0.809 0.809 0.809 0.809 
Kurtosis z-
score 
3.251 -0.161 -1.328 7.512 2.000 3.895 1.370 4.716 10.995 9.983 
 
Table 15 S-W test for normality for Phase 2 inter-participant rCV results (%) (3dp used for resolution from SPSS) 
 
250 V 300 V 350 V 400 V 450 V 500 V 550 V 600 V 650 V 700 V 
S-W statistic 0.901 0.909 0.933 0.821 0.925 0.700 0.792 0.673 0.594 0.623 
Significance 0.007 0.011 0.047 0 0.029 0 0 0 0 0 
Normal/Non-
Parametric 
Non-
parametric 
Non-
parametric 
Non-
parametric 
Non-
parametric 
Non-
parametric 
Non-
parametric 
Non-
parametric 
Non-
parametric 
Non-
parametric 
Non-
parametric 
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Figure 19 Inter-participant rCV distributions when gating fcs files following a protocol (red lines represent mean rCV 
values for each file distribution) 
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For files with notionally ‘good separation’ of peaks (Figure 17 f – j), following a protocol appears to 
converge the average and median rCV results for each file. Less difference between the average 
and median indicates central tendency and therefore a normal distribution. This can be seen by 
the red ‘average’ line markers plotted in Figure 19. Similar to the histograms in Figure 18, the red 
lines have been overlaid onto the inter-participant rCV distributions for each file. For each ‘good 
separation’ file, this average marker sits inside the peak maxima of the histogram in the centre of 
the distribution, because no bimodal distributions are present in this phase of analysis. It is difficult 
to qualitatively determine if the average better represents the distribution of the ‘poor separation’ 
files. However, the distributions for these files no longer appear to be bimodal (Figure 19), which 
could suggest using protocols to interpret data could aid conformance due to better inter-
participant reproducibility, as defined in Chapter 2.  
 
This would be true if the inter-participant rCV range reduced when following a protocol. This is the 
case for all voltage files, although, the 250 V file has only reduced slightly, but not significantly. 
However, this is negligible due to this voltage possibly being too low to run assays with confidence 
in this channel due to cellular autofluorescence [34,158], so participants would not face a triple-
peak cluster in optimal, validated scenarios. The rCV inter-participant range for ‘good separation’ 
peaks is between 0.8 % - 1.5 %, which is considerably lower than when participants gated using 
their own judgement (8.0 % - 10.6 %). This shows that a diagrammatical protocol can possibly help 
in instances when gating is difficult. 
 
The CV of measurements (as defined in Chapter 2, Section 2.3.2) is commonplace as a variance 
metric in FC and the CV of the inter-participant results ranges from 1.1 % to 2.0 % for ‘good 
separation’ files, far below the satisfactory criteria of < 10 % CV for a measurement, which is 
desirable [71]. Alongside the range of data, this supports using diagrammatical protocols to 
possibly reduce inter-participant variation within reported measurements.  
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The shift towards normality and a gaussian shape is not necessarily reflected in the skewness and 
kurtosis z-scores in Table 14. 300 V, 350 V and 450 V fall within the ± 2.58 boundaries for normality 
(defined in Chapter 2). However, all other files have a strong negative skew (aside from the 400 V 
file which has a strong positive skew). These files also have a high kurtosis, indicating a high peak 
within the data. Even though the ‘good separation’ files have a high kurtosis, in this instance that 
is desirable, because conformity of results that cause a centred spike shows better reproducibility 
between participants and less variation within the end result. The high skew and kurtosis results 
indicate a non-parametric distribution, confirmed by the Shapiro-Wilk tests results in Table 15. All 
distributions are significantly non-parametric. 
 
A comparison of Phase 2 results to Phase 1 results will be completed in the following section. By 
individually analysing the descriptive statistics of each phase of results, the type of desired 
distribution can be questioned. Most analysis statistics are designed to work with a normal 
distribution, and this is often an ‘ideal’ data shape that manufacturing communities work towards. 
Not only does it allow use of normal statistical tools, it can be used to drive continuous improvement 
efforts to refine the process which causes data extremes. Strong skewness and kurtosis measures 
are therefore traditionally not ideal, but when looking at variability of data, they could be core 
indicators that show reproducibility of data, due to convergence of results.  
 
3.3.3 Flow Cytometry Pre-study Outlier Discrimination Investigation 
 
The ranges of inter-participant data have been used for comparison of Phase 1 and 2 data. This 
metric includes all participants and excludes no-one as an ‘outlier’, because they have produced a 
result under the same test conditions as other participants. Instead, any extremes of data will be 
investigated to understand the potential root cause of variation. 
  Chapter 3: Pre-Study Variation Investigation 
78 
 
  
Figure 20 Comparison of inter-participant ranges when participants use their own judgement to gate and when they 
follow a protocol [154] 
 
The range of inter-participant results when participants used a protocol is significantly smaller than 
when participants use their own judgement for all files analysed, as shown in Figure 20. The bar 
charts (b) show the percentage reduction of inter-participant range from Phase 1 to Phase 2. This 
was calculated using Equation 19 for each voltage file. 
 
𝑃𝑃𝑎𝑎𝑣𝑣𝑝𝑝𝑎𝑎𝑀𝑀𝑇𝑇𝑇𝑇𝑃𝑃𝑎𝑎 𝑣𝑣𝑎𝑎𝑑𝑑𝑀𝑀𝑝𝑝𝑇𝑇𝑣𝑣𝑇𝑇𝑀𝑀 (%) = 100 % − (�𝑃𝑃ℎ𝑇𝑇𝑎𝑎𝑎𝑎 1 𝑣𝑣𝑀𝑀𝑇𝑇𝑎𝑎𝑣𝑣 − 𝑎𝑎𝑇𝑇𝑣𝑣𝑇𝑇𝑣𝑣𝑝𝑝𝑣𝑣𝑎𝑎𝑇𝑇𝑀𝑀𝑇𝑇 𝑣𝑣𝑇𝑇𝑀𝑀𝑃𝑃𝑎𝑎
𝑃𝑃ℎ𝑇𝑇𝑎𝑎𝑎𝑎 2 𝑣𝑣𝑀𝑀𝑇𝑇𝑎𝑎𝑣𝑣 − 𝑎𝑎𝑇𝑇𝑣𝑣𝑇𝑇𝑣𝑣𝑝𝑝𝑣𝑣𝑎𝑎𝑇𝑇𝑀𝑀𝑇𝑇 𝑣𝑣𝑇𝑇𝑀𝑀𝑃𝑃𝑎𝑎� × 100) 
Equation 19 Percentage reduction from Phase 1 to Phase 2 results 
 
In addition, the rCV ranges for each voltage file have been plotted for Phase 1 (Figure 20a, 
Participant Interpretation of gate placement, blue line) and Phase 2 (Figure 20a, Gating Standard, 
orange line). These lines show the rCV ranges for each phase for each file, and are measured 
against a logarithmic y-axis, so all ranges and differences can be effectively seen. 
 
The ‘good separation’ files from 500 V to 700 V show a large percentage reduction when 
participants use a gating protocol, despite the peaks in these files having a very clear separation. 
This variation reduction shows that using a protocol can help participants to gate histograms 
accordingly, even when noise affects the data at the other extreme, due to high amplification. This 
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noise can be seen in higher voltage files in Figure 17 (g – j) as small shoulders and longer tails on 
the edges of the main peaks. Within the ‘good separation’ peaks, the percentage reduction is high, 
although it appears to get slightly smaller as the voltage increases (from 90 % for the 500 V file to 
86 % for the 700 V file). This could be because the higher the voltage, the more the noise is 
amplified, causing a bit more gating variability for the ‘good separation’ files as the voltage 
increases, due to increased visibility of peak shoulders and tails.  
 
Despite the poor separation making gate application difficult within the ‘poor separation’ files (250 
V to 450 V), this has shown to be aided by a diagrammatical image to copy and inform the correct 
scale points for gate placement. These files show poor separation and resolution of the middle 
peak, which should be identified in early upstream validation phases when using FC for analytical 
measurements. Therefore, these files are not representative of ‘good data’ that would be gated but 
do show difficulty when having to split clusters of beads or cells in analysis. Ultimately, thorough 
optimisation and validation of process steps and settings coupled with diagrammatical protocols 
can greatly influence and reduce the inter-participant range of reported results. This improves 
reproducibility of data between participants, converging to more confident results, analysis and 
interpretation. 
 
Sign tests have also been executed using IBM SPSS Statistics Version 24 to test the use of gating 
protocols in comparison to participants gating using their own judgement. This tests for a significant 
difference in medians of the two test conditions and is used when population distributions are non-
normal and subject to outliers. Sign tests have been used throughout this thesis when testing for 
differences between conditions. Table 16 summarises the results of Sign tests used for each 
voltage file, where the null hypothesis confirms no significant difference between the median inter-
participant rCV ranges, and the alternative hypothesis accepts a significant difference between the 
two test conditions. Red highlighted cells indicate that the alternative hypothesis of a significant 
difference between the medians of the two groups has been rejected, so the null hypothesis of no 
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difference between the medians is retained. Green highlighted cells indicate that the alternative 
hypothesis has been accepted because of a significant difference between the group medians. 
 
Table 16 Results of Sign test to compare medians of two-phase test conditions 
Voltage File Null Hypothesis Test Sig. Decision 
250 V Median difference of P1 & P2 250 V files = 0 Related-samples Sign test 1.000 Retain null hypothesis 
300 V Median difference of P1 & P2 300 V files = 0 Related-samples Sign test 0.735 Retain null hypothesis 
350 V Median difference of P1 & P2 350 V files = 0 Related-samples Sign test 0.043 Reject null hypothesis 
400 V Median difference of P1 & P2 400 V files = 0 Related-samples Sign test 1.000 Retain null hypothesis 
450 V Median difference of P1 & P2 450 V files = 0 Related-samples Sign test 0.100 Retain null hypothesis 
500 V Median difference of P1 & P2 500 V files = 0 Related-samples Sign test 0.021 Reject null hypothesis 
550 V Median difference of P1 & P2 550 V files = 0 Related-samples Sign test 0.003 Reject null hypothesis 
600 V Median difference of P1 & P2 600 V files = 0 Related-samples Sign test 0.072 Retain null hypothesis 
650 V Median difference of P1 & P2 650 V files = 0 Related-samples Sign test 0.011 Reject null hypothesis 
700 V Median difference of P1 & P2 700 V files = 0 Related-samples Sign test 0.248 Retain null hypothesis 
 
To accompany the Sign test to identify significant differences between the two testing conditions, 
the A Priori and Post Hoc power was calculated for each of the Voltage files. The variances for each 
file test condition calculated from SPSS were used, to test for equality of variance using an F-test 
within the G*Power software. Table 17 lists the variance for the inter-participant results for each 
test phase (Variance Phase 1 and Variance Phase 2), the ratio of which is used alongside effect 
size and significance level to define A Priori and Post Hoc power. The use of these Power analysis 
variables has been discussed within the methodology in Chapter 2, Section 2.2.5, and this structure 
is used in subsequent chapters. Even though this has been completed after data gathering, A Priori 
power calculated from the variances gives an indication of the sample size that would be required 
if access to more participants was available, to meet the desired power (0.80). The Post-Hoc power 
has also been calculated, which shows the ‘actual power’ calculated from the results. This is 1 – 
the probability of a Type II error being committed, which is when the null hypothesis fails to be 
rejected when it is false. 
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Table 17 A Priori and Post Hoc Power analysis (3 dp used for resolution specified in SPSS) 
File Variance Phase 1 Variance Phase 2 A-priori power Sample size required Actual power 
250 V 122227.401 200720.528 0.802 103 0.430 
300 V 15415.756 4699.454 0.813 20 0.969 
350 V 2246.926 801.856 0.813 26 0.920 
400 V 247.683 89.533 0.800 26 0.915 
450 V 2.291 0.455 0.825 12 0.999 
500 V 2.947 0.021 0.881 3 1.000 
550 V 4.579 0.029 0.893 3 1.000 
600 V 5.023 0.066 0.800 3 1.000 
650 V 4.796 0.031 0.891 3 1.000 
700 V 4.629 0.111 0.876 4 1.000 
 
All tests conducted and differences seen between test conditions are significant in line with the 
power calculated for all files except for the 250 V files, which had a low ‘actual power’ of 0.430. To 
see a significant difference between test conditions with statistical confidence, 103 participants 
would be required. Due to the difficulty of this gate, it is likely that a small difference would be seen 
between the two test conditions, which requires a large pool of people for valid results. For all 
remaining files, less participants are needed to produce the variance ratio seen from the current 
data, which had 37 participants take part in Phase 1 and 34 of those participants take part in 
Phase 2. The gating completed using a protocol has a very noticeable difference for the well 
separated files, with an actual power of 1.00 for all files and only requiring 3 to 4 participants to 
capture this effect if repeated.  
 
To actually use this data to choose an optimum voltage to run the APC channel, the 500 V file would 
be used, determined by the method described in [34]. This has been demonstrated in Figure 21, 
where the median inter-participant rCV values from each voltage file in Phase 1 were plotted to 
create a Stain Index rCV curve. A Stain Index curve is used to identify the optimum voltage for a 
specific channel, by plotting rCV values for the middle peak of each voltage file acquires with CS&T 
beads. Median inter-participant rCV values were plotted for each file due to non-parametric 
distributions of operator results for files across Phase 1 and 2 analysis. The inflection point that 
changes the curve to a plateau indicates the optimum voltage, minimising the effect of background 
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noise on the data, which can be seen as 500 V. This voltage file was selected to further investigate 
the distribution of an example data set, and the effects of different statistical methods of 
determining outliers and control limits.  
 
 
Figure 21 Stain Index rCV curve [154] 
 
Having this 500 V variable selected as the optimum voltage reduces potential variability within the 
measurement due to amplification of noise or poor detection because of closeness to the limit of 
detection of the instrument [34,158]. Even though this is a low amount of variation carried forwards 
in the file, this variability can be further controlled when gating univariate histograms according to 
a prescribed protocol. A significant difference in range has been shown between participants when 
using this protocol, improving reproducibility to converge results, reducing variation input by the 
operator during data analysis.  
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3.3.4 Flow Cytometry Pre-study Outlier Discrimination Investigation 
 
Normal distribution of data is commonplace to effectively use control limits within manufacturing 
and other product release criteria, however, in this instance all data is highly skewed, making 
normal control limit methods less robust to apply. These will be tested within this section to identify 
how well different methods identify potential outliers, and whether the log transformation process 
so commonly used shows equality to these.  
 
Outliers are common within distributions and can be identified and removed using a series of 
control limit methods. These methods have been used within national and international proficiency 
testing schemes for FC, to maintain continuous improvement [88,95,98,109]. Generally speaking, 
a 95% Confidence interval is applied to the data set, so the ‘out-of-specification’ 5 % can be 
continually reviewed to refine the processes and identify variables that cause participants to fall 
outside of acceptance boundaries. However, more recently robust methods for outlier 
determination (based in median statistics) have been utilised within these schemes, generating a 
set of acceptance criteria, rather than position on a normal distribution [159]. The data presented 
throughout this Chapter is not normally distributed, despite what initial basic statistical measures 
may indicate. Often when data is non-normal, a logarithmic transformation can be applied to shift 
the distribution towards normality so normal statistical tools can be used. However, when 
transformations are applied, the distribution of the original data is lost, which can cause difficulty 
in judgement of outliers.  
 
This can present a problem within CGT manufacturing, because if too much transformation of raw 
data occurs, it could lead to a loss of clarity of the data, potentially causing poor decisions and 
statistical tests to be applied to patient or product data. When undergoing a cell therapy transplant, 
there is limited amount of starting material that can be taken from the patient, so it is imperative 
that poor data analysis does not impact quality metrics of the final therapy product, because this 
could lead to dire consequences for the patient [160]. European and International regulations state 
that control limits for acceptance criteria should be set from validation runs of the product and 
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process [64,139]. However, there is limited validation that can be done on a patient-by-patient 
basis, due to the difficulties discussed.  
 
Dealing with the raw data distribution rather than transforming to fit traditional norms gives a better 
understanding of the quality of the cell therapy product, even if the distribution is more unfamiliar. 
There are also a variety of control limits that can be set for in- and out-of-specification results which 
will be discussed here. Many traditional methods are used to fit normal distributions, but robust 
alternatives will also be considered due to the nature of the data distributions in this Chapter. There 
are no defined criteria for control limit selection, this would be the decision of the manufacturing 
and QC unit. This section applied the 500 V distribution seen earlier to different control limits to 
identify differences between in- and out-of-scope data, as well as transforming it to confer between 
control limits when data is approximated to a more ‘normal’ shape. 
 
Outlier discrimination has been explored using the 500 V Phase 1 analysis data as an exemplar 
data set. Any extreme values can traditionally either be removed from analysis or the outliers are 
addressed to facilitate future improvement in process control.  
 
Table 18 summarizes different boundary specifications used within a variety of industries including 
biomedical and cell therapy manufacture [96,100,164–170,101–103,109,159,161–163]. There 
is no one correct choice for outlier determination, with the choice being based on commercial 
guidelines, quality standards and/or method validation exercises. These boundary estimators 
indicate whether the statistics used are based upon normal or Gaussian distributions or are more 
robust to non-parametric shape. The ‘Data Dimensionality’ indicates whether the boundary 
estimators are used from one set of data (1 parameter) or if multiple sets are required, often seen 
in multiparametric analysis such as regression where commonality between two variables is 
considered. Finally, Table 18 indicates whether the error boundaries calculated by each method 
are used as strict cut-off limits for specifying outliers, so they could be removed from further 
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analysis, or whether the method applies a correction to ‘out-of-specification’ limits and the data 
can then be accommodated within further analysis steps.  
Table 18 Error Boundary Estimators 
Error Boundary Estimator Normal/Robust Statistical 
Methods 
Data Dimensionality Outlier Limits/ 
Accommodates Data 
Shewhart’s Control Charts 
Mean ± 3SD 
Normal 1 parameter Outlier limits 
Mean ± 2SD 
Calculation from Type I errors 
Normal 
Normal 
1 parameter 
1 parameter 
Outlier limits 
Outlier limits 
Exponentially Weighted Moving 
Average (EWMA) charts 
Robust 1 parameter Outlier limits 
10% trimmed Mean ± 2SD Normal 1 parameter Outlier limits 
Median ± 2MAD Robust 1 parameter Outlier limits 
Paxton’s Criterion Robust 1 parameter Outlier limits 
Bootstrapping Normal, or log 
transformation of non-
normal data 
1 parameter Outlier limits 
Linear regression models Normal Minimum 2 
parameters 
Outlier limits 
Robust Multivariate regression Robust, but transforms 
data to normal 
Minimum 2 
parameters 
Outlier limits 
Longitudinal mixed effects 
models 
Robust Minimum 2 
parameters 
Outlier limits 
M-Estimators Robust 1 parameter Accommodates data 
Euroflow 
Personalised outlier estimator 
Robust, but transforms 
data to normal 
1 parameter Outlier limits 
 
Determining outliers is completed by calculation of location and spread values of a data set in 
question. Location parameters such as the mean, median or trimmed means are points used to 
represent a population and spread parameters such as SD or Absolute Deviation represent the 
amount of fluctuation around the defined location parameter. Historically, boundaries such as 
Mean ± 2SD have been used, because they approximately align to a 95% Confidence Interval, 
assuming normally distributed data. 
 
Table 18 is not an exhaustive list but the majority use univariate data to understand distributions. 
However, regression analysis requires two input variables to determine a 95% Confidence Interval. 
Mean ± 3SD are traditional bounds, originally championed in the use of control charts to monitor 
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process quality over time [161]. These have been amended for use in analytical chemistry Quality 
Control [162] but were refined to Mean ± 2SD in the 1990’s FC EQAS [101–103], alongside the 
use of 95% Confidence Intervals, defined by the Standard Error of the data set. 
 
The Exponentially-Weighted Moving Average (EWMA) Chart is a robust alternative to the Mean ± 
3SD method, that adjusts to the data set and is often preferred when detecting small shifts [134]. 
The use of EWMA charts to track data has been recommended more as an internal assessment for 
manufactured products [163], because it can be easily understood in a similar manner to a Levy-
Jennings plot, a traditional control chart format used. Trimmed means are another alternative 
location parameter, involving recalculation of new spread metrics from a refined data set. They 
remove a certain percentile of data from the extremes, making the distribution more centralised 
[163]. This was popular in previous cycles of the UK NEQAS FC Schemes [96,164], allowing 
pathology laboratories identified as extremes to improve over time. However, if used incorrectly it 
can remove extremes that require investigation into causality, and still represent probable events 
occurring. 
 
A robust alternative to Mean ± 2SD, is Median ± 2 Median Absolute Deviations (MAD) [165]. This 
uses the median value of residuals from the location median to estimate spread, which is more 
aligned to non-parametric distributions. Another traditional robust method was described for an 
early FC EQAS (Paxton’s Criterion), that uses parameters calculated to also define Box and Whisker 
plots, from 25th and 75th percentiles, and subtraction and addition of the Interquartile Range 
respectively [166]. Bootstrapping is a resampling method used as an alternative technique for 
validation [167,168] that derives confidence intervals, making assumptions on the data probability 
distribution, and assumes a normal distribution or uses a log-transform of non-normal data. This is 
a suitable way of defining bounds if it fits the raw data or if the transform sufficiently equates.  
 
Regression analysis is a common method for specifying data-fitness bounds. Linear regression 
analysis minimises the residual sum of squares and uses residual plots to detect outliers. Linear 
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regression has been used to compare FC EQAS approaches [109], with further developments 
building upon this by using robust multivariate regression [100], which is less sensitive to outliers 
due to transformation of non-normal data. 
 
Longitudinal mixed effects models have been employed more recently by UK NEQAS [98,169]. This 
uses a mixture of pass criteria based upon different residual and deviate values, allowing for 
multiple stratification levels of the data, based upon robust statistics. An alternative method uses 
M-estimators, that accounts for all the data, but weights extreme values to shift them to an optimal 
boundary, also known as winsorizing means [170]. This does not technically exclude any data 
points as previously described methods do, but still uses normal statistics to define initial boundary 
points. 
 
To demonstrate the effect that different estimators have on data, the Phase 1 500 V data set was 
used to calculate different outlier discrimination intervals, because this was defined as being the 
optimal voltage to run the APC channel from previous calculations. This data set was initially tested 
to describe the distribution, using IBM SPSS Statistics Version 24 software to calculate the 
descriptive statistics as discussed in previous sections. 
 
To apply different error boundaries to the data set, the outlier discrimination methods were 
screened to include those that could be applied to a univariate data set for parameters that do not 
just related to manufactured products and those that act as a set boundary and do not transform 
the extreme values. Both normal distribution and robust statistics have been included. EWMA 
charts have been discounted, because there are multiple ways to calculated these control charts, 
with ambiguous variables which are hard to tailor to the topic in hand [134]. The effect of 
logarithmic transformation on the data has also been investigated, because this is a common 
method used to transform data to make it more normally distributed, applicable to a wider range 
of Gaussian-based statistical analyses and conforming to more traditional manufacturing statistical 
process control paradigms. 
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The calculations used for both the raw and transformed data can be seen in Table 19. 
Bootstrapping relies upon a 95% Confidence Interval calculation, so these have been accounted 
for together, and Mean ± 3SD, 2SD and 10 % trimmed mean ± 2SD all use the same SD calculation 
to generate control limits. These calculations were completed using Microsoft Excel (Windows 10), 
however, Matlab R2019a was used to calculate the 10 % trimmed mean and trimmed SD, and the 
95 % Confidence Interval because it removed subjectivity from the population selection to define 
the extreme 10%. 
 
Figure 22 and Figure 23 show four plots representing these non-parametric and transformed 
results. Figure 22 (a) shows a histogram of operator rCV values for the 500 V file where operators 
were asked to apply gates based upon personal interpretation (Phase 1). The grey stepped bands 
represent the calculated outlier discrimination boundaries derived using the information in Table 
19. Any histogram column falling within these boundaries is determined as being in specification. 
Those falling outside of a boundary would then be classified as an outlier by that method.  
 
The majority of participants fall within all bounds, but this shows the importance of correct selection 
of discrimination for the process. If chosen control limits are too fine, then allowable variation could 
be cut out, causing a high defect rate and false negatives. Too wide, and the process is allowed to 
head towards a more out-of-control state and false positives could be included in analysis, which 
is undesirable and makes location of the source of the variation more difficult.  
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Table 19 Outlier estimators, respective calculations and control limits defined [154] 
Outlier 
estimator 
Location 
Calculation 
Spread 
calculation 
Location 
value 
Spread 
value 
Lower 
Control 
Limit 
Upper 
Control 
Limit 
Control 
Limit 
Distance 
Log 
transformed 
Lower 
Control 
Limit 
Log 
transformed 
Upper 
Control 
Limit 
Log 
transformed 
Control 
Limit 
Distance 
Shewhart 
Control 
Charts 
Mean ± 3SD 
 
For trimmed 
data, 10% 
of the 
ordered 
data are 
removed 
before 
calculation 
 
15.62 
5.19 10.43 20.81 10.37 1.02 1.36 0.35 
Mean ± 2SD 3.46 12.16 19.08 6.92 1.08 1.31 0.23 
10% trimmed 
mean ± 2SD 15.92 1.96 13.96 17.88 3.92 1.15 1.26 0.11 
95% 
Confidence 
Intervals  15.62 0.56 15.06 16.18 1.11 1.17 1.21 0.04 
Bootstrapping 
Med ± 2MAD 
 
 
16.30 
0.70 15.60 17.00 1.40 1.19 1.23 0.04 
IQR Metrics  
 
 
N/A 13.60 18.4 4.80 1.14 1.27 0.13 
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Figure 22 Application of difference control limits applied to data [154] 
 
As seen in Figure 22, all the boundaries scale inwards and outwards, so overlaps can be seen on 
both sides. The mean, 10% trimmed mean and median have all been plotted on top, to show shift 
due to the distribution. The median value of the data fits best to represent the skewed distribution 
because it sits within the histogram maxima.  
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To show the impact of operators following use of a gating standard to obtain results, the Phase 2 
data was overlaid onto discriminatory bounds calculated from Phase 1 data, as seen in Figure 22 
(b). All participants fall within the tightest boundary, specified by the Median ± 2MAD. This confirms 
that causing operators to follow a visual protocol not only reduces inter-operator variation but also 
reduces the chance of ‘outlier’ results, regardless of how outliers are defined in this context. In the 
context of cell therapies and their manufacture, these outliers will represent key patient data 
metrics and cannot be excluded. 
 
 
 
Figure 23 Application of difference control limits applied to log transformed data [154] 
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The boundaries in Figure 22 were recalculated when the skewed data was normalised with a log 
transform and this transformed data and boundaries are shown in Figure 23. Data was transformed 
according to Equation 19. 
 
𝑇𝑇𝑣𝑣𝑇𝑇𝑀𝑀𝑎𝑎𝑜𝑜𝑇𝑇𝑣𝑣𝑀𝑀𝑎𝑎𝑑𝑑 𝑑𝑑𝑇𝑇𝑇𝑇𝑇𝑇 =  𝑇𝑇𝑇𝑇𝑃𝑃10(𝑣𝑣𝑇𝑇𝑠𝑠 𝑑𝑑𝑇𝑇𝑇𝑇𝑇𝑇) 
Equation 20 Log transformation 
 
The outer boundaries all fall within the same gradient pattern towards the centre, however the 95% 
confidence interval and the Median ± 2MAD bounds sit astride one another, discounting various 
operators as outliers. Application of Phase 2 (log transformed) data to these defined boundaries is 
shown again in Figure 23, with operators falling within the tightest boundaries when following a 
diagrammatical protocol to apply their gates. However, the shape of this distribution is not the same 
as the distribution when untransformed, potentially indicating a loss of participant traceability back 
to the raw data, which could cause data integrity difficulty if just using visual data. 
 
To monitor equality of outlier discrimination between the bounds specified for raw and transformed 
data, Table 20 shows the different bounds used, and what outliers are specifically discriminated 
against using this method (outliers identified using anonymous coding). Log transformation is 
deemed appropriate in the context here where the outliers are identical for each context and 
therefore labelled as ‘Equal’.  
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Table 20 Control limits used to specify outliers [154] 
 
Non-
parametric 
Outlier 
frequency 
Outlier code Log 
transformed 
outlier 
frequency 
Outlier Code Equal 
Outliers 
Reason for 
outlier 
Mean ± 3SD 1 C04 1 C04 EQUAL Range gate 
applied over 
smaller % of 
peak 
Mean ± 2SD 2 C01, C04 2 C01, C04 EQUAL Range gate 
applied over 
smaller % of 
peak 
Paxton’s 
Criterion 
3 C01, C04, C07 4 A03, C01, C04, 
C07 
UNEQUAL Additional 
outlier in log 
transform data 
(A03) 
10% trimmed 
mean ± 2SD 
3 A03, C01, C04, 
C07 
3 A03, B11, C01, 
C04, C07 
UNEQUAL Additional 
outlier in log 
transform data 
(B11) 
95% 
Confidence 
Interval 
29 A01-A10, B01-
B05, B07, B08, 
B10-B14, B16, 
B17, C01, C03-
C07 
28 A01- A05, A07-
A10, B01-B05, 
B07, B08, B10-
B14, B16, B17, 
C01, C04,-C07 
UNEQUAL Additional 
outlier in raw 
data (A06, 
C03) 
Median ± 
2MAD 
10 A03, A05, A06, 
B04, B09, B11, 
B15, C01, C04, 
C07 
10 A03, A05, A06, 
B04, B11, B15, 
C01, C04, C07 
UNEQUAL Additional 
outlier in raw 
data (B09) 
 
All outlier boundaries calculated up to Paxton’s Criterion are equal in the number of outliers 
specified when using either the raw data or log transformed data. As these boundaries become 
more refined, outliers are included due to the area of the peak gated by the specific operators. 
Mean ± 3SD has one outlier quantified by the gate applied (participant C04, Figure 24) covering a 
small section of the peak. This does not include all events collected within the peak and therefore 
has a skewed rCV value as a result.  This extreme can be compared to a median participant for this 
gate, because multiple people achieved the same rCV value (median = 16.3 %). This median is 
represented by participant B07, with their respective gate shown in Figure 25.  
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Figure 24 Participant C04 histogram gate applied to middle peak 
 
 
Figure 25 Participant B07 histogram gate applied to middle peak (representative median) 
 
Mean ± 2SD, 10% Trimmed Mean ± 2SD, and Paxton’s Criterion have all specified outliers due to 
gates not covering the entirety of the peak, and the gradual inclusion of these outliers through more 
refined control limits sees these outlier gates become wider to include more of the peak, 
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questioning the outliers have been defined due to differences in spread definition. Figure 26 shows 
the gate applied by participant C01, in addition to C04 they are out of specification for all boundary 
estimators except Mean ± 3SD. 
 
 
Figure 26 Participant C01 histogram gate applied to middle peak 
 
The 10% trimmed Mean ± 2SD and Paxton’s Criterion specify an additional outlier, participant C07, 
who falls outside of the Lower and Upper Control limits specified in Table 19. Figure 27 shows the 
gate applied by participant C07, which is slightly wider again than participant C04 and C01, but it 
still does not include the entirety of the peak.  
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Figure 27 Participant C07 histogram gate applied to middle peak 
 
Paxton’s criterion specifies an additional participant A03 when the data has been log transformed, 
who falls outside of the Lower and Upper Control limits specified for the criteria in Table 19. 
Participant A03’s gate can be seen in Figure 28 respectively, again with slightly wider boundaries 
applied to the peak, but not covering its entirety. The rCV value for this gate sits just outside of the 
rCV lower boundary, suggesting that there could be a difference to outlier definition when applying 
log transforms. Discrepancies can be seen between the raw and log transformed data for the 
different boundaries, due to data sitting very close to a raw or transformed boundary, causing it to 
become in- or out-of-specification. Some more examples have been visualised to identify this, 
because of the fact this data sits very close to the control limits. 
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Figure 28 Participant A03 histogram gate applied to middle peak 
 
Qualitatively, A03’s gate and previous participant gates have slightly smaller boundaries than the 
median participant of the group, supporting the trend seen here that as the boundaries calculated 
become more refined, ‘outliers’ are those who have smaller rCV values because they have not 
captured as much of the peak as the rest of the participant population. The rCV value appears to 
correlate with the percentage cell count captured within each gate the participants have applied. 
This percentage cell count can be seen in the Participant gating figures in this section. 
 
Participant B11 (Figure 29) has gated around a smaller section of the peak causing them to be a 
differential outlier in the log transformed control limits for the 10 % trimmed mean ± 2SD. B11 
applied gating knowledge from other measurement techniques because they had previous 
experience with High Performance Liquid Chromatography (HPLC) measurement techniques, where 
the rule of thumb is to try and capture 80% of the peak to increase measurement confidence and 
minimise spectral overlap. Compared to more experienced Flow Cytometrists, who try and capture 
the entire peak, some differences could be seen in training carried over or assumed from other 
measurement techniques. 
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Figure 29 Participant B11 histogram gate applied to middle peak 
 
Both highly refined control limits (95% Confidence Interval and Median ± 2MAD) have more outliers 
present when applying these boundaries to the data set. When calculating the 95% Confidence 
Interval the raw data contained one extra outlier, which may be expected due to this being a 
statistical test using normal metrics applied to a non-parametric data set. Both the raw and log-
transformed control limits for the 95% Confidence Interval contain a high number of outliers (29 
and 28 respectively), leaving only 7 and 8 respective ‘inliers’ to represent the distribution. Due to 
the distribution having a high kurtosis and skew, this could affect the calculation of this confidence 
interval, due to its dependence on the standard deviation that is not located at the peak maxima. 
Participants A06 and C03 applied a gate which is unequal as an outlier when assessed as raw data 
applied to the 95 % Confidence Interval boundary. They are defined as an outlier within the raw 
data set, not the log transformed data set. As an example, Figure 30 shows A06’s gating strategy, 
with the cell count and rCV following the same trend as the previous examples with wider 
acceptance boundaries. This cell count and rCV value are closer to the median value of the group, 
because this gate includes more of the peak than previous participants have included, but still not 
the full peak as the right tail of the middle peak has been excluded. 
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Figure 30 Participant A06 histogram gate applied to middle peak 
 
The robust Median ± 2MAD control limits are unequal when assessed with both raw and log 
transformed data sets, and they also contain more outliers due to the tighter control limits. 
Participant B09 is the differential outliers specified by this raw data set, in comparison to the log 
transformed data limits. This is the tightest acceptance boundary, so any ‘outliers’ that have just 
fallen outside of boundaries are likely to still look very similar to those results that lie within the 
boundaries.  
 
Qualitatively, the gate applied by B09 can be seen in Figure 31, and it looks as though the left side 
of the gate slightly crosses the trough between the dim peak (furthest left) and the middle peak. 
This could be listed as an outlier because of these other sections of the dim peak being picked up 
instead of the middle. It appears that this gate has shifted towards the left as the gate does not 
cover the right tail of the middle peak, like other participant gates have done.  
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Figure 31 Participant B09 histogram gate applied to middle peak 
 
To conclude, the raw untransformed data will be used for comparison in further studies, to  enable 
a better understanding of the population which is more directly traceable to the study data 
gathered. Even though there is a small difference between outliers defined in raw and log 
transformed distributions, in some instances where there is inequality of outliers, it has shown that 
log transformation may not always be suitable for skewed data. It is important to confirm and 
understand the shape of the data before applying tranforms and control limits to identify outliers. 
These boundaries will be applied to further data sets to show the difference in control limit 
definitions,however, this will not be to specify a perferred option for defining outliers, because it 
requires more manufacturing validation and regulatory or industrial guidelines. 
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3.4 Chapter Conclusions 
 
Chapter 3 shows the amount of variation seen between participants when applying histogram gates 
to the same data, indicating that this needs to be focused on and more specifically measured within 
future work. Across a range of different data histograms, the difference between participant 
analysis can vary greatly according to a number of factors which could depend upon the participant 
experience, how frequently they deal with histogram Flow Cytometry data and what they believe to 
be acceptable cut-off points for data inclusion. This can be used as evidence to formally measure 
baseline operator variability using measurement uncertainty methods when applying gates to data. 
 
Chapter 3 has tested the use of gating protocols for univariate histogram data, providing a basis to 
practice running studies, validating this study design (3 repeats within a 30 minute - 1 hour time 
frame) for future uncertainty analysis trials, which can build in complexity from this univariate 
experiment. 
 
Inter-participant variability was also present when participants had to apply gates following a 
diagrammatical ‘gating protocol’ instead. All the ranges of between-participant results dramatically 
reduced in cases where the peak separation was clear and an obvious split between the three 
peaks could be seen (percentage reductions ranging from 86 % to 92 % for 500 V to 700 V files). 
The gating images provided helped participants to align the gate to the selected upper and lower 
inclusion limits, although some participants expressed they would have applied the gate differently, 
using different tools or settings. However, this is all relative, because these factors were controlled 
to ensure comparability between participants.  
 
Even when gating the poor separation peaks the gating protocol aided participants, because it 
reduced the range across all voltage files, however some were better than others (reduction when 
using the protocol between 2 % to 42% for 250 V to 450 V files). Those files with lower ranges were 
very difficult for participants to gate because there was no visual separation of the peaks to discern 
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the correct one. These lower voltages should not be used when setting up and running a flow 
cytometer, because they are too close to the limit of detection of the channel. This greatly affects 
the ability to discern populations within the data set and is an effective example of showing how 
upstream setup and variables need to be correctly optimised and validated to ensure confidence 
in final interpreted results.  
 
This pre-study has also highlighted the importance of completing a thorough check on not only the 
basic statistics representing a population, but to check the distribution and more complex 
statistical tests because these give more information about departures from normality and 
potential clusters of data that can appear in bimodal instances. It has also called into question the 
need for a normal distribution, when trying to get reproducible data. If trying to get results within a 
certain boundary, measures such as skewness and kurtosis appear to be out-of-specification and 
extreme compared to SPSS boundaries (for normal distribution affinity), but they actually indicate 
a high convergence of results, because these specified limits indicate a normal distribution which 
may not be a necessary shape. 
 
Due to the non-parametric distributions and skewness present, log transformations were 
investigated to see whether the transform could make the distributions appear more normal, to 
then apply various outlier boundary estimators to the data. This was applied to data distributions 
when participants applied gates using their own judgement and then following a protocol. However, 
when following a protocol the distribution was very convergent and therefore highly kurtosed, so 
not much difference was seen when transforming the data, other than flattening the two histogram 
bins present. More of a distribution shape was seen when participants used their own judgement 
and this is more indicative of real-world scenarios.  
 
The power analysis completed on this data has shown that enough participants were recruited to 
identify the difference in variance for most of the files analysed. The one file which did not have 
enough participants, returning a power of 0.430, was the least optimal, so this generally would not 
  Chapter 3: Pre-Study Variation Investigation 
103 
 
be used for FC analysis when setting up voltages for the APC channel. This power analysis structure 
will be used in further chapters where two different testing conditions are present, considering A 
Priori and Post Hoc power to ensure that the correct sample sizes and powers can be identified, 
even if they cannot necessarily be met. 
 
Various error boundary estimators are used throughout manufacturing scenarios and were applied 
to a set of data here to highlight the difference in how many outliers were produced. Boundary 
estimators would usually be selected internally by manufacturers based upon historical validation 
data. However, these are traditionally based upon normal distributions being required, so these 
were tested on a non-normal set of data, alongside robust statistics which are designed to deal 
with more non-normal distributions. In some instances there is equality between the raw and log-
transformed data when using error boundary estimators to identify outliers. However, instances 
where there was not equality between the two data representation methods has highlighted that 
differences could be due to using certain boundary methods such as 95 % Confidence interval. 
These differences are due to log transform boundaries being slightly different to those applied form 
the raw data, which could cause problems when trying to identify outliers in skewed distributions, 
depending on how the analyst interprets the results. Discrepancies between skewed raw and log 
transformed data has been discussed in other biomedical literature, showing that log transforms 
can cause discrepancies in data analysis and consideration from the raw data is perhaps more 
suitable [171,172]. This can give an appreciation of what the data looks like before trying to make 
it fit to a more traditional norm.  
 
This will influence further work presented in this thesis, by ensuring that no transformation of data 
will be made without strong evidence of its use and without understanding the underlying statistical 
distribution first. It also calls into question error boundaries used to define outliers and enforce 
continuous improvement. As baseline uncertainty is measured, these limitations will need to be 
defined by a reputable error boundary discrimination method, which will depend on the shape of 
the distributions to ensure it is robust.  
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Ultimately, this pre-study has shown that there is significant variation present from analyst 
subjectivity, as well as potentially being able to control this with protocols, which will be investigated 
within subsequent Chapters. The investigation of log transformation of data has shown differences 
to occur in outliers, showing that this method needs to be fully understood before applying 
transformations to raw data. This can have a significant impact on CGT manufacturing, because a 
lot of cell and gene measurement distributions are not normal [173,174], and their measurement 
analysis as well as the data distributions themselves need much more attention and understanding 
to make informed decisions.  
 
3.4.1 Consolidation of Objectives 
 
• There is considerable variation in between-participant data analysis when they apply 
gates to the same data. This is seen through all data files given to participants, which 
show variability when peak separation is good (range of 8.0 % rCV for 500 V file) and 
when it is poor (range of 400 % rCV for 300 V). This has been shown on simple univariate 
data and can provide a session structure for subsequent chapters which detail more 
complex data and analysis sequences. 
• In this instance, diagrammatical protocols provided to participants have reduced 
between-participant range of rCV results when copying the gates. This can be tested in 
future variation studies, but they will be more complex in visualisation and structure to 
monitor how the range in variation changes, so this must be taken into account.  When 
peak separation is ‘good’, this reduction is up to 92 %, and when peak separation is 
‘poor’, this reduction of variation is up to 42 %. 
• Log transformation of the raw data has been tested here, with the conclusion that future 
data sets will not be transformed if they are non-normal, because there can be inequality 
of outliers and error boundaries between the two data presentation types. Therefore, raw 
data distributions shall be used, because these present relatable data distributions to 
work with, unless evidence suggests otherwise. 
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• Different outlier boundaries have been tested with the chosen data set here, with normal 
and non-normal parameters. It has highlighted for future work that the distribution of the 
data needs to be thoroughly tested before outliers are determined with a particular 
method, to ensure the data is distributed appropriately. It is likely that even if future 
distributions are normal or non-normal, robust methods may be used as these can be 
used as representative statistics in both cases.  
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Chapter 4: Basic Uncertainty Model 
4.0 Introduction to the Chapter 
Chapter 4 introduces the first uncertainty Gating Exercise, as part of the sequence of studies which 
monitor participant variance in comparison to complexity of data. As discussed in the Prelude, this 
first uncertainty exercise is basic, to set a baseline for understanding variance in non-complex 
analysis scenarios. This sets the basis for further uncertainty gating studies described in Chapters 
5 and 6 with comparisons drawn in Chapter 7. The overall Gauge R&R study design as described 
in Chapter 2 has been followed to obtain statistics which can be taken forwards for uncertainty 
calculations. Further specificity for this basic study exercise is given in this Chapter. Previously in 
Chapter 3, only one variable had been considered, in histogram format, whereas this first 
uncertainty stage tackles FC data analysis in pseudocolour and bivariate formats using an 
immortalised pluripotent cell line (2102 EP Carcinoma line). This is much more prevalent within the 
community, therefore potentially providing a more relevant application of uncertainty to FC 
measurements.  
 
4.1 Chapter Aims 
 
This Chapter provides a basis for comparison of uncertainty in more complex FC analysis strategies 
found in future chapters. The fit of this Chapter to the thesis can be seen in Figure 32, specifically 
within the orange dashed box, providing a base for the core hypothesis: as complexity of FC data 
and processing increases, measurement uncertainty contributed from the participant will also 
increase. CGTs can have very complex analysis and quality control measures, so a better 
understanding of how the participant plays an influencing role in these results is essential for 
product release, continuous improvement and patient safety.  
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Figure 32 Diagram of Chapter position within the whole Thesis 
 
4.1.1 Chapter Aims & Objectives 
 
The Aims and Objectives of this Chapter can be defined as follows: 
• Design a baseline study using a Gauge R&R structure to measure CV and uncertainty of 
participants when gating simple Flow Cytometry data. 
• Identify what causes extreme values in absolute reported results and uncertainty 
measurements by reviewing extremes from this baseline study. 
• Provide easy monitoring tools for understanding uncertainty within a larger participant 
study or facility. 
• Investigate the impact on variance from data visualisation and different gating tools that 
can be used throughout Flow Cytometry Post-Analytical processing.  
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4.2 Methodology 
 
The Embryonal Carcinoma (EC) 2102Ep immortalized cell line used has been suggested as a ‘Ruler 
line’ or ‘Reference Standard’  for culture and research, because it has an antigen expression profile 
similar to conventional human Embryonic Stem Cells (hESCs) [175]. This antigen expression profile 
was unchanging over 10 passages, and this biological stability make the cells a good example for 
quantifying downstream experimental uncertainty, due to minimal biological variation [175]. As 
such, they were chosen as the simple starting model for these studies. 
 
4.2.1 Cell Selection and Culture 
 
A vial of GlobalStem® EC 2102Ep cells (Passage 48) (5 x 106 cells) was removed from a liquid 
Nitrogen Cryobank (See Appendix B for Certificate of Analysis) and was thawed in a water bath for 
3 minutes until a slither of frozen material remained. The material was topped up 1:1 with cell 
culture media, mixed slowly and seeded manually onto a T75 ThermoScientific™ Nunc™ Cell 
Culture Flask in 15 ml Gibco™ DMEM, high glucose, GlutaMAX™ supplement (Cat 61965, Lot 
1813259), fortified with 10 % v/v Fetal Bovine Serum (FBS). Cells were maintained in a humidified 
incubator with 5 % CO2 at 37˚C. 
 
100 % medium exchange was carried out every 2 days after seeding or passage, and once 
confluent after 3 days, the seeded flask was manually passaged into 2 daughter T75 flasks at a 
seeding density of 6.7 x 104 cells/cm2. This equated to a 1:3 split ratio, because cell counting was 
affected by the difficulty in dispersing cell clumps. To aid this dispersion, a 2-step disassociation 
process was used, cells were trypsinised with 1.5 mL Gibco™ Trypsin EDTA (0.25 %) (Cat 
25200072, Lot 1814171) for 5 minutes in a humidified incubator at 37˚C with 5% CO2, quenching 
with 3 mL of the fortified DMEM to stop the enzyme.  
 
Cells were centrifuged at 300g for 5 minutes, waste supernatant aspirated, and the remaining cell 
pellet resuspended in 1.5 mL 0.25 % Trypsin EDTA and incubated for a further 5 minutes. After 
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further quenching and removal of the supernatant, cells were resuspended in the fortified DMEM, 
with cell counts, and viability assessed using a Nucleo-Counter® NC-3000™ and ChemoMetec 
Via1-Cassettes™, to stain and measure cells with Acridine Orange and DAPI dyes. Three repeat 
measures were taken at each count to obtain a mean cell count and viability, before reseeding into 
the next passage. Cells were passaged through 5 successions, with an average cell viability of 87 
± 3 % over the culture period. 
 
4.2.2 . fcs File Generation 
 
A series of fcs files were generated using the EC 2102 Ep cell line in culture through 5 passages 
and harvested as previously described. The cells were fixed, permeabilized and stained using the 
BD Stemflow™ Human/Mouse Pluripotent Stem Cell Analysis Kit (Cat 560477, Lot 7004890), 
according to the included method [156]. Enough cells were harvested to generate the respective 
isotype and Fluorescence Minus One (FMO) controls, alongside the stained cells. 1 x 107 cells were 
harvested and fixed in 1 ml 4 % BD Cytofix™ Fixation Buffer (Cat 51-9006276, Lot 7004890), 
incubated in the dark for 20 minutes and washed twice with 1 ml PBS (no Calcium, no Magnesium).  
 
The cells were mixed slowly with 1 mL BD Perm/Wash Buffer (Cat 51-9006275, Lot 6232552) and 
incubated at room temperature in the dark for 10 minutes. After 2 washes, the cells were split into 
Eppendorf vials of 1 x 106 cells each, suspended in 100 µL Perm/Wash buffer and stained with the 
respective dyes: 15 µL BD Pharmingen™ PerCp-Cy5.5 Mouse Anti-Oct 3/4 (Cat 51-9006267, Lot 
6232550, 10 µL BD Pharmingen™ Alexa Fluor 647 Mouse Anti-SSEA-4 (Cat 51-9006265, Lot 
6316682) and 20 µL BD Pharmingen™ Mouse Anti-SSEA-1 (Cat 51-9006268, Lot 6316683). 
 
Oct 3/4 is a member of the POU (Pit-Oct-Unc) family of transcription factors, which functions in the 
early stages of a pluripotent cell within hESC and EC Cell Lines. Oct 3/4 is expressed in 
undifferentiated cells, but loses expression as cells start to differentiate towards specific cellular 
subsets [176]. SSEA-4 (Stage Specific Embryonic Antigen–4) markers are also identifiers of 
undifferentiated ESCs and ECs [177], with the difference from Oct 3/4 being that SSEA-4 is a cell 
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surface marker. 0ct 3/4 is intracellular, which requires the additional fixation and permeabilization 
step. SSEA-1 is a surface marker of differentiation for Stem cells, often used to compare with SSEA-
4 and other pluripotency markers [178].  
 
Once incubated for 30 minutes in the dark, cells were washed twice and transferred into BD 
Falcon™ Round Bottom 12 x 75 mm tubes (Cat 352063) and kept covered to minimise light 
exposure. Cells were run through a BD FACSCanto™ II Flow Cytometer, using the respective 
fluorescence channel and voltage: FSC 180 V, SSC 374 V, PerCp 420 V, APC (same detection range 
for Alexa Fluor 647) 450 V and PE 352 V, once a daily calibration was completed using Cytometer 
Setup & Tracking beads (Lot: 74538, Successful calibration). A viability stain was not included in 
the FC panel, due to viability being assessed with cell counts, and the need to keep the gating panel 
initially straightforward for participants, following the prescribed method in the Analysis Kit [156].  
 
Each tube and respective fcs file were generated using a medium flow rate (60 µL/min) and by 
acquiring 30,000 cellular events. Multiple stained sample fcs files were generated to build a library 
of repeats to use within the variation studies. These are representative of the product samples 
described in the manufacturing scenario used to describe Gauge Repeatability & Reproducibility in 
Section 2.3.1. Files were exported as fcs 3.0 version types for use in Flowjo Version 10.0.8r1 third 
party analysis software [123] and saved as a workspace. This was repeated twice for each 
participant, so they could analyse data across a total of three workspaces.  
 
4.2.3 Questionnaire Design & Ethical Approval for Study 
 
Ethical approval was obtained from Loughborough University Human Participants Ethics sub-
committee for the study and all participants were informed of the intentions of the study, as 
previously described in Section 3.2.2. Before the FC gating study commenced, participants 
completed an online questionnaire, to identify differences between participants and understand 
their experience background. This questionnaire was also given to participants to repeat at the end 
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of the FC complex gating exercises. Results comparing these two sections are discussed in Chapter 
8, to identify factors that attribute to measured variance.  
 
All participants and their respective data were anonymised at the point of data collection, and data 
stored in accordance to the ethical clearance obtained. All data analysis relating to questionnaire 
or gating results was completed anonymously, and participant coding was restructured from 
previous work to remove the possibility of analysis bias. Any questions requiring written text 
answers were analysed and qualitatively coded based upon prescribed manual coding methods 
[179]. These codes were counted to measure the frequency of issues reported, and more 
information on the qualitative coding can be found in Chapter 8. 
 
4.2.4 Flow Cytometry Study Organisation 
 
A total of 38 Participants from three separate centres (10 from an academic institution, 19 and 9 
participants from separate industrial institutions) were invited to complete the study in a quiet 
analysis space, to avoid distraction and the possibility of others seeing the study content and 
analysis. Study sessions had a one-hour maximum duration, and participants were shown three 
Flowjo workspaces, which contained a series of fully stained EC 2102 Ep fcs files. One identical file 
was included in each workspace, and participants were instructed to gate through a three-plot 
sequence to identify target cells (using Forward Scatter (FSC) plot against Side Scatter (SSC)), then 
the option to gate single cells, and finally to apply a quadrant gate to the double positive stem cell 
marker population to identify the final percentage cell count of respective pluripotent stem cells.  
Flowjo was the choice of platform due to access of the software across all three collaborator and 
participant sites, meaning a higher number of participants were likely to be familiar with the 
platform. 
 
Participants were also provided with isotype controls and FMO controls in each workspace to aid 
gate application and were allowed to use whatever manual gating tool on Flowjo they felt best to 
gate the population in hand. Due to the variety of ways in which people gate single cells, these axes 
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were left to the discretion of the participant and their preference. An overall schematic of the gating 
sequence they were asked to follow is shown in Figure 33, and participants gated each workspace 
of files separately to ensure a correct quantification of uncertainty through standard deviation 
calculation in accordance with Gauge R&R methodology principles described earlier. 
 
 
Figure 33 Gating sequence participants were asked to follow, to identify the target single cell population, with double 
positive expression for both Pluripotency markers 
 
This data exercise aims to identify if variance does exist when reporting results from the same data 
and that uncertainty values can be calculated for participants to contribute towards an overall 
uncertainty estimation. This was designed to estimate a general absolute result median and 
uncertainty. Calculating significant differences between certain groups or testing conditions was 
irrelevant, meaning that standard power calculations to determine appropriate sample size could 
not be used. In addition, a one-sample T-test cannot be used because it requires a hypothesised 
value for the sample to differ from. Because this data set was supposed to be exploratory, the initial 
results from this uncertainty study can be used for future comparison.  
 
When completing Gauge R&R studies it is recommended for repeats to exceed n ≥ 10 [133], so 
that there is a good number of participants for inter-participant comparison of results. To calculate 
uncertainty, it is recommended that a minimum number of measurement repeats to take is 
between 4 to 10 to try and best eliminate anomalies whilst being time efficient [142]. Participants 
made 3 repeat measures, because when trialled, 4 repeats could not be successfully conducted 
within a 1-hour time slot, whereas 3 repeats could be comfortably achieved and this still allows for 
  Chapter 4: Basic Uncertainty Model 
113 
 
SD to be calculated. A 1-hour slot was used because this was the maximum allowance given for 
each participant’s time, agreed across the three institutions.  
 
4.2.5 Uncertainty Calculation 
 
Once studies had been completed, target cell, single cell and final percentage positive cell 
population metrics were extracted from the data, using the results from the identical repeated file 
situated in each Flowjo workspace. These were then used to calculate a mean cell count, SD and 
CV for each gating stage, per participant using Microsoft Excel software. Finally, a combined 
uncertainty (uc) was calculated by combining these Type A uncertainties by summation in 
quadrature. The uc value was expanded with a coverage factor of k = 2, representing a 95 % 
Confidence Interval for the uncertainty statement, which gave each participant a representative 
expanded uncertainty (U) figure, to show individual variance. The mathematical methodology used 
to calculate uncertainty metrics has been previously discussed in Section 2.4. An example of the 
data extraction through to calculation of metrics and uncertainty can be seen below.  
 
 
Figure 34 Example of data extraction through to calculation of absolute results and uncertainty  
Total Starting Cell Events Repeated File Target Singlet Double Positive
30000 Repeat 1 Wsp1, File 1 6027 5981 5972
Repeat 2 Wsp2, File 2 6097 6041 6012
Repeat 3 Wsp3, File 3 6608 6562 6515
Target Singlet Double Positive
Wsp1, File 1 20.09 19.94 19.91
Wsp2, File 2 20.32 20.14 20.04
Wsp3, File 3 22.03 21.87 21.72
Target Singlet Double Positive
Average 20.81 20.65 20.55
STDEV 1.06 1.07 1.01
CV 5.08 5.16 4.91
k 2
uc 1.81
U 3.62
Respective Percentages of Cell Events in each gate as a 
function of total starting cell number
Total Cell Events within each gate in sequence
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4.3 Validation of Gating Tools and Plot Visualisations 
 
A small pilot study with 8 participants from 1 site was conducted to see if the gating tools or plot 
visualisations used had an impact on the range of variation seen within the analysis. This fed into 
the main study to possibly restrain visualisation and gating tool variables that participants used in 
the software. 
 
The repeated .fcs files used for repeats in Flowjo workspaces within the main study was analysed 
by the participants in a random order of repeats. Three visualisation methods were tested; a 
contour plot, a greyscale plot and a pseudocolour plot (Figure 35). The target cell population was 
gated using three different tool types: an ellipse, a manual polygon tool and an autogate tool (Figure 
36). For each gating tool and visualisation used, three randomised repeats were taken. 
 
Figure 35 Visualisations tested within pilot to see if data visuals affect participant gating variance 
 
Figure 36 Gate tools tested to see if they have an impact on participant gating variance 
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This data was captured over 3 separate 30-minute sessions, as shown in Figure 37. No participants 
were deemed colour blind (when tested using a Farnsworth-Munsell D-15 test (Figure 38)), which 
is a potential source of variance for a participant and could be investigated as part of future work. 
A Farnsworth-Munsell D15 test uses 15 coloured discs that range from the blue end of the colour 
spectrum to the red end. These discs are randomly mixed up and participants had to arrange them 
from what they considered to be blue to red. These were then analysed by the study coordinator, 
because the reverse of the discs has a numerical order. If the order of the numbers is not correct, 
this can indicate colour blindness.  
 
Figure 37 Visualisation pilot study structure diagram for comparison of gating tools and visualisation between 
participants 
 
Figure 38 Farnsworth-Munsell D-15 Colour Vision Test; a) Random pieces for participants to order, b) Correct order for 
colour tags 
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The orange dashed boundaries in Figure 37 separate the reproducibility boundaries for each tool 
and plot, from which an understanding of gating range was looked into. The cell count percentage 
as a function of the original file cell event number (30,000 events) was used for comparison. SDs 
of the three repeats were compared for each tool and plot, with total inter-participant SD ranges 
for each configuration shown in Figure 37 for tool types and plots used [180], generated using a 
combination of Microsoft Excel and Matlab R2019a for processing and visualisation respectively.  
, 
Figure 39 Ranges of inter-participant SD for each gate tool on each visualisation plot 
 
Figure 39 shows that using a greyscale plot will potentially contribute greater variance to the overall 
measurement, especially if using an autogate tool. Unlike using this tool on a contour plot or a 
pseudo colour plot, greyscale provides no other perception of density of the cell events, leaving 
participants to make less informed decisions, increasing variability in their measurements. The 
autogate tool also had significantly higher between participant range when using pseudocolour 
density plots. The autogate tool could not effectively separate the boundary between the target cell 
population and the dying cells. This software issue led to participants making variable decisions on 
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where to place the gate. During the sessions, participants commented on the autogate tool, often 
feeling they either cut out too much of the population or included irrelevant cells from another.  
 
Contour plots had the smallest difference between gate tool ranges, possibly because the contour 
lines provided guidance for participants to follow and place gates. Even though the ellipse gate 
fitted the target cell population very well, the manual polygon has consistently low variation range 
on each visual plot. This may be because the participant ultimately has more control over the shape 
of the gate and the placement of gate indices. Whilst the autogate tool allows adjustment once the 
gate has been placed, it produced so many indices that participants did not want to spend the time 
adjusting them all.  
 
Ultimately, the tool used will be based on a variety of factors including but not limited to the general 
shape of the cell population, density, scaling, personal preference and knowledge of other tools (or 
lack of knowledge). Overall the SD ranges shown here are very small so the choice of visual plot or 
gating tool chosen may not have a significant effect on the overall measurement, however, the 
pseudocolour plot will be used for the main study, because it shows generally low variance with the 
gating tools tested and it is also the default layout in the Flowjo software used. One should be aware 
of other factors that can influence these measurements such as colour vision and time taken to 
complete these studies. In high-pressure situations where participants may not have full colour 
vision, results could be skewed or greater in uncertainty.  
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4.4 Results & Discussion 
 
4.4.1 Flow Cytometry Basic Gating Exercise absolute results 
 
The absolute results reported here are the targeted cell population that participants were asked to 
identify using the gating sequence defined in Figure 33. These are akin to what would be reported 
in literature for specific cell types, in this instance it is single, pluripotent stem cells. The uncertainty 
of the gating sequence will be discussed in the next section of this Chapter.  
 
Table 21 Measures of Location for the absolute results of the Base Gating Study (%) 
Arithmetic Mean 32.1 
Median 32.5 
Mode N/A 
Minimum 19.7 
Maximum 51.3 
 
Table 22 Measures of Spread for the absolute results of the Base Gating Study (%) 
Range 31.6 
25th Percentile 30.6 
75th Percentile 33.9 
Interquartile Range 3.3 
Standard Deviation 5.7 
CV 17.8 
Median Absolute Deviation 1.9 
 
Table 23 Measures of Skew for the absolute results of the Base Gating Study (%) (3dp for better resolution) 
Skewness 0.492 
Skewness standard Error 0.383 
Skewness z-score 1.280 
Kurtosis 3.271 
Kurtosis Standard Error 0.750 
Kurtosis z-score 4.560 
 
Table 24 Measures of Normality for the absolute results of the Base Gating Study (%) (3dp for better resolution) 
Shapiro-Wilk statistic 0.904 
Significance 0.003 
Normal/Non-parametric Non-Parametric 
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Using descriptive statistics to give a general report on the size and shape of the data, the 
distribution approximates to a normal shape because the mean and median are very close 
together, as quoted in Table 21. However, the Shapiro-Wilk statistical test for normality (Table 24) 
significantly concludes the distribution is not normal. This non-parametric definition is most 
probably indicated by the spread of the distribution, rather than any specific location parameters. 
Measures of spread (Table 22) show that there is a wide range between the highest and lowest 
participant averages, but the IQR of the participant data fell within a boundary of 3.3%, which is 
9.5 times smaller than the overall range.  
 
The measures of skew tests further confirm the non-normality due to data extremes (Table 23). The 
actual skewness measure indicates the distribution is normal, but the kurtosis of the data set 
confirms that the distribution is heavily affected by ‘outliers’ in the data. These extreme values can 
be seen in Figure 40. Most participant averages lie close to the median, and the error bars show ± 
1SD from each individual’s repeated measures.  
 
Figure 40 Absolute Results of Target Cell population, represented by each participant's average and ± SD. 
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Participant deviation from the median has been more clearly visualised in Figure 41, with bars 
depicting each participant’s average from the median group value. The SD limits have also been 
plotted, because these are most commonly used within traditional manufacturing to define out of 
control/out of specification limits. 76 % of participants are within 1SD of the median, showing good 
corroboration of final results. Of those who fell out of bounds, two participants had results above + 
1SD, one participant above + 2SD, one participant below - 1SD and three participants below - 2SD.  
 
Figure 41 Participant average result deviations from overall group median. 
 
The other control limits discussed in Chapter 3 have also been applied to this data, to further 
exemplify the difference between acceptance performance if different boundaries are specified by 
manufacturers. Figure 42 shows the control limits applied to this data set, cutting off different high 
and low extreme values, based on the mean and median of the data set. There is central tendency 
so there is no skewness of the data which could cause more outliers on one side of the distribution 
than the other. 
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Figure 42 Acceptance boundaries applied to the Basic model averages to show difference in outlier classification. 
 
To compare both positive and negative deviation data extremes, Figure 43 shows participant B08’s 
gating strategy, one of the participants very close to the group median value. The three images 
show the gating sequence steps used to define the final population cell count, with B08’s three 
repeats collated onto each sequence step image. This layout has been used for the remainder of 
qualitative participant analysis figures throughout this thesis. By comparing the extreme 
participants to a median participant, there are obvious differences between participants when 
identifying populations based on the visualised density. This is also coupled with personal 
preferences on inclusion or exclusion of data points to further refine the data set in search of a 
particular target. 
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Figure 43 Participant B08 Gating Strategy interpretation, close to median result. 
 
Focusing on those who fell outside of 2SD, participant B09 returned the highest population average 
(51.3%). Reviewing the participant’s gating strategy has shown that most of bias is due to their 
initial conclusion of a larger cell population, consisting of doublets, which should have been 
excluded if following the defined sequence. This gating strategy can be seen in Figure 44, also 
showing a high variance in how this initial gate was applied.  
 
Figure 44 Participant B09 Gating Strategy interpretation 
 
Participants A08, B05 and C09 also fell outside of this specification limit, with an average value 
significantly lower than the group median. Figure 45 to Figure 47 show their respective gating 
strategies, again noting that in each case, their first gate applied is situated within the target 
population, and therefore causing the low final result. 
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Figure 45 Participant A08 Gating Strategy interpretation 
 
Participant A08 did not gate a single cell population because this was not something they have 
previously experienced in their own FC processes. Participant A08’s final quadrant gates intersects 
the final population, because gates were applied against control files and not checked against the 
fully stained sample files. In this instance, poor gating ‘clean-up’ procedures and awareness of 
preliminary ‘data-cleaning’ processes have potentially caused this variance, alongside the 
participant perception of density.  
 
 
Figure 46 Participant B05 Gating Strategy interpretation 
 
Figure 47 Participant C09 Gating Strategy interpretation 
 
Participants B05 and C09 have applied their gates within the target cell population in the first 
instance. They all preferred to apply more refined gates to have better certainty of result to 
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removing any boundary outliers early on. These participants have all used different strategies to 
further clean the data to identify the single cell population. Participants were allowed to choose 
what axes they preferred to gate the single cell population, so even though each axis configuration 
does not have much noise, it will contribute a small amount of variation.  
 
This analysis of the absolute results used to represent cell populations shows a 31.8 % cell count 
range between participants when determining final single pluripotent cell population percentages.  
The further qualitative analysis of the extremes identifies 4 participants who fall outside of initial 
control limits. These extreme participants account for over half of the cell population percentage 
range. If these 4 extreme participant values were removed, the range would fall to 16.3% (a 
difference in cell count of 4,890 cells) between participants (minimum value of 26.0% and 
maximum value of 42.3%). 
 
Potential inclusion of more information of areas to gate would aid location of gate placement to 
improve general result conformity, although this may not necessarily improve intra-participant 
variability.  
 
Variability of absolute results is commonly assessed using the CV, which combines the average and 
standard deviation of final cell count measurand. The distribution histogram of participant CV of 
reported results can be seen in Figure 48, plotted on top of 3 specification limits derived from the 
ICSH boundaries. The ICSH and ICCS have set imprecision criteria for Cell-based fluorescence 
assays as a desirable target of < 10 % CV or when dealing with rare-cell cases or minimal residual 
disease detection < 20 % CV is acceptable [71]. In this study ‘Good Performance’ is represented at 
5 % CV, half of the ICSH guideline acceptance criteria. ‘Satisfactory Performance’ shows the amber 
region at 10 % CV and the ‘Revision Required’ limit is set to 20 % CV, because this basic model is 
not designed to detect rare cell events, it is designed to be easy for participants to complete with 
no questionable populations or events. Therefore, this amount of variance is not ideal in this 
  Chapter 4: Basic Uncertainty Model 
125 
 
exemplar. These boundaries have been defined using the equation of a straight line in Equation 
20, where m is the gradient of the line and c is the y-axis intercept. 
 
𝑣𝑣 = 𝑀𝑀𝑀𝑀 + 𝑝𝑝 
Equation 21 Equation of a straight line 
 
The optimal scenario would have all 38 participants (n) with < 1 % CV, which sets the total height 
at y-intercept of the graph. Using the equation of a straight line, boundaries can be drawn from the 
optimal CV position, or y-intercept, to the uncertainty specification limits on the x-axis. A right-angle 
triangle shape shows progression towards the desired positive skew and optimal variation 
positions. Applying this to a traffic light style quality monitoring diagram would show performance 
levels within a facility and ideal variance which can be quickly and easily understood by all.  
 
In a similar manner, this schematic has also been used for uncertainty of measurements 
throughout this thesis, because this is a measure of variability that combines SDs from the 
additional gating steps in the sequence, not just the final gate which is used to calculate CV.  
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Figure 48 CV Performance of Participant Absolute results 
Using these guidelines as boundaries, two participants fall outside of the ‘good’ and ‘satisfactory’ 
performance regions. These extreme outliers had more variation within the final quadrant gate they 
drew when identifying the final positive pluripotent cell population. Participant A08 had the highest 
CV, and their final gate can be seen already illustrated in Figure 45. A08 intersects the final 
population more than the rest of the participants and has one of the three repeated gates 
significantly higher than the rest, causing greater variation between the repeated measures.   
 
 
Figure 49 Participant C01 Base Model Study Gating interpretation 
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Participant C01 (Figure 49) also had a CV that fell within the ‘Revision Required’ region of the graph, 
and again the variation is caused in the final gate due to one of the repeats being placed 
significantly higher than the other two. It can be seen in the first two gates applied in participant 
C01’s sequence that they are also very variable throughout the gating sequence, however, this is 
not captured within the representative population CV measurement, because it is only calculated 
from the final population cell counts derived using the whole sequence. Separate CV values could 
be calculated individually for each gate applied in the sequence. However, this can become 
cumbersome to use because the amount of data to analyse has tripled. In more complex sequences 
this would be even more time consuming.  
 
Measurement uncertainty provides a way of combining variability measures (SDs) of each gate 
within the sequence, to provide a measurement that is more representative of the components of 
the gating sequence. When extremes in measurement uncertainty arise, uncertainty values can be 
easily deconstructed to identify which part of the gating sequence is responsible for causing 
variation within the measurement.  
 
4.4.2 Flow Cytometry Basic Gating Exercise uncertainty results 
 
The uncertainty results reported here are a combination of the three gating stages defined in Figure 
33. The uncertainty values have been quantified following the prescribed methodology in Chapter 
2 and Section 2.5. The uncertainty would better represent variance of measurements with greater 
confidence, because this combines variability from all gates applied in the sequence, not just the 
variance of the final gate applied.  
 
Table 25 Measures of Location for Uncertainty of the Base Gating Study (%) 
Arithmetic Mean 4.0 
Median 3.6 
Mode N/A  
Minimum 0.7 
Maximum 13.1 
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Table 26 Measures of Spread for Uncertainty of the Base Gating Study (%) 
Range 12.4 
25th Percentile 2.0 
75th Percentile 5.6 
Interquartile Range 3.6 
Standard Deviation 2.7 
Median Absolute Deviation 2.0 
 
Table 27 Measures of Skew for Uncertainty of the Base Gating Study (%) (3dp for resolution) 
Skewness 1.288 
Skewness standard Error 0.388 
Skewness z-score 3.320 
Kurtosis 2.311 
Kurtosis Standard Error 0.759 
Kurtosis z-score 3.045 
 
Table 28 S-W test for normality for Uncertainty of the Base Gating Study (%) (3dp for resolution) 
Shapiro-Wilk statistic 0.900 
Significance 0.003 
Normal/Non-parametric Non-parametric 
 
Similar to the descriptive statistics for absolute results for this study, the mean and the median are 
close together, indicating a normal distribution, as monitored in Table 25. The median is less than 
the mean, indicating a slight positive skew to the data. This is further supported by the Shapiro-
Wilk test for normality, shown in Table 28, indicating that the distribution is non-parametric in 
shape, indicating skewness. 
 
There is a wide range (12.4 %) between minimum and maximum participant uncertainties, which 
does not include Participant B19. Their Standard Deviation of zero (as seen in Figure 50), further 
showed that they had copied gates across the repetition workspaces, giving a comparable absolute 
result but no measure of precision, disqualifying them from this uncertainty analysis. Table 26 also 
shows the interquartile range as 3.6%, indicating a strong central tendency, because half of the 
data lies within 31% of the total distribution. 
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Figure 50 Expanded Uncertainty of all Participant Gating within the Base Model Study 
 
The measures of skew tests (Table 27) further confirms this non-normality, because the skewness 
z-score also falls outside of the 2.58 bandwidth of normality (as described in Chapter 2, Section 
2.2.2). The kurtosis z-score also falls positively outside of the 2.58 bandwidth (both skewness and 
kurtosis use the same scaling), although it is not as large as the skewness value, meaning the non-
normality is more likely due to the shape of the data than extreme data points, although these can 
still have a significant impact on the final distribution statistics. This distribution shape can be 
observed within Figure 51, showing the positive skew with 2 or 3 larger uncertainty extremes. 
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Figure 51 Histogram of Participant Uncertainty from repeats of Base Model Study 
 
Whilst deviation from a median can help to explain the distribution parameters, when analysing 
variance, a positively skewed distribution towards zero is preferred. Comparing uncertainty in its 
size order allows boundaries to be set for permissible specification limits for product 
release/laboratory quality that increase in value.  
 
The ICCH and ICS imprecision values described earlier for measurement CV have also been used 
here to define example specification limits if monitoring participant uncertainty. CV is a measure 
usually used to represent variability of a final metric because it considers both the mean and SD of 
a measurement. This only works for the final cell population count, whereas uncertainty combines 
in quadrature the SDs of all the gates applied in the sequence.  In this instance the CV specification 
limits have been substituted for uncertainty, because there is a positive correlation (using a line of 
best fit) between the result CV per participant and their respective uncertainty for this cell model 
(Figure 52), and no other uncertainty specifications have been defined in the public body of 
knowledge from research or industry. 
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Figure 52 Final Cell Count Population Percentage versus Gating Uncertainty for participants 
 
 
Figure 53 Participant performance monitoring diagram for uncertainty results of basic model 
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Figure 53 shows the base model uncertainty histogram from Figure 51, plotted on top of 3 
specification limits derived from the ICSH boundaries. ‘Good Performance’ is represented at 5 %, 
half of the ICSH guideline acceptance criteria. ‘Satisfactory Performance’ shows the amber region 
at 10 % and the ‘Revision Required’ limit is set to 20 % once again. A permissible limit for 
uncertainty (pU) [181] has also been plotted as another variance discriminator, defined in Equation 
2, assuming a 95 % Confidence Interval to the data.  
 
𝑎𝑎𝑈𝑈 = 2.39 × 𝑟𝑟𝐷𝐷 
Equation 22 Permissible Uncertainty 
 
Participant C01 (Figure 49) had an uncertainty that fell within the ‘Revision Required’ region, with 
participants A07 and B16 being at the higher variation end of ‘Satisfactory Performance’. Figure 
49, Figure 54 and Figure 55 show their respective gating strategies, compared with Participant B18 
(Figure 56) who had the lowest uncertainty, exemplified as an ideal participant in this instance.  
 
Participant C01’s uncertainty can be attributed to the three gate phases drawn for target cells, 
single cells and the double positive pluripotent cells in a respective 40:33:27 % split. The SDs are 
the inter-participant group maximum for each gate applied in sequence. The target gate identifies 
the same population each time, but varies to capture smaller, possibly dying cells and varies again 
to make the ellipse more spherical. Consistency of gating shape could reduce this variability slightly, 
provided that the cell population boundary is well defined. Single cell gate variance is attributed to 
2 of the 3 gates being consistently smaller in size, with the third gate capturing the majority of the 
population. C01 applied smaller gates on this window with each repeat, suggesting potential 
refinement (from memory) for each session repeat. The final gate had understandably smaller 
variance in comparison, being produced by one offset quadrant refining the density of the 
population.  
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Figure 54 Participant A07 Base Model Study Gating interpretation 
 
Participant A07’s uncertainty is attributed to the target cells gate, single cells gate and double 
positive in the ratio of 44: 36: 20 % respectively. Most of the variance comes from the target cells, 
where differences can be seen in the gating at the boundary of dying cells, in a similar manner to 
Participant C01. The single cells gate is causing variance because of the gates being applied very 
closely to the corners of the dense cell population. A small fraction of the tip of the population has 
caused a significant difference in the number of cells captured in the gate each time. Finally, the 
quadrant gate has two repeatable gates applied, with one gate applied further out. Even though 
this captures more of the cell population this is still different from the other two gates drawn.   
 
Figure 55 Participant B16 Base Model Study Gating interpretation 
 
Both the target and single cell gates contribute 35% to B16’s gating uncertainty. The target cell 
variance is likely due to varied inclusion of the smaller, possibly dying cells which caused variance 
for C01 and A07, because this is a region of gating difference overlaying more dense regions of 
data. The single cell variance is likely to be due to one gate applied which cuts off the top-right 
underside ‘corner’ of the data. 
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Figure 56 Participant B18 Base Model Study Gating interpretation 
 
Participant B18 had the lowest uncertainty at 0.7 %, with their respective gating strategy shown in 
Figure 56. B18’s initial target gate was repeatable in shape, as well as having minimal distance 
between gates at the cut-off for dead or dying cells, which has shown to cause variance for other 
participants. Again, their single cell gates were very similar in shape, and they captured the whole 
of the population without cutting any edges. Finally, the quadrant gates were very precise, having 
minimal effect because they do not intersect any high-density areas due to good use of control files 
provided. Control files provided were isotypes, Fluorescence Minus-One (FMO) controls and a 
negative sample, which were used to set the position of the gates using a positive/negative split 
on respective axes.  
4.5 Chapter Conclusions 
 
The EC 2102 Ep Cell line used was a good model for the baseline study because it has been shown 
to not differentiate over time, providing a good starting point for analysis due to simplicity of marker 
discrimination and very limited biological variation. Hence there are very limited/negligible 
upstream effects on downstream analysis. The studies run with the 3-workspace configuration for 
repeats worked well within the time available for participants so this structure should be used going 
forwards. The three-step process that each participant had to work through was also straight-
forward to follow from the image, ensuring there was little deviance from the prescribed method.  
 
Initial validation of plots and tools used has provided an interesting insight into how different 
layouts can affect subjectivity and therefore results. Greyscale plots are currently uncommon as 
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technology has progressed to allow more data dimensions to be shown at once, but the initial pilot 
has shown they should not be used over colour plots due to increased variance in analysis 
reproduction. A greater number of participants in this study would strengthen results and 
conclusions, but generally manual polygon tools provide more control over gate placement and 
exhibit a smaller difference in range across different visual scenarios.  
 
The mean and median values (32.1 % and 32.5 % respectively) for the absolute cell count reported 
results are very similar, usually indicative of a normal distribution but upon further investigation the 
population is non-parametric, due to the distance of extreme values. These extremes appear to be 
attributed to variance in the first target cell gate applied. Due to the noise, debris and doublet 
populations present, more training should be given to Cytometrists when learning to gate, ensuring 
greater uniformity of results.  
 
Knowledge of correct populations and decisions made on cell cluster boundaries could aid 
reproducibility between participants. Similarly, decisions on population density boundaries should 
be determined within a ‘gating specification’ possibly through the validation of population 
percentage and use of tools such as Gating-ML to determine gate shape and size parameters. 
 
CV of measurements is a commonly used tool throughout Flow Cytometry to quickly monitor 
variation, however, this only accounts for repeat measures on the final gate of a sequence. 
International committees have defined acceptance criteria for Flow Cytometry CV measurements, 
which have been applied and adjusted to assess initial base model CV results here, although other 
variance criteria have been defined, as discussed in Chapter 1. Reviewing these extremes shows 
variability in the final gate applied, but it also highlights that other variability seen upstream of this 
gate is not taken into consideration, making measurement uncertainty a more suitable metric for 
accommodating variation throughout the whole gating sequence.  
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This base model with 3-step sequence has shown that calculating measurement uncertainty is 
possible for participants by using traditional measurement uncertainty methods. This was 
calculated successfully, by presenting participants with three repeated workspaces of data, 
informed by Gauge R&R testing layouts and extracting one repeated file located in each workspace 
randomisation. The Gauge R&R randomisation layout was useful to test but it caused some 
participants to exceed the 1-hour time limit due to the number of files used around the main 
analysis file. It also caused slightly more difficulty in traceability of the repeated file across each 
workspace. In subsequent Chapters this complexity of study design and randomisation will not be 
used, in order to have greater control over the data analysis variables which could affect the overall 
uncertainty contributed from participants. 
 
The uncertainty was also skewed with an absolute median of 3.6 %, although it is preferable to 
have as low an uncertainty as possible to reduce measurement variation passed on to the final 
reported result. The overall range of participant uncertainty was 12.37 %, which is outside of the 
‘satisfactory performance’ boundary assumed from the ICCH data, so revision of more extreme 
participants has been completed, showing that when data is more clustered and noisy at the start 
of the analysis sequence, this can have a knock on effect to their uncertainty contribution. 
 
Acceptance limits determined from the ICSH have enabled this uncertainty data to be compared 
and put into manufacturing quality control context using the diagram generated in Figure 53. 
Simple traffic-light visuals have been proposed here and help show the quality status of a 
product/service/facility quickly and can be easily updated and adapted to suit the number of 
participants/participants and continuous improvement quality levels. A better knowledge of 
uncertainty visualised in this way potentially improves quality by addressing gating that falls outside 
of satisfactory boundaries and a good working culture that does not attribute blame can help a 
facility grow to tighten overall measurement uncertainties.  
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4.5.1 Consolidation of Objectives 
 
• This study ran smoothly, acting as a good baseline for comparison of absolute reported 
results, CV and uncertainty measures. The session structures were suitable in time, and 
3 repeats was suitable for participants to understand study context, but not become 
tired.  
• A pilot study showed that different plot visualisations and gating tools contribute variance 
to a measurement, albeit a small amount. Grayscale plots are not recommended for use 
as they increase inter-participant variance, and they do not include as much information 
about density on the plot. 
• Extreme values in absolute reported results were due to participants either over 
constraining or under constraining the initial target cell population within the first gate. 
In some cases, lack of knowledge of using controls to set gates led to variance in final 
pluripotent population metrics. 
• Extreme values in uncertainty results were due to participant variability in applying a gate 
to separate the target cell population from the dead or dying cells. 
• The performance monitoring diagrams visualised in Figure 48 and Figure 53 provides a 
straight forward way to monitor uncertainty performance with respect to the number of 
people in the study and defined quality satisfaction limits. These will be used in 
subsequent chapters to monitor uncertainty performance in more complex gating 
scenarios. 
• This study defines participant uncertainty for a highly constrained, very stable 2 colour 
panel cell model, which can be used as a baseline for development into more complex 
cell models, to monitor potential growth of between participant uncertainty in more 
difficult analysis scenarios. 
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Chapter 5: Intermediate Uncertainty Model 
5.0 Introduction to the Chapter 
Chapter 5 introduces the second uncertainty gating exercise (intermediate model), as part of the 
sequence of studies which monitor participant variance in comparison to complexity of data. As 
discussed in the prelude, this second uncertainty exercise is intermediate, to further monitor 
uncertainty in a more complex analysis scenario. This is more representative of FC analysis and T-
cell lineage markers used to monitor cell therapy products. This continues to build the pathway for 
further uncertainty gating studies described in Chapter 6 with comparisons drawn between all three 
models in Chapter 7. Previously in Chapter 4, only three gating steps had been considered with an 
immortalised cell line (Basic model), whereas this second uncertainty stage tackles more complex 
FC data analysis using primary Peripheral Blood Mononuclear Cells (PBMCs) which are used as a 
basis for many autologous engineering cell therapies. This becomes more relevant for the CGT 
manufacturing community, therefore potentially providing a more translational application of 
uncertainty to FC measurements. This Chapter uses a five-step analysis sequence, and similar to 
Chapter 3, sees participants analyse this data across two sessions using their own judgement and 
then using a diagrammatical protocol respectively.  
 
5.1 Chapter Aims 
 
This Chapter develops comparison of uncertainty in more complex FC analysis strategies. The fit of 
this Chapter to the thesis can be seen in Figure 57, specifically within the orange dashed box, 
providing development for the core hypothesis: as complexity of FC data and processing increases, 
measurement uncertainty contributed from the participant will also increase.  
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Figure 57 Diagram of Chapter position within the whole Thesis 
 
5.1.1 Chapter Aims & Objectives 
 
The Aims and Objectives of this Chapter can be defined as follows: 
• Design an intermediate two-phase study structure to measure CV and uncertainty of 
participants when gating an intermediate complexity set of FC data. 
• Identify whether using diagrammatical protocols to apply gates reduces between 
participant absolute reported results and uncertainties. 
• Identify what causes extreme values in absolute reported results and uncertainty 
measurements by reviewing extremes from this intermediate study. 
• Further test monitoring tools for understanding uncertainty within a more complex 
participant study or facility. 
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5.2 Methodology 
 
Primary Peripheral Blood Mononuclear Cells (PBMCs) were acquired from LGC-ATCC cell banks for 
use within this phase of research (Cat Number: PCS-800-011, Lot number: 80628171).  
 
5.2.1 Cell Selection and Culture 
 
The vial of PBMC material acquired from LGC-ATCC cell banks was primary biological material, 
meaning this has been taken straight from the donor and separated to remove additional whole 
blood cell types. It has not been expanded in vitro before cryopreservation, so this material was 
handled in accordance to the Human Tissue Act (HTA) regulations [182]. Before acquiring this 
material, the Certificate of Analysis for the PBMC material was obtained, along with confirmation of 
donor consent from the supplier for this material to be used for research purposes. These 
documents can be found in Appendix C. Human Tissue Act training was also completed within the 
Centre for Biological Engineering, Loughborough University and through the Medical Research 
Council (MRC) online Research and Human Tissues legislation (Certificates in Appendix C), to 
ensure the correct handling, disposal and ethical treatment of the material was adhered to.  
 
A vial of ATCC PBMCs (25 x 106 cells, suspended in 1 mL of cryoprotective fluid) was removed from 
a liquid nitrogen Cryobank and was thawed in a water bath for 3 minutes until a slither of frozen 
material remained. The material was topped up 1:1 with RPMI 1640 cell culture media (Cat Number 
11875093, Lot Number: 1906058) (fortified with 10 % v/v Fetal Bovine Serum (FBS)), mixed slowly 
and transferred into a centrifuge tube. 1 mL of Flow Cytometry buffer fluid (Biolegend Cell Staining 
Buffer Cat Number 420201, Lot Number B228788) was used to wash the inside of the cryovial to 
remove any additional cells which remained after transfer. This 1 mL flow buffer suspension was 
also added to the centrifuge tube. The centrifuge tube was then topped up to 25 mL with an 
additional 22 mL of RPMI 1640 cell culture media, and a 250 µL sample was taken for an initial 
cell count. Three counts were completed using a Nucleo-Counter® NC-3000™ and ChemoMetec 
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Via1-Cassettes™, to stain and measure cells with Acridine Orange and DAPI dyes, calculating an 
average of 0.8 x 106 cells / mL, totalling approximately 20 x 106 cells within the resuspension. 
 
The remaining cell suspension was centrifuged at 300 g for 5 minutes, transferred into a Biological 
Safety Cabinet (BSC), and the supernatant removed from the cell pellet. 29 mL of RPMI 1640 
fortified media was added to a T75 flask, and the cell pellet was resuspended and slowly mixed 
with 1 mL of cell culture media, before being transferred into the T75 flask. This T75 flask was 
moved into a humidified incubator at 37˚C with 5% CO2, for 24 hours to allow the cells to proliferate. 
To comply with HTA good practice, a sign was placed on the incubator to notify other users of the 
contents, and the material location was updated on the biological material database, Procuro. 
 
After 24 hours had elapsed, cells were counted by taking a 250 µL sample from the mixed cell 
suspension. An average of 0.83 x 106 cells / mL was measured from the sample, totalling 
approximately 24.7 x 106 cells within the total resuspension, at an average viability of 94.8 %. The 
increase in cell count after 24 hours shows a successfully maintained cell population after being 
thawed, so the cells could be used for further analysis. In this instance, further cell culture or 
monitoring of certain cellular features was unnecessary because only ‘snapshot’ fcs files of the 
PBMC material were required. PBMCs are suspension cells, so no disassociation process was 
required to remove the cells from the surface of the tissue culture flask. The cell suspension was 
transferred into a 50 mL centrifuge tube and centrifuged for 5 minutes at 300 g to form a cell 
pellet.  
 
5.2.2 .fcs File Generation 
 
A series of fcs files were generated using the primary PBMCs kept in culture for the last 24 hours.  
Cells were resuspended in 2.5 mL of Cell Staining buffer and gently mixed, then recentrifuged to 
form a pellet and resuspended in 2.5 mL of Cell Staining buffer to wash the cells and remove any 
cell culture media remaining. 0.1 mL aliquots of the master cell suspension were placed into 
separate labelled microcentrifuge tubes so there were approximately 1 x 106 cells per tube (three 
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fully stained samples, one unstained sample, one live/dead stained sample, five single stain 
controls, five isotype controls, five FMO controls). The unstained sample was wrapped in foil and 
placed in a 4˚C fridge because this was not needed until the final analysis. 
 
1 µL of Biolegend Zombie Aqua Viability dye (Cat Number: 423101, Lot Number: B243783) was 
added to all tubes and gently mixed, except for the unstained sample. The Eppendorf tubes were 
covered in foil to minimise light exposure and left to incubate for 20 minutes. Amine-reactive dyes 
or Live/Dead fixable dead cell stains cross the cell membrane of dead cells and react with free 
amines in the cytoplasm. Live cells exclude these dyes when they are intact so free stain can be 
washed away after staining, allowing for discrimination of live and dead cells in the population 
[183]. Amine-reactive dyes were used because they could be compensated for within the Flow 
Cytometry panel using amine-reactive compensation beads. Once incubated, all cells were washed 
twice with 1 mL Cell Staining Buffer, centrifuged (300 g for 5 minutes) and supernatant removed. 
Cells were then resuspended in 100 µL Cell Staining Buffer. 
 
5 µL of Biolegend Human TruStain FcX™ Fc blocker (Cat Number: 422301, Lot Number: B235079) 
was added to all cell samples aside from the isotype controls and incubated covered in foil for a 
further 15 minutes. Human Fc receptors are expressed on a variety of cells and cells with Fc 
receptor expression can sometimes give false positives or false negative results within 
immunofluorescent staining because of Fc receptor non-specific binding. Human TruStain FcX™ is 
a blend of specialised IgG immunoglobulins that join to Fc receptors to stop non-specific binding 
occurring. Once incubated, all cells were washed twice with 1 mL Cell Staining Buffer, centrifuged 
(300 g for 5 minutes) and supernatant removed. Cells were then resuspended in 100 µL Cell 
Staining Buffer. 
 
The live/dead sample then kept alongside the unstained sample in the fridge and was removed 
when Flow Cytometry analysis was undertaken. The remaining cells were then stained according to 
the following stain protocols in Table 29, Table 30, Table 31 and Table 32. Isotype controls for each 
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marker were stained with the respective antibody isotype control, single stain controls were stained 
with just the antibody marker for that specific stain and the FMO controls were stained with all 
stains aside from the stain aligned to that specific channel. This is to monitor any fluorescence 
spillover into the required channels from other markers being used. 
 
The antigen markers used for the Single Stain controls (Table 29), FMO controls (Table 30) and 
Fully Stained Samples (Table 32) are Biolegend FITC anti-human CD3 antibody (Cat Number: 
300306, Lot Number: B218086), Biolegend APC anti-human CD4 antibody (Cat Number: 357405, 
Lot Number: B223335), APC/Cy7 anti-human CD8 antibody (Cat Number: 300926, Lot Number: 
B231191), Biolegend PE anti-human CD45RA antibody (Cat Number: 362552, Lot Number: 
B210221) and Biolegend BV421 anti-human CD56 antibody (Cat Number: 423101, Lot Number: 
B246952). 
 
Table 29 Staining volumes for Single Stain Controls 
Channel Antigen 
Marker 
FITC Single 
Stain 
APC Single 
Stain 
APC/Cy7 
Single Stain 
PE Single 
Stain 
BV421 
Single Stain 
633 nm 
laser, 
660/20 filter 
CD3 FITC 5 µL     
488 nm 
laser, 
530/30 filter 
CD4 APC  5 µL    
633 nm 
laser, 
780/60 filter 
CD8a 
APC/Cy7 
  5 µL   
488 nm 
laser, 
585/42 filter 
CD45RA PE    5 µL  
405 nm 
laser, 
450/50 filter 
CD56 BV421     5 µL 
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Table 30 Staining volumes for FMO Controls 
Channel Antigen 
Marker 
FITC FMO APC FMO APC/Cy7 
FMO 
PE FMO BV421 FMO 
633 nm 
laser, 
660/20 filter 
CD3 FITC  5 µL 5 µL 5 µL 5 µL 
488 nm 
laser, 
530/30 filter 
CD4 APC 5 µL  5 µL 5 µL 5 µL 
633 nm 
laser, 
780/60 filter 
CD8a 
APC/Cy7 
5 µL 5 µL  5 µL 5 µL 
488 nm 
laser, 
585/42 filter 
CD45RA PE 5 µL 5 µL 5 µL  5 µL 
405 nm 
laser, 
450/50 filter 
CD56 BV421 5 µL 5 µL 5 µL 5 µL  
 
The antigen markers used for the Isotype controls (Table 31) are Biolegend FITC Mouse IgG2a ĸ 
Isotype Control antibody (Cat Number: 400207, Lot Number: B235551), Biolegend APC Mouse 
IgG2b ĸ Isotype Control antibody (Cat Number: 400329), APC/Cy7 Mouse IgG1 ĸ Isotype Control 
antibody (Cat Number: 400127, Lot Number: B235070), PE Mouse IgG2b ĸ Isotype Control 
antibody (Cat Number: 400313, Lot Number: B246304) and Brilliant Violet 421 Mouse IgG1 ĸ 
Isotype Control antibody (Cat Number: 400157, Lot Number: B237449). 
 
Table 31 Staining volumes for Isotype Controls 
Channel Antigen 
Marker 
FITC Isotype APC Isotype APC Fire 750 
Isotype 
PE Isotype BV421 
Isotype 
633 nm 
laser, 
660/20 filter 
CD3 FITC 5 µL     
488 nm 
laser, 
530/30 filter 
CD4 APC  5 µL    
633 nm 
laser, 
780/60 filter 
CD8a 
APC/Cy7 
  5 µL   
488 nm 
laser, 
585/42 filter 
CD45RA PE    5 µL  
405 nm 
laser, 
450/50 filter 
CD56 BV421     5 µL 
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Table 32 Staining volumes for Fully Stained Samples 
Channel Antigen 
Marker 
Fully Stained 
Sample 1 
Fully Stained 
Sample 2 
Fully Stained 
Sample 3 
633 nm 
laser, 
660/20 filter 
CD3 FITC 5 µL 5 µL 5 µL 
488 nm 
laser, 
530/30 filter 
CD4 APC 5 µL 5 µL 5 µL 
633 nm 
laser, 
780/60 filter 
CD8a 
APC/Cy7 
5 µL 5 µL 5 µL 
488 nm 
laser, 
585/42 filter 
CD45RA PE 5 µL 5 µL 5 µL 
405 nm 
laser, 
450/50 filter 
CD56 BV421 5 µL 5 µL 5 µL 
 
CD3 (Cluster of differentiation 3) is a T-cell co-receptor that helps to identify lymphocyte subsets 
and activate cytotoxic and helper T-cells. It transduces the activating signals to the cytoplasm of 
the T-cell [184]. CD4 (Cluster of differentiation 4) is an extracellular protein marker found on the 
surface of immune cells, specifically T helper cells [185,186]. This white blood cell subset signals 
to other immune cells to destroy foreign bodies found. If patients have low CD4+ counts, they are 
susceptible to lots of infections which can become difficult for the immune system to fight. CD8 
(Cluster of differentiation 8) is a cell surface protein on cytotoxic T cells and also natural killer cells. 
These cells are able to kill virus-infected cells, cancer cells and can use cytokines to recruit other 
cells when mounting an immune response [187,188]. CD4:CD8 ratios are often used to measure 
the balance of the immune system [189]. 
 
CD45RA (Cluster of differentiation 45RA) is used to identify naïve T-cell subsets and is often 
compared with CD45RO which is used to monitor memory T-cells, because a cell cannot express 
both markers and this can be used to understand the population split of T-cells [190]. Finally, CD56 
(Cluster of differentiation 56) is used to identify natural killer cells and is a marker for cytotoxicity 
[191]. 
 
These antibody quantities for the single stain controls, FMO controls and Isotype controls were 
added according to the quantities listed and incubated in the dark at 4˚C for 30 minutes. Once 
incubated, the cells were washed twice and transferred to BD Falcon™ Round Bottom 12 x 75 mm 
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tubes (Cat 352063) and kept covered to minimise light exposure. Cells were run through a BD 
FACSCanto™ II Flow Cytometer, using the respective fluorescence channel and voltage: FSC 310 V, 
SSC 400 V, FITC 389 V, APC 420 V, APC/Cy7 472 V, PE 350 V, BV421 300 V and BV510 451 V for 
the live-dead stain, once a daily calibration was completed using CS&T beads (Lot: 74538, 
Successful calibration). 
 
Each tube and respective fcs file were generated using a medium flow rate (60 µL/min) and by 
acquiring 30,000 cellular events. 3 stained sample fcs files were generated to build a library of 
repeats to use within the variation studies, alongside the control files listed. Files were exported as 
fcs 3.0 version types for use in Flowjo Version 10.0.8r1 third party analysis software [123] and 
saved as a workspace. 
 
5.2.3 Flow Cytometry Study Organisation 
 
A total of 23 Participants from three separate centres (5 from an academic institution, 13 and 5 
participants from separate industrial institutions) were invited to complete the study in a quiet 
analysis space, to avoid distraction and the possibility of others seeing the study content and 
analysis. As in the previous uncertainty exercise, participants made 3 repeat measures within a 1-
hour slot, because this was the maximum allowance given for each participant’s time, agreed 
across the three institutions.  
 
Study sessions had a one-hour maximum duration, and participants were shown three Flowjo 
workspaces, which contained a series of fully stained PBMC .fcs files. Identical files were included 
in each workspace, and participants were instructed to gate through a five-plot sequence to identify 
target cells (using Forward Scatter (FSC) plot against Side Scatter (SSC)), single cells, live cells, 
CD3+ cells and finally to apply a quadrant gate to the double positive naïve T-cell CD4+ CD45RA+ 
population to identify final positive population cell counts. Flowjo was the choice of platform due to 
access of the software across all three collaborator and participant sites, meaning a higher number 
of participants were likely to be familiar with the platform. 
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Although an additional marker for CD56 was acquired, this was not used within the final analysis 
sessions for participants to identify natural killer subsets. To identify an additional population 
meant sessions would run over the allotted 1-hour time slot. The CD4+ CD45RA+ pipeline was kept, 
because of the suitability of this panel to current engineered T-cell product panels and to provide a 
good basis to increase complexity for the subsequent studies (Chapter 6, complex model) to more 
representative CGT T-cell product analysis. 
 
Participants were also provided with isotype controls and FMO controls in each workspace to aid 
gate application and were allowed to use whatever manual gating tool on Flowjo they felt best to 
gate the population in hand. An overall schematic of the gating sequence they were asked to follow 
is shown in Figure 58, and participants gated each workspace of files separately to ensure a correct 
quantification of uncertainty through standard deviation calculation in accordance with principles 
described earlier in Chapter 2. 
 
 
Figure 58 Gating sequence participants were asked to follow, to identify the target single live cell population, with CD3+ CD4+ 
CD45RA+ for naïve T-cells. 
 
In a similar manner to the pre-study completed in Chapter 3, participants took part in a second 
phase, where they repeated the same gating process for the CD3+ CD4+ CD45RA+ cell population 
but were asked to copy a diagrammatical protocol to apply gates instead of using their own 
judgement, shown in Figure 59. To remove additional variability when placing these gates, 
participants were only given the three fully stained samples to apply the gates in each workspace, 
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so no control files could influence gate placement once the images had been copied, and 
participants followed the same gating sequence provided in Figure 58.  
 
 
Figure 59 Diagrammatical protocol given to participants to copy gates instead of using personal judgement 
 
All participants and their respective data were anonymised at the point of data collection, and data 
stored in accordance to the ethical clearance obtained. Participant coding was restructured from 
previous work to remove the possibility of analysis bias.  
 
5.2.4 Uncertainty Calculation 
 
Once studies had been completed, target cell, single cell, live cell, CD3+ and CD4+ CD45RA+ cell 
population metrics were extracted from the data, using the results from the identical repeated file 
situated in each Flowjo workspace. These were then used to calculate a mean cell count, SD and 
coefficient of variation (CV) for each gating stage, per participant using Microsoft Excel software 
(Office 16). Finally, a combined uncertainty (uc) was calculated by combining these Type A 
uncertainties by summation in quadrature. The uc value was expanded with a coverage factor of k 
= 2, representing a 95 % Confidence Interval for the uncertainty statement, which gave each 
participant a representative expanded uncertainty (U) figure, to show individual variance. The 
mathematical methodology used to calculate uncertainty metrics has been previously discussed in 
Section 2.5. An example of the data extraction through to calculation of metrics and uncertainty 
can be seen in Figure 60 for this intermediate model.  
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Figure 60 Example of data extraction through to calculation of absolute results and uncertainty  
Total Cells Workspace 1 Workspace 2 Workspace 3
30000 Target Lymphocytes 16517 16754 16599
Single Cells 16384 16494 16390
Live Cells 14985 14779 14746
CD3+ 10675 10545 10475
CD4+ CD45RA+ 2072 2088 2074
Workspace 1 Workspace 2 Workspace 3 AVERAGE STDEV CV uc U
Target Lymphocytes 55.06 55.85 55.33 55.41 0.40 0.72 0.71 1.42
Single Cells 54.61 54.98 54.63 54.74 0.21 0.38
Live Cells 49.95 49.26 49.15 49.46 0.43 0.87
CD3+ 35.58 35.15 34.92 35.22 0.34 0.96
CD4+ CD45RA+ 6.91 6.96 6.91 6.93 0.03 0.42
Total Cells Workspace 1 Workspace 2 Workspace 3
30000 Target Lymphocytes 18936 18734 21639
Single Cells 14711 14685 14689
Live Cells 14255 14135 14270
CD3+ 10375 10238 10366
CD4+ CD45RA+ 1800 1832 1823
Workspace 1 Workspace 2 Workspace 3 AVERAGE STDEV CV uc U
Target Lymphocytes 63.12 62.45 72.13 65.90 5.41 8.20 5.42 10.84
Single Cells 49.04 48.95 48.96 48.98 0.05 0.10
Live Cells 47.52 47.12 47.57 47.40 0.25 0.52
CD3+ 34.58 34.13 34.55 34.42 0.26 0.74
CD4+ CD45RA+ 6.00 6.11 6.08 6.06 0.06 0.91
Percentages
CD4+CD45RA+
Percentages
CD4+CD45RA+
Stage 2
Absolute Values
Coverage 
factor
2
Coverage 
factor
2
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5.3 Results & Discussion 
 
5.3.1 Flow Cytometry Intermediate Gating Exercise absolute results – Phase 1 Personal 
judgement 
 
The absolute results reported here are the targeted cell population that participants were asked to 
identify using the gating sequence defined in Figure 58, during the first gating session where they 
used their own judgement to apply gates. These are akin to what would be reported in literature for 
specific cell types, in this instance it is naïve T-cells. The uncertainty of the gating sequence will be 
discussed in subsequent sections of this Chapter.  
 
Table 33 Measures of Location for the absolute results of the Intermediate Gating Study using personal judgement (%) 
Arithmetic Mean 6.28 
Median 6.01 
Mode N/A 
Minimum 3.46 
Maximum 7.99 
 
Table 34 Measures of Spread for the absolute results of the Intermediate Gating Study using personal judgement (%) 
Range 4.53 
25th Percentile 5.65 
75th Percentile 7.27 
Interquartile Range 1.62 
Standard Deviation 1.14 
CV 18.15 
Median Absolute Deviation 6.01 
 
Table 35 Measures of Skew for the absolute results of the Intermediate Gating Study using personal judgement (%) (3dp for better 
resolution) 
Skewness -0.351 
Skewness standard Error 0.481 
Skewness z-score -0.730 
Kurtosis 0.042 
Kurtosis Standard Error 0.935 
Kurtosis z-score 0.045 
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Table 36 Measures of Normality for the absolute results of the Intermediate Gating Study using personal judgement (%) (3dp for 
better resolution) 
Shapiro-Wilk statistic 0.945 
Significance 0.231 
Normal/Non-parametric Normal 
 
Using descriptive statistics to give a general report on the size and shape of the data, the 
distribution approximates to a normal shape because the mean and median are very close 
together, as quoted in Table 33. This is supported by the skewness and kurtosis z-scores (Table 
35) and the Shapiro-Wilk statistical test for normality (Table 36) significantly concludes the 
distribution is normal. This normality definition is most probably indicated by the spread of the 
distribution, rather than any specific location parameters. Measures of spread (Table 34) show that 
there is a small range (in comparison to the Base Model Study) between the highest and lowest 
participant averages and the IQR of the participant data was just over half the size of the range, 
again indicating normality. However, because this model is based upon a more specific sub-
population the ranges may not be as small as initially perceived, they may just be relative to the 
respective cell population. 
 
These participant average cell count values can be seen in Figure 61. With most participant 
averages lying close to the median, and the error bars show ± 1SD from each participant’s repeated 
measures.  
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Figure 61 Absolute Results of Target Cell population, represented by each participant's average and ± SD. 
 
Participant deviation from the median has been more clearly visualised in Figure 62, with bars 
depicting each participant’s average from the median group value, or residual value (calculated by 
subtracting participant averages from the group median). The SD of the total group has also been 
plotted, because these are most commonly used within traditional manufacturing boundaries to 
define out of control/out of specification limits. 70 % of participants are within 1SD of the median, 
showing good corroboration of final results. Of those who fell out of bounds one participant had a 
result above +2SD and six participants below -1SD.  
 
Figure 63 further shows this variability around the central location metrics to compare different 
outlier limits specified in Chapter 3, and further applied to the data in Chapter 4. The skew to the 
data shows how different boundaries would affect determination of outliers, however the data did 
fall within the most extreme boundary specified, which could indicate there is no real extreme in 
skewness or kurtosis of the data. This all depends on the acceptance criteria chosen for 
manufacturing distributions. 
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Figure 62 Participant average result deviations from overall group median. 
 
Figure 63 Acceptance boundaries for permissible limits of variability of Intermediate model personal judgement data 
 
To compare both positive and negative deviation data extremes, Figure 64 shows participant B09’s 
gating strategy, one of the participants very close to the group median value. By comparing the 
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extreme participants to a median participant, there are obvious differences between participants 
when identifying populations based on the visualised density. This is also coupled with personal 
preferences on inclusion or exclusion of data points to further refine the data set in search of a 
particular target. The count average comes from the final gate applied only, but further back in the 
gating sequence gates have been applied to capture most of the relevant populations. Variation in 
the vertical quadrant line does not impact the results because there is a very low cell count across 
this bandwidth. In contrast, the horizontal quadrant line shows less variance in the final cell count 
result because two of the repeats are identical in position. There appears to be a big difference in 
the CD3+ gate applied, because on one repeat B09 set the axes to bi-exponential instead of 
logarithmic, so when compiled, the gates appear different but actually capture similar data which 
has been transformed differently. 
 
 
Figure 64 Participant B09 Gating Strategy interpretation, close to median result. 
 
Focusing on those who fell outside of 2SD, only one participant (C01) had this much deviation from 
the median, with an overall percentage cell count of 3.5 %. Qualitatively reviewing the participant’s 
gating strategy has shown that most of this bias is due to the gate applied to the live cells (BV510+, 
gate 3) which has been applied to a restrained proportion of the population (shown in Figure 65). 
C01 has applied this gate to follow the green density boundary, although there are more cells that 
could fall within this population that are less dense This gating strategy shown in Figure 65, 
identifies how under-constraining the cell populations leads to an overall lower cell count than the 
median.  
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Within a cell therapy manufacturing context, if a particular gate is under-constrained throughout 
the process, this will lead to an overall lower cell count population. Depending on the manufacturer-
specific acceptance limit for cell counts, this could cause a therapy to have a false-negative 
measurement, potentially rejecting a treatment that is suitable to be delivered to a patient. 
Alternatively, if the therapy is given longer to culture due to a perceived low cell count, this becomes 
an inefficient and expensive use of resources.  
 
 
Figure 65 Participant C01 Gating Strategy interpretation 
 
Participants A02, B01, B03, B10, B12 and C04 fall outside of the ± 1SD boundary, although all of 
these participants have average cell counts higher than the median value. Two examples have 
been selected to explore here; A02 has the smallest deviation (within this bandwidth) from the 
median and B10 has the greatest deviation (within this bandwidth). Figure 66 and Figure 67 show 
their respective gating strategies. 
 
Figure 66 Participant A02 Gating Strategy interpretation 
 
Participant A02 has a higher average result than the median inter-participant value because in the 
final step of their gating process (gate 5) they have included more cells than the median user. 
Whilst their final gate applied is very repeatable, the horizontal arm of the quadrant is lower than 
other median users, which has included a greater number of cells in the final count. In this instance, 
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A02 has applied gates very precisely, however they are potentially inaccurate, due to their use of 
control files to set the boundary limitations for the final fluorescence gates.  
 
 
Figure 67 Participant B10 Gating Strategy interpretation 
 
Participant B10 has again included additional cell populations which has caused the average cell 
count to be higher than the median. The doublets have not been excluded from the analysis in the 
first or second gates where they would usually be ‘cleaned up’ and they can be seen through the 
gating sequence as additional populations around the densest target population. They do appear 
to be gated out from the CD3+ gate (gate 4), however this is due to the compilation process of 
these images, with larger gates applied to the smaller one, so this population has been cut out.  
 
This analysis of the absolute results used to represent cell populations shows a 4.5 % cell count 
range between participants when determining final naïve T-cell population percentages.  The 
further quantitative analysis of the extremes identifies 1 participant (C01) who falls outside of initial 
control limits. This extreme participant accounts for one third of the cell population percentage 
range. If this extreme participant value was removed, the range would fall to 3.1 % between 
participants (minimum value of 4.9 % and maximum value of 8.0 %). 
 
The distribution histogram of participant CV of reported results can be seen in Figure 68, plotted 
on top of 3 specification limits derived from the ICSH boundaries used within Chapter 4. The optimal 
scenario would have all 23 participants (n) with < 1 % CV, which sets the total height at the y-
intercept of the graph.  
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Figure 68 CV Performance of Participant Absolute results for personal judgement of intermediate model 
 
Using these guidelines as boundaries, three participants were outside of the ‘revision required’ 
region due to very high CV and an additional three participants were outside of the ‘good’ and 
‘satisfactory’ performance regions. These extreme outliers had more variation within the final 
quadrant gate when identifying the final naïve T-cell cell population. Participant B08 had the highest 
CV, and their final gate can be seen in Figure 69. B08 intersects the final population more than the 
rest of the participants with one gate significantly higher than the rest, causing this variation.  
 
Figure 69 Participant B08 Intermediate Model Study Gating interpretation 
 
Participants B06 and B12 (Figure 70 and Figure 71) also had CVs that fell outside the ‘Revision 
Required’ region of the graph, and again the variation is caused in the final gate due to one of the 
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quadrant repeats being placed significantly higher than the other two. Any gating variance observed 
throughout the gating sequence is not captured within the representative population CV 
measurement, because CV is only calculated from the final population cell counts derived using 
the whole sequence.  
 
Figure 70 Participant B06 Intermediate Model Study Gating interpretation 
 
Figure 71 Participant B12 Intermediate Model Study Gating interpretation 
 
Measurement uncertainty provides a way of combining variability measures (SDs) of each gate 
within the sequence, to provide a measure of variation that is more representative of the 
components of the gating sequence. When extremes in measurement uncertainty arise, 
uncertainty values can be easily deconstructed to identify which part of the gating sequence is 
responsible for causing variation within the measurement. Measurement uncertainty results for 
this phase are discussed in Section 5.3.4, once absolute results for phase 1 and 2 of this study 
have been reviewed and compared. 
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5.3.2 Flow Cytometry Intermediate Gating Exercise absolute results –  
 Phase 2 Following Protocol 
 
The absolute results reported here are the targeted cell population that participants were asked to 
identify using the gating sequence defined in Figure 58, during the second gating session where 
they used the diagrammatical protocol in Figure 59 to apply gates. A comparison of these results 
to Phase 1 and the uncertainty of the gating sequence is discussed in the subsequent section.  
 
Table 37 Measures of Location for the absolute results of the Intermediate Gating Study using diagrammatical protocol (%) 
Arithmetic Mean 6.17 
Median 6.06 
Mode N/A 
Minimum 5.70 
Maximum 7.64 
 
Table 38 Measures of Spread for the absolute results of the Intermediate Gating Study using diagrammatical protocol (%) 
Range 1.94 
25th Percentile 5.97 
75th Percentile 6.25 
Interquartile Range 0.28 
Standard Deviation 0.39 
CV 6.38 
Median Absolute Deviation 6.06 
 
Table 39 Measures of Skew for the absolute results of the Intermediate Gating Study using diagrammatical protocol (%) (3dp for 
better resolution) 
Skewness 2.910 
Skewness standard Error 0.512 
Skewness z-score 5.684 
Kurtosis 10.629 
Kurtosis Standard Error 0.992 
Kurtosis z-score 10.715 
 
Table 40 Measures of Normality for the absolute results of the Intermediate Gating Study using diagrammatical protocol (%) (3dp for 
better resolution) 
Shapiro-Wilk statistic 0.688 
Significance 0.000 
Normal/Non-parametric Non-parametric 
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Using descriptive statistics to give a general report on the size and shape of the data, the 
distribution approximates to a normal shape because the mean and median are very close 
together, as quoted in Table 37. However, this is not supported by the skewness z-score (Table 39), 
and the high kurtosis z-score indicate a more non-parametric distribution due to outliers. The 
Shapiro-Wilk statistical test for normality (Table 40) also significantly indicates the distribution is 
non-parametric. This non-parametric definition is most probably indicated by a few outliers and a 
lot of uniform inliers, rather than any specific location parameters. Measures of spread (Table 38) 
show that there is a small range between the highest and lowest participant averages when 
participants followed a protocol and the IQR of the participant data was 86 % smaller than the total  
range, again indicating non-normality due to outliers.  
 
These values can be seen in Figure 72. Most participant averages lie close to the median, and the 
error bars show ± 1SD from each participant’s repeated measures.  
 
 
Figure 72 Absolute Results of Target Cell population when following a protocol, represented by each participant's average and ± SD. 
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Participant deviation from the median (residual values) has been more clearly visualised in Figure 
73, with bars depicting each participant’s average from the median group value (calculated by 
subtracting participant averages from the group median). The standard deviation limits have also 
been plotted, because these are most commonly used within traditional manufacturing to define 
out of control/out of specification limits. 95 % of participants are within 1SD of the median, showing 
good corroboration of final results. Of those who fell out of bounds one participant (B03) had a 
result outside of the  - 2SD specification limit listed in Figure 73.  
 
Figure 73 Participant average result deviations from overall group median. 
 
The acceptance boundaries defined for the data collected when participants applied gates 
according to their personal judgement has been applied to the ‘following protocol’ data set in Figure 
74. This data has become more refined when participants use a protocol, with the distribution 
falling within more of the acceptance limits. The 95 % Confidence Interval is very small, however 
the mean ± 2SD, trimmed mean ± 2SD and median ± 2MAD are all fairly similar in width, returning 
the same number of inliers and outliers. In this instance, further testing on the shape of the 
distribution should be complete before choosing the correct discrimination methods for extreme 
values. 
  Chapter 5: Intermediate Uncertainty Model 
162 
 
 
Figure 74 Acceptance boundaries of personal judgement data applied to data when participants followed a protocol 
 
Qualitatively reviewing the extreme participant gating strategy has shown that most of this bias is 
due to the final gate applied to the CD4+ CD45RA+ cells (gate 5), because this gate includes more 
of the CD45RA- cell population that smears below the desired double positive population, with no 
clear density separation. This cuts across a dense region of this population, keeping a higher 
proportion of cells within the gate boundary. This gating strategy can be seen in Figure 75, which 
shows how over-constraining the final cell population leads to an overall higher cell count than the 
median.  
 
Figure 75 Participant B03 Gating Strategy interpretation 
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The distribution histogram of participant CV of reported results can be seen in Figure 76, plotted 
on top of 3 specification limits derived from the ICSH boundaries used throughout this thesis. Only 
20 participants took part in this second gating session so the optimal scenario would have all 20 
participants (n) with < 1 % CV, which sets the total height at the y-intercept of the graph.  
 
 
Figure 76 CV Performance of Participant Absolute results when following a protocol within intermediate model 
 
Using these guidelines as boundaries, one participant fell outside of the ‘revision required’ region 
due to very high CV and two participants fell just outside of the ‘good’ and ‘satisfactory’ 
performance regions. These extreme outliers had more variation within the final quadrant gate 
(gate 5) they drew when identifying the final naïve T-cell cell population. Participant B04 had the 
highest CV when gating using the protocol, seen in Figure 77. B04 intersects the final population 
more and has one of the three repeated gates significantly higher than the rest, causing greater 
variation, similar to the variation seen in extremes in absolute cell count results.  
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Figure 77 Participant B04 Intermediate Model Study Gating interpretation 
 
5.3.3 Flow Cytometry Intermediate Gating Exercise absolute results – Comparison of 
Phase 1 and Phase 2 
 
The average cell counts for each participant when they gated following their own judgement and 
then a protocol have been compiled into the histograms in Figure 78. Any dark orange areas are 
overlap of the two respective histograms. The range of cell counts has reduced by 2.59 % when 
participants followed the protocol, indicating that protocols could help participants conform to more 
reproducible cell counts. This is also reflected in higher skewness and kurtosis z-scores for the 
protocol data set. However, as discussed in Chapter 3, higher kurtosis could be a more suitable 
metric of conformity than trying to achieve a normal distribution when aiming for reproducible data. 
 
Figure 78 Comparison of inter-participant absolute cell counts when gating using their own judgement and when 
following a protocol (brown areas indicate overlap between the two distributions) 
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Further comparison of inter-participant data when gating using their own judgement and following 
a protocol has been completed with a Sign statistical test (Table 41), to compare equality of 
medians between each test condition. Although the Sign test results reject the alternative 
hypothesis of a difference in medians, this is potentially desirable when considering the cell count 
values themselves. In this instance there is no ‘ideal correct’ cell count answer for the cell 
population targeted for gating, so equality of the two testing conditions shows that protocols are 
comparable when identifying the target population and remove the variability from participant 
subjectivity around gating preferences to identify the population. 
 
Table 41 Sign test results for comparison of Intermediate Gating Study Stages 
Null Hypothesis Test Sig. Decision 
Median difference of P1 & P2 cell counts = 0 Related-samples Sign test 0.824 Retain null hypothesis 
 
To further compare these two testing conditions the A Priori and Post Hoc power were calculated 
(Table 42) to identify whether a suitable number of participants had been gathered based upon the 
difference in variance of absolute cell counts in each test condition.  
 
Table 42 A Priori and Post Hoc Power analysis for Intermediate Study absolute cell counts 
Variance Phase 1 Variance Phase 2 A-priori power Sample size required Actual power 
1.300 0.156 0.840 8 0.999 
 
The A Priori and Post Hoc power analyses in Table 42 show that for the variances achieved between 
the two test condition average cell counts, only 8 participants would have been required to show 
this difference, to the required minimum power of 0.80. The actual power achieved through this 
study is 0.999, showing that the differences in variance of absolute cell counts are due to the two 
test conditions used and no other underlying factors.  
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Figure 79 Comparison of participant absolute cell count CVs when gating using their own judgement and when 
following a protocol (brown areas indicate overlap between the two distributions) 
 
Aside from one extreme value, the protocol appeared to reduce the range of results CV between 
participants when they followed this, but this only really considers the final gate applied within the 
repeats. Figure 79 shows that the CV is much more positively skewed towards 0 when participants 
followed a protocol, showing that following a protocol is more likely to reduce your final cell count 
gating variability and improve reproducibility of results overall.  
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5.3.4 Flow Cytometry Intermediate Gating Exercise uncertainty results – Phase 1: 
Personal Judgement 
 
The uncertainty results reported here are a combination of the five gating stages defined in Figure 
33 for gates applied when participants use their own judgement. The uncertainty values have been 
quantified following the prescribed methodology in Chapter 2, Section 2.5. The uncertainty would 
better represent variance of measurements with greater confidence, because this combines 
variability from all gates applied in the sequence, not just the variance of the final gate applied.  
 
Table 43 Measures of Location for Uncertainty of the Intermediate Gating Study using personal judgement (%) 
Arithmetic Mean 3.8 
Median 2.1 
Mode N/A 
Minimum 0.4 
Maximum 16.1 
 
Table 44 Measures of Spread for Uncertainty of the Intermediate Gating Study using personal judgement (%) 
Range 15.7 
25th Percentile 1.4 
75th Percentile 3.8 
Interquartile Range 2.3 
Standard Deviation 4.3 
Median Absolute Deviation 0.8 
 
Table 45 Measures of Skew for Uncertainty of the Intermediate Gating Study using personal judgement (%) (3dp for resolution) 
Skewness 1.942 
Skewness standard Error 0.481 
Skewness z-score 4.037 
Kurtosis 2.899 
Kurtosis Standard Error 0.935 
Kurtosis z-score 3.101 
 
Table 46 Shapiro-Wilk test for normality for Uncertainty of the Intermediate Gating Study using personal judgement (%) (3dp for 
resolution) 
Shapiro-Wilk statistic 0.692 
Significance 0.000 
Normal/Non-parametric Non-parametric 
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Unlike the descriptive statistics for absolute results for this study phase, the mean and the median 
are not close together, indicating a more skewed distribution, as monitored in Table 43. The median 
is less than the mean, indicating a slight positive skew to the data. This is further supported by the 
Shapiro-Wilk test for normality, shown in Table 46, indicating that the distribution is non-parametric 
in shape, indicating skewness. 
 
There is a wide range (15.4 %) between minimum and maximum participant uncertainties. Table 
44 also shows the interquartile range as 2.3 %, indicating a high kurtosis, because half of the data 
lies within 15 % of the total distribution range.  This is supported by the skewness and kurtosis 
values in Table 45 with skewness and kurtosis z-scores falling outside of the ±2.58 boundaries 
specified for normality defined in Chapter 2. The raw data for each participant can be seen in Figure 
80 with various extremes within the dataset. This distribution shape can be observed within Figure 
81, showing the positive skew with a potential bimodal split and 4 larger uncertainty extremes. 
 
 
Figure 80 Expanded Uncertainty of all Participant Gating within the Intermediate Model Study 
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Figure 81 Histogram of Participant Uncertainty from repeats of Intermediate Model Study 
 
Whilst deviation from a median can help to explain the distribution parameters, when analysing 
variance, a positively skewed distribution towards zero is preferred. Comparing uncertainty in its 
size order allows boundaries to be set for permissible specification limits for product 
release/laboratory quality that increase in value.  
 
The ICCH and ICCS imprecision values have also been used here to define example specification 
limits if monitoring participant uncertainty. Again, in this instance the CV specification limits have 
been substituted for uncertainty (Figure 83), and no other uncertainty specifications have been 
defined in the public body of knowledge from research or industry. However, unlike the previous 
model, this correlation is not strong because of the four participants with extreme uncertainty 
values, which will be explored within the extremes identified within Figure 82. Even if these 4 
‘outliers’ were removed, the slope (indicating correlation) only increases slightly to 0.0699x. 
Although this correlation was used to justify the use of CV boundaries for uncertainty 
measurements in Chapter 4, this correlation is not present here. However, for continuity of 
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reporting, the uncertainty distributions will still be binned according to these guidelines, to aid 
comparison between the uncertainty exercises. 
 
Figure 82 Final Cell Count Population Percentage versus Gating Uncertainty for participants 
 
Figure 83 Participant Uncertainty performance monitoring diagram when using their own judgement during the intermediate model 
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Participant B10 had the highest overall uncertainty that fell within the ‘revision required’ region of 
the plot, followed by Participant B04, and participants C01 and C05 sitting on the boundary of 
‘satisfactory performance’ and ‘revision required’. A deeper review of B10’s gating in Figure 84 
shows their greatest variance came from the third gate applied to discriminate live/dead cells. The 
amine-reactive dye used stains dead or dying cells, so the live cells appear as the densest 
population on the left side of the plot. Reviewing B10’s repeats has highlighted different ways this 
live/dead boundary was selected. B10 used the unstained control file to set areas for negative 
expression (live cells). The inclusion of the doublet cells and dying cells has caused confusion and 
therefore variability when choosing this boundary because they had not been previously ‘cleaned 
up’ from the data.  
 
Figure 84 Participant B10 Intermediate Model Study Gating interpretation 
 
This gate also caused the most variability for participant B04, who in one repeat also included this 
doublet population within their gate (shown in Figure 85, gate 3), causing variation and a higher 
population value as a result. B04 has also used a bi-exponential scale instead of a logarithmic 
scale, which could be an additional variable affecting their overall uncertainty. 
 
 
Figure 85 Participant B04 Intermediate Model Study Gating interpretation 
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The quadrant gates used to locate the final CD4+ CD45RA+ population were very precise, having 
minimal effect because they do not intersect any high-density areas through good use of control 
files provided. Control files provided were isotypes, FMO controls and a negative sample, which 
were used to set the position of the gates using a positive/negative split on respective axes. Control 
files were provided for other gates in the sequence but those who have extremes in their data 
appear to not have used these in the same manner to apply gates reproducibly. 
 
5.3.5 Flow Cytometry Intermediate Gating Exercise uncertainty results – Phase 2: 
Following Protocol 
 
The uncertainty results reported here (calculated as per Section 2.5 and Section 5.3.5) are a 
combination of the five gating stages defined in Figure 58 using the gating protocol provided, shown 
in Figure 59.  
 
Table 47 Measures of Location for Uncertainty of the Intermediate Gating Study when following a protocol (%) 
Arithmetic Mean 5.8 
Median 2.2 
Mode N/A  
Minimum 0.5 
Maximum 12.6 
 
Table 48 Measures of Spread for Uncertainty of the Intermediate Gating Study when following a protocol (%) 
Range 12.1 
25th Percentile 1.4 
75th Percentile 10.9 
Interquartile Range 9.5 
Standard Deviation 5.1 
Median Absolute Deviation 2.2 
 
Table 49 Measures of Skew for Uncertainty of the Intermediate Gating Study when following a protocol l(%) (3dp for resolution) 
Skewness 0.226 
Skewness standard Error 0.512 
Skewness z-score 0.441 
Kurtosis -2.065 
Kurtosis Standard Error 0.992 
Kurtosis z-score -2.082 
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Table 50 Shapiro-Wilk test for normality for Uncertainty of the Intermediate Gating Study when following a protocol (%) (3dp for 
resolution) 
Shapiro-Wilk statistic 0.757 
Significance 0.000 
Normal/Non-parametric Non-parametric 
 
Unlike the descriptive statistics for absolute results for this study, the mean and the median are 
not close together, indicating a more skewed distribution, as monitored in Table 47. The median is 
less than the mean, indicating a positive skew to the data. This is further supported by the Shapiro-
Wilk test for normality, shown in Table 50, indicating that the distribution is non-parametric in 
shape, indicating skewness. There is a wide range (12.0 %) between minimum and maximum 
participant uncertainties. Table 48 also shows the interquartile range as 9.5 %, however, unlike 
previous distributions this supports a low kurtosis, because half of the data lies within 79 % of the 
total distribution.  This is supported by the skewness and kurtosis values in Table 49 with skewness 
and kurtosis z-scores inside of the ±2.58 boundaries specified for normality defined in Chapter 2. 
The raw data for each participant can be seen in Figure 86 with various extremes within the dataset. 
This ordered distribution shape can be observed within Figure 87, showing the positive skew with 
a bimodal split and 9 larger uncertainty extremes. Qualitatively assessing the shape of the 
distribution shows a different shape to the data than the descriptive statistics, because the mean 
calculated does not reflect central tendency of the raw data as would be assumed. This bimodal 
split will be investigated further to understand the difference between the high variance and low 
variance clusters. 
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Figure 86 Expanded Uncertainty of all Participant Gating within the Intermediate Model Study when participants 
followed a protocol 
 
 
Figure 87 Histogram of Participant Uncertainty from repeats of Intermediate Model Study when participants followed a 
protocol 
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Whilst deviation from a median can help to explain the distribution parameters, when analysing 
variance, a positively skewed distribution towards zero is preferred. Comparing uncertainty in its 
size order allows boundaries to be set for permissible specification limits for product 
release/laboratory quality that increase in value.  
 
The ICCH and ICS imprecision values described earlier for measurement CV and in previous 
Chapters have also been used here to define example specification limits if monitoring participant 
uncertainty. Again, in this instance the CV specification limits have been substituted for Uncertainty 
from this gating phase (Figure 88), because no other uncertainty specifications have been defined 
in the public body of knowledge from research or industry.  
 
 
Figure 88 Participant Uncertainty performance monitoring diagram when following protocol during the intermediate 
model 
 
Participants B04 and B07 had the highest overall uncertainty that fell within the ‘revision required’ 
region of the plot, followed by C04, who is just under the limit of permissible uncertainty on the 
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chart in Figure 88. However, there is a participant cluster of high variance which has its own maxima 
at 11 % Uncertainty, populated by participants A03, A05, B01, B05 and B10.  
 
Participant B07’s most variable gate was the on the first gate in the sequence. This has been 
enlarged in Figure 89 to better identify the source of this variation. The repeats are qualitatively 
very uniform in size and structure, with a repeatable cut-off separating the primary population from 
the dead and dying cells. The quantitative variability appears to come from differences in the right 
edge of the gate, where in one instance the gate applied includes a data spike that sits on the 
boundary of the plot. The axes of the plot have been scaled down slightly so this spike can be clearly 
seen. This data spike could be an amalgamation of all the data points that exceed the plot limits, 
so they have been complied and added to the boundary, however, there is no information from 
Flowjo on this visualisation effect. 
 
 
Figure 89 Enlargement of Participant B07's first plot and gates applied in Phase 2 
 
Additionally, other Flow Cytometry data from other research teams using different cell models were 
checked to see if a boundary effect was present, and it appears that any cell events that exceed 
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the highest boundary scale point on the plots get concatenated in this way, making it seem to be a 
function of the software data binning and visualisation process. This intermediate data set was 
imported into two other Flow Cytometry Analysis Software packages, FlowLogic and FCS Express 
and qualitatively compared to the FlowJo output, seen in Figure 90. Not only do the other two 
software packages use different colour gradient scales to visualised cluster density, the boundary 
effect has been removed by FlowLogic, but is present and even more noticeable in FCS Express. 
This therefore falls to operator subjectivity, not only in which software they choose for analysis but 
whether they are aware of this boundary effect and if they consciously include or exclude it from 
their analysis.  
 
 
Figure 90 Visualisation of Intermediate Gating Study data in different Flow Cytometry Software 
 
B04’s Phase 2 gate has already been featured as an extreme in this Chapter (Section 5.3.2) due 
to high absolute cell count CV. Figure 77 depicts B04’s gating strategy, with most of their gating 
variability introduced from the first gate applied to start ‘cleaning’ the data, to remove dead cells 
and debris. An enlargement of this plot has been provided in Figure 91. Although this plot has a lot 
of different overlapping populations, the repeated gates are very similar in size shape and where 
they intersect and cut off the dead and dying cells, because this area has a lot of clustering overlap, 
making it difficult to identify the main area of variation on this plot. Similar to B07’s plots, the right 
edge sits along the boundary effect which could be causing some variability within the analysis. The 
majority of variation in the overall uncertainty of B07, C04, A03, A05, B01 and B05’s gates were 
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also from this first plot, strengthening the need for further investigation into this variation and its 
cause. 
 
 
Figure 91 Enlargement of Participant B04's first plot and gates applied in Phase 2 
 
To further investigate if the cause of this higher group cluster variability is a function of the first 
gate in the sequence, a selection of participants with low uncertainties were looked at to see if 
there was a difference or obvious understanding of this boundary effect, away from the data spike 
during their analysis. Participants B02 and B08 had very low uncertainties from their total gating 
process and both fall within the lower variance cluster. Their initial plots can be respectively seen 
in Figure 92 and Figure 93. Participant B02 has applied gates close to this boundary effect, 
however none touch this edge and they are very repeatable in size and shape. Upon closer 
inspection B08 has clearly not included any of this boundary effect and there is a clear distance 
from this edge and the right side of their gates. This initially shows that this difference in high and 
low variance groups could be down to participant knowledge and awareness of this boundary effect, 
however this was not something captured within the gating sessions themselves, nor could it be 
something that the participants were consciously aware of.  
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Figure 92 Enlargement of Participant B02's first plot and gates applied in Phase 2 
 
Figure 93 Enlargement of Participant B08's first plot and gates applied in Phase 2 
 
A follow-up questionnaire was given to participants during the complex model (Chapter 6) to try and 
identify knowledge of this effect without asking leading questions and the results are discussed in 
more detail within Chapter 8.  
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5.3.6 Flow Cytometry Intermediate Gating Exercise uncertainty results – Comparison of 
Phase 1 and Phase 2 
 
The uncertainties for each participant when they gated following their own judgement and then a 
protocol have been compiled into the histograms in Figure 94. Any dark orange areas are overlap 
of the two respective histograms. The range of cell counts has reduced by 3.4 %, indicating that 
protocols could help participants conform to reproducible cell count, however a bimodal distribution 
appeared so potentially more consideration needs to be applied to understanding how subjectivity 
and interpretation of a protocol and visual images impact the final uncertainty calculated. The 
skewness and kurtosis z-scores have reduced when participants use a protocol, however this is 
showing a tendency towards normality, which the distribution shape does not support in this 
instance.  
 
When participants used their own judgement to apply gates, a split between higher and lower 
uncertainty groups appears, but the shape of the overall distribution is positively skewed, with only 
a few extremes exhibiting high variance, so it can be described as bimodal, similar to the protocol 
uncertainty distribution. The protocol participants were asked to copy included the boundary effect 
observed, which is potentially causing the difference in variance clusters, which is something that 
requires further investigation, but has been used to aid the instructions for the complex model in 
Chapter 6. 
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Figure 94 Overlaid histograms of participant uncertainties when gating the naïve T-cell population following their own 
judgment and then using a protocol (brown areas indicate overlap between the two distributions) 
 
Further comparison of participant data when gating using their own judgement and following a 
protocol has been completed with a Sign statistical test, to compare equality of median 
uncertainties between each test condition, shown in Table 51. The Sign test results reject the 
alternative hypothesis, because the uncertainty medians of the two testing conditions are not 
statistically different. This does not statistically show that the uncertainties are smaller when 
participants use a protocol, however this only considered location values, so other measures of 
variability should also be considered before deciding whether a protocol effectively reduces inter-
participant variability, or not.  
 
However, the reduction in overall range shows that the distribution can potentially be controlled to 
minimise extreme values occurring in the data set, although use of this protocol is causing 
subjective behaviour to divide the population into high and low variance clusters.  
 
  Chapter 5: Intermediate Uncertainty Model 
182 
 
Table 51 Sign test for median difference between Phase 1 and Phase 2 uncertainties 
Null Hypothesis Test Sig. Decision 
Median difference of P1 & P2 uncertainties = 0 Related-samples Sign test 1.000 Retain null hypothesis 
 
To further compare these two testing conditions the A Priori and Post Hoc power were calculated 
(Table 52) to identify whether a suitable number of participants had been gathered based upon the 
difference in variance of absolute cell counts in each test condition.  
 
Table 52 A Priori and Post Hoc Power for Phase 1 and 2 uncertainties 
Variance Phase 1 Variance Phase 2 A-priori power Sample size required Actual power 
18.193 26.388 0.80 181 0.213 
 
The A Priori and Post Hoc power analyses in Table 52 show that for the variances achieved between 
the two test conditions uncertainties, 181 participants would have been required to show this 
difference, to the required minimum power of 0.80. The actual power achieved through this study 
is 0.213. This low power indicates that any differences seen from the data have a low probability 
of being just due to the two test conditions used and no other underlying factors present. Again, in 
a manner similar to the Sign test, this needs to be considered carefully. A greater number of 
participants in the study could always benefit and provide more confidence in the results, however, 
the distributions are not normally distributed, so the variance calculated assumes a distribution 
with central tendency (whether this is normally distributed or non-parametric). In this instance, the 
range of data becomes more important to consider, due to the distribution shape and clusters 
appearing within the uncertainty data. 
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5.4 Chapter Conclusions 
 
The primary PBMC material used was a good model for the intermediate study because it provided 
an appropriate step up in complexity of the analysis pipeline participants were required to 
complete, and it also provided affinity towards current cell therapy treatments which are T-cell 
based. The studies completed with the 3-workspace configuration in Flowjo for repeats continued 
to work well within the time available for participants so this structure has shown to be a good 
working model for these studies and also will be used for the final, most complex model. The five-
step gating process that each participant had to work through was also straight-forward to follow 
from the gating sequence protocol and the diagrammatical protocol, to help control additional 
variance within the study. 
 
When reporting the absolute cell count percentages for the results, the mean and median values 
for Phase 1 and Phase 2 were very similar (mean = 6.3 % and median = 6.0 % for Phase 1, mean 
= 6.2 % and median = 6.1 % for Phase 2). These results both indicate a normal distribution within 
both data sets, but it also shows that a protocol can achieve the same target cell counts compared 
to when participants used their own judgement. The difference when using a protocol is the 
reduction in between-participant cell count results. The protocol reduced the range of cell count 
results between-participants by 2.6 % of the overall cell count (777 cell events). This is a 57 % 
reduction in range from Phase 1 and Phase 2, indicating protocols can potentially aid reproducible 
cell counts between participants. The Sign test confirmed there was no significant difference 
between the medians of the two testing conditions, showing that protocols can produce similar 
results to the null testing condition, however, the power analysis completed indicated the variance 
of these two groups is different enough such that only 8 participants would have been required to 
attain the same distribution results. 
 
CV is a common variation metric used within cellular measurements within Flow Cytometry, 
however, when considering the use of protocols, the range of CV in reported results remained the 
same as when participants used their own judgement (up to 25 %). However, the use of the protocol 
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made the distribution much more positively skewed towards 0 %, which is desirable for variation 
metrics, indicating that more participants were less variable (in their final cell count) when using a 
protocol to apply gates. Reviewing the extremes in CV using the adjusted traffic light diagram shows 
variability in the final gate applied, but it also highlights that other variability seen upstream of this 
final gate can have an impact on cell count. However, gate variability across the five gating stages 
itself is not taken into consideration in the CV calculation, making measurement uncertainty a more 
suitable metric for accommodating variation throughout the whole gating sequence and increasing 
confidence in the results. 
 
This intermediate model with the 5-gate sequence has shown that calculating measurement 
uncertainty is possible for participants by using traditional measurement uncertainty methods. This 
was calculated successfully, by presenting participants with three repeated workspaces of data, 
and extracting one repeated file located in each workspace randomisation.  
 
The uncertainties calculated to accompany the cell counts are more non-parametric than the 
absolute cell counts. The mean and median uncertainties went from 3.8 % and 2.1 % respectively 
in Phase 1 to 5.8 % and 2.2 % respectively in Phase 2. The medians are very close together between 
the two sessions and is a more suitable metric due to the skewness present. The means are 
unsuitable metrics because they do not represent the peak maxima, especially in Phase 2, where 
the bimodal distribution causes the mean to sit between two peaks. However, the range of inter-
participant uncertainty reduced when using a protocol which shows this could possibly improve 
reproducibility of results between FC analysis. Whilst following a protocol reduced the range of 
uncertainty, the distribution shape separated into two peaks, indicating clusters of high and low 
variance participants.  
 
Further investigation has shown a high probability of this variation being caused by a boundary 
effect within the data visualisation software. Cells in the file that have a fluorescence signal higher 
than the visualisation axes are concatenated on the boundaries. Inclusion of these (either in a 
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consistent or inconsistent manner) in the repeated analysis can skew the cell counts and 
uncertainty significantly. Those in the lower variance cluster have not included these cells in their 
analysis, or repeatedly have so the overall variation would be lower between repeats (although they 
would have a higher average cell count). Revision of extreme participants using the uncertainty 
traffic light diagrams has shown most of the variation is contributed within this first gate applied, 
where the boundary effect is initially seen, increasing the possibility that the boundary effect causes 
this higher variation. 
 
Overall, the structure of these analysis sessions and data extraction processes works well, so this 
structure will be used to inform and run the subsequent complex model, which can increase in 
complexity due to the required cell population target and the number of gates required to obtain it. 
So far, this chapter has potentially shown affinity to the core hypothesis of this thesis. The overall 
range of uncertainty has increase from the basic model (Chapter 4, 12.37 %) to this intermediate 
model (Chapter 5, 15.7 %) showing that the range of uncertainty between-participants has increase 
as the data has become more complex. This needs to be further tested with a more complex model, 
presented in Chapter 6, and a diagrammatical protocol will also be tested in this instance, because 
it has shown to reduce the range of participant results within this intermediate model (12.1 %).  
  
  Chapter 5: Intermediate Uncertainty Model 
186 
 
5.4.1 Consolidation of Objectives 
 
• This study ran smoothly, acting as a good intermediate model for comparison of absolute 
reported results, CV and uncertainty measures. The session structures were suitable in 
time, and 3 repeats was suitable for participants to understand study context, but not 
become tired. The randomised Gauge R&R structure used for the previous model 
(Chapter 4) was not used here, because of the extra time incurred during analysis.  
• Diagrammatical protocols used by participants during the second phase of this study 
have shown to reduce the range in absolute results reported and reduce the range of 
inter-participant uncertainties, showing promise for use in future analysis pipelines. This 
will be further tested in the subsequent complex model (Chapter 6). 
• Extreme values in absolute reported results were due to participants either over 
constraining or under constraining the live cell population within the third gate, or being 
variable with the final gate applied, over- or under-constraining the quadrant around the 
desired double positive population. In some cases, lack of knowledge of using controls 
to set gates led to variance in population metrics. 
• Extreme values in uncertainty results were due to participant variability in applying a gate 
to separate the target cell population from the dead or dying cells, alongside additional 
variation caused in this first gate by boundary effects on the edge of the visualisation 
plot, caused by concatenated data that would otherwise be outside the plot axes. 
• The performance monitoring diagrams visualised continue to provide a straightforward 
way to monitor uncertainty performance with respect to the number of people in the study 
and defined quality satisfaction limits. These will be used in the subsequent chapter 
(Chapter 6) to monitor uncertainty performance in a more complex gating scenario. 
• This study defines participant uncertainty for a highly constrained 5 colour panel cell 
model, which can be used as an intermediate model for development into more complex 
cell models, to monitor potential growth of participant uncertainty in more difficult 
analysis scenarios. 
  
  Chapter 6: Complex Uncertainty Model 
187 
 
Chapter 6: Complex Uncertainty Model 
6.0 Introduction to the Chapter 
Chapter 6 introduces the third and final uncertainty gating exercise, as part of the sequence of 
studies which monitor participant variance in comparison to complexity of data. As discussed in the 
prelude, this final uncertainty exercise is more complex in panel design and therefore gating 
difficulty, to further monitor uncertainty in a more difficult analysis scenario. This is more 
representative of FC analysis pipelines and engineered T-cell markers used to monitor cell therapy 
products. This allows comparisons to be drawn between all three models in Chapter 7.  
 
Previously in Chapter 5, a five-step pipeline was used to monitor naïve T-cells within primary PBMC 
populations. This Complex model expands upon the FC panel used in the previous chapter to 
monitor additional markers for engineered-product specificities, such as programmed cell death 
and transduction efficiency. This is relevant and translational for the community, therefore 
potentially providing a more representative application of uncertainty to FC measurements. This 
Chapter uses an eight-step analysis sequence, and similar to Chapter 5, sees participants analyse 
this data across two sessions using their own judgement and then using a diagrammatical protocol 
respectively.  
6.1 Chapter Aims 
 
This Chapter develops comparison of uncertainty in complex FC analysis strategies. The fit of this 
Chapter to the thesis can be seen in Figure 95, specifically within the orange dashed box, providing 
development for the core hypothesis: as complexity of FC data and processing increases, 
measurement uncertainty contributed from the participant will also increase. This Chapter further 
investigates the influence of using measurement uncertainty to quantify subjectivity, and if 
diagrammatical protocols can aid this situation. 
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Figure 95 Diagram of Chapter position within the whole Thesis 
 
6.1.1 Chapter Aims & Objectives 
 
The Aims and Objectives of this Chapter can be defined as follows: 
• Design a complex two-phase study to measure CV and uncertainty of participants when 
gating complex FC data. 
• Identify whether using diagrammatical protocols to apply gates reduces inter-participant 
absolute reported results and uncertainties. 
• Identify what causes extreme values in absolute reported results and uncertainty 
measurements by reviewing extremes from this intermediate study. 
• Further test monitoring tools for understanding uncertainty within a more complex 
participant study or facility. 
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6.2 Methodology 
 
Engineered T-cells, derived from Peripheral Blood Mononuclear Cells (PBMCs) were provided by a 
collaborator, and all staining, file generation and analysis templates were completed by the 
collaborator, in line with the collaboration agreement. Due to commercial sensitivity, further details 
on the engineered T-cell vector or cell cannot be provided. Likewise, specific volumes for staining 
and process steps cannot be provided.  
 
Engineered T-cells have been used for this complex stage because they are representative of 
current and developing therapies on the market. Current treatments are based upon Chimeric 
Antigen Receptor (CAR-T) or engineered T-cell Receptor (TCR) treatment methods, using autologous 
T-cells, derived from patient PBMC material. By using a complex FC panel which develops upon the 
T-cell lineage panel in the previous model (Chapter 5), it has included more complexity (gating steps 
and difficulty) and more specificity to a Cell Therapy product. This shows an industrially relevant 
assay to define the population of transduced T-cells that exhibit appropriate markers for a TCR 
product. 
 
6.2.2 fcs File Generation 
 
A series of fcs files were generated using the engineered T-cell product created at the collaborator 
site. Genetically Modified Cells were washed with Cell Staining buffer to remove any cell culture 
media remaining. 0.1 mL aliquots of the master cell suspension were placed into separate labelled 
microcentrifuge tubes so there were approximately 1 x 106 cells per tube (3 fully stained samples, 
1 unstained sample, 7 FMO controls). The unstained sample was wrapped in foil and placed in a 
4˚C fridge because this was not needed until the final analysis. 
 
To detect expression of engineered TCR, a PE-conjugated dextramer reagent specific for the 
engineered TCR was utilized, according to the manufacturer recommended protocol (Immudex, 
Denmark). The cells were then stained for additional antigen markers, according to the following 
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stain protocols in Table 53 and Table 54. Staining was performed according to manufacturer 
recommendations and standard flow cytometry staining protocol. Isotype controls for each marker 
were not produced because these are no longer recommended for use, as FMO controls are more 
effective and economical. The FMO controls were stained with all stains aside from the stain aligned 
to that specific channel. This is to monitor any fluorescence spillover into the required channels 
from other markers being used. Fully stained samples were stained with collaborator-optimised 
volumes of all the antigen markers in use. 
 
The antigen markers used for the FMO controls (Table 1) and fully stained samples (Table 2) are: 
• Miltenyi CD197 (CCR7) – VioBlue, human (Cat Number: 130-117-353) 
• Miltenyi CD4 – VioGreen, Human (Cat Number: 130-113-221) 
• Miltenyi CD3 – FITC, Human (Cat Number: 130-113-128) 
• Miltenyi CD45RA – PE-Vio770, Human (Cat Number: 130-113-357) 
• Miltenyi CD95 (FAS) – APC, Human (Cat Number: 130-113-070) 
• Miltenyi CD8 – APC-Vio770, Human (Cat Number: 130-110-681)  
• Miltenyi 7AAD – PerCp-Vio770 Staining Solution (Cat Number: 130-111-568).  
Table 53 Staining volumes for FMO Controls 
Channel Antigen 
Marker 
VioBlue 
FMO 
VioGreen 
FMO 
FITC FMO PE FMO PE-Vio770 
FMO 
APC FMO APC-
Vio770 
FMO 
405 nm 
laser, 
450/50 
filter 
CCR7 
VioBlue 
X       
405 nm 
laser, 
525/50 
filter 
CD4 
VioGreen 
 X      
488 nm 
laser, 
525/50 
filter 
CD3 FITC   X     
488 nm 
laser, 
585/40 
filter 
Dextramer 
PE 
   X    
488 nm 
laser, 
750LP filter 
CD45RA PE-
Vio770 
    X   
635 nm 
laser, 655-
730 filter 
CD95 APC      X  
635 nm 
laser, 
750LP filter 
CD8 APC-
Vio770 
      X 
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Table 54 Staining volumes for Fully Stained Samples 
Channel Antigen 
Marker 
Fully Stained 
Sample 1 
Fully Stained 
Sample 2 
Fully Stained 
Sample 3 
405 nm 
laser, 
450/50 filter 
CCR7 
VioBlue 
X X X 
405 nm 
laser, 
525/50 filter 
CD4 
VioGreen 
X X X 
488 nm 
laser, 
525/50 filter 
CD3 FITC X X X 
488 nm 
laser, 
585/40 filter 
Dextramer 
PE 
X X X 
488 nm 
laser, 655-
730 filter 
7AAD PerCp-
Vio770 
X X X 
488 nm 
laser, 750LP 
filter 
CD45RA PE-
Vio770 
X X X 
635 nm 
laser, 655-
730 filter 
CD95 APC X X X 
635 nm 
laser, 750LP 
filter 
CD8 APC-
Vio770 
X X X 
 
Antigen markers CD3, CD4, CD8 and CD45RA have been previously described in Chapter 5. The 
naïve T-cell staining panel used has been built upon in this chapter to develop an 8-colour panel to 
identify engineered T-cells and monitor different product characteristics. C-C chemokine receptor 
type 7 (CCR7), also known as Cluster of Differentiation 197 (CD197), is expressed in lymphoid 
tissues and stem cell memory T-cells (derived from naïve T-cells) [192]. Cluster of Differentiation 
95 (CD95), or Fas-receptors are indicators of programmed cell death within engineered T-cell 
products [193,194].  Dextramer is the marker to monitor the transduction efficiency of the viral 
vector delivering the gene to the T-cell. This is a measure of how many cells will make the 
functioning protein required for this cell and gene therapy [195]. Finally, the viability stain used is 
7-aminoactinomycin D (7-AAD), a nucleic acid stain that emits fluorescent emission spectra when 
it binds with DNA. This indicates ruptured, dead cells that have exposed nuclei from live cells with 
intact cell membranes [196]. 
 
Cells were run through a Miltenyi MACSQuant Analyser 10 Flow Cytometer (3 lasers, 8 optical 
channels), once a daily calibration was completed. 
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Three fully stained sample files were acquired as 3 representative repeats, along with the FMO 
controls. Files were exported as fcs 3.0 version types for use in Flowjo version 10.0.8r1 third party 
analysis software [123] and saved as a workspace. 
 
6.2.3 Flow Cytometry Study Organisation 
 
A total of 22 participants from three separate centres (4 from an academic institution, 13 and 5 
participants from separate industrial institutions) were invited to complete the study in a quiet 
analysis space, to avoid distraction and the possibility of others seeing the study content and 
analysis. Study sessions had a one-hour maximum duration, and participants were shown three 
Flowjo workspaces, which contained a series of fully stained engineered T-cell .fcs files. Identical 
files were included in each workspace, and participants were instructed to gate through an eight-
plot sequence to identify single cells, target cells, live cells, CD3+ cells, CD4+ CD8- cells, CD45RA+ 
CCR7+ cells, CD95+ cells and finally to identify transduced engineered T-cells. Flowjo was the 
choice of platform due to access of the software across all three industrial and participant sites, 
meaning a higher number of participants were likely to be familiar with the platform. 
 
Participants were also provided with FMO controls in each workspace to aid gate application and 
were allowed to use whatever manual gating tool on Flowjo they felt best to gate the population in 
hand. An overall schematic of the gating sequence they were asked to follow is shown in Figure 96, 
and participants gated each workspace of files separately to ensure a correct quantification of 
uncertainty through standard deviation calculation. 
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Figure 96 Gating sequence participants were asked to follow, to identify the transduced engineered T-cells. 
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Similar to the pre-study completed in Chapter 3 and intermediate model in Chapter 5, participants 
took part in a second phase, where they repeated the same gating process for the transduced 
engineered T-cell population but were asked to copy a diagrammatical protocol to apply gates 
instead of using their own judgement, shown in Figure 97. Participants were given the same three 
fully stained samples along with the FMO controls to aid them in applying the gates in each 
workspace, alongside the images given in the diagrammatical protocol. Participants followed the 
same gating sequence provided in Figure 96.  
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Figure 97 Diagrammatical protocol given to participants to copy gates instead of using personal judgement 
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This data exercise aimed to build upon previous work in Chapter 4 and 5 to identify if inter-
participant variance does exist when reporting results from the same data and that uncertainty 
values can be calculated for participants to contribute towards an overall uncertainty estimation. It 
also aims to investigate if the participant range in uncertainty increases as the complexity of the 
gating exercise increases. This was designed to estimate a general absolute result median and 
uncertainty. Calculating significant differences between certain groups or testing conditions can be 
completed in this instance because participants took part in a two-phase analysis exercise, similar 
to the Pre-study in Chapter 3 and intermediate model in Chapter 5. Standard power calculations to 
determine appropriate sample size can be generated for future development reference, but also 
give an indication of current power from the number of participants that took part in the study.  
 
As in the previous uncertainty exercises, participants made 3 repeat measures, within a 1-hour slot, 
because this was the maximum allowance given for each participant’s time, agreed across the 
three institutions.  
 
6.2.4 Uncertainty Calculation 
 
Once studies had been completed the separate gated cell population metrics were extracted from 
the data, using the results from the identical repeated file situated in each Flowjo workspace, and 
were transformed into respective cell count percentages as a function of the original cell event 
number in the file. These were then used to calculate a mean cell count, SD and CV for each gating 
stage, per participant using Microsoft Excel software. Finally, a combined uncertainty (uc) was 
calculated by combining these Type A uncertainties by summation in quadrature. The uc value was 
expanded with a coverage factor of k = 2, representing a 95 % Confidence Interval for the 
uncertainty statement, which gave each participant a representative expanded uncertainty (U) 
figure, to show individual variance. The mathematical methodology used to calculate uncertainty 
metrics has been previously discussed in Section 2.5. An example of the data extraction through 
to calculation of metrics and uncertainty can be seen in Figure 98 for this complex model.  
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Figure 98 Example of data extraction through to calculation of absolute results and uncertainty per participant 
  
File 1 76012
File 2 72449
File 3 62475 COUNTS
File 1 File 2 File 3 File 1 File 2 File 3 File 1 File 2 File 3
Exclude Doublets 54360 50538 43035 55340 51449 43786 55186 51328 43690
Target Cells 28107 25725 21182 27805 25458 20929 27493 25117 20679
Live Cells 26750 24393 19945 26662 24374 19907 26272 23922 19554
CD3+ Cells 26725 24367 19930 26642 24354 19894 26247 23896 19538
CD4+ CD8- Cells 19558 17760 14534 19544 17825 14430 19244 17466 14261
CD45RA+ CCR7+ Cells 6348 6211 4931 8362 8032 6376 7485 7198 5742
CD95+ Cells 6348 6211 4930 8361 8032 6375 7484 7198 5741
Dextramer+ Cells 4475 4330 3437 5931 5595 4430 5099 4809 3875
PERCENTAGES
File 1 File 2 File 3 File 1 File 2 File 3 File 1 File 2 File 3
Exclude Doublets 71.52 69.76 68.88 72.80 71.01 70.09 72.60 70.85 69.93
Target Cells 36.98 35.51 33.90 36.58 35.14 33.50 36.17 34.67 33.10
Live Cells 35.19 33.67 31.92 35.08 33.64 31.86 34.56 33.02 31.30
CD3+ Cells 35.16 33.63 31.90 35.05 33.62 31.84 34.53 32.98 31.27
CD4+ CD8- Cells 25.73 24.51 23.26 25.71 24.60 23.10 25.32 24.11 22.83
CD45RA+ CCR7+ Cells 8.35 8.57 7.89 11.00 11.09 10.21 9.85 9.94 9.19
CD95+ Cells 8.35 8.57 7.89 11.00 11.09 10.20 9.85 9.94 9.19
Dextramer+ Cells 5.89 5.98 5.50 7.80 7.72 7.09 6.71 6.64 6.20
FILE 1 AVERAGE STDEV CV
Exclude Doublets 72.31 0.69 0.96
Target Cells 36.58 0.40 1.10
Live Cells 34.94 0.33 0.96
CD3+ Cells 34.91 0.34 0.96
CD4+ CD8- Cells 25.59 0.23 0.91
CD45RA+ CCR7+ Cells 9.73 1.33 13.65
CD95+ Cells 9.73 1.33 13.64
Dextramer+ Cells 6.80 0.96 14.13
uc 2.32
k 2 U 4.64
Coverage Factor
Total Cell Counts
Repeat 1 Repeat 2 Repeat 3
Repeat 1 Repeat 2 Repeat 3
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6.3 Results & Discussion 
 
6.3.1 Flow Cytometry Complex Gating Exercise absolute results –   
 Phase 1 Personal judgement 
 
The absolute results reported here are the targeted cell population that participants were asked to 
identify using the gating sequence defined in Figure 96, during the first gating session where they 
used their own judgement to apply gates. These are akin to what would be reported in literature for 
specific cell types, in this instance it is transduced engineered T-cells. The uncertainty of the gating 
sequence will be discussed in subsequent sections of this Chapter.  
 
Table 55 Measures of Location for the absolute results of the Complex Gating Study using personal judgement (%) 
Arithmetic Mean 5.81 
Median 5.45 
Mode N/A 
Minimum 1.18 
Maximum 10.50 
 
Table 56 Measures of Spread for the absolute results of the Complex Gating Study using personal judgement (%) 
Range 9.33 
25th Percentile 4.04 
75th Percentile 7.61 
Interquartile Range 3.56 
Standard Deviation 1.03 
CV 12.10 
Median Absolute Deviation 1.73 
 
Table 57 Measures of Skew for the absolute results of the Complex Gating Study using personal judgement (%) (3dp for better 
resolution) 
Skewness 0.168 
Skewness standard Error 0.491 
Skewness z-score 0.342 
Kurtosis -0.669 
Kurtosis Standard Error 0.953 
Kurtosis z-score -0.702 
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Table 58 Measures of Normality for the absolute results of the Complex Gating Study using personal judgement (%) (3dp for better 
resolution) 
Shapiro-Wilk statistic 0.980 
Significance 0.911 
Normal/Non-parametric Normal 
 
Using descriptive statistics to give a general report on the size and shape of the data, the 
distribution approximates to a normal shape because the mean and median are very close 
together, as identified in Table 55. This is supported by the skewness and kurtosis z-scores (0.342 
% and -0.702 % respectively, Table 57) and the Shapiro-Wilk statistical test for normality (p = 0.911 
%, Table 58) significantly concludes the distribution is normal. This normality definition is most 
probably indicated by the spread of the distribution, rather than any specific location parameters. 
Measures of spread (Table 56) show that the IQR of the participant data was approximately half 
the size of the range, again indicating normality. These participant average cell count values can 
be seen in Figure 99. Participant averages are more variable around the median than the previous 
model, and the error bars show ± 1SD from each participant’s repeated measures.  
 
Figure 99 Absolute Results of Target Cell population, represented by each participant's average and ± SD. 
 
Participant deviation from the median (residuals) has been more clearly visualised in Figure 100, 
with bars depicting each participant’s average from the median group value (calculated by 
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subtracting participant averages from the group median). The SD of the total group has also been 
plotted, because these are most commonly used within traditional manufacturing boundaries to 
define out of control/out of specification limits. 59 % of participants are within 1SD of the median, 
showing good corroboration of final results. Of those who fell out of bounds one participant had a 
result below -2SD, four participants below -1SD and two participants above +1SD.  
 
To compare the different types of error boundary estimator that can be used, the histogram of 
participant average cell counts has been plotted in Figure 101. This confirms that nearly all 
participants fall within Paxton’s Criterion, mean ± 3SD and mean ± 2SD. Almost all fall inside the 
trimmed mean ± 2SD. A further 3 participants fell outside of the Median ± 2MAD range, whereas 
only 7 participants were contained within the 95 % Confidence Interval applied to this data set.  
 
Figure 100 Participant average result deviations from overall group median. 
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Figure 101 Comparison of average engineered T-cell counts to additional error boundaries 
 
To compare both positive and negative deviation data extremes, Figure 102 shows participant 
B12’s gating strategy, one of the participants very close to the group median value. By comparing 
the extreme participants to a median participant, there are obvious differences between 
participants when identifying populations based on the visualised density. This is also coupled with 
personal preferences on inclusion or exclusion of data points to further refine the data set in search 
of a particular target. The count average comes from the final gate applied only, but further back 
in the gating sequence gates have been applied to capture most of the relevant populations. 
Variation in the transduced T-cell population does not impact the results because there is a very 
low cell count across this bandwidth (gate 8). The layouts used in this Chapter to visualise the 
gating strategies are all uniform, with the top row showing gates 1-4 (left to right) and the bottom 
row showing gates 5-8 (left to right), also shown in Figure 97. 
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Figure 102 Participant B12 Gating Strategy interpretation, close to median result. 
 
Focusing on those who fell outside of 2SD, only one participant (B11) had this much deviation from 
the median, with an overall percentage cell count of 10.00 %. This gating strategy shown in Figure 
103, identifies how over-constraining the cell populations leads to an overall higher cell count than 
the median. The eight images show the gating sequence steps used to define the final population 
cell count, with B11’s three repeats collated onto each sequence step image. Qualitatively 
reviewing the participant’s gating strategy has shown that most of this bias is due to the gate 
applied to the lymphocytes (gate 2) and live cells (PerCp-Vio700+, gate 3) which has been applied 
to a restrained proportion of the population. B11 has applied this gate closer around the main T-
cell population in the second gate and applied the separation boundary between the live and dead 
cells closer to the live cell population in the third gate, to not include the dying cells.  Additionally, 
within the CD45RA+ CCR7+ gate (gate 6) the quadrant includes slightly more of the population 
than the median user has, which has increased the average cell count overall. 
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Figure 103 Participant B11 Gating Strategy interpretation 
 
Participants A01, C03 and B09 fell outside of the ± 1SD boundary, because these participants 
have average cell counts lower than the median value. Figure 104 and Figure 105 show the 
respective gating strategies for the largest deviators, A01 and C03. 
 
Figure 104 Participant A01 Gating Strategy interpretation 
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Figure 105 Participant C03 Gating Strategy interpretation 
 
Participant A01 and C03 have lower average results than the median inter-participant value 
because throughout their gating process they have included less cells than the median user. This 
is specifically due to the second gate applied in the sequence, which has been more tightly 
constrained around the central lymphocyte population than the median user. In addition, the sixth 
gate applied to identify CCR7+ CD45RA+ cells, required participants to use FMO controls to 
intersect the dense cluster of cells to define those which had double positive expression. The 
vertical line placed by participants A01 and C03 have been placed to the right of the most dense 
region of this cluster, therefore selecting a smaller population that are expressing the desired 
markers, in comparison to the median user, who placed the gate more to the left of the most dense 
region. In this instance, different applications of gating ‘clean-up’ procedures and use of FMO 
controls has potentially caused this variance, alongside the participant perception of density.  
 
Participants B02, B03, B07 and C02 all had average cell counts that fell outside of the median – 
1SD boundary. To illustrate examples of these gating strategies, Participants B02 and B03 (who 
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had the highest cell counts within this boundary) can be seen in Figure 106 and Figure 107 
respectively. 
 
 
Figure 106 Participant B02 Gating Strategy Interpretation 
 
 
Figure 107 Participant B03 Gating Strategy Interpretation 
 
Participant B02 has a higher cell count than the median participant, which can be seen from their 
second gate applied, and the sixth gate. The second gate applied includes a second larger cell 
  Chapter 6: Complex Uncertainty Model 
206 
 
population to the right of the cell population in question. The larger overall cell count is also due to 
the sixth gate applied to identify the double positive CCR7+ CD45RA+ cell population. In contrast 
to participant A01 and C03, the vertical line has been placed to the left of the densest region of 
the cell population, including the majority of the population within the final average cell count for 
engineered T-cells.  Participant B03 has also applied the sixth gate in this manner, to end up with 
the final average cell count population within this boundary, the only difference being they did not 
gate an additional population of cells within the second gate applied. The difference between these 
participants within the median +1SD boundary and participant B11 who fell outside of the median 
+2SD boundary is that B11 included a greater number of cells within gate 2. This carried forward 
through the rest of the gates applied, so the average cell count is greater as a result. 
 
This analysis of the absolute results used to represent cell populations shows a 9.32 % cell count 
range between participants when determining final engineered T-cell population percentages.  The 
further qualitative analysis of the extremes identifies 1 participant (B11) who falls outside of initial 
control limits. This extreme participant accounts for one third of the cell population percentage 
range. If this extreme participant value was removed, the range would fall to 7.60 % between 
participants (minimum value of 2.38 % and maximum value of 9.99 %). 
 
Variability of absolute results is commonly assessed using the CV, which combines the average and 
standard deviation of final cell count measurand (as defined in Chapter 2). The distribution 
histogram of participant CV of reported results can be seen in Figure 108, plotted on top of 3 
specification limits derived from the ICSH boundaries used within Chapter 4 and 5. Therefore, this 
amount of variance is not ideal in this exemplar. The optimal scenario would have all 22 participants 
(n) with < 1 % CV, which sets the total height at y-intercept of the graph.  
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Figure 108 CV Performance of Participant absolute results when using personal judgement to gate complex cell model 
 
Using these guidelines as boundaries, nine participants fell outside of the ‘revision required’ region 
due to very high CV and an additional two participants fall outside of the ‘good’ and ‘satisfactory’ 
performance regions. These extreme outliers had more variation within the final quadrant gate they 
drew when identifying the final naïve T-cell cell population. Participant B13 has been used as an 
example here, because they had the highest CV. Participant B04 had a CV of 36 %, and their final 
gates can be seen in Figure 109. B13 intersects the CCR7+ and CD45RA+ population much more 
on one of the gating repeats, creating a lower value for the final average cell count population of 
one repeat, carried forwards through the remaining gates. Therefore, there is more variation in the 
result, shown by the CV of the three repeats. This is the case for the other participants who fall 
outside of this region. 
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Figure 109 Participant B13 Complex Model Study Gating interpretation 
 
Participants A04, B01, B06, B07, B10, B13, C03 and C05 also had CV values that fell outside the 
‘Revision Required’ region of the graph. Similarly, the variability in the final result is caused by the 
placement of the sixth gate, separating the CCR7+ CD45RA+ population from the rest of the cluster. 
It appears that variability caused using FMOs at this phase has a knock-on effect for the final cell 
count, rather than being caused by the final gate applied in the sequence. In some instances, the 
variability between repeats is carried over from earlier in the gating sequence (typically the second 
or third gates). 
 
Measurement uncertainty provides a way of combining variability measures (SDs) of each gate 
within the sequence, to provide a measurement that is more representative of the components of 
the gating sequence. When extremes in measurement uncertainty arise, uncertainty values can be 
easily deconstructed to identify which part of the gating sequence is responsible for causing 
variation within the measurement. Measurement uncertainty results for this phase are discussed 
in Section 6.3.4, once absolute results for phase 1 and 2 of this study have been reviewed and 
compared. 
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6.3.2 Flow Cytometry Complex Gating Exercise absolute results – Phase 2 Following 
Protocol 
 
The absolute results reported here are the targeted cell population that participants were asked to 
identify using the gating sequence defined in Figure 96, during the second gating session where 
they used the diagrammatical protocol in Figure 97 and FMO controls to apply gates. A comparison 
of these results to Phase 1 and the uncertainty of the gating sequence will be discussed in the next 
section of this Chapter.  
Table 59 Measures of Location for the absolute results of the Complex Gating Study using a diagrammatical protocol (%) 
Arithmetic Mean 11.98 
Median 12.23 
Mode N/A 
Minimum 3.36 
Maximum 16.60 
 
Table 60 Measures of Spread for the absolute results of the Complex Gating Study using a diagrammatical protocol (%) 
Range 13.24 
25th Percentile 9.78 
75th Percentile 15.06 
Interquartile Range 5.28 
Standard Deviation 1.47 
CV 12.27 
Median Absolute Deviation 2.66 
 
Table 61 Measures of Skew for the absolute results of the Complex Gating Study using a diagrammatical protocol (%) (3dp for better 
resolution) 
Skewness -0.859 
Skewness standard Error 0.491 
Skewness z-score 1.749 
Kurtosis 0.626 
Kurtosis Standard Error 0.953 
Kurtosis z-score 0.657 
 
Table 62 Measures of Normality for the absolute results of the Intermediate Gating Study using a diagrammatical protocol (%) (3dp 
for better resolution) 
Shapiro-Wilk statistic 0.936 
Significance 0.165 
Normal/Non-parametric Normal 
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Using descriptive statistics to give a general report on the size and shape of the data, the 
distribution approximates to a normal shape because the mean and median fairly close together 
(11.98 % and 12.23 % respectively), as quoted in Table 59, however, these values are over double 
the mean and median for Phase 1. The skewness z-score (1.749 %,Table 61), and the low kurtosis 
z-score (0.657 %) also indicate a more normal distribution, supporting these measures of location. 
This is further supported by the Shapiro-Wilk statistical test for normality (Table 62) which indicates 
the distribution is normal. The measures of spread (Table 60) indicate that the IQR is approximately 
half the size of the total range of inter-participant results, which again alludes to a normal 
distribution shape of the data.  
 
Participant average cell counts and SDs when gating following the protocol can be seen in Figure 
110. Participant averages are more variable in Phase 2 of this complex study in comparison to the 
intermediate study, however, qualitatively, the inter-participant average results do appear to lie 
closer to the median, aside from a couple of extreme values.  
 
Figure 110 Absolute Results of Target Cell population when following a protocol, represented by each participant's average and ± SD. 
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Participant deviation from the median (residuals) has been more clearly visualised in Figure 111, 
with bars depicting each participant’s average from the median group value (calculated by 
subtracting participant averages from the group median). The standard deviation limits have also 
been plotted, because these are most commonly used within traditional manufacturing to define 
out of control/out of specification limits. 82 % of participants are within 1SD of the median, showing 
good corroboration of final results. Of those who fell out of bounds one participant had a result 
above +2SD, two participants are above +1SD and one participant below -1SD. 
 
The application of the Phase 1 error boundaries to the histogram of Phase 2 cell counts, created 
when participants followed the protocol can be seen in Figure 112. A shift in the whole population 
can be seen, with more participants returning a higher cell count when following the protocol. This 
is primarily due to a greater inclusion area specified in the second gate applied in the sequence, 
which overall has increased the cell count from what most participants highlighted when using their 
own judgement.  Whilst there is still some variability around the final cell count achieved using a 
protocol, it shows that protocols can be used to improve the assumed accuracy of a gating strategy, 
to ensure the target cell populations are reproducibly selected. In this instance we cannot have 
metrological accuracy because a true value is unknown, however, if a protocol is used as a 
benchmark, then a known value can be taken from the benchmark to aim towards, creating an 
‘experimental accuracy’ rather than a theoretical or traceable one.  
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Figure 111 Participant average result deviations from overall group median. 
 
Figure 112 Application of Phase 1 error boundaries to engineered T-cell counts when participants follow a protocol 
 
Qualitatively reviewing the extreme participant (B13) gating strategy outside of the Median ± 2SD, 
highlighted from the residual diagram in Figure 113, has shown that most of this bias could be due 
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to the fifth and sixth gates applied to the engineered T-cells, because these gates cut off a portion 
of the CD4+ CD8- cells in gate 5, and the quadrant placed on the sixth gate sits to the right of the 
densest region of the cell cluster. This cut across the dense region of this population, keeps a lower 
proportion of cells within the gate boundary. This gating strategy shows how over-constraining the 
cell population leads to an overall lower cell count than the median, with Participant B13 returning 
a final cell count of 3.56 % in comparison to the interparticipant median of 12.23 %.  
 
Figure 113 Participant B13 Gating Strategy interpretation when following a protocol 
 
The distribution histogram of participant CV of reported results can be seen in Figure 114, plotted 
on top of 3 specification limits derived from the ICSH boundaries used throughout this thesis. All 
22 participants took part in this second gating session so the optimal scenario would have all 22 
participants (n) with < 1 % CV, which sets the total height at y-intercept of the graph.  
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Figure 114 CV Performance of Participant Absolute results when following a protocol during the complex cell model 
 
Using these guidelines as boundaries, eight participants fell outside of the ‘revision required’ region 
due to very high CV and a further five participants fell just outside of the ‘good’ and ‘satisfactory’ 
performance regions. These extreme outliers had more variation within the final quadrant gate they 
drew when identifying the final naïve T-cell cell population. Participant B07 had the highest CV when 
gating using the protocol, and their final gate can be seen in Figure 115. This variation comes from 
gate 6 applied to separate the CCR7+ CD45RA+ population from the remainder of the cell 
population. The second repeat did not intersect this population in the same way as repeat one and 
three, because B07 did not include any of the positive population within this gate, causing the large 
CV. The small amount of remaining cells is passed onto the remaining two gates, resulting in a 
small overall cell count for repeat two, a skewed average cell count and a larger CV due to the large 
SD between repeats.  
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Figure 115 Participant B07 Complex Model Study Gating interpretation 
 
The most extreme participant has been included here as an example of outlying CV results. 
Participant B07 had a CV of 86 % due to disparity between the three repeated gates applied to the 
data. The bulk of this deviation comes from the quadrant gates applied to the data to identify CD4+ 
CD8- populations (gate 5) and CCR7+ CD45RA+ populations (gate 6).  One gate has been applied 
differently from the other two repeats. This is very noticeable in gate 6, where B07 has removed all 
of the same double positive population from one of the gates applied. This dramatically reduced 
the population count carried forward, causing the large CV result. The deviated gate was applied 
because B07 did not use both FMO controls to set the gate limits. One control was set for CCR7+ 
but B07 failed to cross-reference with the CD45RA+ control, causing the lower population count 
carried forward. 
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6.3.3 Flow Cytometry Complex Gating Exercise absolute results –   
 Comparison of Phase 1 and Phase 2 
 
The average cell counts for each participant when they gated following their own judgement and 
then a protocol have been compiled into the histograms in Figure 116. Any dark orange areas are 
overlap of the two respective histograms. The range of cell counts has increased by 6.18 % when 
participants followed the protocol, indicating that protocols may not be as helpful to participants 
when trying to conform to more reproducible cell counts, or the protocol specified gating areas that 
were wider than what participants would have personally drawn. Both phases of data have normally 
distributed populations, so in this instance the protocol has not made the population more kurtosed 
and repeatable to a specific cell count value.  
 
Figure 116 Comparison of Participant Absolute cell counts when gating using their own judgement and when following 
a protocol (brown areas indicate overlap between the two distributions) 
 
Further comparison of inter-participant data when gating using their own judgement and following 
a protocol has been completed with a Sign statistical test (Table 63), to compare equality of 
medians between each test condition. The Sign test results reject the null hypothesis of no 
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difference in medians, confirming the qualitative histogram conclusion that there is a significant 
difference between the two medians of the two phases.  
 
Table 63 Sign test results for comparison of Intermediate Gating Study Stages 
Null Hypothesis Test Sig. Decision 
Median difference of P1 & P2 cell counts = 0 Related-samples Sign test 0.000 Reject null hypothesis 
 
Comparison of these averages has been visualised in Figure 117, plotting the differences of 
participants average cell counts from the actual cell counts from the protocol gates they were 
provided to copy in Phase 2. Whilst this only considers the cell count values, not the size, shape or 
area of the gates, this potentially indicates that when participants copy the protocol, they are more 
likely to over constrain their gates, than when using their own judgement to place gates.  
 
When applied to a CGT context, this could become dangerous when releasing products due to 
potential false positives. If an operator includes more cells due to their interpretation of a protocol, 
this indicates more cells of interest have grown within the therapy product, meeting the required 
threshold for filtration and patient infusion. If the desired cell count is not met, the therapy would 
either need more time to sufficiently expand, or it should be rejected when analysed in QC. If not 
given this time, the product would be filtered and prepared for the patient, but not actually provide 
the correct therapeutic dose of treatment. This could lengthen the treatment time if more starting 
material needs to be taken from the patient, causing them more distress, and more inefficiencies 
within the manufacturing process which in turn increase the costs of cell therapy treatments.  
  Chapter 6: Complex Uncertainty Model 
218 
 
 
Figure 117 Comparison of Participant averages to the benchmark protocol given to follow in Phase 2 
 
To further compare these two testing conditions the A Priori and Post Hoc power were calculated 
again (Table 64) to identify whether a suitable number of participants had been gathered based 
upon the difference in variance of absolute cell counts in each test condition. The use of these 
power analysis variables has been discussed within the methodology in Chapter 2.  
 
Table 64 A Priori and Post Hoc Power analysis for Complex Study absolute cell counts 
Variance Phase 1 Variance Phase 2 A-priori power Sample size required Actual power 
6.364 11.092 0.800 82 0.343 
 
The A Priori and Post Hoc power analyses in Table 64 show that for the variances achieved between 
the two test condition average cell counts, 82 participants would have been required to show this 
difference, to the required minimum desired power of 0.80. The actual power achieved through 
this study is 0.343, indicating a 34 % probability of the differences in variance of absolute cell 
counts being due to the two test conditions used and no other underlying factors.  
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Figure 118 Comparison of participant absolute cell count CVs when gating using their own judgement and when 
following a protocol (brown areas indicate overlap between the two distributions) 
 
The CV of cell counts is commonly reported alongside average cell counts within Flow Cytometry 
data and in this instance the range of participant CVs was greater when participants used the 
protocol to apply gates to the cell population, shown in Figure 118. The extreme value obtained 
here is due to FMO controls not being used properly during one repeat, causing a large overall CV. 
Aside from this extreme value the protocol appeared to then reduce the range of results CV between 
participants when they followed this, but this only really considers the final gate applied within the 
repeats. Measurement uncertainty provides a better way to compile and monitor variation over the 
whole gating process.  
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6.3.4 Flow Cytometry Complex Gating Exercise uncertainty results –   
 Phase 1: Personal Judgement 
 
The uncertainty results reported here are a combination of the eight gating stages defined in Figure 
96 for gates applied when participants use their own judgement. The uncertainty values have been 
quantified following the prescribed methodology in Chapter 2, Section 2.5. The uncertainty would 
better represent variance of measurements with greater confidence, because this combines 
variability from all gates applied in the sequence, not just the variance of the final gate applied.  
 
Table 65 Measures of Location for uncertainty of the Complex Gating Study using personal judgement (%) 
Arithmetic Mean 10.6 
Median 6.2 
Mode N/A  
Minimum 0.8 
Maximum 34.9 
 
Table 66 Measures of Spread for uncertainty of the Complex Gating Study using personal judgement (%) 
Range 34.0 
25th Percentile 4.0 
75th Percentile 13.2 
Interquartile Range 9.1 
Standard Deviation 10.8 
Median Absolute Deviation 3.0 
 
Table 67 Measures of Skew for uncertainty of the Complex Gating Study using personal judgement (%) (3dp for resolution) 
Skewness 1.375 
Skewness standard Error 0.491 
Skewness z-score 2.800 
Kurtosis 0.468 
Kurtosis Standard Error 0.953 
Kurtosis z-score 0.491 
 
Table 68 Shapiro-Wilk test for normality for uncertainty of the Complex Gating Study using personal judgement (%) (3dp for resolution) 
Shapiro-Wilk statistic 0.758 
Significance 0.000 
Normal/Non-parametric Non-parametric 
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Unlike the descriptive statistics for absolute results for this study phase, the mean and the median 
are not close together (10.6 % and 6.2 % respectively), indicating a more skewed distribution, as 
monitored in Table 65. The median is less than the mean, indicating a slight positive skew to the 
data. This is further supported by the Shapiro-Wilk test for normality (p < 0.0005 %), shown in Table 
68, indicating that the distribution is non-parametric in shape, indicating skewness. 
 
There is a wide range (34.0 %) between minimum and maximum participant uncertainties. Table 
66 also shows the interquartile range as 9.1 %, indicating a high kurtosis, because half of the data 
lies within 27 % of the total distribution range.  This is supported by the skewness value in Table 
67 (2.800 %) with skewness z-score falling outside of the ±2.58 boundaries specified for normality 
in Chapter 2. The raw data for each participant can be seen in Figure 119 with various extremes 
within the dataset. This distribution shape can be observed within Figure 120, showing the positive 
skew with a possible bimodal split and 4 larger uncertainty extremes. 
 
 
Figure 119 Expanded Uncertainty of all Participant Gating within the Intermediate Model Study 
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Figure 120 Histogram of Participant Expanded Uncertainty from repeats of Intermediate Model Study 
 
Whilst deviation from a median can help to explain the distribution parameters, when analysing 
variance, a positively skewed distribution towards zero is preferred. Comparing uncertainty in its 
size order allows boundaries to be set for permissible specification limits for product 
release/laboratory quality that increase in value.  
 
Again, in this instance the CV specification limits have been substituted for Uncertainty (Figure 
122), and no other uncertainty specifications have been defined in the public body of knowledge 
from research or industry. However, unlike the previous model, this correlation is not strong 
because of the six participants with extreme uncertainty values, which will be explored within the 
extremes identified within Figure 121. Even when these extremes are removed the gradient is still 
low (0.1457x). 
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Figure 121 Final Cell Count Population Percentage CV versus Gating Uncertainty for participants 
 
 
Figure 122 Participant Uncertainty performance monitoring diagram when using their own judgement during the 
complex model 
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Participants B04, B10, B07 and A04 had the highest overall uncertainties of the population, which 
fall outside of the ‘Revision required’ boundary, and are also above the limit of permissible 
uncertainty, shown as the black line on the graph in Figure 122.  
 
Figure 123 Standard Deviation of each gate applied in the sequence by each participant 
 
The distribution of all participant SDs from each gate applied in the sequence can be seen in Figure 
123. These standard deviations are combined in quadrature to create the total expanded 
uncertainty value, used to identify extreme participants. Participants B04, B10, B07 and A04, who 
are the uncertainty extremes in this instance can be identified as the top four lines of this standard 
deviation breakdown graph. Visualising the data in this way shows that all four participants had a 
large variation due the live cell gate (gate 3) applied in the sequence. This had a knock-on effect 
for the following two gates, which then lowered when gating the CCR7+ and CD45RA+ cells. 
Interestingly, this was not anticipated because of the difficulty of separation of the population, it 
was thought that there would be more variability here. However, because of the difficulty of 
separation, participants adhere to the FMO controls and instructions a lot more, causing the low 
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variation. As examples, the gating sequence for Participant B10 can be seen in Figure 124, in 
addition to Participant B04 (Figure 125), because these participants had the largest uncertainties.  
 
 
Figure 124  Participant B10 Complex Model Study Gating interpretation 
 
Figure 125 Participant B04 Complex Model Study Gating interpretation 
 
In all instances there is one repeated gate that is significantly larger or smaller than the remaining 
two. Upon closer inspection, the larger gates all sit against the right, lower edge of the vertical axis 
and another pseudocolour stripe can be seen running along the edge of the boundary. Inclusion or 
  Chapter 6: Complex Uncertainty Model 
226 
 
exclusion of this boundary effect is causing this variability, which is then carried forward into the 
CD3+ gate due to the population count.  The remainder of the population had very small Standard 
Deviations, aside from Participants B08 and C03, who had mid-range variabilities. These 
variabilities are due to one gate being different from the rest, however there are differences 
between these two participants. Participant C03’s gates have already been visualised in Figure 
105, and Participant B08’s gate can be seen in Figure 126.  Participant C03 has variation due to 
the live gate (gate 3), with two repeats cutting through the population and one repeat placed around 
the entire population. This was due to the participant’s inexperience with using control files to place 
gates, and a lack of final checking at each level of the gating sequence.  
 
The difference with Participant B08, is that the largest gate applied to the live cell population cuts 
through the boundary effect seen on the left side, causing the higher cell population and larger 
standard deviation for that gate. This boundary effect has been investigated in further detail in 
Chapter 5, when additional cells were compiled together on the right edge of the plot. In this 
instance, smaller live cells that are not in the fluorescence range have been compiled on the left 
side. Where this has been cut through to including the lower density region, a spike in the 
population has been carried forward. 
 
Figure 126 Participant B08 Complex Model Study Gating interpretation 
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6.3.5 Flow Cytometry Complex Gating Exercise uncertainty results –   
 Phase 2: Following Protocol 
 
The uncertainty results reported here are a combination of the eight gating stages defined in Figure 
96 using the gating protocol provided, shown in Figure 97 and FMO controls. The uncertainty values 
have been quantified following the prescribed methodology in Chapter 2.5. The uncertainty would 
better represent variance of measurements with greater confidence, because this combines 
variability from all gates applied in the sequence, not just the variance of the final gate applied.  
 
Table 69 Measures of Location for uncertainty of the Intermediate Gating Study when following a protocol (%) 
Arithmetic Mean 22.0 
Median 19.3 
Mode N/A  
Minimum 2.1 
Maximum 43.9 
 
Table 70 Measures of Spread for uncertainty of the Intermediate Gating Study when following a protocol (%) 
Range 41.8 
25th Percentile 4.4 
75th Percentile 38.8 
Interquartile Range 34.4 
Standard Deviation 16.6 
Median Absolute Deviation 17.1 
 
Table 71 Measures of Skew for uncertainty of the Intermediate Gating Study when following a protocol (%) (3dp for resolution)  
Skewness 0.083 
Skewness standard Error 0.491 
Skewness z-score 0.169 
Kurtosis -1.800 
Kurtosis Standard Error 0.953 
Kurtosis z-score -1.889 
 
Table 72 S-W test for normality for uncertainty of the Intermediate Gating Study when following a protocol (%) (3dp for resolution) 
Shapiro-Wilk statistic 0.836 
Significance 0.002 
Normal/Non-parametric Non-parametric 
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Similar to the descriptive statistics for absolute results for this study, the mean and the median are 
close together (22.0 % and 19.3 % respectively), indicating a less skewed distribution, as monitored 
in Table 69. The median is less than the mean, indicating a slight positive skew to the data, which 
is preferable for uncertainty results. However, the Shapiro-Wilk test for normality, shown in Table 
72, indicating that the distribution is non-parametric in shape (p = 0.002 %), indicating more 
skewness than the mean-median difference shows. 
 
There is a wide range (41.8 %) between minimum and maximum participant uncertainties. Table 
70 also shows the interquartile range as 34.4 %, which indicates a low kurtosis, because half of 
the data lies within 83 % of the total distribution.  This is supported by the skewness and kurtosis 
values (0.169 % and -1.889 % respectively) in Table 71 with skewness and kurtosis z-scores inside 
of the ±2.58 boundaries specified for normality in Chapter 2. The raw data for each participant can 
be seen in Figure 127 with various extremes within the dataset. This ordered distribution shape 
can be observed within Figure 128, showing the positive skew with a bimodal split and 9 larger 
uncertainty extremes. Qualitatively assessing the shape of the distribution shows a different shape 
to the data than the descriptive statistics, because the mean calculated does not reflect central 
tendency of the raw data as would be assumed, which will be investigated further. 
 
Figure 127 Expanded Uncertainty of all Participant Gating within the Complex Model Study when participants followed a protocol 
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Figure 128 Histogram of Participant uncertainty from repeats of Intermediate Model Study when participants followed a protocol 
 
Whilst deviation from a median can help to explain the distribution parameters, when analysing 
variance, a positively skewed distribution towards zero is preferred. Comparing uncertainty in its 
size order allows boundaries to be set for permissible specification limits for product 
release/laboratory quality that increase in value.  
 
The ICCH and ICCS imprecision values described earlier for measurement CV and in previous 
Chapters have also been used here to define example specification limits if monitoring participant 
uncertainty. Again, in this instance the CV specification limits have been substituted for uncertainty 
from this gating phase (Figure 129), and no other uncertainty specifications have been defined in 
the public body of knowledge from research or industry.  
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Figure 129 Participant uncertainty performance monitoring diagram when using their own judgement during the 
complex cell model 
 
There were nine outliers that exceeded the higher control limits with five of these also exceeding 
the limit of permissible uncertainty. Participants B09 and B10 had the highest overall uncertainty, 
followed by Participants B07 and B02, who all exceeded the limit of permissible uncertainty, as 
well as exceeding the defined control limits. However, again there qualitatively appears to be a high 
variance participant cluster which has its own maxima at 39 % uncertainty. 
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Figure 130 Participant B09 Complex Model Study Gating interpretation 
 
Figure 131 Participant B10 Complex Model Study Gating interpretation 
 
Participant B09 (Figure 130) and B10’s (Figure 131) most variable gates were the on the third plot 
in the sequence. The repeats are very uniform in size and structure, with a repeatable cut-off 
separating the primary population from the dead and dying cells. The variability appears to come 
from differences in the left edge of the gate, where the gates applied cut through a data spike that 
sits on the boundary of the plot, as first discussed in Chapter 5. In this instance, the axes of the 
plot could not be scaled up to better see this spike, because this spike always sits on the left 
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boundary, at the lowest scale point of 10-3. This data spike could be an amalgamation of all the 
data points that exceed the plot limits, so they have been complied and added to the boundary, 
however, there is no information from Flowjo on this visualisation effect. 
 
Figure 132 Standard Deviation of each gate applied in the sequence by each participant 
 
The distribution of all participant standard deviations from each gate applied in the sequence can 
be seen in Figure 132. These standard deviations are combined in quadrature to create the total 
expanded uncertainty value, used to identify extreme participants. Participants B09, B10, B07, 
B05 and B02, who are the uncertainty extremes in this instance can be identified as the top lines 
of this standard deviation breakdown graph. Visualising the data in this way shows that these 
participants had a large variation due the live cell gate applied in the sequence, like the previous 
session where no protocol was used. This had a knock-on effect for the following two gates, which 
then lowered when gating the CCR7+ and CD45RA+ cells.  
 
In a manner similar to Phase 1 uncertainty, there is a mid-range uncertainty group, populated by 
Participants A01, B01, B06, B08 and C03. These participants had a mid-range standard deviation 
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when gating the live cell population in gate 3. Examples of these can be seen in Figure 133 and 
Figure 134 for participants A01 and B01. 
 
Figure 133 Participant A01 Complex Model Study Gating interpretation 
 
 
Figure 134  Participant B01 Complex Model Study Gating interpretation 
 
To further investigate this, gate 3 was investigated for A01 and B01 as representatives of this mid-
range group. Figure 135 and Figure 136 show the gates applied here for A01 and B01 respectively. 
The left images show the original scaling used for these gates, and the right images show the 
extended log scale to better see the left edge of the gates drawn. 
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a) 
 
b) 
 
Figure 135 Participant A01 gate 3. a) Standard gates drawn with logarithmic scaling. b) Gates drawn to biexponential 
scaling 
 
a) 
 
b) 
 
Figure 136 Participant B01 gate 3. a) Original gates drawn with logarithmic scaling. b) Scale extended to show shape 
of left edge 
 
It is possible from looking at the two examples here that the mid-range standard deviations for this 
gate is due to the location of where the left edge is dragged to past the original logarithmic axis 
limit, and what angle this ends up being at. A01 gates are not placed in line with the 100 mark that 
the scale was set to, at which the boundary effect would have been displayed. Upon review of their 
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session recording, Participant A01 changed the axis scaling to biexponential, which is causing this 
variation, shown in Figure 135 (b), in comparison to the correct logarithmic layout in Figure 135 
(a). However, B01 has a gate that is angled across this scale point, possibly causing the mid-range 
variability Both participants are consistent with the size and shape of the overall gates applied, and 
consistent with the cut off between the live, dead and dying cell populations. 
 
To further investigate if the cause of this cluster variability in the third plot in the sequence, a 
selection of participants with low uncertainties were examined to see if there is a difference or 
obvious understanding if this boundary effect has been avoided during their analysis. Participants 
B03 and B13 had very low uncertainties from their total gating process and both fall within the 
lower variance cluster. Their initial plots can be respectively seen in Figure 137 and Figure 113.  
Further detailed plots of gate 3 can be seen in Figure 138 and Figure 139. 
 
 
Figure 137 Participant B03 Complex Model Study Gating interpretation 
 
Participants B03 and B13 have applied gates close to this boundary effect, however they are very 
repeatable in size and shape. Upon closer inspection B03 has drawn gates to all include the 
boundary effect. These are repeatable so the standard deviation is low, although this causes the 
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overall cell count to be higher. Participant B13 has consistently gated just inside the boundary 
effect, causing a lower variance and lower cell count due to the consistency of this edge. 
 
a) 
 
b) 
 
Figure 138 Participant B03 gate 3. a) Original gates drawn with logarithmic scaling. b) Scale extended to show left 
edge 
a) 
 
b) 
 
Figure 139 Participant B13 gate 3. a) Original gates drawn with logarithmic scaling. b) Scale extended to show left 
edge 
 
Throughout this complex study, the variability has consistently arisen from a different gate in the 
series, not the first gate or quadrant gates which have been previously identified. This was due to 
the presence of a boundary effect appearing again as in Chapter 5, but in this instance it has 
appeared on the low fluorescence edge, due to the required cell population having low fluorescence 
  Chapter 6: Complex Uncertainty Model 
237 
 
staining. This visual artefact has been considered again within different software platforms when 
it appears on a different edge. Figure 140 shows these outputs across different visualisation 
software, with FlowLogic removing this effect in the top and left edges of the plot, and Flowjo also 
removing it when figures are moved into the layout editor for exporting. Within the analysis window 
the boundary effect can still be seen, hence its effect on the data analysis, and the same can be 
said for FCS express, although the axes are defined and scaled differently to Flowjo and FlowLogic 
Logarithmic scaling. 
 
Figure 140 Software visualisations of live cell gate (gate 3) to identify boundary effect 
 
6.3.6 Flow Cytometry Complex Gating Exercise uncertainty results – Comparison of Phase 
1 and Phase 2 
 
The uncertainties for each participant when they gated following their own judgement and then a 
protocol have been compiled into the histograms in Figure 141. Any dark orange areas are overlap 
of the two respective histograms. The range of cell counts has increased by 7.8 %, indicating that 
protocols may not help participants conform to reproducible cell counts. However, a 
bimodal/trimodal distribution has appeared so more needs to be completed to understand how 
subjectivity and interpretation of a protocol and visual images impact the final uncertainty 
calculated. An improvement in training to highlight boundary effects discussed could have a 
positive impact when trying to reduce inter-participant uncertainty in Flow Cytometry analysis. The 
skewness and kurtosis z-scores have reduced when participants use a protocol, however this is 
showing a tendency towards normality, which the distribution shape does not support in either 
instance.  
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When participants used their own judgement to apply gates, a split between higher and lower 
uncertainty groups appears, but the shape of the overall distribution is positively skewed, with only 
a few extremes exhibiting high variance. Use of a protocol has created further clustering effects, 
seen in Chapter 5 for the intermediate model, potentially caused by boundary effects within the 
software. This requires future investigation to understand what contributions training and 
awareness can do to remove this source of variation, as well as finding ways to remove this from 
the data. In addition, some software platforms remove these data spikes from the data, which can 
change the values operators specify for cell counts across different programs. 
 
  
Figure 141 Overlaid histograms of participant uncertainties when gating the engineered T-cell population following 
their own judgment and then using a protocol (brown areas indicate overlap between the two distributions) 
 
Further comparison of inter-participant data when gating using their own judgement and following 
a protocol has been completed with a Sign statistical test, to compare equality of median 
uncertainties between each test condition, shown in Table 73. The Sign test results reject the 
alternative hypothesis, because the uncertainty medians of the two testing conditions are not 
statistically different. This does not statistically show that the uncertainties are smaller when 
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participants use a protocol, however this only considered location values, so other measures of 
variability should also be considered before deciding whether a protocol effectively reduces inter-
participant variability, or not. This is especially true in this instance due to the bimodal/trimodal 
nature of one of the populations, meaning a robust statistic such as the median is not a reliable 
location measure to represent the population. 
 
In this study, an increase in overall range has been seen, indicating that diagrammatical protocols 
alone are not enough to control inter-participant variability and uncertainty contributions to 
measurements. Future considerations would need to look at incorporating training of noise 
parameters around data sets to ensure participants are aware of this effect on the variability of 
their subjectivity and interpretation, especially when cleaning the data at the start of a gating 
sequence. The use of this protocol is causing subjective behaviour to divide the population into 
high, medium and low variance clusters, which requires further testing to confirm this effect, and 
the effect of identifying boundary effects to participants before they apply gates to data.  
 
Table 73 Sign test for median difference between Phase 1 and Phase 2 uncertainties 
Null Hypothesis Test Sig. Decision 
Median difference of P1 & P2 uncertainties = 0 Related-samples Sign test 0.520 Retain null hypothesis 
 
Table 74 A Priori and Post Hoc Power for Phase 1 and 2 uncertainties 
Variance Phase 1 Variance Phase 2 A-priori power Sample size required Actual power 
117.422 273.981 0.807 37 0.601 
 
The A Priori and Post Hoc power analyses in Table 74 show that for the variances achieved 
between the two test conditions uncertainties, 37 participants would have been required to show 
this difference, to the required minimum power of 0.80. The actual power achieved through this 
study is 0.601, so less participants would be required if only uncertainty was being considered, not 
absolute cell counts (actual power of 0.343). This low power indicates that any differences seen 
from the data have a low probability of being just due to the two test conditions used and no other 
underlying factors present. Again, like the Sign test, this needs to be considered carefully. A greater 
number of participants in the study could always benefit and provide more confidence in the 
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results, however, the distributions are not normally distributed, so the variance calculated assumes 
a distribution with central tendency. In this instance, the range of data becomes more important to 
consider, due to the distribution shape and clusters appearing within the uncertainty data. 
6.4 Chapter Conclusions 
 
The engineered T-cell material used was a good model for the complex study because it provided 
an increase in complexity of the analysis pipeline participants were required to complete, and it 
also provided affinity towards current cell therapy treatments which are T-cell based. The studies 
run with the 3-workspace configuration for repeats continued to work well within the time available 
for participants, so this structure has shown to be a good working model for all studies in this 
experimental work. The eight-step process that each participant had to work through was also 
straight-forward to follow from the gating sequence protocol and the diagrammatical protocol, 
ensuring there was little deviation from the prescribed method. 
 
When reporting the absolute cell count percentages for the results, the mean and median values 
for each Phase were very similar (mean = 5.8 % and median = 5.5 % for Phase 1, mean = 12.0 % 
and median = 12.2 % for Phase 2). These results both indicate a normal distribution within both 
data sets, however, the mean and median for Phase 2 is over double that of Phase 1. In this 
instance, there was an increase in the range of inter-participant cell counts when using a protocol. 
The protocol increased the absolute range of cell count results between-participants by 3.9 % of 
the overall cell count (2964 cell events) (which is a 42 % increase with respect to Phase 1 absolute 
range). This indicates protocols may not aid reproducible cell counts between participants in this 
instance, as initially identified in previous chapters.  
 
The Sign test confirmed there was a significant difference between the medians of the two testing 
conditions (average cell counts), showing that protocols can potentially aid gating accuracy of the 
desired cell population. However, the Sign test to compare the medians of the uncertainties was 
not significant, indicating that the two phases did not have significant variabilities. Whilst this is a 
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definitive statistical test, the qualitative shape of the distributions was considered, and the 
bimodal/trimodal nature of the Phase 2 uncertainties indicates that a single location measure 
should not be used for sole comparison.  The power analysis completed for both average cell counts 
and uncertainties indicated that more participants would be required to identify significant 
differences between the two testing conditions, requiring 82 and 38 participants for average cell 
counts and uncertainties respectively. 
 
The use of the protocol made the distribution more bimodal, similar to the uncertainty for this 
Phase. Participants using their own judgement were more positively skewed towards 0 %, which is 
desirable for variation metrics, indicating that more participants were less variable (in their final 
cell count) when using their own judgement to apply gates. Reviewing the extremes in CV using the 
adjusted traffic light diagram shows variability in the final gate applied, but it also highlights that 
other variability seen upstream of this gate can have an impact on cell count, but the gate variability 
itself is not taken into consideration in the CV calculation, making measurement uncertainty a more 
suitable metric for accommodating variation throughout the whole gating sequence. 
 
This complex model with an 8-step sequence has shown that calculating measurement uncertainty 
is possible for participants by using traditional measurement uncertainty methods. This was 
calculated successfully, by presenting participants with three repeated workspaces of data, and 
extracting one repeated file located in each workspace randomisation.  
 
The uncertainties calculated to accompany the cell counts are more non-parametric than the 
absolute cell counts. The absolute mean and median uncertainties went from 10.6 % and 6.2 % 
respectively in Phase 1 to 22.0 % and 19.3 % respectively in Phase 2.  The mean and medians in 
Phase 1 are not close together, indicating skewness. The mean and median in Phase 2 are closer 
together, indicating a normal distribution of uncertainty, although the central location measure has 
shifted to a higher uncertainty. The means are unsuitable metrics because they do not represent 
the peak maxima, especially in Phase 2, where the bimodal distribution causes the mean to sit 
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between two peaks. The range of participant uncertainty increased when using a protocol (absolute 
increase = 7.8 %, percentage increase with respect to Phase 1 = 23 %), indicating this may not 
reduce inter-participant uncertainty in the same way as observed for the basic and intermediate 
stages. Once more, the distribution shape of Phase 2 uncertainty separated into two bimodal 
peaks, indicating clusters of high and low variance participants, potentially due to understanding 
and bias when using the nominated software platform.  
 
Further investigation has shown a high probability of this variation split coming from a boundary 
effect within the data visualisation software. Cells in the file that have a fluorescence signal lower 
than the visualisation axes are compiled on the boundaries. Inclusion of these in the repeated 
analysis can skew the cell counts and uncertainty significantly. Consistent inclusion or exclusion of 
the fluorescence spike gives a low variance, with high or low absolute cell counts respectively. 
Inconsistent inclusion/exclusion of the data spike leads to high variance. Those in the lower 
variance cluster have not included these cells in their analysis, or repeatedly have so the overall 
variation would be lower between repeats. Revision of extreme participants using the uncertainty 
boundary diagrams has shown most of the variation is contributed within the third gate applied, 
where the boundary effect is initially seen on the lower axis, increasing the possibility that the 
boundary effect causes this higher variation. 
 
Overall, the structure of these analysis sessions and data extraction processes has worked well 
over the subsequent analysis phases, allowing for appropriate comparison between data in Chapter 
7.  
 
6.4.1 Consolidation of Objectives 
 
• This study ran smoothly, acting as a good complex model for comparison of absolute 
reported results, CV and uncertainty measures. The session structures were suitable in 
time, and 3 repeats was suitable for participants to understand study context, but not 
become tired.  
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• Diagrammatical protocols used by participants during the second phase of this study 
have shown to increase the range in absolute results (3.9 %) reported and increase the 
range of participant absolute uncertainties (7.8 %), which calculates as a 23 % increase 
with respect to to Phase 1 counts). This is different to subsequent chapters and could 
possibly be due to the higher dimensionality of the data causing additional difficulty for 
participants.  
• Extreme values in absolute reported results were due to participants either over 
constraining or under constraining the live cell population predominantly within the sixth 
gate, due to over- or under-constraining the quadrant around the desired double positive 
population. In some cases, lack of knowledge of using controls to set gates led to 
variance in population metrics. 
• Extreme values in uncertainty results were due to participant variability in applying a gate 
to separate the live cell population from the dead or dying cells, alongside additional 
variation caused in the third gate by boundary effects on the left edge of the visualisation 
plot, caused by concatenated data that would otherwise be outside the plot axes. In 
addition, separating the CD45RA+ CCR7+ (gate 6) population from the remaining cells 
has caused some extremes in absolute cell counts due to placement of these quadrant 
gates. This gate was thought to be more variable, however, because of the difficulty of 
the gate, participants have been more repeatable when using FMO controls to place 
gates. 
• The performance monitoring diagrams visualised continue to provide a straightforward 
way to monitor uncertainty performance with respect to the number of people in the study 
and defined quality satisfaction limits. These will be used in the subsequent chapter to 
monitor uncertainty performance in a more complex gating scenario. 
• This study defines participant uncertainty for a more complex, industrially relevant, 8-
colour panel cell model, which can be used as a complex model compare potential 
growth of inter-participant uncertainty through more difficult analysis scenarios. 
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Chapter 7: Comparison of Models 
7.0 Introduction to the Chapter 
Chapter 7 provides a comparison of key metrics monitored throughout the different complexity 
models discussed in Chapters 4 to 6. Basic statistics as well as more complex statistical tests such 
as the Friedman test have been used within this chapter to critically evaluate the different 
complexity models and their effect on cell counts and participant uncertainties. 
7.1 Chapter Aims 
 
This Chapter compares complexity models to identify whether the core hypothesis of this research 
has been met, showing an increase in range of CV and uncertainty with increased data complexity. 
This Chapter aims to compare the ranges of absolute cell counts, CVs and uncertainties, to identify 
a potential in case in between-participant variability. Only data from personal judgement has been 
compared, because a protocol phase was not conducted within the basic model (Chapter 4). 
7.1.1 Chapter Aims & Objectives 
 
The Aims and Objectives of this Chapter can be defined as follows: 
• Identify potential changes in the range of absolute cell counts with complexity of data. 
An increase in range of reported cell counts would indicate greater variability between 
participants when reporting Flow Cytometry results. 
• Identify potential changes in the range of absolute cell count CVs with complexity of data, 
because this is the most common variability reporting methods within the Flow Cytometry 
method so an indication of how this changes with data complexity could aid the 
community with a representative value for analyst contributions. 
• Identify potential changes in the range of uncertainties calculated with complexity of 
data. This is an alternative measure of variation explored within this research and will be 
compared to CV to identify its suitability within Flow Cytometry measurements.  
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7.2 Methodology 
 
To compare the three models across Chapter 4 to 6, basic statistical reporting has been 
considered, as well as more specific statistical tests to define differences between the models. This 
has been completed for all absolute cell counts and CVs reported, as well as respective 
uncertainties. This methodology section explains why these comparison methods have been 
chosen along with justification. Both IBM SPSS Statistics Version 24 and Matlab R2019a have 
been used to complete the more advanced statistical analysis and visualisation. 
 
7.2.1 Basic Statistical Reporting 
 
Basic statistical reports used within Chapter 4 to 6, with statistical definitions from Chapter 2, have 
been compared and discussed here. In addition to the compilation of these data sets, box plots 
have also been produced to visually compare the distributions of the separate data sets. A box plot 
shows the 25th, 50th (median) and 75th percentiles (%iles) to visualise the distribution of the 
Interquartile Range (IQR). Whiskers have also been added to the box plot to show the distance of 
1.5 x IQR. This is a common distribution marker for outliers. Anything within the whiskers is an inlier, 
or acceptable measurement. Any data point marked as a cross outside of the whiskers is defined 
as an outlier.  
 
7.2.2 Further statistical testing for differences 
 
Despite conclusions drawn from the basic statistics, more extensive statistical testing to confirm 
there are statistically significant differences between the three models has been completed for 
absolute cell counts and uncertainties. 
 
A Friedman test has been used in this instance, because the data is non-parametric in distribution 
shape and three different groups or testing conditions have been considered [197]. This is the 
robust alternative to a one-way repeated measures ANOVA, which required the data to be normally 
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distributed. A Friedman test has also been used in place of a Kruskal Wallis H test, because it 
compares related data. Mostly the same participants were present in each testing model, making 
the Friedman test more suitable for analysis, whereas a Kruskal Wallis H test requires 
independence between participants in the separate testing conditions.  
 
The Friedman test requires the same participants in each group, and each group represents 
repeated measures on the same dependent variable. In this instance there were not the same 
number of participants in each group, and some participants were not present in each group, which 
could compromise the power of the analysis. However, this was not in the control of the 
experimental studies. The Friedman test is an extension of the Sign test, which only compares two 
groups and has been used to compare test conditions within Chapters 5 and 6. The hypothesis of 
the Friedman test is as follows: 
 
HO = the distribution of results in each group are the same 
HA = at least two distributions differ 
 
If the null hypothesis is rejected because at least two distributions differ, Post Hoc tests (Pairwise 
comparisons) are used to identify similar distributions. These tests are like the Wilcoxon rank tests 
used to compare two non-parametric distributions [197].  
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7.3 Comparison of Results 
 
The results reported here are split between the absolute cell count results and the uncertainties 
calculated from the gating sequences, as previously defined within Chapter 4 to 6. The results 
reported within these chapters have been repeated here for easier comparison.  
 
7.3.1 Comparison of Absolute Cell Count Results 
 
The statistical report results from the absolute cell counts generated from personal judgement of 
each complexity model can be found in Table 75, Table 76, Table 77 and Table 78. Only personal 
judgement results have been compared because the basic model does not have a ‘protocol’ phase, 
so only judgement has been assessed. Box plots to compare distributions of each complexity model 
are shown in Figure 142. It should be noted that the absolute results have been compared for 
continuity of the thesis structure, although the difference in cell type between the stages cannot 
be compared fairly, so these results are purely an indication of possible differences. Further testing 
with the same cell type at different gating stages could better investigate this. 
 
Table 75 Measures of Location for the absolute results of the complexity models (%) 
 Basic (Chapter 4) Intermediate (Chapter 5) Complex (Chapter 6) 
Arithmetic Mean (%) 32.1 6.3 5.8 
Median (%) 32.5 6.0 5.5 
Mode (%) N/A N/A N/A 
Minimum (%) 19.7 3.5 1.2 
Maximum (%) 51.3 8.0 10.5 
 
Table 76 Measures of Spread for the absolute results of the complexity models (%) 
Range 31.6 4.5 9.3 
25th Percentile (%) 30.6 5.7 4.0 
75th Percentile (%) 33.9 7.3 7.6 
Interquartile Range (%) 3.3 1.6 3.6 
Standard Deviation (%) 5.7 1.1 1.0 
CV (%) 17.8 18.2 12.1 
Median Absolute Deviation (%) 1.9 6.0 1.7 
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Table 77 Measures of Skew for the absolute results of the complexity models (%) (3dp for better resolution) 
Skewness (%) 0.492 -0.351 0.168 
Skewness standard Error (%) 0.383 0.481 0.491 
Skewness z-score (%) 1.280 -0.730 0.342 
Kurtosis (%) 3.271 0.042 -0.669 
Kurtosis Standard Error (%) 0.750 0.935 0.953 
Kurtosis z-score (%) 4.560 0.045 -0.702 
 
Table 78 Measures of Normality for the absolute results of the complexity models (%) (3dp for better resolution) 
Shapiro-Wilk statistic 0.904 0.945 0.980 
Significance 0.003 0.231 0.911 
Normal/Non-parametric Non-Parametric Normal Normal 
 
 
Figure 142 Absolute cell count distributions for each cell complexity model 
 
The locations of the basic model distributions are qualitatively significantly different due to no 
overlap with distributions of the more complex models. This is quantified by the basic model median 
(32.5 %), compared to the medians of the intermediate and complex model (6.0 % and 5.5 % 
respectively). The shape of the distributions are significantly different according to the results of 
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the Friedman test, as shown in Figure 143 (Basic model = S1_Av, Intermediate model = S2_1_Av, 
Complex model = S3_1_Av). Absolute cell counts between models were statistically different, 
according to the related samples Friedman two-way analysis of variance by ranks, 𝟀𝟀2 (2) = 19.538, 
p < 0.0005, but this could be expected because of the difference in cell type.  
 
Pairwise comparisons were performed as Post Hoc tests to further identify whether the significant 
differences were between some or all the models, shown in  Figure 144. A Bonferroni correction 
was applied to adjust the significance levels [197,198]. Multiple comparisons increase the risk of 
a Type 1 error, which is why adjusted significance was used, and has been used for all subsequent 
Friedman tests in this Chapter. Absolute cell counts were statistically different between the basic 
and intermediate models (p = 0.001) and the basic and complex models (p < 0.0005). This 
statistical significance confirms the qualitative differences observed, but also because the basic 
model was based upon a different cell type (Embryonal Carcinoma cell line) in comparison to the 
intermediate and complex models which look at T-cell subsets. 
 
Figure 143 IBM SPSS results for the Friedman test comparing absolute cell counts for complexity models 
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Figure 144 IBM SPSS pairwise comparisons for the Friedman test comparing absolute cell counts for complexity models 
 
The range of absolute results is largest in the basic model, which possibly could be because of the 
lower level of stratification required for this dataset, potentially suggesting that the larger the cell 
population cluster, the greater the range of participant cell counts. However, this is a different cell 
type, so this could confound this analysis. The range of absolute cell count results decreased for 
the intermediate model (4.5 %) and then increased again for the complex model (9.3 %). This may 
possibly have been due to the cell event number in the final model, which contained 76,012 cell 
events in comparison to 30,000 cell events gathered in the previous two stages. All cell counts 
were compared as percentages of the original cell count number to have better comparison 
between the files, to try and remove the inconsistent cell event numbers.  
 
However, this would require further experimental clarification to formally design and test this 
possibility. For further comparison the ranges of the third gate applied in the intermediate and 
complex model have been considered, because these are both larger cell populations, comparable 
in size to the basic model as just shown. The range of results of the third gate applied in the 
intermediate and complex models are 25.8 % and 33.1 % respectively, which are similar to the 
basic model range (31.6 %). This potentially suggests that as further stratification of the data 
through gating steps occurs, there is a smaller range of inter-participant absolute cell counts, due 
to a smaller stratified cell population. 
 
Due to the nature of gating, smaller cell counts through each gating step are logical. However, the 
ranges reported across the three models contradict this because the range of the complex model 
results is greater than the intermediate model. This is also seen in the IQR, so it is not just extreme 
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values that have an effect. More cell events were acquired in the complex model file than the 
previous two models, however, percentages of cell count populations have always been reported 
to standardise this. Gate 5 in the complex model has a range of 23.1 %, so it could be that because 
this model is more complex it is causing more deviation throughout the sequence, which could be 
expected.  
 
This is not supported by other methods of variation measurement, such as the SD, which does 
decrease with every data set (5.7 %, 1.1 %, 1.0 %) respectively. However, consideration of the data 
shape is required before drawing these conclusions because the basic model is more skewed and 
kurtosed than the other model, shown by skewness and kurtosis z-scores and Shapiro Wilk test 
results for normality. This could suggest that SD values are not valid for use in this context, however 
they are still suitable to consider because of their use within general statistical reporting. 
 
A more robust measure to use instead of SD is Median Absolute Deviation (MAD), but this shows 
no obvious trend in the data, with MAD starting at 1.9 % for the basic model, increasing to 6.0 % 
for the intermediate model and decreasing to 1.7 % for the complex model. Finally, the most 
common metric of variation in the Flow Cytometry community, Coefficient of Variation (CV) is fairly 
constant between each test model, reporting 17.8 %, 18.2 % and 12.1 % for each model increase. 
This CV will be known as inter-participant CV, because it is the CV of the absolute cell counts 
reported by each participant. This shows that if CV is to be continually used in the field, an average 
inter-participant CV of 16 % could be considered as an operator analysis component, taken from 
inter-participant absolute cell counts reported. This falls within the allowable CV specified by the 
ICSH guidelines, and also NHS KPIs for uncertainty, for Flow Cytometry discussed in Chapter 1 [72].  
 
Intra-participant CV has also been investigated throughout this research and is defined as the CV 
across the repeated measures of the three repeats each participant completed. The difference 
between inter-CV and intra-CV has been depicted in Figure 145, re-imagined from the earlier Gauge 
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R&R explanations in Chapter 2. In this instance, intra-CV is the repeatability of each participant, 
and the inter-CV is CV of absolute cell counts between participants.  
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Figure 145 Diagram of Inter-CV and Intra-CV for subjectivity comparison 
 
Figure 146 shows boxplot distributions of intra-participant CV results, from their 3 repeats acquired 
in each cell complexity model. 
 
Figure 146 Absolute cell count CV distributions for each cell complexity model 
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It is clear that the range of intra-participant CVs increase with cell complexity, with gradual increase 
in the median of each group. A related-samples Friedman rank test was completed to further 
confirm a significant difference between the test conditions. Cell count CVs were statistically 
different through the different models, 𝟀𝟀2 (2) = 14.000, p < 0.001, shown in Figure 147. Post Hoc 
pairwise comparison tests were then conducted to identify which pairs were significant, 
summarised in Figure 148. These was a significant difference between the basic and intermediate 
models (p = 0.043) and the basic and complex model (p = 0.001), but not between the intermediate 
and complex model as their distribution shape was deemed similar.  
 
 
Figure 147 IBM SPSS results for the Friedman test comparing absolute cell counts CVs for complexity models 
 
Figure 148 IBM SPSS pairwise comparisons for the Friedman test comparing absolute cell count CVs for complexity 
models 
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All distributions have a positive skew, aligning with the traffic light diagrams in Chapter 4 to 6, used 
to monitor the individual CV distributions. Even though the distribution of the complex model is the 
largest, it contains no outliers specified by the whisker limitations (Figure 146). Therefore, the data 
is less likely to by kurtosed because it may have a more evenly distributed shape than the other 
two test conditions. 
 
Overall, this indicates that as the complexity increases, the CV of the participant is likely to increase, 
confirming the thesis hypothesis if intra-participant CV is the variation metric of choice. If a general 
CV of absolute cell counts of a population is used (inter-participant CV), an increase has not been 
observed as cell models become more complex. An average of 16 % CV was achieved across the 
three models, so this could possibly be used as a rule of thumb when considering general operator 
variation around a measurement. 
 
7.3.2 Comparison of Cell Count Uncertainty Results 
 
Currently CV is commonly used within Flow Cytometry communities as a measure of variability along 
with the absolute reported result. Uncertainty has been explored as a potential alternative to CV, 
because of the better resolution it provides when monitoring variability between participants 
through the gating sequences. Uncertainty has also been explored as an alternative to CV because 
uncertainties for equipment are required to be calculated for ISO 15189 to show competency of 
medical testing laboratories [82]. This replaced Clinical Pathology Accreditation (CPA) in the United 
Kingdom, where every pathology laboratory in the National Health Service (NHS) must be 
accredited to this new standard. If interpretation forms part of a measurement, this should also be 
monitored and included in the uncertainty budget, stated alongside the final measurement 
reported. 
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The statistical report for the uncertainty results across all three complexity models can be found in 
Table 79, Table 80, Table 81 and Table 82. These results have been taken from ‘personal 
judgement’ phases through each stage for comparison. Boxplots representing each of these 
populations has been visualised in Figure 149. 
 
Table 79 Measures of Location for the uncertainty results of the complexity models (%) 
 Basic (Chapter 4) Intermediate (Chapter 5) Complex (Chapter 6) 
Arithmetic Mean (%) 4.0 3.8 10.6 
Median (%) 3.6 2.1 6.2 
Mode (%) N/A  N/A N/A  
Minimum (%) 0.7 0.4 0.8 
Maximum (%) 13.1 16.1 34.9 
 
Table 80 Measures of Spread for the uncertainty results of the complexity models (%) 
Range (%) 12.4 15.7 34.0 
25th Percentile (%) 2.0 1.4 4.0 
75th Percentile (%) 5.6 3.8 13.2 
Interquartile Range (%) 3.6 2.3 9.1 
Standard Deviation (%) 2.7 4.3 10.8 
Median Absolute Deviation (%) 2.0 0.8 3.0 
 
Table 81 Measures of Skew for the uncertainty results of the complexity models (%) (3dp for better resolution) 
Skewness (%) 1.288 1.942 1.375 
Skewness standard Error (%) 0.388 0.481 0.491 
Skewness z-score (%) 3.320 4.037 2.800 
Kurtosis (%) 2.311 2.899 0.468 
Kurtosis Standard Error (%) 0.759 0.935 0.953 
Kurtosis z-score (%) 3.045 3.101 0.491 
 
Table 82 Measures of Normality for the uncertainty results of the complexity models (%) (3dp for better resolution) 
Shapiro-Wilk statistic 0.900 0.692 0.758 
Significance 0.003 0.000 0.000 
Normal/Non-parametric Non-parametric Non-parametric Non-parametric 
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Figure 149 Absolute cell count uncertainty distributions for each cell complexity model 
 
There is no steady increase of mean or median between the analysis stages because these location 
measures for the intermediate model are lower. However, as identified in Table 80 there is a steady 
increase in the range of participant uncertainties from basic model (12.4 %) through the 
intermediate model (15.7 %) to the complex model (34.0 %). This indicates more participant 
variability throughout the entire gating process as the data they analyse becomes more complex. 
Unlike CV, this combines variability from each gate applied, rather than just the final cell counts, 
giving better resolution and traceability to the variability. 
 
The shape of the distributions were significantly different according to the Friedman test, 𝟀𝟀2 (2) = 
6.167, p < 0.046, shown in Figure 150. However, when conducting a Post Hoc examination using 
pairwise comparisons, no significant differences between individual pairings were reported, shown 
in Figure 151. The Friedman test assesses the distribution shape, so the positively skewed nature 
of all three models may have caused this outcome. All models returned positive skewness z-scores 
(3.320 %, 4.037 %, 2.800 % respectively) for the increase in complexity. All are outside of the 2.58 
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boundary limits for normality, but some are more skewed than others. This could be why the 
Friedman test is initially significant and the pairwise comparisons show no significant differences.  
 
 
Figure 150 IBM SPSS results for the Friedman test comparing absolute cell counts uncertainties for complexity models 
 
 
Figure 151 IBM SPSS pairwise comparisons for the Friedman test comparing absolute cell count uncertainties for 
complexity models 
 
The kurtosis of the basic and intermediate models were also high (3.045 % and 3.101 % 
respectively), whereas the complex model has a much lower kurtosis z-score (0.491 %), indicating 
this distribution is less affected by outliers. This can be further supported by the boxplots in Figure 
149 showing outliers across a smaller range in the basic and intermediate models rather than in 
the complex model. 
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The comparison of variation between the stages again comes down to how the data is presented 
and what variation metrics are chosen to describe the data. In this instance, the SD shows a similar 
trajectory to the range, increasing in size as the complexity of data increases. However, the MAD 
score decreases from basic to intermediate models and then increases from intermediate to 
complex models again.  
 
7.3.3 Comparison of CV and Uncertainty Results as variation metrics 
 
Although uncertainty was not significantly different with regards to the distribution shapes of the 
separate models, the range of the intra-participant uncertainty increased with complexity, 
comparable to CV in this instance, because CV also increased in range as the complexity of the 
data increased, although the range is larger for CV than uncertainty.  
 
Rather than replacing CV with uncertainty because it is more specific, both metrics could be used 
when training and reporting FC measurements. Uncertainty gives much more resolution to the 
variability within data, shown when analysing uncertainty components throughout Chapters 4 to 6. 
The method shown to obtain participant uncertainties can be used to combine other sources of 
uncertainty within the FC measurement, to obtain a representative combined and expanded 
uncertainty value that meets required standards. 
 
CV can also be used to obtain a quick point-in-time measure of variability used alongside 
uncertainty which is a lot more specific and takes longer to achieve. It can be used within training 
and refresher exercises to quickly monitor an analyst’s variation on a specific instrument or analysis 
pipeline. Ultimately, both variation measures can be used, however, it cannot be assumed that an 
analyst’s uncertainty could be judged from their CV or vice versa, so one should not be used to 
provide an indication or estimation of other metrics and variability. The ‘CV versus uncertainty’ 
scatter graphs created in Chapter 4 to 6 show very poor correlations, so CV should not be used to 
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assume a participant’s uncertainty. If an analyst’s CV is high, their uncertainty may not also be high. 
Uncertainty requires much more structured methodology and analysis in order to calculate a 
combined uncertainty figure.  
 
Overall, the core thesis hypothesis has been proven for both CV and uncertainty of participant Flow 
Cytometry results. As the complexity of Flow Cytometry data increases, the range of participant CV 
of results will also increase (Figure 152), as well as the range of participant measurement 
uncertainty (Figure 153). 
 
Figure 152 Core hypothesis of thesis, showing an increased range of intra-participant CV with FC data complexity 
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Figure 153 Core hypothesis of thesis, showing increased range of inter-participant uncertainty with FC data complexity  
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7.4 Chapter Conclusions 
 
When considering reporting of absolute cell counts (means and medians), the lower cell counts 
reported as the complexity increased could be a function of the number of analysis steps used 
within the gating analysis sequence. If so, this could mean rare cell events are lost through gating, 
or the true cell count of populations is skewed. However, this is a comparison across different cell 
types, so this could confound results. The more sequence steps completed, the lower the mean or 
median cell count could be due to increased stratification of the cell populations. This could 
intensify when 18 colour panels are used to consider specific markers, although all 18 markers 
would not necessarily all be used to investigate or monitor one specific function, they may monitor 
three or four targets at a time, requiring less processing steps for each target.  
 
Although the location metrics reduces as the complexity of the models increased, this cannot be 
assumed for the range or inter-participant absolute results reported for each model. As the 
complexity increased, the range of results between participants did not decrease. As the target 
becomes smaller and perhaps more specific, this does not necessarily mean that the range of 
results reported by participants will become smaller or more focused.  
 
The absolute range of results for the basic model was the largest (31.6 %) when three gating steps 
were completed, which reduced to 4.5 % for the intermediate model (5 steps), however, this 
increased again when 8 steps were completed in the complex model, giving an inter-participant 
range of 9.3 %. All cell counts were compared as percentages of the original cell count number to 
have better comparison between the files, to try and remove the inconsistent cell event numbers 
between files used in each model.  
 
All cell model distributions were deemed to be statistically different from each other using the 
related-measures Friedman test, and when investigated further using Post Hoc pairwise 
comparisons between each pair of models, it was found that the intermediate and complex models 
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were statistically different from the basic model, but not different from each other. These 
differences may be due to the lower number of gating steps used in the basic model, but also that 
the exemplar used in the basic model was an immortalised cell line, where pluripotent stem cell 
markers were identified. However, in the intermediate and complex model, T-cell lineages were 
investigated, so this change in cell type could have impacted the results because of different sized 
sub-populations. This was investigated by looking at the ranges for the third gate applied within the 
intermediate and complex models, returning absolute ranges of 25.8 % and 33.1 % respectively 
between participants. These values are comparable to the range reported for the basic model, so 
this higher range is more likely due to the lower number of stratification steps to identify the target 
cells, at this point.  
 
Using the basic statistical reports to compare the three models has shown further inconsistency 
between different statistical variability metrics, building upon the findings in Chapter 3, where 
different boundary estimators were tested. When considering the variability of the absolute cell 
counts, there were inconsistencies in trend between the total range, Standard Deviation and 
Median Absolute Deviation of all three cell models. This further supports the conclusion that the 
data distributions need to be properly understood before choosing the most appropriate metric to 
define and monitor variance.  
 
Inter-participant CV was stable across all three models (17.8 %, 18.2 % and 12.1 %, with an average 
of 16.0 % respectively), however, it does not concur with other manual gating analyses conducted 
on Flow Cytometry data which show higher CVs for individual gating or centralised gating [1,2]. This 
CV metric is indicative of what is normally reported in FC literature, as a calculation from repeated 
absolute cell counts reported. Therefore, the stability across the three models of this inter-
participant CV, could suggest that an overall value for participant CV contributions is 16.0 %. This 
could be used when considering variations of measurements as well as within quality control 
documentation and training purposes. However, if this were to be considered alongside the ICSH 
guidelines, this indicates that participants do not fall within satisfactory variation limits, because 
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having < 10 % CV is highlighted as being satisfactory, and the cell types and populations used 
within this research were not rare [71]. This satisfactory value was quoted for the overall 
measurement, but it could also be used for individual measurement components such as analyst 
variation or biological variation. 
 
When considering the intra-participant CVs, the absolute range of results increased each time with 
an increase in complexity (6 %, 22 %, 34 % respectively with each complexity model), showing that 
as the data becomes more difficult to analyse, the range in reported CVs increases, showing more 
variability as a result. If CV is used as a variance metric, it was confirmed using the Friedman test 
that there is a significant difference between the stages, showing that there is a difference in 
variance between the complexity stages. When considering using CV these ranges can be used 
effectively within training exercises and when considering repeatability of analysts on the same 
test. The greater range of variability reported for more complex models indicates that a wider range 
of CVs should perhaps be anticipated when running FC assays with larger panels, although they 
may not be initially acceptable.  
 
Continuous improvement efforts to reduce variability can potentially be monitored using CV as the 
dependent variable measured, to identify how these small changes impact the variability of 
analysts and therefore data over time. This has been effectively shown through many proficiency 
testing schemes, using CV as the comparable measure between participating laboratories to 
indicate good and poor performance [94,95]. 
 
A similar trend in range was also observed for uncertainty across each of the complexity phases. 
An increase in range was seen as the complexity of the model increased (12 % to 16 % to 34 % 
respectively with each complexity model), which was further confirmed as a significant difference 
by the Friedman test, to show differences in shape. However, when further investigated, there were 
no significant differences between the pairs of models, possibly due to the smaller ranges. 
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The mean and median uncertainties did not go up continually compared to the range, there was a 
decrease from the basic model (mean = 4.0 %, median = 3.6 %) to the intermediate model (mean 
= 3.8 %, median = 2.1 %) and an increase from the intermediate model to the complex model 
(mean = 10.6 %, 6.2 %). This shows that if location metrics were only used to describe each 
population, the increase in the whole population would not be seen. Although the mean and median 
values have been considered throughout the whole research, the core hypothesis of the thesis 
investigates the variability and spread of the uncertainty of the data, rather than location metrics, 
so range is considered as a more important marker of comparison at this stage.  
 
The core thesis hypothesis has been confirmed, because the range of inter-participant 
uncertainties has increased with more complex data. This further consolidates using uncertainty 
as a variance metric within FC, specifically in a manufacturing and quality control environment, not 
just a clinical one. This can also benefit research and development communities, because a full 
understanding of uncertainty can provide more specific root cause analysis when high variance is 
detected. This can then help deliver better training and continuous improvement as a result. 
 
Uncertainties reported alongside measurements gives a much more informed judgement on the 
cell therapy product through all stages of manufacture, sorting and release. If an uncertainty 
reported alongside a cell count result is high, it enables the manufacturer, inspector or clinician to 
really question the product, measurement equipment, process and reagents involved, before 
making a more conclusive decision. Uncertainty reporting provides better resolution to the whole 
measurement, with quantitative traceability back through the components, to identify significant 
contributions of variance. This overall provides better awareness and control to all products and 
processes contributing to the measurement. If a measurement is close to acceptance limits for 
signing off the product or approval for the next manufacturing phase and the uncertainty boundary 
causes concern for a specific batch, this could provide more solid grounds to ask for further testing 
of the product. This would be preferred over potentially providing a false positive or negative result, 
which when passed onto the patient could have costly impacts.   
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7.4.1 Consolidation of Objectives 
 
• There was no increase in range of absolute cell counts reported as the complexity of the 
data increased. The target population medians got smaller as the complexity increased, 
due to further stratification of the data, however, the range of participant reported cell 
counts did not decrease in line with this.  
• Inter-participant CV, calculated from all the participant cell counts across each 
complexity phase was very stable, with an average of 16 % CV. This could possibly be 
used as an indication of variation within the Flow Cytometry community, to highlight the 
significant impact analysts can have on the analysis and conclusion of results. 
• Intra-participant CV range increased significantly with each complexity model (6 %, 22 %, 
34 % respectively), showing that as the complexity of the data increases, a greater range 
of CV results can be expected between participants.  
• There was a significant difference in range between the cell complexity models when 
measurement uncertainty was calculated. As the complexity of the data increased, the 
range of uncertainties between participants also increased (12 %, 16 %, 34 % 
respectively). This confirms the core hypothesis of this thesis, that as the complexity of 
the data models increases, the uncertainty contributed from participants also increases. 
• The use of CV is common within Flow Cytometry communities, and it still has significant 
strengths as a reporting and training tool when looking at FC data. It shows that as 
operators are trained to analyse more complex data, initially larger ranges of results are 
to be expected from more difficult analysis panels. This is also the case for uncertainty, 
which allows laboratories to better conform to ISO 15189 requirements for competency 
within medical testing laboratories, by showing more specificity of uncertainty 
calculations by including quantified subjective elements. 
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Chapter 8: Participant Surveys 
8.0 Introduction to the Chapter 
Chapter 8 introduces the participant experience surveys, which participants completed at the start 
and end of the study period (2 years apart) to capture training state and issues observed over time. 
This gave a better understanding of the participants and allowed certain experience metrics to be 
investigated in relation to uncertainty study outcomes. This provides some human factor context to 
the quantitative data explored in Chapters 4 - 6. This also stratified common issues participants 
faced when gating their own Flow Cytometry data, or when interpreting it from another source, to 
identify areas for improvement within protocols and standardisation. 
8.1 Chapter Aims 
 
This Chapter aims to give a better understanding of the participants (and their training background) 
who were involved in some or all stages of this research. Not only will this identify dichotomous 
indicators of preference and experience, but ordinal metrics such as use frequency are investigated 
alongside uncertainty results from previous Chapters. This indicates whether correlations can be 
drawn between use frequency metrics, experience and the results achieved as well as the 
measurement uncertainty, which were so commonly assumed by participants. 
8.1.1 Chapter Aims & Objectives 
 
The Aims and Objectives of this Chapter can be defined as follows: 
• Stratify the results of the initial and end surveys, to compare key dichotomous markers 
that define the population for various personal, experience and motivational factors. 
• Investigate the preferences for manual or automated gating over time, stratifying the key 
reasons why, to see if these can be addressed with data analysis, software or cultural 
changes. 
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• Investigate problems encountered by participants when they gate manually, and if these 
stratified issues change through the course of the research studies.  
• Investigate problems encountered by participants when interpreting Flow Cytometry 
gating data from literature, and what issue this may cause for reproducibility. 
• Investigate possible correlations between continuous participant experience metrics and 
the range of results from the previous uncertainty studies (Chapter 4-6), focusing on the 
range of absolute cell counts, CV and expanded uncertainty results obtained. 
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8.2 Methodology 
 
A total of 43 participants provided answers to the initial questionnaire. These participants took part 
in either one or all of the uncertainty studies, and if they joined part way through the total 
experimental phase, they were given this initial questionnaire to complete before starting the 
respective study. Sixteen participants provided answers to the follow-up questionnaire. This 
difference between participant involvement is due to a staffing change at one of the centres just 
before the intermediate uncertainty model. Once these new participants had completed the first 
questionnaire, it was deemed too close in time to send the follow-up questionnaire, so they were 
excluded from this final survey exercise. 
 
The timescale and delivery of the starting and ending questionnaire will be defined throughout this 
section, moving on to provide further detail on the structure of each questionnaire provided to 
participants. 
 
8.2.1 Questionnaire timescales and delivery 
 
To ensure background information of Flow Cytometry participants could be captured, participants 
answered an initial questionnaire. This was hosted electronically using Google Forms to minimise 
disruption to participants and provide automatic stratification into Microsoft Excel file formats (.xls). 
Once participants had provided consent to take part in the research (as discussed in Chapter 3) 
and 24 hours had elapsed (cooling off period, to ensure all participants were happy to take part), 
the questionnaire was sent to participants, with instructions to complete it before their first analysis 
session took place. This progression is shown in Figure 154, depicting the sequence of 
questionnaires and the main analysis models. The pre-study analysis discussed in Chapter 3 has 
not been included, because the results obtained from this study are not comparable with the 
absolute cell counts, CVs and uncertainties investigated in Chapters 4 to 6.  
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Figure 154 Questionnaire timescale in conjunction with analysis models 
 
Following the Intermediate Uncertainty model (Chapter 5) and the investigation of the boundary 
effects present in the software visualisation, a follow-up questionnaire was introduced to identify 
additional participant understanding of Flow Cytometry. This was given to participants before the 
complex uncertainty model (Chapter 6) took place, to ensure a good rate of response. Online 
Surveys (previously Bristol Online Surveys) was utilised for this questionnaire [199], due to 
institutional access and migration away from Google platforms, as well as the ability to download 
the data into different analysis platforms previously used, such as Microsoft Excel (.xls) and IBM 
SPSS Statistics (.sav), for more streamlined analysis. A series of questions were repeated from the 
initial questionnaire, to monitor experience gained over time, for example, to see whether 
collectively the experience distribution changed, or whether specific participant experiences 
affected results. New questions were introduced to ask participants about what noise parameters 
they identified and how there were dealt with. This was to identify underlying understanding about 
the boundary effects, without asking a leading question.  
 
8.2.2 Initial Questionnaire Outline 
 
A series of dichotomous, scalar and ordinal questions were asked to participants throughout this 
survey, stratified into groups to identify personal Flow Cytometry qualifications, experience with FC, 
any visual impairment that could affect their judgement during the studies and motivations factors 
to identify enjoyment. Each of these sessions will be discussed throughout the methodology, with 
results discussed later in this chapter. A full template of the initial questionnaire given can be found 
in Appendix D. 
  Chapter 8: Participant Questionnaires 
270 
 
8.2.2.1 Personal Questions 
 
These questions were simple identifiers, to log who the participants were (name) and their 
responsible manager or Principal Investigator. This was to group people into teams, with the 
understanding that they had all received similar training, and potentially may have similar biases, 
if splits appeared in the data. Upon analysis participants were all anonymised and given 
alphabetical codes for further analysis. 
 
Participants were also asked if they had any formal Flow Cytometry Qualifications. This refers to 
being a Chartered Cytometrist (C.Cy), recently updated to Specialist in Cytometry (SCYM). This is a 
qualification required for clinical pathologists using Flow Cytometry to perform diagnostic assays, 
so this question aimed to investigate whether anyone in a research, manufacturing or process 
development setting in the 3 centres used in this study had this level of externally approved 
qualification.  
 
8.2.2.1 Experience Questions 
 
The experience questions covered personal experience with Flow Cytometry, with respect to the 
length of time they have used Flow Cytometry for, and how often they use the equipment. This was 
to avoid situations where participants may have completed an FC experiment 5 years ago, but not 
completed any analytical work since. This section also asked participants to highlight what they 
predominantly use FC for; Cell counting, Immunophenotyping, Cell Sorting (FACS) or other assays. 
This was also coupled with what cell types participants were most familiar with when running FC 
assays, to identify what cells types were most common across the three centres.  
 
Training was also investigated, to identify whether participants had been taught to gate internally, 
externally (by training courses or manufacturers) or were self-taught using text/online resources. 
To expand on the training questions, participants were also asked if they used protocols to apply 
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gates to their data and whether these were listed within internal Standard Operating Procedures 
(SOPs) or from external publications.  
 
Participants were asked to identify their preference between manual and automated gating. In this 
instance, manual gating refers to software platforms that allow users to manually draw or identify 
cell populations of interest, whilst also giving more flexibility over the scaling and axes used. 
Automated gating platforms refer to machine learning algorithms and statistical tools that cluster 
data to find common sub-groups due to different dimensionality factors. Populations are then 
selected by the user, and no multi-step sequence of gates is required as found in manual gating. 
Participants were also asked to identify why they chose their preferred gating style (manual or 
automated), which was given as a written text answer. These text answers were further coded and 
analysed (Section 8.2.4.5). 
 
Finally, participants were asked to identify whether they had experience using the Flowjo software 
platform, or not, to identify additional training that may be required to complete the studies. 
Participants were also asked if they had taken part in any External Quality Assessment Schemes 
(EQAS) throughout their career, or likewise, submitted data files for central processing.  
 
8.2.2.1 Vision Questions 
 
Participants were asked if they had any visual impairment that could affect their ability to 
participant in the study or use a laptop computer for a maximum duration of one hour. If 
participants had issues such as colour blindness or mentioned other visual impairments that could 
affect their perception of shape or density, they were not able to take part in the further studies, 
due to known differences in observation of the data that could skew results [200,201]. In Chapter 
3, this was explored with a small number of participants, however, no participants had colour 
blindness according to the test used, so this is something that could be investigated in future with 
two distinctive test groups to quantify potential differences. 
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8.2.2.1 Motivational Factors Questions 
 
Motivational Factors focused on identifying situations that were preferential for participants to 
complete FC gating during their day-to-day tasks, and what problems were caused through their 
own experience of gating data or interpreting data.  
 
Participants were asked to list problems they encountered when they manually gated, and what 
solutions they have to rectify or deal with these issues. They were also asked to identify problems 
that occur when trying to interpret published Flow Cytometry data from another source, to 
investigate whether better reporting standards may be required throughout the community. Both 
questions required written text responses, which were coded manually, as detailed in section 
8.2.4.5.  
 
Participants were then asked to provide an ordinal response, to specify how much they enjoyed 
gating (scale of 1- to 5, 1 = strongly dislike, 5 = strongly like) and dichotomous results (yes/no) to 
identify whether they had to be in a certain mood to gate, a certain environment to complete the 
analysis, and whether they preferred to complete their analysis at a certain time of day. If 
participants responded ‘yes’ to preferring to gate at a certain time of day, they were then asked to 
specify further and results were stratified into morning or afternoon bins.  
 
8.2.3 Follow-up Questionnaire Outline 
 
A further series of dichotomous and scalar questions were asked to participants throughout the 
follow up questionnaire, to follow-up on factors from the previous questionnaire, and to ask new 
questions that arose during Chapter 4 and 5 data analysis. This questionnaire was divided into 
sections to cover FC usage and FC gating preferences. Each of these sessions will be discussed 
throughout the methodology, with results discussed later in this chapter. A full template of the 
follow-up questionnaire given can be found in Appendix D. 
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8.2.3.1 FC Usage Questions 
 
In a similar manner to the personal questions, FC usage questions were simple identifiers, to log 
who the participants were (name) and their responsible manager or Principal Investigator. Again, 
this was to group people into teams, with the understanding that they had all received similar 
training, and potentially may have similar biases, if splits appeared in the data. Also, over time 
participants may have left the company or changed reporting roles, so this change in participant 
number was also captured. 
 
More specificity was asked about what Flow Cytometers and analysis software packages 
participants had the most experience with. Further to stratifying into research groups, it became 
apparent through the different analysis models that different teams/centres used different brands 
of Flow Cytometer and different software. These biases could also cause bias in results analysis so 
this information was captured for reference if necessary. 
 
The experience questions covered personal experience with Flow Cytometry, with respect to the 
length of time they have used Flow Cytometry for, and how often they use the equipment. 
Participants were also asked to identify whether their usage was consistent over time, or on and 
off with a project, and to highlight if they were currently working on a project that required FC. To 
further diversify FC usage, participants were also asked to identify how often they analyse FC data, 
as well as use the equipment. 
 
8.2.3.1 FC Gating Preferences Questions 
 
Participants were again asked to identify whether they preferred manual or automated gating 
platforms, and to list why. This was to monitor changes over time with usage, hence the staggered 
questionnaires, because automated gating software and plug-ins are becoming more apparent 
throughout FC literature.  
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Similarly, participants were asked to identify problems they had when gating FC data and when 
interpreting it from other sources, to monitor whether the initial issues identified from the first 
questionnaire were addressed over time, or whether they are still an issue in the community.  
 
Participants were asked to identify (on a scale) how much they actively read or research FC gating 
techniques to stay aware of current findings, to possibly indicate motivation around completing 
‘good’ analysis. This could possibly suggest that those who do more self-directed reading may have 
lower variation because they are more aware of the different controls and variables to aid their 
analysis. Finally, participants were asked to list what noise parameters they consider affecting FC 
gating and how these are dealt with when analysing data. This new question was determined by 
the boundary effect observed within Chapter 5, to see if participants are aware of this issue, without 
being asked a leading question.  
 
8.2.4 Questionnaire Analysis and Coding 
 
After both questionnaires were completed by participants, the results were downloaded and coded 
where necessary. Data was stored in accordance with GDPR requirements, although no sensitive 
personal information was gathered through these surveys. This section will address how each type 
of question was coded (where necessary) for further analysis. Questions could be stratified into five 
types: Dichotomous (Yes/No), Continuous (numerical measures), Nominal (pick from a selection of 
options), Ordinal (choose an option from a scale of answers), and written text responses. Three 
software platforms were used to store, analyse and visualise the data: Microsoft Excel 2016, 
Matlab R2018a and IBM SPSS Statistics Version 24. 
 
8.2.4.1 Dichotomous Questions 
 
Questions where participants had to select from two options, for example either a ‘Yes’ or ‘No’ were 
coded within the respective platforms, and then visualised using either pie or bar charts to 
represent the data split of the population.  
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 8.2.4.2 Continuous Questions 
 
Continuous questions were questions where participants had to list a numerical measurement 
factor. For example, total experience duration with FC were formatted to ensure all results were 
displayed in terms of months of use (standard unit). Some participants had specified their answers 
in years, so for further stratification, this data was transformed to the same time scale.  
 
8.2.4.3 Nominal Questions 
 
Nominal questions were questions where participants had to select one of a series of different 
options that nearest matched their personal experience. For example, when asked how often they 
used FC, they were asked to choose from: ‘Everyday’, ‘More than once a week’, ‘Once a week’, 
‘Once a month’ or ‘Less than once a month’. This data could then be easily visualised in the form 
of a bar chart to compare the population. 
 
8.2.4.4 Ordinal Questions 
 
Ordinal questions were questions where participants had to select one of a series of scalar options 
that nearest matched their personal opinion of a particular topic. For example, when asked how 
much they enjoyed gating on a scale of 1 to 5, they were asked to choose from: ‘1 – Strong Dislike’, 
‘2 – Dislike’, ‘3 – Neutral’, ‘4 – Like’ and ‘5 – Strong Like’. These are commonly used to monitor 
satisfaction levels and hence were used in the Motivational Factors section of the initial 
questionnaire. 
 
8.2.4.5 Written Text Responses 
 
These were questions where participants had to expand on choices made or identify particular 
problems they encountered, by providing a written text answer. This did not limit them to 
preconceived options that could potentially display bias from the questionnaire author. These 
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responses were qualitatively coded using manual analysis protocols [179]. Comments were added 
to stratify responses into one- or two-word answers to represent the problem identified. These 
results were tallied, and a second round of coding was completed to further align and stratify the 
responses into similar bins. For example, if a participant mentioned ‘fluorescence spill over into 
different channels’ and ‘accounting for fluorescence of the data set’ were mentioned, these would 
be coded into a ‘Compensation’ tally, which then logged how many times particular issues were 
mentioned to build up a picture of the landscape. Full definitions for the stratified text responses 
for all questions, along with examples of inclusion and exclusion criteria can be found in Appendix 
D. 
8.3 Survey Results 
 
8.3.1 Experience Results 
 
Participants surveyed predominantly used Flow Cytometry for immunophenotyping purposes, 
followed by Cell counting. In this instance participants were able to select multiple options, because 
of the diverse assays that can be run with a Flow Cytometer. Most participants were focused on 
development of immune therapies, shown by the high use of Hematopoietic lineage cells defined 
within the survey, shown in Figure 155. Use of pluripotent stem cells for other cell therapy research 
was common, as well as the use of HEK293 cells which are used within the development of viral 
vectors for autologous treatments.  
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Figure 155, a) Common uses for Flow Cytometry, b) Common cell types analysed using Flow Cytometry 
 
Participants were asked about what they most commonly used, indicating current usage for both 
Flow Cytometry equipment and software (Figure 156). The most common Flow Cytometry 
equipment used was a MACSQuant Analyser 10 [202], followed by BD instruments [203,204]. This 
is a core piece of equipment for participants located at the cell therapy product development 
centre, hence the popular results. Flow Cytometry software used was a lot more variable and based 
on user preference. Flowjo [123] was the most popular software because participants found it easy 
to use and it gave them more control to complete more complex analysis. However, MACSQuantify 
[205] was popular due to use in cell therapy process development at one site. It is not as flexible 
for the user; however, it was mentioned on multiple occasions that the automated sample gating it 
provided was beneficial. 
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Figure 156, a) Flow Cytometers used by participants, b) Flow Cytometry analysis platforms used by participants 
 
Participant experience (total time using a FC) for the initial and follow-up questionnaire has been 
overlaid using the histograms in Figure 157. More participants took part in the initial survey, hence 
the wider range of results. Experience was captured alongside use frequency of a Flow Cytometer.  
 
Figure 157 Overlaid histograms of participant experience with Flow Cytometry 
 
The initial survey experience values have been plotted against results from all three uncertainty 
studies to show the range of absolute cell counts (Figure 158a), CVs (Figure 158b) and 
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uncertainties (Figure 158c) in comparison to the experience of the operator. These results, as well 
as results for Figure 159, have been taken from the ‘personal judgement’ phases of the uncertainty 
models, because this was the only phase tested for the basic model and is thus comparable. This 
was to identify if there was a potential convergence of results as the experience of an operator 
increased.  
 
Experience of operators has been considered in different contexts throughout Flow Cytometry 
literature. Often for comparison studies, a selection of ‘experienced users’ are chosen to complete 
analysis, to ensure participants are all familiar with analysis pipelines [1,206], because it has been 
noted that differences between operators can cause variance in final data analysis, among other 
steps [19]. 
 
Correlations between analyst experience and variation has not been conducted within Flow 
Cytometry literature, so a formal, wide-range study could aid this information. However, many 
comparisons have been made in other healthcare and screening fields. For instance, variability of 
dentin adhesion and resin cements have been explored between students and fully qualified 
dentists [207,208], with one study identifying qualified dentists having a lower CV, however, the 
other study found no difference in adhesive cement performance between student and dentist 
application. The impact of training and practice has been monitored for carotid artery procedures 
between students and registrars, highlighting the improvements simulation training can provide to 
aid novices [209]. Comparisons between human and automated, novice and expert judgement of 
luggage screening has also been investigated, with monitoring of advice given how much this is 
subjectively trusted. ‘Novice’ automation showed more reliability than novice humans, however, 
‘expert’ automation had lower compliance relative to expert humans. Perhaps stratified experience 
or particular job roles are a more suitable way to consider experience going forwards, however the 
distribution of experience with results was required here, so stratification has not taken place 
[210]. 
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Figure 158 Comparison of participant experiences with a) Absolute cell counts, b) Reported CVs, c) Reported expanded 
uncertainties 
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There is no apparent correlation between participant experience and the absolute cell count 
achieved in any of the cell complexity models (Figure 158 scatter diagrams shown on log scales for 
clearer identification of population shapes). This is the same for CV and uncertainties for all three 
cell complexity models. The absolute cell count median for the basic model was higher than the 
remaining models, however this model required less stratified analysis than the others and a 
different cell type, so cell counts are higher because of these reasons.  
 
Experienced operators are more knowledgeable on the topic having spent longer using equipment 
(assuming constant use). However, these results have shown that knowledge should not be 
confused with result accuracy or repeatability. More ‘experienced’ users are not necessarily more 
accurate, shown by the scatter plot in Figure 158a, because experienced users are not more 
convergent towards the median value, assuming this to be the ‘most true’ cell count. If the true 
value of a cell count was known, and more experienced users were more accurate, there would be 
a higher probability of achieving this result. 
 
This is also the case for precision, whether it is represented by CV or uncertainty. There appears to 
be no convergence of CV or uncertainty results for any of the gating models, as shown by Figure 
158b and Figure 158c respectively. Again, it should be noted that more ‘experience’ does not 
necessarily mean operators are more repeatable, although they may be more knowledgeable of 
the sources of variation. Continuous improvement efforts for reducing variation within FC gating 
are required, to constantly identify sources of variation that impact inter-operator reproducibility. 
Throughout this research, boundary effects have been identified to be potential influencers on both 
the accuracy and precision of data, depending on the software platform in use. A new training 
session or information provided to participants within future studies should identify this issue, to 
ensure it is a variable removed from analysis. Software platforms could also make a unified effort 
to align visualisation methods.  
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The use frequencies that participants specified in the initial questionnaire have also been plotted 
against the absolute cell counts, CVs and expanded uncertainties for each model, visualised in 
Figure 159 (y axis scales are linear to ensure easy comparability across different plots). The use 
frequencies have been coded as follows: 1 = Use every day, 2 = Mode than once a week, 3 = Once 
a week, 4 = Once a month, 5 = Less than once a month. 
 
Figure 159 Use frequency compared to a-c) Absolute cell counts per model, d-f) Cell Count CVs, g-i) Expanded 
Uncertainties 
 
There is no significant difference between the different use frequencies with respect to absolute 
cell counts across any of the cell models (Figure 159a-c). However, in the basic model (a) there is 
a greater range in those who use a Flow Cytometer the least (5). Those who used a FC less than 
  Chapter 8: Participant Questionnaires 
283 
 
once a month also have the greatest interquartile range (IQR) of inter-participant CV in each model, 
however, this is not the case for uncertainties. Those who use a Flow Cytometer more than once a 
week have the largest IQR within the base and intermediate model, and the second largest IQR in 
the complex model, after those who use FC most infrequently.  
 
In a similar manner to the experience data, there is no significant evidence to suggest that those 
who use a flow cytometer more frequently are more accurate or more precise. This is especially the 
case with the uncertainty data (g-i), because those who use it the most frequently and the most 
infrequently have the greatest ranges of uncertainties. This could be due to under- and over-
familiarity with the process. However, further studies to achieve statistical power would be required 
to confirm this. Those who are using FC regularly will probably commit protocols to memory and 
over time possibly find shortcuts or ways to speed up the process. This could cause deviations in 
measurement, impacting accuracy and repeatability. Those who are unfamiliar with the process 
will probably take longer to identify the necessary populations and may not be aware of all the 
factors that could affect their subjectivity of the final population.  
 
Further work could investigate these factors in relation to the range of cell counts and variability 
between participants, gathering a wider range of experience and use frequency of participants. In 
addition, covariance between the experience of a participant and their use frequency could also be 
explored, to identify whether a combination of total experience with FC and how often it is used 
could better identify sub-populations of participants who contribute to greater inter-participant 
variation.  
 
This could help within Cell and Gene Therapy manufacturing scenarios, to better inform training 
protocols, and also identify suitable intervals for ‘refresher’ or ‘retraining’ periods for operators. 
These would have to be carefully integrated into the work environment, with an emphasis on 
fostering a good working culture, to ensure participants see it as an opportunity to improve 
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themselves and the quality of their product, rather than it being seen as a test or reprimand if they 
are not within the manufacturer-defined control limits.  
 
8.3.2 Training and Proficiency Results 
 
 
Participants were predominantly trained internally by another member of staff when they were 
required to use Flow Cytometry (Figure 160). Some had attended training courses instead, but the 
courses listed were operational Flow Cytometry training, ensuring all participants could turn on, 
calibrate and run FC experiments with correct compensation, but none covered how to gate. 
Arguably, there are so many different cell types to gate that there is no ‘one size fits all’ policy for 
applying gates to data, hence why internal supervision or learning was more popular. Some 
participants supported their training with self-led activities such as watching online tutorials or 
videos to show how others applied gates to similar data or cellular subpopulations. This highlights 
the need for some uniform gating templates or a good practice guide to possibly be created for 
particular cell types, which gives a cheap and effective point for users to tailor to their needs.  
 
Figure 160 Flow Cytometry training 
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Participants were also asked if they used Standard Operating Procedures (SOPs) to apply gates to 
their data, as well as using protocols to gather the data, with the analysis shown in Figure 161. 
Most participants did not use a protocol to apply gates to their data, however, of those who did the 
majority used an internal SOP to apply gates. When asked about this in the gating sessions, most 
indicated they had a rule of thumb when applying gates to control files. For example, they would 
get as close as possible to 1 % positive cells in the FMO control, rather than use features of the 
visualisation such as axis scale points or images of protocols. This highlighted that individuals 
completed analysis separate of one another, so a general rule worked better for alignment of 
protocols, because there was no guarantee that the compensation, voltages used, or scaling would 
be the same between participants running the same assay.  
 
 
Figure 161, a) SOPs used to apply gates, b) Types of SOPs used 
 
In addition, no participants had taken part in an External Quality Assessment Scheme (EQAS) or 
submitted files for central processing. These schemes or file transfers are common within clinical 
cytometry to monitor laboratory proficiency and reduce inter-participant variation. It remains to be 
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seen whether these are schemes that the wider manufacturing community could also benefit from, 
to reduce subjectivity, and continually identify sources of variations contributed within analysis. 
This questionnaire was only given to the three collaborator sites, so if this were to be repeated it 
could be sent to participants across a diversity of centre and job roles. No participants had formal 
FC qualifications unlike their clinical counterparts, so this could be something that may be required 
in future for operators within manufacturing environments.  
 
8.3.3 Manual and Automated Gating 
 
Participants were asked in both the initial and follow-up questionnaires to identify their preference 
for manual or automated gating platforms. Manual gating allowed the user to completely identify 
where they want to place the gates, and automated uses a machine learning algorithm to create 
separate population clusters. Figure 162 shows the split between participant preference for 
manual or automated gating, within the initial questionnaire and the follow-up questionnaire. The 
results are shown as response frequency percentages, because the follow-up questionnaire 
contained less responses. The follow-up questionnaire asked this question to identify whether the 
increased prevalence of automation algorithms within analysis software were becoming more 
popular to use than manual gating. In both instances, manual gating was greatly preferred to 
automated gating, with stratified reasons presented in Figure 163. 
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Figure 162 Preference for manual or automated gating within the two questionnaires 
 
From the initial questionnaire responses, the only beneficial reason given for using automated 
platforms was due to the speed of analysis, with more dimensional data being more cumbersome 
for an analyst to review. Even though manual gating was preferred within both questionnaires, a 
greater amount of reasoning for using automated platforms was identified within the follow-up 
questionnaire, suggesting that the benefits of automation are starting to make traction within the 
community.  
 
To further monitor this, the results from one site were compared between the two questionnaires. 
This site had the least changeover of staff, for better consistency and tracking of automation 
popularity. 3/20 participants preferred automation to start with, however two of these operators 
did not take part in the follow-up survey. The remaining participant still felt automation was better 
in the second survey, with a total of 5/13 participants preferring automated algorithms at the time 
of the follow-up survey. Only one of these participants was a new member of staff, so there had 
been a few preferences changed to automated gating platforms over the course of the research. It 
was expressed that algorithms can be trained to identify particular subsets, hence can potentially 
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be accurate, but cannot identify or deal with biological variation as well as a manual analyst, so it 
lacks precision and reproducibility.  
 
Both questionnaires identified users wanting much more analytical control, for visualisation 
purposes as well as double-checking findings. This, as well as legacy of use (‘I prefer manual gating 
because it’s what I’ve always known’), identify a potential resistance to change to new techniques, 
especially where removal of specialist human analysis is concerned. Many participants identify that 
they don’t trust automated platforms, and they would have less control with exploration of the data 
once it had been clustered using a machine-learning algorithm. 
 
Figure 163 Preferential reasons for choosing manual or automated gating across both questionnaires. 
 
Automated platforms need to improve in accuracy, precision and handling of biological variation to 
allow participants to move away from manual analysis. Equally, an awareness of a participants own 
variation when gating would give them a personal benchmark when testing and potentially 
validating new algorithms for use in population identification, which is partially what this research 
aims to show.   
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Consideration of automated gating requires a user to be working with Flow Cytometry very 
frequently, due to the time taken for the algorithms to learn from historical data or training sets, 
which is suitable for those in process development or manufacturing, but not those in a research 
environment, who may use bespoke panels at infrequent time points, making manual analysis 
more convenient. At all developmental stages of a cell therapy product, from research through to 
approved manufacture, an analyst should have an awareness of their variability, to ensure false 
positives or false negatives are not declared, which could become more costly to patients, research 
groups and manufacturers if carried forwards. 
 
8.3.4 Problems identified when gating 
 
Participants were asked to identify what problems they encountered when gating FC data. This was 
asked in both questionnaires to see if the same issues were prevalent after two years had passed, 
in case more had been done in the community to resolve well-known issues. Figure 164 identifies 
the stratified results from both questionnaires, with the biggest issue being reliable cell cluster 
separation. The ability to separate clusters was a key issue for many participants, even when proper 
titration and voltage setup had taken place, and it was still the main problem identified within the 
follow-up questionnaire. More cell separation and clustering algorithms are present for the Flow 
Cytometry community, however, they often require knowledge of an additional software package 
such as R or Matlab to process the data, which many analysts may find difficult if this is not a main 
component of their job role [1].  
 
Participants were asked to detail general problems they deal with when gating, outside of the 
constraints of the studies they took part in. Analyst variation was noted as much more of a problem 
in the initial questionnaire, however, inclusion in these experimental studies could have potentially 
skewed the follow-up analysis because this is the focus of the research, so they listed other issues. 
Dealing with biological variation was also noted as a difficulty when analysing lots of donor 
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information together, calling into question the validity of the gates, and where definitive cut-offs 
should be places for positive and negative discrimination. Staining quality can potentially help here, 
if all the upstream process steps have been followed to minimise fluorescence spillover, however, 
differences between analysts could cause these differences to have knock on effects within the 
final analysis. The introduction of automation could be a good way to potentially alleviate these 
issues to remove differences in staining times and temperatures, due to standardised, repeatable 
processing.  
 
 
Figure 164 Identified problems when gating 
 
After observing boundary effects during the participant analysis for the intermediate model, an 
additional question was added to the follow-up questionnaire, to identify whether participants were 
already aware of this effect, without asking leading questions. This boundary effect was not listed 
among the noise parameters specified by participants, stratified in the bar chart in Figure 165. The 
noise parameters identified mostly concerned upstream analysis of the sample itself, either due to 
the sample preparation or instrumental variables during file generation and acquisition of data. 
Fluorescence spillover can affect the noise within a file and subsequent gating of the data, however, 
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participants always discussed this issue as a feature of poor compensation, which occurs before 
the file generation, rather than the post-analytical gating itself.   
 
Cell debris and doublets were the only noise issues that occur at the post-analytical gating phase. 
Removal of these is usually completed during the first two gates, where the desired population 
must be separated from the smaller broken pieces of dead cells (debris) and the cells which stick 
together through the laser interaction point during sample acquisition (doublets). During the basic 
and intermediate models, the cell debris and doublet gates were the gates which caused the most 
variation within the uncertainty budget, so there is a need to focus on these to reduce variation. In 
addition to this, FC has many uses outside of cellular measurement, once of which is bacterial 
measurement. Bacteria are much smaller than cells, which would cause the cut-off for debris to be 
even closer to the required population, making subjectivity of gate application more important 
[211]. 
 
Figure 165 Noise parameter issues identified by participants 
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8.3.5 Interpretation problems from literature 
 
Participants were asked in both the initial and follow-up questionnaire to identify what issues they 
encountered when they interpreted FC data or gating methods from published literature. This gave 
an indication of the initial problems faced, and whether standardisation in the community had 
improved between the questionnaires or whether the sample problems were still being faced.  
 
Gating standardisation was the most common problem faced within both questionnaires (Figure 
166), officially defined in the codebook located in Appendix D. Participants identified that more 
information on the gating hierarchy completed and standardised gating sequences for well-known 
marker panels were required for reproducibility. This was followed (in both questionnaires) by a 
lack of control file images provided by authors, to show the reader how the gates were applied to 
the fully stained sample. This can guide the reader to show what percentage positive to work to if 
not specified, to aid reproducibility of FC data. Better reporting of reagents (and staining 
methodology) was also a common issue, as well as poor visualisation of the Flow Cytometry data 
itself.  
 
Figure 166 Identified problems when interpreting FC gating from literature 
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Minimum Information for a Flow Cytometry experiment (MIFlowCyt), is a reporting standard 
generated by the International Society for Advancement of Cytometry (ISAC), which lists the 
minimum requirements for a Flow Cytometry experiment, from sample preparation information 
through to how the sample has to be acquired and gated [49]. Despite these excellent efforts in 
the right direction by ISAC, many participants were not aware of these sorts of standard reporting 
formats, because they do not follow the Flow Cytometry community journals (such as Cytometry A 
& B) and relevant publications from ISAC. When asked if they undertook self-driven reading to stay 
up-to-date on current methods, most participants were only familiar with what was listed in the 
training protocols provided at their institution/company. Any additional reading completed (if a 
participant wanted to) was mostly focused around specific cell types they worked with, rather than 
Flow Cytometry as a technique. Therefore, if this information is not provided to wider communities, 
or they do not actively seek it, it will always be an achievable unknown, hence the need for Good 
Practice Guides (GPGs) that can be universally accessed to address general issues or training tips. 
 
8.4 Chapter Conclusions 
 
Providing two questionnaires throughout the process of the experimental research, has delivered 
potential correlations between experience metrics and study results to be investigated. In addition, 
key issues participants have identified as problems when gating are consistent over time, indicating 
key areas of work for the Flow Cytometry community. 
 
The structure of both questionnaires has been successful and sending the surveys as online links 
for participants to complete was the most convenient way to gather the data for participants as 
well as providing secure storage of the results for quick download and analysis. Manual coding of 
written text responses was completed by the author, following manual coding protocols, with two 
analysis cycles for effective stratification and codebooks written to ensure complete definitions of 
the code were provided for all.  
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Most participants used Flow Cytometry for immunophenotyping haematopoietic lineages or 
pluripotent stem cells. This relates to the three centres that took part, which are all focused on the 
research, development and manufacture of cell therapies, most of which are currently 
haematopoietic-based and relevant to the wider Cell and Gene Therapy community. 
Immunophenotyping allows participants to build panels to monitor the progress of cell-based 
treatment for different antigen markers that are features of cells or engineered additions. A 
MACSQuant Analyser 10 Flow Cytometer was the most popular piece of equipment, due to most 
participants involved being located at the centre where these are the validated FCs for research 
and development. These participants therefore were all trained to use the MACSQuantify analysis 
software that comes with the instrument, as well as most participants using Flowjo to complete 
their analysis.  
 
Flowjo was the chosen platform for the uncertainty studies, due to all participants and centres 
being familiar with the software, requiring less pre-participation training, and it was straight forward 
to transport as a plug-in dongle.  Participants preferred this platform due to easy of use and the 
amount of control it gave them, further identified when asked about preference of manual or 
automated gating platforms. Most participants preferred to use manual gating rather than 
automation within both questionnaires 85 % and 70 % respectively for the initial and follow-up 
questionnaire), because of the control it gave them to investigate and explore the data with 
different visualisation methods. Legacy was also a prominent factor, with participants resistant to 
change because they are familiar with this style of analysis, and sceptical of more automated 
methods being introduced to try and help more highly dimensional datasets. Possible culture 
changes are needed to help address this ‘I’ve always done it this way’ attitude, by empowering 
employees with training opportunities and easy access to validated software (if proven to be 
suitable for use). 
 
Most participants within the initial questionnaire had less than 12 months experience with FC, 
hence why this was followed-up in the second questionnaire. Experience was continually identified 
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by participants through their training experiences because they had been trained internally by 
someone who had worked on the equipment longer (suggesting they were better because they had 
done it for longer), in addition to also attending just a few external training courses delivered by 
instrument manufacturers. This training mostly covers ‘operational’ FC, so participants are signed 
off to show competency when turning the machine on and off, running calibrations and 
compensation for experiments. These training courses generally do not include gating principles 
because of the diversity of FC application, but there is an opportunity for training to include this for 
client specificity. Therefore, this gating training is completed internally by observing others, reading 
protocols or a combination of both. Most participants did not use SOPs to apply their gates, but 
those who did used an internal SOP to complete this rather than using external references or a self-
made protocol.  
 
No obvious correlations were identified between the amount of experience or use frequency of a 
participant in relation to the range of absolute cell counts reported, CVs from cell counts or 
respective expanded uncertainties across any of the cell models investigated. The amount of 
experience a participant has does not mean they are more precise or accurate than a participant 
with no experience at all. Further research is required into this to ensure a wide range of 
participants are gathered to represent the complete diversity of experience and use frequency for 
statistically significant, powered experimental design. Experience can indicate the number of 
variables a participant is aware of that can affect the final outcome of the data, due to greater 
repeats of the experiments.  
 
In addition, participants were made aware of the aims of the study to meet ethical requirements, 
but this informed them that their data would be subsequently investigated to anonymously quantify 
their variability through uncertainty calculations. Because this was not completely blind, this could 
have inferred Hawthorne’s effect because participants knew they were being reviewed, so changed 
their behaviour and gating accordingly during the experimental studies. Some participants 
mentioned this during their study session, making remarks such as ‘I’ll gate this properly for you, 
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not how I usually do it’, indicating they would have done things a different way to how they want a 
third-party observer to see. This could indicate that the results identified throughout the studies 
could be conservative, not just because they were tightly controlled but because participants knew 
the data would be reviewed, so tried to be as uniform as possible, defeating the objectives of the 
research. To address this over time, routine analysis could be taken form participants, but it would 
be difficult to do blindly due to ethical consent and how the reporting and feedback will be handled. 
 
EQAS can be used to monitor proficiency of the laboratory and its participants, but it requires the 
right culture and participant behaviour to support its introduction and integration, to ensure that all 
behave professionally and use it as an opportunity to learn rather than becoming a big brother 
environment, fostering blame culture in the workplace. Employees need to be empowered through 
training and given the opportunity to speak openly and safely about the problems they have faced 
to ensure a team-led dynamic can enable effective solutions to improve the quality of a product. 
Equally, management also needs to handle the data responsibly, to deliver continuous 
improvement professionally and anonymously, identifying potential issues that can affect 
employees without making those involved feel responsible for issues which brought these 
opportunities to their attention. 
 
This is a community wide issue, not just one that could reside within one company or site. 
Participants identified many problems when they gate data which could cause variation, with key 
difficulties being cell separation of multiple populations and biological variation of samples. This 
was identified at the start and end of the research, indicating these issues are still prevalent within 
the community. Many separate initiatives have tried to address cell separation issues using 
automation platforms, especially where high-dimensionality data is concerned [1,118,212]. 
However, these are all still research-focused and not validated for mass manufactured products. 
As well as this validation requirement for use in CGT manufacturing, this questionnaire has 
highlighted a resistance to using these tools, indicating that providers need to demonstrate 
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usability of the platforms as well as very good accuracy and precision, and the ability to handle 
biological variation between donors.  
 
There also needs to be a community moves towards gating standardisation and better identification 
of the use of controls used to set gates, according to these questionnaires. When interpreting data 
from literature, many participants struggled to identify key factors from the text of figures that 
enabled good reproducibility of the data. Participants also failed to mention key efforts that have 
taken place in the FC field to standardise FC experimental reporting. Better cross-over between 
assay-focused and cell-based journals is needed to enforce effective reporting standards to the 
wider community. Additionally, within teams or departments, nominated employees could be 
responsible for staying abreast of the latest updates in certain development journals and 
disseminating this information within the team, to ensure all are aware of current methods to 
improve reproducibility and good practice. 
 
8.4.1 Consolidation of Objectives 
 
• These questionnaires were implemented and managed well, allowing effective analysis 
of a series of dichotomous, ordinal, nominal and written text responses for personal, 
experience and motivational factors.   
• No observed correlations between participant experience and FC use frequency was 
seen with respect to the range of absolute cell counts, CVs or uncertainties. It could be 
possible that experience, or overall knowledge on the topic infers that people are better 
at gating if they are more knowledgeable about FC. However, more knowledge on the 
topic does not necessarily mean they are more repeatable and precise in their analysis. 
• Both questionnaires showed a majority of participants preferring manual analysis of data 
(85 % and 70 % respectively) using platforms such as Flowjo, because of the amount of 
control they had of the data, as well as a resistance to change to new methods and 
platforms being addressed in the literature and from companies. However, those 
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preferring automated methods indicated it is much quicker than manual analysis of large 
data sets, setting a precedent for future development. 
• Problems identified from manual gating were the same at both time points, with Cell 
separation and Biological variation being the biggest issues participants faced when 
analysing lots of data. These were also things that automated platforms struggled with, 
suggesting a focused effort is needed in this area. 
• Reproducibility of data from literature is a big concern for participants, with key issues 
for improvement in the community being standard experimental and visual gate reporting 
as well as including images of the control files used to help others repeat the analysis 
when potentially using different instrumentation. Wider knowledge of standards such as 
ISAC MIFlowCyt reporting is needed across different cell-based communities, to 
maximise the standardisation of reported data. 
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Chapter 9: Translational Outlook 
 
9.0 Introduction to the Chapter 
 
Chapter 9 investigates whether subjective issues seen within Flow Cytometry processing and post-
analytical data analysis, such as cell population area selection are also present within other assays 
and platforms used by Cell and Gene Therapy Process Development teams. 8 interviews were 
conducted with industrial contacts who work with the Center for Biomedical Innovation at MIT, 
during a 6-week secondment, hosted by Jacqueline Wolfrum and Anthony Sinksey. The platforms 
investigated as part of this translation analysis were Flow Cytometry, Imaging Platforms and 
quantitative Polymerase Chain Reaction (qPCR) assays. Therefore, this Chapter captures some 
subjectivity issues already addressed and discussed from the main uncertainty models in Chapter 
3-7, and from the questionnaire results in Chapter 8. This Chapter aims to give a high-level review 
of translational similarities to human factor variables seen within Flow Cytometry but does not aim 
to deep-dive into specific factors at this stage. 
 
Imaging platforms were considered for the interviews because of the prevalence of imaging-based 
technology within CGT manufacturing. qPCR was also considered in one case where a participant 
had qualified this assay against a viral plaque imaging assay. This was considered across a range 
of exemplar CGT products, such as viral vectors, CAR-T suspension culture and Mesenchymal 
Stromal Cell (MSC) adherent cell culture, so was suitable for a wide range of potential interviewees. 
 
Operator subjectivity has been investigated across a wide variety of applications within medical 
imaging [213–215], however, with the recent use of imaging platforms to monitor to progress of 
cell therapy growth [216], differentiation and quality of products [217], the variability of analysts 
needs to be understood. A lot has been done to develop automated analysis for cell imaging 
platforms, to monitor cell morphology in relation to cell therapy development [218–220], because 
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it has the potential to be used as an in-line measurement tool. This is an attractive alternative to 
current invasive or off-line sampling methods to monitor CGT expansion. The interviews conducted 
here aim to identify how imaging platforms can be enhanced to make them more standardised 
measurement tools for monitoring CGT products throughout manufacture and release 
measurements. This translational outlook also investigated whether there was a possibility to 
quantify subjectivity across other platforms, using measurement uncertainty principles exemplified 
throughout this thesis. This would show a broad applicability of the technique within 
biomanufacturing, to improve measurement variation, resolution and control in manufacturing.  
9.1 Chapter Aims 
 
This Chapter aims to highlight subjective and cultural issues when analysing data across other 
instrumental platforms used within Cell and Gene Therapy Process Development teams, that are 
similar to subjectivity seen within FC assays.  This focuses on the measurement process, to identify 
subjective human factor influences within measurements. The second half of the interviews 
focused on training to identify what training processes are followed and what cultural differences 
could affect the variability of results between analysts. 
 
9.1.1 Chapter Aims & Objectives 
 
The Aims and Objectives of this Chapter can be defined as follows: 
• Interview a selection of industrialists who use cell imaging platforms within CGT process 
development and research teams to identify subjectivity within the measurement 
process. 
• Identify common causes for subjectivity across these imaging platforms and assays, for 
future work to address process improvements. 
• Identify similarities and differences between training, and attitude to training and using 
Standard Operating Procedures to remove variation between analysts.  
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9.2 Methodology 
 
These imaging exemplars were chosen in collaboration with MIT hosts through a review of core 
measurement techniques used across different CGT products. A lot of optical spectroscopy 
techniques are used (Flow Cytometry falls into this category), but because of the heavily automated 
nature of these instruments, it was decided that there was only small scope for application here. 
Imaging platforms were identified as being heavily used, along with qPCR, so it was decided these 
techniques would be the core focus. The MIT Center for Biomedical Innovation host a network of 
international CGT industrial and academic contacts, so this provided a suitable base for this six-
week long translational study, ensuring all relevant contacts could be accessed. 
 
9.2.1 Interviewee selection 
 
Relevant industrial contacts known to be working with one of the three exemplars were contacted 
through the MIT Centre for Biomedical Innovation. An additional conference call with each 
individual contact was made after verbal acceptance of the initial interview scope to further explain 
the scope and boundaries of the exercise, to confirm the most suitable interviewees could be 
contacted and the imaging platform they used was discussed in more detail. This ensured the 
interview would be suitable for their assay application and if they wanted to discuss a different 
platform, which they felt had subjectivity issues (other than Optical Spectrometry methods, because 
this has been largely standardised for Spectrophotometers, and Flow Cytometry has been 
previously investigated within this research), this was identified and confirmed with the research 
team. Interviews were held with 8 delegates from across 7 large USA biomanufacturing and 
standards companies.  
 
9.2.2 Ethical Approval 
 
Ethical Approval was granted from the Loughborough University Human Participants Ethical Sub-
committee and the MIT Committee on the Use of Humans as Experimental Subjects (COUHES). All 
approval documents and consent templates can be found in Appendix E. Participants were required 
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to consent to the interview at least 24 hours before it was scheduled to take place and forms were 
stored securely throughout the duration of the project according to UK GDPR regulations. 
Participants were all anonymised at the point of transcription, so any further analysis was 
completed blindly by the author. 
 
9.2.3 Interview Questions 
 
Interview questions were split into sections, detailed in the following subsections. An interview 
template of all the questions asked can be found in Appendix E. One hour was allocated for these 
interviews, so that all questions could be answered. The interview questions were a mix of 
continuous, nominal, scalar, and text response questions, as defined and coded previously in 
Chapter 8. Throughout these interviews, various questions aimed to identify where subjectivity was 
present in the measurement processes, to identify where translational subjective variation could 
also be measured, as shown throughout this thesis using measurement uncertainty within FC. 
 
9.2.3.1 Technique Use Questions 
 
In a manner similar to the questionnaires described in Chapter 8, participants identified how 
frequently they used the respective measurement platform, what the specific measurand used was 
and whether it was used for quantitative or qualitative analysis. This aimed to identify whether 
participants used imaging platforms for purely qualitative analysis, or if quantitative analysis was 
used (viral plaque counting, for example), and what level of automation was used for quantification. 
 
9.2.3.2 Process mapping exercise 
 
Participants detailed the full measurement process for the respective assay, going through pre-
process, in-process and post-process sections, described as follows: 
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• Pre-Process: Any sample preparation required to tag or label the biological product for 
analysis, as well as preparing substrates or master mixes for analysis. 
• In-Process: Instrumental preparation required to run the sample, such as instrumental 
calibration and background measurements if participants conducted these steps. 
• Post-Process: Once the analysis file or exported measurand has been obtained, any further 
image processing, selection or calculation steps that were required for final reporting. 
 
Once these process steps were defined, participants went through each specified step and 
identified what human contact time was required, and what elements of each step could be 
affected by operator subjectivity. Once all interviews were completed, results for similar processes 
were compiled and transcripts were coded for further stratification, using coding methods 
previously described [179]. These stratified variables were then tallied for the three process 
sections to identify subjectivity issues prevalent across the measurement processes. This identified 
similarities and differences to FC post-analytical variation specifically, to further identify other 
biomanufacturing platforms that could benefit from harmonisation and subjective variation 
quantification. 
 
9.2.3.4 Training and Standard Operating Procedure (SOP) Questions 
 
Participants were asked whether they were responsible for training new users on the respective 
platforms and if so, whether this was purely operational or whether theoretical training was also 
provided. Participants also identified whether they felt there was a difference between new and 
experienced users, and why. Finally, participants indicated whether additional reference materials 
were used for the platform and whether SOPs for data analysis were provided. If yes, they described 
whether these were internal or from external literature sources. 
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9.3 Survey Results 
 
Fifty percent of interviewees spoke about their experiences with viral infectivity assays, used in the 
production and release of viral vector products used in other therapies, so this has been used as 
an exemplar throughout this results section. Only 8 interviews could be conducted within the 
secondment time-frame (due to preparation time, geography and interviewee availability), which is 
a limitation of this study, but it was only designed to be an initial pilot investigation to highlight 
issues for future clarification with more structured experimental work. This will provide a translation 
of the FC variation analysis techniques and evidence for application of measurement uncertainty 
techniques to further quantify operator subjectivity within other biometrology platforms. 
 
9.3.1 Training and Proficiency Results 
 
In a manner similar to the questionnaires in Chapter 8, interviewees were asked how often they 
actually completed the respective assay themselves. Most participants aimed to complete assays 
at least once a week, to ensure they stayed familiar with the technology and processes. Those who 
did not use the assays as regularly were in more managerial positions. Within the CGT space there 
is a lot to explore with respect to experience and use frequency, however, it is difficult to complete 
within this research, because participants are based across different companies. Different 
company structures can possibly indicate different levels of interaction with equipment, which are 
perhaps better understood from an internal perspective before comparing between different sites 
and structures.  
 
Table 83 indicates whether these assays were used for quantitative or qualitative purposes by 
interviewees (or both). It shows results for all interviews, not just those focused on Viral Infectivity. 
If participants stated it was a qualitative test, they explained what they used as a ‘determination of 
success’ to satisfy a decision on the product. Only one process stated was purely qualitative, where 
Fluorescence Microscopy was used to monitor cell growth over time by a visual increase in 
fluorescence. Other imaging platforms have been used for qualitative analysis as well as 
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quantitative analysis. In these instances, the qualitative is used to support the quantitative results 
if further clarity is required. A qPCR experiment had been validated for viral plaque counting against 
an imaging platform, so this quantitative method was discussed by the relevant interviewee. 
 
Table 83 Quantitative or Qualitative nature of assays 
Assay Measurement Quantitative/Qualitative Qualitative: Determination of 
Success 
Quantitative: Final 
Metric 
Numeric
? 
Cell Count/Viability Both Images to match control Cell Count Yes 
Viability Yes 
Cell Size (µm) Yes 
Cell Growth Qualitative Visual increase in 
fluorescence 
    
Viral Infectivity Both Images for sanity checking Transducing Units / 
mL 
Yes 
Viral Infectivity Quantitative   Transducing Units / 
mL 
Yes 
Viral Infectivity Both Manual subjective counting of 
plaques 
Transducing Units / 
mL 
Yes 
Viral Infectivity Quantitative   Transducing Units / 
mL 
Yes 
Cell Count/Viability Quantitative   Viability Yes 
Cell Shape 
Quantification 
Quantitative   Differentiation 
score 
Yes 
Immunophenotyping Quantitative   Cell Count Yes 
 
Any interviewee who stated a quantitative metric was used was asked to describe the final reported 
metric. This identified whether different metrics could be reported from the same assay or platform. 
Viral Infectivity assays all produced a Transducing Units / mL measure, from counts of viral plaques 
or through qPCR. Despite the methods of achieving these results being different (described in the 
subsequent process mapping exercise results section), the reported result is the same. This 
requires further quantitative experimentation, because differences between platforms and 
methods could return consistently different measures. Counts were provided for any cell counting 
method for MSC or CAR-T exemplars as well as novel scoring methods being created to monitor cell 
shape with respect to differentiation. 
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9.3.3 Process mapping exercise results 
 
Each interviewee gave a detailed process breakdown of their respective assay, from the start of 
pre-processing to the final measurement and/or decision. Viral infectivity maps have been 
exemplified here because they were most commonly discussed, have the same reported metric 
(Transducing Units / mL), yet all methods of obtaining this metric were different between 
interviewees, as shown in process maps in Figure 167 to Figure 170. 
 
 
Figure 167 Process Flow Map for qPCR Viral Infectivity measurements 
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Figure 168 Process Flow Map for imager Viral Infectivity measurements 
 
 
Figure 169 Process Flow Map for manual & imageJ Viral Infectivity measurements 
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Figure 170 Process Flow Map for manual Viral Infectivity measurements 
 
The four Viral Infectivity process maps have been organised into the pre-process, in-process and 
post-process columns defined in Section 9.2.3.2. Participants were also asked to identify human 
factor or subjectivity issues that arose at each step in the process, listed in italics next to the 
respective step. Some participants also gave an indication of contact time for each step. Where 
possible, this is listed next to the respective step in bold. These maps have been listed in reverse 
order of measurement automation, i.e., the more automated procedures are first, with the most 
manual procedures last. The qPCR method has been included although it is not a cell imaging 
method, because the relevant company and interviewee had validated this against a cell imaging 
assay and used qPCR as a more robust method. 
 
It became evident that the presence and use of automation made operators believe any human 
subjectivity is removed from the process. In Figure 168, where a Cytation-1 cell analyser imaging 
platform was used, the addition of an automated plate loading machine also made the interviewee 
strongly believe there were no subjective components, because the operator had been replaced 
with robotics. However, when discussing the setup of imaging platforms, there was significant 
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operator involvement to obtain good image for further use. Imaging platforms can be affected by 
many factors such as digital image parameters (brightness and contrast), as well as spatial issues 
such as selecting quadrants of wells for imaging or choosing a specific population by eye. 
Interviewees did not identify these as potential variables, however, human factor or subjectivity 
variables they initially provided were all concerned with sample preparation, mainly pipetting error, 
speed of work and operator confidence. 
 
All subjectivity variables listed through the interview process were stratified into core themes, listed 
in the bar charts in Figure 171. Full definitions of these bins can be found in Appendix E.  This bar 
chart is stacked to show how variables featured across the three process sections. The responses 
are frequency of results as a function of the total number of subjectivities listed across all three 
sections for all assay types.  
 
 
Figure 171 Stratified subjectivity issues within imaging platforms 
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Protocol Optimisation and Spatial Image parameters were the most frequent variables identified 
as subjectivity concerns for imaging platform. Both are defined, but protocol optimisation 
concerned parameters that would have been investigated before the actual measurement process, 
during previous validation experiments, so are discounted here. Therefore, Spatial Image 
Parameters were the most prevalent subjectivity factor, followed by Copy Errors and Digital Image 
Parameters. These variables contrasted with interviewee conception of subjectivity only being 
present during sample preparation, because this is where there was a lot of human contact with 
the physical sample. Statements like ‘pipetting error’ have been stratified under ‘Haptic Variables’ 
because they were all physical interactions between analyst and sample. ‘Haptic Variables’ are 
affected by the operator completing a physical task or manual manipulation of the product, 
whereas ‘Non-Haptic Variables’ are affected by the operator but are not physical in completion. 
These often involve software-based tasks where the operator is using a computer to select and test 
a variety of parameters. Full coding definitions are located in Appendix E. 
 
Most of the subjectivity variables physically listed by participants were located within in-process 
and post-process sections, contrary to initial verbal interviewee opinions. Although Spatial Image 
Parameters may be difficult to standardise to image plaques or cells, participants did also discuss 
ways they have achieved this. One participant used Haematocytometer grids to select imaging 
areas, to remove subjectivity of camera placement. Further validation runs with camera 
magnifications, fields of view and other digital image parameters can all be standardised for 
uniform image quality. This can also aim to standardise process parameters upstream, such as the 
thickness of viral plaque substrates, to ensure imaging, depth and focus can be uniform each time. 
There are many subjectivity variables listed across these process stages which can be categorised 
accordingly, but these cannot begin to be addressed or standardised if the entire process is not 
uniform. It may be acceptable to have different processes to achieve the same metric, but 
validation is first required to ensure there are no significant differences of results obtained.  
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9.3.4 Training and SOP results 
 
Interviewees were asked whether training provided for the respective assay was operational, 
theoretical or a combination of both. Figure 172 shows that no one delivered purely theoretical 
training because this was not industrially pragmatic. However, 45 % delivered theoretical 
understanding where relevant alongside operational training. The remaining 55 % provided purely 
operational training in how to run the assay and equipment. If employees wanted further 
information, it was up to the individual to research it. 
 
Figure 172 Types of training provided on respective assays 
 
All training discussed was very front-end in an employees’ use of the equipment. Employees would 
have to read relevant risk assessments, SOPs and documentation, then some employees also 
calculated CV of training repeats, so they were only signed off when their CV was below a certain 
level of acceptance. In the case of manual plaque counting, this was ≤ 40 % CV. This supports the 
use of intra-participant CV calculated as a training tool, as discussed in Chapter 7. No mention of 
measurement uncertainty or combined errors was made amongst the interviewees, indicating a 
significant opportunity for uncertainty quantification across other biometrology platforms to 
monitor subjectivity.  Interviewees discussed variability predominantly in terms of CV indicating an 
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awareness of precision, which is very similar to the FC community who also heavily use CV as a key 
variation metric, as discussed previously in Chapter 1 and throughout Chapters 4 to 6. 
 
All participants stored training documents appropriately to meet auditing requirements, so 
documents were always accessible. Despite the general training processes being similar, there 
were differences observed that could affect subjectivity at the learning and training stage.  A 
cultural attitude needs addressing once training has been completed, as many interviewees felt it 
was inappropriate to tell others what they did was incorrect and why, if they returned abnormal 
results. Rather than addressing employee differences in cell culture or image acquisition, 
employees were often asked to repeat the assay and learn from their own mistakes. Whilst this is 
a good way to learn, differences between operators should be able to be confidently and 
confidentially addressed in the workplace, to minimise variance on the CGT product.  
 
One participant explained how they tackled this issue in the workplace, by going back and 
addressing training from SOPs. For each step in an SOP, images and written content was provided 
to define good and bad process steps, consequences and further actions. Using this in future 
training enabled new employees to better understand why they completed certain tasks, giving 
them ownership and confidence in their work. Consequently, they had a very open team culture, so 
whenever a problem arose, it was comfortable to address and inform the wider team to work 
together to find the root cause and develop a robust solution, rather than foster a blame culture. 
 
88 % of interviewees used SOPs for post-process data analysis and when questioned further, these 
were mostly internal documents. SOPs for data analysis mostly provided images of endpoints or 
good data for relevant steps. Most did not include examples of bad data or consequences of poor 
variable selections but mentioned it would be good to include in future SOP versions. 
 
Overall, a culture change to the whole measurement process is required, in order for other process 
changes to have maximum benefit. Standardisation of processes can be achieved, if there is an 
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open culture to allow employees and managers to discuss continuous improvement efforts, without 
people feeling subjected to blame or ‘big brother’ ideology. This has been identified as a function 
of the broader remit of the interviews here, which could also be further investigated within Flow 
Cytometry, because the core research within this thesis does not address work culture effects. 
 
9.4 Chapter Conclusions 
 
This translational exercise has shown that human subjectivity issues exist within other 
measurement platforms used across a variety of CGT products, not just in Flow Cytometry. Imaging 
and qPCR are highly utilised techniques across many CGT processing stages, so a better 
understanding of operator subjectivity may have a significant impact on standardisation efforts. 
 
The interviewees have further demonstrated the diversity of processes to obtain ‘comparable’ 
results, with many levels of autonomy used to achieve a quantifiable result. Even though only 8 
interviewees were included, it still demonstrates diversity of results, which could be investigated 
more rigorously in future analysis. It became evident that most interviewees believe operator 
subjectivity issues were found only in pre-processing steps. However, from the actual variables the 
interviewees listed, most subjectivity was identified as being in the later processing stages. This 
reflects the variability seen within the Flow Cytometry uncertainty models in Chapters 4 to 6. The 
comparison in Chapter 7 has shown that variation exists in operator analysis in the post-analytical 
phase also.  Whilst regulatory frameworks exist for the use of validation of software within medical 
measurement, more needs to be done to ensure user variability is reduced as a function of the 
platform, or to ensure that its use by different operators does not induce more uncertainty into the 
measurement.  
 
The lack of participant recognition on the subjective spatial and digital image parameters indicates 
that further education is required on this topic, especially when the general perception is that 
automation removes operators and therefore any subjectivity. Automation only transforms the 
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subjectivity, from manual handling, to manual selection and determination of manufacturing and 
measurement parameters. When combined with the additional issues of maintenance and 
accreditation, there are a large number of subjective elements that an operator must understand 
to make an informed, confident decision when manufacturing a CGT product using automated 
platforms, especially if measures are close to defined performance limits, which currently causes 
issues for automation, as  discussed in Chapter 1. There is significant subjectivity that resides 
within the post-analytical processing for imaging platforms, which could greatly benefit from similar 
measurement uncertainty application that has been successfully demonstrated throughout this 
thesis. Well defined imaging assays could use the subjectivity breakdowns within this thesis to 
isolate specific processes for quantification of manual and automated analysis uncertainty where 
relevant, showing translation of this research across a wide application of biometrology CGT assays. 
 
Whilst considerable effort is put towards training to ensure all new employees receive it and the 
documentation is stored correctly, a cultural change may be needed to empower employees to 
foster a more open working culture to speak openly about issues and problem solving. Interviewees 
stated that additions to SOPs and training to teach more about good and bad data, consequences 
and root causes could foster a healthier attitude to problem solving when differences arise. In a 
similar manner to Flow Cytometry, all imaging users will use platforms for diverse measurements, 
so it could be difficult to deliver standardised training in analytical image processing. However, 
more internal validation could be used to ensure better standardisation and therefore quality of 
images used for qualification of CGT products.  
 
9.4.1 Consolidation of Objectives 
 
• 8 participants were interviewed around imaging platforms they used to monitor CGT 
products they worked with their respective research and process development roles. 
Throughout the process mapping exercise and other elements of the interview, they 
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identified various subjectivity elements affecting imaging of CGT products, throughout 
pre-process, in-process and post-process phases. 
• Common causes for subjectivity were spatial image parameters, that occur during in-
process and post-process analysis phases. These are variables used to select areas of a 
well or plate to image, as well as Z-height where three dimensions are required. 
• Most interviewees believed subjectivity was only based in the pre-process phase during 
sample preparation, however, most of the subjectivity elements listed were later in the 
analysis process. 
• All interviewees identified that there was a procedure in place for training and 
documentation, however, participants agreed this could be enhanced by a protocol that 
contained more information on good and bad data for each step. 
• A cultural change is possibly needed in some instances to ensure employees and 
managers can speak openly about issues that need addressing, or problems they 
identify, to ensure continuous improvement can be instigated.  
• This high-level review of alternative CGT analysis techniques has identified the potential 
of translation of the novel uncertainty-based analysis methods developed for FC, within 
this thesis. 
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Chapter 10: Conclusion & Future Work 
 
10.0 Introduction to the Chapter 
 
The aim of this thesis was to investigate the following research hypothesis as defined in the Prelude 
(along with the key objectives): 
 
“As the complexity of Flow Cytometry data increases, the variability contributed to the 
measurement (either CV or measurement uncertainty) from operator subjective analysis also 
increases.”  
10.1 Thesis Conclusions 
 
With reference to the aims of this thesis key conclusions based upon the results of this research 
are identified and discussed as follows: 
• A succinct review of External Quality Assessment Schemes (EQAS) (Chapter 1) has shown 
that there are opportunities for translation from the clinical environment into Cell and Gene 
Therapy manufacturing environments. Current and relevant schemes in clinical Flow 
Cytometry (FC) have direct application to CGT manufacturers, to ensure measurement 
quality is passed onto the patient in the form of a correct decision and appropriate 
treatment. Clinical Chemistry EQAS have also shown how integration of measurement 
uncertainty into EQAS is achievable, providing further measurement resolution, control and 
potential alignment to ISO 17025 and ICH Q7 standards for CGT manufacture. 
 
• Measurement uncertainty principles (described in Chapter 2 and applied in Chapters 4 to 
6) have been shown to be very applicable to FC inter-participant data, giving an indication 
of overall participant variation, but also identify specific gates that cause issues. This shows 
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its’ worth as a continuous improvement tool within CGT measurement and manufacturing. 
One drawback of using measurement uncertainty is the number of repeats recommended 
for SD calculations (between 4 to 10 according to the GUM). No more than 3 repeats could 
be taken for this data (due to participant fatigue), which could affect the results, but the 
benefits of using measurement uncertainty outweigh this. Further repeats could be 
conducted in future work, because it was not practical as part of this experimentation, to 
indicate an optimum number of repeats for human participant variation quantification. 
 
• To model an increase in complexity throughout the uncertainty models, three cellular 
profiles were chosen for fcs file generation. The Embryonal Carcinoma 2102 Ep 
immortalised cell line was used for the basic model (Chapter 3) because it had been shown 
to remain pluripotent over 10 passages, contributing less biological variation to the 
analysis. This ensured the basic model could be used as a baseline. The intermediate 
model files were created from Peripheral Blood Mononuclear Cells (PBMCs) because this 
population contained further sub-populations which provided greater depth and complexity. 
The 2102 Ep line did not have this capability, and the PBMC material was more comparable 
to current autologous therapies available to patients, that collaborators were also focused 
on. This PBMC model enabled further complexity enhancement for the final model, which 
used engineered T-cells derived from PBMCs to measure transduction efficiency. This is 
representative of assays used in current CGT expansion, and was provided by one of the 
collaborators, giving affinity to relevant therapies and their manufacture. 
 
• Throughout the complexity models in Chapters 4 to 6, a standard reporting structure of 
metrics has been used to report; the absolute results obtained by participants, respective 
Coefficients of Variation (CV) and measurement uncertainty. Only CV and measurement 
uncertainty are considered within these overall conclusions, because the absolute results 
were not stated within the initial hypothesis to monitor variability, and they are not 
comparable to a metrologically ‘true value’ due to lack of traceability through Flow 
Cytometry standards. 
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• It is possible that Hawthorne’s effect could have impacted the results of this human 
participant research. This effect can be attributed when participants are aware they are 
being watched, monitored or evaluated within their work. Participants were aware of their 
work being analysed due to the information and consent provided to take part in the 
research. It is also very difficult to conduct Gauge R&R and measurement uncertainty 
analysis session without this impact, because of the experimental specificity required for 
calculation, which informs measurement participants.  
 
• During the pre-study investigation in Chapter 3 (in which participants applied gates to 
histograms), there was a range of 8 % rCV (for optimal 500 V file) between participants 
when analysing a data file that had the correct instrument setup. The range increased up 
to 400 % rCV (250 V– 450 V) when the instrument was poorly setup, clarifying the need for 
appropriate instrument optimisation to reduce downstream measurement variance 
between analysts. 
 
• Throughout this research, many non-parametric distributions are identified when 
participants gate with or without the use of protocols. Many of the basic statistical tools 
such as skewness and kurtosis define non-parametric distributions by their discordance 
with normal distribution metrics. The in-built assumption of desirable normal distribution 
shape is challenged here. When trying to reduce variation, conformance to specific 
performance criteria is required, which can mean distributions should become more 
kurtosed or concentrated within a smaller distribution range. This questions how data is 
processed, to identify core metrics of success to ensure that all statistics used are relevant. 
 
• Chapter 3 has also highlighted the differences between performance criteria (as explained 
in Chapters 1 and 2) used across various industries and respective outliers of the data set. 
There is no harmonisation between these methods, although the correct choice should be 
informed from thorough normality assessment of the distribution, and data should not 
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necessarily be log transformed, due to discrepancies between outlier definitions. The 
analysis reported here has therefore been kept closer to the raw data, making analysis and 
decisions easier to interpret for manufacturers and regulators. 
 
• Experimental studies were well designed (as discussed in Chapter 2) because the relevant 
amount of data was captured within the allotted participant time frames for each complexity 
model (Chapters 4 to 6). Data was stored in accordance to ethical guidelines, once 
participant consent was obtained. These have provided a suitable methodology for future 
uncertainty calculations where subjectivity estimations are required, to obtain at least three 
repeats within 1 hour of participant processing time.  
 
• Measurement uncertainty was quantified successfully across all three complexity models, 
by calculating the SD of three repeats of each gate applied in the gating sequences. These 
were successfully combined in quadrature using the GUM principles to create combined 
uncertainties and expanded uncertainties to show a 95 % Confidence Interval of data (k=2). 
Median uncertainties of the basic to complex model were 3.6 %, 2.1 % and 6.2 % 
respectively, indicating location parameters do not show any relation to increase variation. 
 
• Inter- and intra-CV have been defined as; CV of a participant population of results, and CV, 
of a participant’s individual repeats, respectively. An inter-CV mean of 16 % has been found 
across all three complexity models for participant judgement when gating data. Inter-CVs 
across the three complexity models were 17.8 %, 18.2 % and 12.1 % respectively as 
complexity increased. 16 % could be used as a rule of thumb for participant variability, 
although it falls outside of ICSH satisfactory criteria of < 10 % CV. 
 
• An increase in the intra-participant range of CV and measurement uncertainty was seen as 
the complexity increased, shown in Table 84, and illustrated in Figure 173 and Figure 174 
(rounded to the nearest integer). This is the primary novel result that confirms the 
hypothesis of the thesis, showing more variability is contributed to the measurement from 
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the operator conducting the data analysis. This has significant implications within CGT, 
because FC panels can increase in dimensionality to 18 colours in some instances, 
contributing more variation to the final measurement and interpretation. This becomes 
more complicated when monitoring rare cell events and minimal residual diseases, 
although these elements were not a feature of the study. As cell emission spectra get closer 
to the limit of sensitivity of the instrument, it can increase the probability of false positives 
/ false negatives as a function of operator subjectivity and thresholds, causing a therapy to 
be inappropriately given, or a product discarded when it could have provided a patient a 
treatment. 
 
Table 84 Comparison of intra-participant CV and uncertainty ranges across the cell complexity models 
 Basic Intermediate Complex 
CV (%) 6 22 34 
Uncertainty (%) 12 16 34 
 
 
Figure 173 Core hypothesis of thesis, showing an increased range of intra-participant CV with FC data complexity. 
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Figure 174 Core hypothesis of thesis, showing increased range of inter-participant uncertainty with FC data complexity. 
 
• CV is a commonly used variability metric within FC and other biological assays. Throughout 
these analyses, it has shown it is more difficult to identify sources of variance from CV 
extremes, because this metric only accounts for variation from repeats of the final gate 
measurements. Measurement uncertainty calculated variability using a bottom-up 
approach, combining uncertainties from individual gates applied within the FC analysis 
sequence (in this instance). It facilitates easier root cause analysis of variation, to better 
identify process elements or operators that are more variable. This continuous 
improvement loop provides opportunity for appropriate optimisation of the process, and 
appropriate training of staff. On this note, CV is a useful measure of initial competency, 
because it is quick to calculate, whereas uncertainty requires well controlled experiments 
for quantification that are more time-consuming. Throughout each model (Chapters 4 to 6) 
it has been shown there is no strong correlation between CV and uncertainty, so these 
metrics should not be used to estimate each other.  
 
• Using the ICSH guideline criteria for acceptable CV, a performance diagram was created by 
adapting these guidelines, exemplified here in Figure 175. The satisfactory limit (10 %) was 
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halved to 5 % to show ‘good’ performance and doubled to 20% to show where revision is 
required, with actual histogram data overlaid. This was used effectively to monitor intra-
participant CV throughout Chapters 4 to 6, as well as substituting these values to monitor 
uncertainty. No defined limits for uncertainty have been provided in the Flow Cytometry 
literature, so these were used alongside permissible uncertainty defined for clinical 
chemistry values. This diagram was effective at monitoring extreme data and showed how 
it could be used as an indication within a manufacturing facility to easily monitor quality 
towards a common goal of lower variance.  
 
Figure 175 Example of the novel performance monitoring diagram, highlighting good, satisfactory and revision regions 
based upon ICSH guidelines 
 
• The use of a protocol showed initial promise within the pre-study, reducing operator 
variability (CV) when copying histogram gates by up to 90 % in optimal conditions (Chapter 
3). There was also a 57 % reduction in range seen during the intermediate model when 
participants used the protocol to identify naïve T-cells (Chapter 5). However, there was an 
increase in range of count results (42 % increase) and uncertainties (23 % increase) when 
participants used the protocol in the complex model (Chapter 6), indicating that copying a 
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protocol in lengthy gating sequences may not be optimal to reduce variation between 
participants, or it requires redesigning and investigating protocol usage sensitivities. 
 
• Bimodal distributions were observed within Chapters 5 and 6, although only through visual 
observation. Basic statistics used did not identify this shape, often placing mean values 
where no data maxima were present. This highlights the importance of visual 
representation of the data, to further identify extreme or unexpected deviances. These high 
and low distributions were due to boundary effects identified on the edges of plots, and 
how participant gates were affected by these. 
 
• Throughout the complexity models, it was noticed that the same gates in each sequence 
were causing high variability between participants. Upon further investigation, participants 
with higher uncertainties due to these gates were mostly affected by the boundary effect 
on the respective edges of the high variance gates. Improper use of controls was the other 
main cause of variance between participants. 
 
• A difference in high and low uncertainty clusters has been identified during the intermediate 
and complex model, due to the boundary effects observed on the axes limits during these 
respective studies. Repeatable inclusion or exclusion of this data gives a low uncertainty, 
but low or high respective cell counts. Inconsistent gating on edges where repeats do not 
all contain this effect have a high uncertainty. This has shown that these boundary artefacts 
require future investigation to identify the impact they have on measurement variability 
when removed. Boundary effects were also observed when the data was visualised in some 
software platforms, but not others, highlighting a significant issue for reproducibility of data 
and analysis across Flow Cytometry measurements. 
 
• Power analysis was conducted for all analysis studies where two test conditions were 
evaluated (Chapters 3, 5, 6), although these studies were conducted without initial sample 
size limitations to ensure an initial variance could be quantified. Power was used to define 
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the appropriate number of participants across the models, to identify whether a suitable 
number of participants were acquired to determine differences between test conditions. A-
Priori and Post Hoc power indicated ideal sample sizes from variances gathered from data 
and the actual power of the models respectively. Power analysis could not be conducted 
for singular test conditions (Chapter 4), because there was no comparison to another test 
condition or a hypothesised ideal value. Whilst some power analysis indicated further 
participants were required, this could not have been determined before the studies took 
place, because initial variation was unknown. These values can now be used to inform 
further validation studies. 
 
• The results of this questionnaire (Chapter 8) indicated that there was no correlation 
between experience of a participant and their respective uncertainty, in any of the gating 
models. This was also true of use frequency of a Flow Cytometer, with no correlation to 
measurement uncertainty as the equipment is used more regularly. This potentially 
requires more investigation; however, it indicates that more knowledge of Flow Cytometry 
does not identify if participants are going to be more precise when applying their gates. 
Further work on how training is implemented could further expand upon this. 
 
• The questionnaires also showed the majority of participants prefer manual gating to 
automated algorithms for cluster identification, due to scepticism of the automated 
methods (relating to literature in Chapter 1). This indicates a cultural barrier needs to be 
addressed in order for these methods to be fully adopted, in addition to better 
quantification and validation of automation precision. Participants also indicated that cell 
cluster separation was the biggest issue facing FC data analysis, despite many automation 
efforts in this area. Many participants identified the need for better reporting standards of 
FC experiments, although typically did not note the MIFlowCyt standard, suggesting that 
these reporting standards (discussed in Chapter 1) need to cross boundaries into different 
cell-based communities. 
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• It was evident from the FC questionnaires for gating (Chapter 8) and the translational work 
for imaging and qPCR (Chapter 9), that the training provided for assay specificity is all 
internally driven. Further focus on gating training or uniform guidelines that could aid 
general analysis are required to ensure internal training is reproducible. 
 
• Chapter 9 has shown the range of subjectivity issues prevalent across imaging and qPCR 
platforms used within CGT process development and manufacturing, with many people not 
realising that subjectivity also appears within data analysis, not just sample handling and 
upstream pipetting error. This translation exercise has identified a possible need for 
training across multiple platforms, to highlight further sources of variation that can impact 
a measurement during post-analytical analysis of images and assays. Even when 
automation is used to aid manufacture, this does not necessarily remove the operator 
subjectivity, it translates it to other areas, such as validation and setup options, as well as 
the additional issues of maintenance and calibration. 
 
• This identification of subjectivity in downstream measurement across other platforms 
demonstrates the applicability to quantify subjectivity in other measurement techniques, 
where quantitative measurements are derived from interpreted images, plots or qualitative 
data. 
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10.2 Thesis Novelty 
 
The perceived novelty of this research was originally identified in the Prelude of this thesis. Table 
85 identifies how well these objectives have been met, and the perceived novelty of each element 
of the work, as well as other novel contributions that have developed during the research. 
Table 85 Comparison of Novelty 
Perceived Novelty Relevant Chapter Novelty 
This thesis provides a critical 
review of current External 
Quality Assessment Schemes 
(EQAS), to identify 
opportunities for integration 
into CGT manufacturing.  
1 Low/ Medium 
This review has shown current EQAS 
that are used for clinical FC, and also 
current EQAS for clinical chemistry 
that have quantified measurement 
uncertainty. This highlights a potential 
for CGT manufacturing, to learn and 
adapt these principles to a new focus 
but is not novel in terms of uncertainty 
consideration into EQAS. 
Relevance of application of 
manufacturing outlier 
definitions to define process 
control limits. 
3 Low/Medium 
A review of different performance 
criteria definitions across various 
industries has shown that there are 
many different control limits that can 
be applied, but a lot of these require 
normal data, so are unsuitable for 
skewed data. More robust methods 
should be used for non-parametric 
data, with various suggestions made 
in this research. 
Application of Gauge 
Repeatability & Reproducibility 
techniques to Flow Cytometry 
post-analytical variation. 
4 High 
This is a novel approach to 
determining post-analytical FC 
variation, purely isolating the gating 
from the rest of the FC measurement 
process. Gauge R&R is an effective 
way to quantify variation using 
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electronic data files, making the 
application of this easy to implement 
across different scenarios. 
Use of measurement 
uncertainty for Flow Cytometry 
post-analytical variation. 
4, 5, 6 High 
Measurement uncertainty has for the 
first time been demonstrated and 
used to quantify purely the post-
analytical variation stage of FC, and 
importantly for the first time within a 
CGT manufacturing context. 
Use of measurement 
uncertainty for better 
measurement resolution and 
control with CGT 
manufacturing.  
4, 5, 6 High 
The bottom-up uncertainty calculated 
for each respective gate provides 
better root cause analysis for extreme 
values and shows how this can be 
utilised for precision, accreditation 
and continuous improvement. 
Quantification of participant 
subjectivity as a function of 
cell model complexity. 
4, 5, 6 High 
This is the first-time intra-participant 
and inter-participant subjectivity from 
the gating process has been 
quantified within a FC context and 
within CGT analysis scenarios. This 
can be used in conjunction with other 
uncertainty estimates to create a more 
confident uncertainty budget for FC 
measurements and their 
interpretation. 
Increased variability as a 
function of cell complexity. 
4, 5, 6 High 
This is the first time that increase 
variation has been shown with respect 
to cell complexity, using intra-
participant CV or uncertainty. 
Development of a new 
performance monitoring 
4, 5, 6 High 
This diagram and respective code was 
developed to allow centres to define 
their own performance limits in 
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diagram to aid continuous 
improvement of variation. 
relation to the number of people in the 
facility, to easily monitor conformance 
and performance to highlight extreme 
data and subsequent learning 
opportunities. This challenges the 
central tendency seen as ‘ideal’ for 
normal distributions, because 
variation always aims to be as low as 
possible, indicating a strong positive 
skew, which used equation of a 
straight line to inform this shape from 
the input performance parameters. 
This has been a very significant tool to 
identify extremes in this research and 
shows applicability in many other 
quality and monitoring situations. 
Comparison of measurement 
variability metrics suitable for 
precision of FC measurements 
within CGT manufacturing 
contexts.  
7 Medium/ High 
CV and measurement uncertainty 
represent different levels of controlled 
and quantified variation, with 
uncertainty giving more resolution, but 
CV being more pragmatic. These have 
been combined for KPIs for the NHS 
(Chapter 1), showing how they could 
be utilised within CGT manufacture for 
better manufacturing control. 
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10.3 Further work 
 
This research has already successfully shown there is an increase in variability input to Flow 
Cytometry measurements, when data being analysed becomes more complex. However, further 
time and effort are still needed to expand and investigate areas of this work. Further work has been 
stratified into ‘general’ and ‘detailed’ further work, to identify larger experimental studies and 
focused validation efforts in relation to this work respectively. 
 
10.3.1 General Further work 
 
• A top priority for this work, is translation of the precision of human operators in comparison 
to machine learning algorithms for cluster definition. This work can be used as a benchmark 
for automated analysis of the same files, to compare variability of clustering methods. Even 
though this complex model precision is high, it can be used to identify performance criteria 
for automation: for example, automation precision to be 10 % of the human counterpart. 
 
• Further measurement uncertainty calculations of other FC variation sources could be 
completed to estimate expanded uncertainty for a particular FC assay. This can indicate 
the amount of variation present for the whole assay, as well as identifying sources of 
variation to reduce. 
 
• Further experimental repeats could be taken, to strengthen the validity of this work. This 
would require significant experimental design to choose suitable repeats and obtain them 
without causing participant fatigue or enabling them to learn the sequence. However, this 
would need to be well defined due to Hawthorne’s effect and recognition of the data. 
 
• Further human participant work would focus on measurement/identification of rare cell 
events and residual disease, because these measurements will be needed to monitor 
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participant treatment and progression, so measurement uncertainty becomes of utmost 
importance to ensure results are not reported or interpreted incorrectly.  
 
• Development of EQAS for CGT FC measurements is required, to ensure standardised 
instrumental setup and analysis between sites and manufacturers, to improve 
reproducibility of data. 
 
• Application of the novel performance monitoring diagram created in this research to other 
biomanufacturing environments. 
 
• Extension of the complexity versus measurement uncertainty research to capture more 
complex panels, such as 12- and 18-colour panels, because these are becoming more 
common within Flow Cytometry analysis. 
 
10.3.2 Detailed Further work 
 
• Further benchmarking of the Intermediate Model (Chapter 5) could be completed, to 
monitor participant results in relation to the cell count values extracted from the 
diagrammatical protocol provided to participants in Phase 2, similar to benchmarking for 
the Complex model (Chapter 6). 
 
• Comparison of machine learning parameter repeatability (similar to t-SNE parameters 
discussed in Chapter 1) needs to be completed for each analysis file used for the Basic, 
Intermediate and Complex model. This would provide a comparable precision measure 
against the participant results calculated in this research, to define where improvements 
in precision are required. 
 
  Chapter 10: Conclusions 
331 
 
• Conduct similar uncertainty studies for alternate cell types that are common within CGTs, 
such as Mesenchymal Stromal Cells (MSCs) to build a database of uncertainty ranges of 
post-analytical variation. 
 
• Recruit more participants to take part in further studies, to provide more confidence in the 
results, and possibly repeat some of the current models that had bimodal distributions due 
to boundary effects within the files. Educating participants about this issue before the study 
(or identifying how to remove this effect from the data), could potentially remove the 
difference in variance seen, to get a better understanding of gating the data with or without 
a protocol. 
 
• Detailed analysis of the prevalence and influence of boundary effects in different software 
platforms. 
 
• Further studies to test the use of a protocol need to be conducted, to identify how these 
can be useful and provide training, without negatively impacting variance of results. A focus 
on culture change to ensure operators speak openly about their analysis and difference 
would help harmonisation efforts. 
 
• Protocol design sensitivity exercise to develop protocols that helps at the higher 
dimensional analysis stages, to identify where higher or lower variance between 
participants is introduced as a function of interpretation. 
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Appendix D 
D.1 Initial Questionnaire Outline 
 
D.1.1 Personal Questions 
1) What is your name? 
2) Who is your Principal Investigator/ Team Leader (if applicable)? 
3) Do you hold any Flow Cytometry qualifications (e.g. C.Cy)? 
If you answered yes, please list what these qualifications are and when you attained 
them. 
D.1.2 Experience Questions 
4) Please tick what you have experience using Flow Cytometry for. 
5) How much experience (in years and months) do you have with Flow Cytometry? 
6) On average, how frequently do you use a Flow Cytometer? 
7) How were you originally taught to apply gates? 
8) Have you attended any Flow Cytometry Training courses? If so, when? 
9) What cell types do you most commonly work with when using a Flow Cytometer? 
10) Do you use a written/diagrammatical protocol to apply gates to your data? 
10a) If yes, is this a protocol you have written, an internal SOP or an external publication? 
11) Do you prefer to use automated or manual gating? 
11a) Why do you prefer to use automated or manual gating? If you use automated gating, 
please list the software package used. 
12) Do you have experience using Flowjo Software? 
13) Have you ever participated in an External Quality Assessment Scheme (EQAS) for 
Flow Cytometry? 
14) Have you ever submitted your files for central processing (e.g. quality scheme)? 
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D.1.3 Vision Questions 
Do you have colour blindness, or any other visual impairment that can affect your 
judgement of colour and shape on a computer screen? 
D.1.4 Motivational Factors Questions 
15) What problems do you encounter when gating manually? How do you deal with 
these? 
16) What problems do you encounter when interpreting published Flow Cytometry data 
from another source? 
17) How much do you enjoy gating? 
18) Do you feel you have to be in a certain mood to gate? 
19) Do you have to be in a certain environment to gate? 
20) Do you prefer to analyse your data by applying gates at a certain time of day? If so, 
when do you like to apply your gates? 
 
D.2 Follow-up Questionnaire Outline 
D.2.1 Usage Questions 
1) What is your Forename? 
2) What is your Surname? 
3) Who is your Principal Investigator/Team leader (if applicable)? 
4) What Flow Cytometer do you most commonly have experience with? 
5) Which analysis software package(s) do you most commonly use to analyse Flow 
Cytometry data? If you use multiple software packages, please indicate why and what 
benefit each package brings. 
6) How long have you been working with Flow Cytometry? Please indicate length of time 
in years and months. 
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7) Has your Flow Cytometry usage been consistent over time, or on and off with projects? 
8) How often do you currently use a Flow Cytometer? 
9) How often do you analyse Flow Cytometry data? 
D.2.2. Gating Preferences 
10) Do you prefer manual/automated gating? 
11) What problems or frustrations do you encounter when gating flow data? 
12) What problems or frustrations do you have when interpreting flow data from literature 
sources? 
13) Do you actively read/research into Flow Cytometry gating techniques to stay aware of 
up to date literature and findings? 
14) Please indicate what noise parameters you consider affecting Flow Cytometry gating 
and analysis and how you deal with these when analysing data. 
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Short Description Inclusion criteria Exclusion criteria
Fluorescence spillover
Compensation'; 
Fluorescence spillover'
No mention of the 
antigen itself of the 
biological conjugate, this 
is purely focused on the 
fluorophore.
Reagents
Antibody lot variaitons'; 
Staining processes and 
repeatability'
Does not include the 
actual fluorescence 
spillover that occures 
due to the 
fluoreochromes, this has 
more concern with the 
impact on biological 
variation.
Voltage setup
Setting up PMTs'; 'gain'; 
'voltage setup'
Does not include the 
upstream staining and 
fluorochromes used, or 
spillover of the 
fluorochromes into 
different channels.
Non-specific binding
Non-specific staining'; 
'Fc blockers'; 'Non-
specific binding
Does not inclue the 
fluorochromes 
themselves or anythign 
to do with Fluorescence 
spillover
Instrument to 
instrument variation
Discussino of 
instrumental 
differences or specific 
manufacturer setting
Does not relate to laser 
lines used or voltages 
used for specific setup, 
nor reagents
S/N ratio
Limit of detection; 
Sensitivity; Signal to 
Noise; Small particle 
amplification
Does not include 
fluorescence particle 
signals or spillover, not 
specific voltages used for 
setup.
Cell Debris & Doublets
Cell debris; Dead cells' 
Dying cells';  Doublets
Does not include control 
files or specific methods 
for defining gating 
boundaries.
This relates to variability in the use of reagents upstream of the gating process. 
Antigen markers and fluoreochromes as well as staining buffers used can cause 
noise due to fluorescene spillover but also if the process of using this varies there 
can be differences in fluorescence measures.
This relates to setting the PMTs or PDs for the the acquision of data within each 
channel being used. The voltages allow suitable amplification of the fluorecence 
in order to see the required populations and discern from overalpping 
populations by using controls.
The Signal to Noise ratio relats to the limit of detection of the instrument and 
how this is defined with smaller cell types that are harder to detect doe to 
smaller size and potentially weaker signals, This can be difficult to separate from 
instrumental noise which could be over-amplified when looking for small or weak 
particles. 
This relates to dead or dying cell populations and doublet cell populations that 
would normally be cut out of analysis in early 'clean up' gates applied/. These 
cells can often overlap required populations so their removal can be difficult 
when trying to fully etract  the population.
This relates to non-specific binding that occurs due to FC receptors wtthin 
immune cells and certain antigen markers that can bind to incorrect surface 
markers due to this.
This relates to difference between different FC instruments made by different 
manufacturers or located at different sites.
Long description
This relates to any fluorescence spillover that can occur between optical 
channels in the FC. Any mention or correction or compensation to rectify this 
issue is included. 
Noise parameters Codebook
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Short Description Inclusion criteriaExclusion criteria
Gating 
standardisation
Gating 
standards'; 
'Ambiguous 
analysis'; 'Poor 
conclusions'; 'No 
gating hierarchy'
Does not include 
upstream 
standardisation 
such as reagent 
panels or voltage 
setup.
Cell population 
definition
Know what you 
are looking for'; 
Understanding 
of markers for 
populations
Does not include 
how markers 
bind to cells or 
gating standards 
used to define 
certain target 
populations.
Visualisation 
quality
Colour of plots'; 
Ability to 
visualise with 
Nothing 
upstream of the 
gating that could 
Poor reagent 
information
Lack of 
information on 
concentrations'; 
'Lack of 
information on 
titrations used'
This does not 
relate to the cell 
number or event 
count within the 
file itself. Not 
does it relate to 
spillover with 
regards to the 
conjugated 
fluorophore.
Lack of controls
FMOs'; 'Isotypes'; 
'Live/dead 
stains'; 'Negative 
markers'
Does not include 
replicates of the 
sample itself or 
upstream 
optimisation 
such as titration.
Fluorescence 
spillover
Compensation'; 
Fluorescence 
spillover'
No mention of 
the antigen itself 
of the biological 
conjugate, this is 
purely focused on 
the fluorophore.
Lack of control files used to place the gates shown in the fully stained sample. These provide information on how the 
gate was placed, and how much separation can be seen between positive and negative populations.
This relates to any fluorescence spillover that can occur between optica channels in the FC. Any mention or correction or 
compensation to rectify this issue is included. 
This refers to any way the data can be visualised and the resolution of the data points that are used for the analysis. 
This can include colour of plots, density mapping and aspet ratios, for example.
Lack of information surrounding reagents used, with respect to quantities and concentrations of each reagent, 
incubation times and titrations completed.
Long description
This includes the use of well defined and populat gating strategies,validated through the FC community, which also 
includes information provided on hwo the gating was completed, such as the hierarchy and process of gating steps to 
crate the gating images.This also includes difficulty to understand the analysis from descriptions given, along with 
understanding the conclusions drawn from the results in the literature.
This relates to the ability to understand how the target cell population is defined, but in  attached descriptions. This also 
relates to the wider body of knowledge on how well certain sub-populations re determined and defined by specific 
markers and techniques.
Interpretation problems
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ORGANISATION 
Introductory stage 
• Basic information about the purpose of the interview and the research project of which it is a 
part 
• Clear idea of why they have been asked 
• Idea of probably length of the interview; and that I would like to record it and why 
• A clear idea of where and when the interview will take place 
 
You are participating in a research project which aims to identify sources of variation within cell and 
gene therapy manufacturing & measurement platforms, attributed by human factors involved. This will 
have a specific focus on operator subjectivity within data analysis and processing, whilst also 
encompassing differences between operator experience and training.  
 
Your input helps us identify new areas for research and focus, to reduce variation within cell and gene 
therapy manufacturing processes by understanding where human factors play a key role in 
determination of final measures and decisions. This will ultimately improve the consistency and quality 
of the final product manufactured, and therefore a better quality of treatment for the recipient.  
 
You were selected as a possible participating this study because of your expertise and experience in 
carrying out analytical evaluations for the purpose of manufacturing cell or gene therapy products or in 
performing analytical testing in support of those manufacturers.  This interview is voluntary, you have 
the right not to answer any question, and to stop the interview at any time or for any reason. We expect 
that the interview will take one hour.  
 
INTERVIEWEE PROFILE 
 
1. What are your roles/responsibilities and what techniques do you work with most commonly? 
• Create a profile for interviewees career/technique history to aid this question. 
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2. How much experience have you had with cellular imaging for viability/confluency (in years & 
months)? 
 
 
 
 
TECHNIQUE USE 
 
3. How frequently do you use the cell imaging platform? 
 
 
 
4. What do you use these techniques to measure?  
• (Cell measurement, organic compounds, metabolites etc) 
 
 
 
EXERCISE 
5. Could you outline the process of obtaining a measurement with the respective technique, and 
identify the relevant tasks within the sample preparation and optimisation, instrument setup 
and data acquisition and analysis stages of the measurement process? (Example provided, 
interviewee to talk through process to confirm what they do, along with the next question). 
 
 
 
6. From the process stages you have identified, could you highlight which of these are affected by 
the operator’s judgement and their respective variability, and how much human contact time 
they take? 
 
DATA ANALYSIS 
7. Focusing on the data analysis elements, do they require human or machine learning 
interpretation to provide a quantitative result? 
 
 
 
8. Are you familiar with how the software computes to obtain a final answer? What does it look for 
to determine differences between cells? Do different analysis packages use different 
methods/algorithms? 
 
 
 
9. Could you go through this data analysis process in detail and explain variables that can be 
optimised/changed/altered to obtain the image (or analyse it) and how significant the variation 
could be? (Yes/No/detailed answer) 
 
 
TRAINING 
10. Are you responsible for training new users on this instrumentation? 
 
 
11. Do you see differences between new and experienced users when they interpret data from this 
technique? 
 
 
 
12. How are users trained in your facility (process)? Are there recognised training courses/material 
that are encouraged to use as reference material/information to help with 
quantification/diagnosis? 
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STANDARD OPERATION 
13. Do you use Standard Operating Procedures for analysis of data? Is this internal/external? 
(Yes/No; Internal/External) 
 
14. Do you use proprietary software for data processing (i.e. comes with the instrument), or do you 
use 3rd party software? If the latter, why? 
 
CLOSURE 
• Give interviewee a verbal summary of what you feel you have gained from the interview and 
thank them for their time and contribution. 
• State time of interview end and interview duration. 
 
 
Short Description Detailed Description Inclusion Criteria Exclusion Criteria 
Sample 
Preparation First 
Cycle Code 
defined as liquid handling and sample 
handling required for an analytical 
measurement. This does not include any 
instrumental setup for measurement 
platforms or data processing. It also does not 
include ant cell culture required for 
expansion. 
    
        
Product 
interations 
Refers to matrix effects of additional 
materials used within culture that can affect 
the final measurement, or effects of reagents 
used in the measurement process.  
Matrix effects, mAb 
conjugation, buffers and 
reagents 
Instrumental 
setup or protocol 
specifications. 
        
Protocol 
Optimisation 
Refers to optimised steps of the protocol, 
which contribute variability due to time, 
volume, concentration or other 
environmental factors. 
Longitudinal effects, 
volume, concentration 
environment 
Instrumental 
setup, product 
interactions and 
biological variation 
     
Process 
Familiarity 
Refers to operator human factors when 
repeating process steps. This includes factors 
such as experience, use frequency, 
competence, confidence and speed of work 
that impact how an operator completes a 
process and impacts variability 
Experience, 
troubleshooting, use 
frequency, competence, 
confidence, speed of 
work 
Protocol steps and 
detail, training 
     
Copy Errors 
Processing errors that are introduced when 
an operator is required to intervene and 
transfer information manually from one 
platform to another. 
Copying values from 
instruments to excel 
docs, further manual 
calculation, file naming 
and overwriting 
Does not include 
creating macros or 
automated file 
name generation/ 
information 
transfer 
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Haptic Variables 
Variables affected by the operator completing 
a physical task or manual manipulation of the 
product. 
Pipetting error, removal of 
superanatant 
Does not include 
software based 
variables that 
require users to 
understand 
workings of 
parameters and 
adjustment 
thereof 
        
Non-Haptic 
Variables 
Variables affected by the operator which are 
not seen as physical in completion. These 
often involve software-based tasks where the 
operator is using a computer to select and 
test a variety of parameters. 
Manual size gating of 
images 
Pipetting error, 
removal of 
superanatant 
     
In-Process First 
Cycle Code 
In-process is defined as an instrumental 
setup required to facilitate the measurement. 
It does not include any prior sample handling, 
or post-processing of data if required. It 
related to setup parameters required to be 
tuned in order to take the measurement. 
    
     
Protocol 
Optimisation 
These are parameters that have been set in a 
protocol, defined by prior testing and 
validation. It does not include parameters 
that need adaptive tuning for each 
measurand. 
Cell line selection, 
concentrations, volumes, 
doubling times, cycle 
times, temperatures. 
Variables tuned 
for each 
measurement, e.g. 
focus/ autofocus 
on cells. 
     
Digital Image 
Parameters 
These are variables which can be adjusted to 
improve the visual image of the product, 
often relating to camera variables. It does not 
include the spatial positioning of the camera 
or dynamic ranges thereof. 
Brightness, contrast, 
masking, image stitching 
Dynamic range of 
image, cell 
focusing, size 
thresholds 
        
Spatial Image 
Parameters 
These are area parameters reating to the 
chosen area for imaging in the x, y and z 
planes of focus and measurement. It also 
relates to the frequency of image capture and 
size thresholds if captured in real time. 
Centering on well, size 
thresholds, z-scan height. 
Brightness, Gain, 
Contrast. 
        
Process Setup 
These are human factor decisions and 
actions that are required to be made during 
the process of instrumental setup. They 
require the user to know the correct 
decisions have been made and 
troubleshooting if not. It does not include any 
digital or spatial parameters that can be 
adjusted.  
Choosing correct optical 
channel, focusing, correct 
objective. 
Brightness, gain, 
choosing area for 
image. 
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Copy Errors 
Processing errors that are introduced when 
an operator is required to intervene and 
transfer information manually from one 
platform to another. 
Copying values from 
instruments to excel 
docs, further manual 
calculation, file naming 
and overwriting 
Does not include 
creating macros or 
automated file 
name generation/ 
information 
transfer 
        
Post-Process 
Cycle Code 
Post-processing is defined as any processing 
completed on the image/data once the 
measurement/ image has been taken. This 
includes any thresholding for background 
and cell/pixel size. It does not include any 
image setup parameters used to take the 
image.  
    
        
Copy Errors 
Processing errors that are introduced when 
an operator is required to intervene and 
transfer information manually from one 
platform to another. 
Copying values from 
instruments to excel 
docs, further manual 
calculation, file naming 
and overwriting 
Does not include 
creating macros or 
automated file 
name generation/ 
information 
transfer 
        
Spatial Image 
Parameters 
These are area parameters reating to the 
chosen area for imaging in the x, y and z 
planes of focus and measurement. It also 
relates to the frequency of image capture and 
size thresholds if captured in real time. 
Centering on well, size 
thresholds, z-scan height. 
Brightness, Gain, 
Contrast. 
        
Digital Image 
Parameters 
These are variables which can be adjusted to 
improve the visual image of the product, 
often relating to camera variables. It does not 
include the spatial positioning of the camera 
or dynamic ranges thereof. 
Brightness, contrast, 
masking, image stitching 
Dynamic range of 
image, cell 
focusing, size 
thresholds 
        
Non-Haptic 
Variables 
Variables affected by the operator which are 
not seen as physical in completion. These 
often involve software-based tasks where the 
operator is using a computer to select and 
test a variety of parameters. 
Manual size gating of 
images 
Pipetting error, 
removal of 
superanatant 
        
Protocol 
Optimisation 
These are parameters that have been set in a 
protocol, defined by prior testing and 
validation. It does not include parameters 
that need adaptive tuning for each 
measurand. 
Cell line selection, 
concentrations, volumes, 
doubling times, cycle 
times, temperatures. 
Variables tuned 
for each 
measurement, e.g. 
focus/ autofocus 
on cells. 
 
